
<html lang="en"     class="pb-page"  data-request-id="c0c74fa7-ab84-42bc-a26c-f0c36151d36f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.6b00883;issue:issue:10.1021/jmcmar.2016.59.issue-17;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family" /></meta><meta name="dc.Creator" content="Jeff B.  Smaill" /></meta><meta name="dc.Creator" content="Andrea J.  Gonzales" /></meta><meta name="dc.Creator" content="Julie A.  Spicer" /></meta><meta name="dc.Creator" content="Helen  Lee" /></meta><meta name="dc.Creator" content="Jessica E.  Reed" /></meta><meta name="dc.Creator" content="Karen  Sexton" /></meta><meta name="dc.Creator" content="Irene W.  Althaus" /></meta><meta name="dc.Creator" content="Tong  Zhu" /></meta><meta name="dc.Creator" content="Shannon L.  Black" /></meta><meta name="dc.Creator" content="Adrian  Blaser" /></meta><meta name="dc.Creator" content="William A.  Denny" /></meta><meta name="dc.Creator" content="Paul A.  Ellis" /></meta><meta name="dc.Creator" content="Stephen  Fakhoury" /></meta><meta name="dc.Creator" content="Patricia J.  Harvey" /></meta><meta name="dc.Creator" content="Ken  Hook" /></meta><meta name="dc.Creator" content="Florence O. J.  McCarthy" /></meta><meta name="dc.Creator" content="Brian D.  Palmer" /></meta><meta name="dc.Creator" content="Freddy  Rivault" /></meta><meta name="dc.Creator" content="Kevin  Schlosser" /></meta><meta name="dc.Creator" content="Teresa  Ellis" /></meta><meta name="dc.Creator" content="Andrew M.  Thompson" /></meta><meta name="dc.Creator" content="Erin  Trachet" /></meta><meta name="dc.Creator" content="R. Thomas  Winters" /></meta><meta name="dc.Creator" content="Haile  Tecle" /></meta><meta name="dc.Creator" content="Alexander  Bridges" /></meta><meta name="dc.Description" content="Structure–activity relationships for inhibition of erbB1, erbB2, and erbB4 were determined for a series of quinazoline- and pyrido[3,4-d]pyrimidine-based analogues of the irreversible pan-erbB inhi..." /></meta><meta name="Description" content="Structure–activity relationships for inhibition of erbB1, erbB2, and erbB4 were determined for a series of quinazoline- and pyrido[3,4-d]pyrimidine-based analogues of the irreversible pan-erbB inhi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 22, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b00883" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00883" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b00883" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b00883" /></link>
        
    
    

<title>Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b00883" /></meta><meta property="og:title" content="Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0017.jpeg" /></meta><meta property="og:description" content="Structure–activity relationships for inhibition of erbB1, erbB2, and erbB4 were determined for a series of quinazoline- and pyrido[3,4-d]pyrimidine-based analogues of the irreversible pan-erbB inhibitor, canertinib. Cyclic amine bearing crotonamides were determined to provide rapid inhibition of cellular erbB1 autophosphorylation and good metabolic stability in liver microsome and hepatocyte assays. The influence of 4-anilino substitution on pan-erbB inhibitory potency was investigated. Several anilines were identified as providing potent, reversible pan-erbB inhibition. Optimum 4- and 6-substituents with known 7-substituents provided preferred irreversible inhibitors for pharmacodynamic testing in vivo. Quinazoline 54 and pyrido[3,4-d]pyrimidine 71 were identified as clearly superior to canertinib. Both compounds possess a piperidinyl crotonamide Michael acceptor and a 3-chloro-4-fluoroaniline, indicating these as optimized 6- and 4-substituents, respectively. Pharmacokinetic comparison of compounds 54 and 71 across three species selected compound 54 as the preferred candidate. Compound 54 (PF-00299804) has been assigned the nomenclature of dacomitinib and is currently under clinical evaluation." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b00883"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b00883">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b00883&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b00883&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b00883&amp;href=/doi/10.1021/acs.jmedchem.6b00883" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 8103-8124</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b00869" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b00986" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-<i>d</i>]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeff+B.++Smaill">Jeff B. Smaill</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrea+J.++Gonzales">Andrea J. Gonzales</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Julie+A.++Spicer">Julie A. Spicer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Helen++Lee">Helen Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jessica+E.++Reed">Jessica E. Reed</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Sexton">Karen Sexton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Irene+W.++Althaus">Irene W. Althaus</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tong++Zhu">Tong Zhu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shannon+L.++Black">Shannon L. Black</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Adrian++Blaser">Adrian Blaser</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+A.++Denny">William A. Denny</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+A.++Ellis">Paul A. Ellis</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Fakhoury">Stephen Fakhoury</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Patricia+J.++Harvey">Patricia J. Harvey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ken++Hook">Ken Hook</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Florence+O.+J.++McCarthy">Florence O. J. McCarthy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+D.++Palmer">Brian D. Palmer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Freddy++Rivault">Freddy Rivault</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Schlosser">Kevin Schlosser</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Teresa++Ellis">Teresa Ellis</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrew+M.++Thompson">Andrew M. Thompson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Erin++Trachet">Erin Trachet</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=R.+Thomas++Winters">R. Thomas Winters</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Haile++Tecle">Haile Tecle</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexander++Bridges">Alexander Bridges</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105-1047, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 64 9 373 7599 ext 86789. Fax: 64 9 373 7502. E-mail: <a href="/cdn-cgi/l/email-protection#b8d296cbd5d9d1d4d4f8d9cddbd3d4d9d6dc96d9db96d6c2"><span class="__cf_email__" data-cfemail="a0ca8ed3cdc1c9cccce0c1d5c3cbccc1cec48ec1c38eceda">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00883&amp;href=/doi/10.1021%2Facs.jmedchem.6b00883" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 8103–8124</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 4, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 June 2016</li><li><span class="item_label"><b>Published</b> online</span>22 August 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 September 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b00883" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00883</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8103%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJeff%2BB.%2BSmaill%252C%2BAndrea%2BJ.%2BGonzales%252C%2BJulie%2BA.%2BSpicer%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D17%26contentID%3Dacs.jmedchem.6b00883%26title%3DTyrosine%2BKinase%2BInhibitors.%2B20.%2BOptimization%2Bof%2BSubstituted%2BQuinazoline%2Band%2BPyrido%255B3%252C4-d%255Dpyrimidine%2BDerivatives%2Bas%2BOrally%2BActive%252C%2BIrreversible%2BInhibitors%2Bof%2Bthe%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BFamily%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8124%26publicationDate%3DSeptember%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b00883"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2278</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">29</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b00883" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jeff&quot;,&quot;last_name&quot;:&quot;B. Smaill&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;J. Gonzales&quot;},{&quot;first_name&quot;:&quot;Julie&quot;,&quot;last_name&quot;:&quot;A. Spicer&quot;},{&quot;first_name&quot;:&quot;Helen&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Jessica&quot;,&quot;last_name&quot;:&quot;E. Reed&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Sexton&quot;},{&quot;first_name&quot;:&quot;Irene&quot;,&quot;last_name&quot;:&quot;W. Althaus&quot;},{&quot;first_name&quot;:&quot;Tong&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Shannon&quot;,&quot;last_name&quot;:&quot;L. Black&quot;},{&quot;first_name&quot;:&quot;Adrian&quot;,&quot;last_name&quot;:&quot;Blaser&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;A. Denny&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;A. Ellis&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Fakhoury&quot;},{&quot;first_name&quot;:&quot;Patricia&quot;,&quot;last_name&quot;:&quot;J. Harvey&quot;},{&quot;first_name&quot;:&quot;Ken&quot;,&quot;last_name&quot;:&quot;Hook&quot;},{&quot;first_name&quot;:&quot;Florence&quot;,&quot;last_name&quot;:&quot;O. J. McCarthy&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;D. Palmer&quot;},{&quot;first_name&quot;:&quot;Freddy&quot;,&quot;last_name&quot;:&quot;Rivault&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Schlosser&quot;},{&quot;first_name&quot;:&quot;Teresa&quot;,&quot;last_name&quot;:&quot;Ellis&quot;},{&quot;first_name&quot;:&quot;Andrew&quot;,&quot;last_name&quot;:&quot;M. Thompson&quot;},{&quot;first_name&quot;:&quot;Erin&quot;,&quot;last_name&quot;:&quot;Trachet&quot;},{&quot;first_name&quot;:&quot;R.&quot;,&quot;last_name&quot;:&quot;Thomas Winters&quot;},{&quot;first_name&quot;:&quot;Haile&quot;,&quot;last_name&quot;:&quot;Tecle&quot;},{&quot;first_name&quot;:&quot;Alexander&quot;,&quot;last_name&quot;:&quot;Bridges&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;8103-8124&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b00883&quot;},&quot;abstract&quot;:&quot;Structure–activity relationships for inhibition of erbB1, erbB2, and erbB4 were determined for a series of quinazoline- and pyrido[3,4-d]pyrimidine-based analogues of the irreversible pan-erbB inhibitor, canertinib. Cyclic amine bearing crotonamides were determined to provide rapid inhibition of cellular erbB1 autophosphorylation and good metabolic stability in liver microsome and hepatocyte assays. The influence of 4-anilino substitution on pan-erbB inhibitory potency was investigated. Several anilines were identified as providing potent, reversible pan-erbB inhibition. Optimum 4- and 6-substituents with known 7-substituents provided preferred irreversible inhibitors for pharmacodynamic testing in vivo. Quinazoline 54 and pyrido[3,4-d]pyrimidine 71 were identified as clearly superior to canertinib. Both compounds possess a piperidinyl crotonamide Michael acceptor and a 3-chloro-4-fluoroaniline, indicating these as optimized 6- and 4-substituents, respectively. Pharmacokinetic comparison of compounds 54 and 7&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00883&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00883" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00883&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00883" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b00883&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00883" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b00883&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b00883&amp;href=/doi/10.1021/acs.jmedchem.6b00883" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b00883" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b00883" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b00883%26sid%3Dliteratum%253Aachs%26pmid%3D27491023%26genre%3Darticle%26aulast%3DSmaill%26date%3D2016%26atitle%3DTyrosine%2BKinase%2BInhibitors.%2B20.%2BOptimization%2Bof%2BSubstituted%2BQuinazoline%2Band%2BPyrido%255B3%252C4-d%255Dpyrimidine%2BDerivatives%2Bas%2BOrally%2BActive%252C%2BIrreversible%2BInhibitors%2Bof%2Bthe%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2BFamily%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D17%26spage%3D8103%26epage%3D8124%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/jmcmar.2016.59.issue-17/20160908/jmcmar.2016.59.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Structure–activity relationships for inhibition of erbB1, erbB2, and erbB4 were determined for a series of quinazoline- and pyrido[3,4-<i>d</i>]pyrimidine-based analogues of the irreversible pan-erbB inhibitor, canertinib. Cyclic amine bearing crotonamides were determined to provide rapid inhibition of cellular erbB1 autophosphorylation and good metabolic stability in liver microsome and hepatocyte assays. The influence of 4-anilino substitution on pan-erbB inhibitory potency was investigated. Several anilines were identified as providing potent, reversible pan-erbB inhibition. Optimum 4- and 6-substituents with known 7-substituents provided preferred irreversible inhibitors for pharmacodynamic testing in vivo. Quinazoline <b>54</b> and pyrido[3,4-<i>d</i>]pyrimidine <b>71</b> were identified as clearly superior to canertinib. Both compounds possess a piperidinyl crotonamide Michael acceptor and a 3-chloro-4-fluoroaniline, indicating these as optimized 6- and 4-substituents, respectively. Pharmacokinetic comparison of compounds <b>54</b> and <b>71</b> across three species selected compound <b>54</b> as the preferred candidate. Compound <b>54</b> (PF-00299804) has been assigned the nomenclature of dacomitinib and is currently under clinical evaluation.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42620" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42620" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">There is considerable interest in small molecule inhibitors of the human epidermal growth factor receptor family of tyrosine kinases for the treatment of cancer. The family consists of four members, erbB1 (EGFR, HER-1), erbB2 (HER-2, neu), erbB3 (HER-3), and erbB4 (HER-4). Hyperactivation of this family due to overexpression of the receptors, mutations leading to constitutive activation or overexpression of the growth factors themselves results in inappropriate signal transduction cascades driving cellular functions such as proliferation, differentiation, migration, and angiogenesis in a process known to correlate with poor prognosis in patients.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1-4)</a></div><div class="NLM_p">The erbB1 selective, reversible ATP-competitive inhibitors gefitinib (<b>1</b>)<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> and erlotinib (<b>2</b>)<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> are approved as front line therapy for nonsmall cell lung cancer (NSCLC) that has been determined through genetic analysis to harbor somatic mutations in erbB1. In this setting, they demonstrate impressive response rates (60–80%) and significant improvements in progression-free survival over chemotherapy.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> While some patients may experience a durable response, resistance to these agents eventually emerges, with approximately half of patients having acquired a second T790M mutation in the kinase active site.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> Early attempts to improve the efficacy of these inhibitors was centered around improving their potency for inhibition of erbB2, which is known to be overexpressed in 25–30% of breast cancers.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> This was achieved by introducing large lipophilic substituents to the 4-position of the aniline ring, as typified by lapatinib (<b>3</b>),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> which is approved for use in combination with Xeloda as the last line treatment for erbB2 positive breast cancer.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a></div><div class="NLM_p">The recognition that erbB1, 2, and 4 possess a unique unpaired cysteine residue (Cys 773, 784, and 778, respectively)<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> at the mouth of the ATP-binding domain, in a position normally occupied by a glutamine or serine in other kinases, has led ourselves<a onclick="showRef(event, 'ref15 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref15 ref17 ref18 ref19 ref20">(15, 17-20)</a> and others<a onclick="showRef(event, 'ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29">(21-29)</a> to develop small molecule irreversible inhibitors of the erbB family of tyrosine kinases. The design concept is typified by canertinib (CI-1033; <b>4</b>),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> the first irreversible pan-erbB inhibitor to enter clinical trials.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> This compound bears an electrophilic 6-acrylamide substituent ideally positioned to alkylate the key cysteine residues of erbB1, 2, and 4, providing for low nanomolar potency against these kinases. Potent inhibition of erbB3 signaling is also achieved through blockade of its transphosphorylation partners.</div><div class="NLM_p">While a number of alternate Michael acceptors have been explored in the development of irreversible erbB inhibitors, the most widely employed is the dimethylamino crotonamide originally developed by Tsou and colleagues.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> This is exemplified in the quinoline-3-carbonitrile pelitinib (EKB-569; <b>5</b>),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> which was investigated in human clinical trials.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Here the dimethylamine group plays a critical role as an intramolecular base catalyzing reaction of the sulfhydryl group and the Michael acceptor through a five-membered transition state, increasing the reactivity of the Michael acceptor toward sulfur nucleophiles when compared to the unsubstituted crotonamide.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> Optimisation of pelitinib focused on improving erbB2 potency,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> resulting in the irreversible erbB1/2 inhibitor neratinib (HKI-272; <b>6</b>),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> currently in phase III clinical trial for erbB2-positive breast cancer.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Application of the dimethylamino crotonamide Michael acceptor to a quinazoline scaffold provided the potent irreversible erbB1/2 inhibitor afatinib (BIBW-2992; <b>7</b>),<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> which is approved for mutant erbB1-positive NSCLC (<a class="ref internalNav" href="#cht1" aria-label="Chart 1">Chart 1</a>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><figure id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0002.jpeg" id="GRAPHIC-d7e486-autogenerated" class="inline-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Irreversible inhibitors of the erbB family have been proposed for the treatment of T790M-mediated relapse of first-generation erbB1 inhibitors based on preclinical efficacy against T790M-positive cell lines<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> and human tumor xenograft models, although this efficacy may be at supraphysiological concentrations.<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38-40)</a> Third-generation inhibitors that are selective for mutant forms of erbB1 (including T790M), while sparing wild-type erbB1, have now been reported. Examples include WZ4002,<a onclick="showRef(event, 'ref38 ref41'); return false;" href="javascript:void(0);" class="ref ref38 ref41">(38, 41)</a> rociletinib (CO-1686),<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> and osimertinib (AZD9291).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The latter derivative demonstrates impressive efficacy in clinical trials against T790M-positive NSCLC<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and is now approved by the FDA in this setting.</div><div class="NLM_p">Returning to canertinib, phase I trials of this agent administered orally for 7 or 14 days of a 21-day cycle established 650<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> or 450 mg/day<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> as the respective maximum tolerated doses. Diarrhea, acneiform rash, emesis, and anorexia were described as the dose-limiting toxicities and are typical of the class. Other toxicities such as transient thrombocytopaenia and hypersensitivity reactions were also reported.<a onclick="showRef(event, 'ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref45 ref46">(45, 46)</a> It has been speculated that these toxicities may be due to off-mechanism kinase activity.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Indeed, canertinib is reported to be a potent inhibitor of BMX and BTK, TEC-kinases that possess a target cysteine in the same relative position of the ATP-binding domain as erbB1, 2, and 4.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Kinase screening against 317 protein kinases revealed off-target micromolar binding affinity to approximately 12.6% of kinases tested and submicromolar affinity to 5.7%, with particularly strong affinity to BLK, GAK, LCK, MKNK1, and RIPK2.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> We herein also identify canertinib as a potent inhibitor of JAK3 (IC<sub>50</sub> = 128 nM), another kinase to share an appropriately positioned cysteine in its ATP-binding domain. Phase II studies of canertinib in previously treated advanced ovarian cancer were disappointing, with a lack of responses precluding further clinical development.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The modest pharmacokinetic profile of canertinib in humans, in particular a short plasma elimination half-life (4 h) has been proposed as limiting efficacy,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> while the observed lack of canertinib excretion in urine indicates elimination is primarily metabolic.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> Consistent with this, the major metabolite in cellular studies is the glutathione adduct of the Michael acceptor.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p last">In the present study, we describe our work to develop an improved analogue of canertinib. We sought to identify a window of opportunity whereby the metabolic stability of the Michael acceptor could be improved without disrupting the desired irreversible inhibition of erbB1, 2, and 4. We argued this would minimize first-pass metabolism and provide improved pharmacokinetic parameters. Analogues were screened in vitro against recombinant JAK3 kinase seeking to eliminate off-target potency against this enzyme, thought to contribute to the myleotoxicity observed for canertinib. Dose potency and duration of suppression of erbB1 autophosphorylation was assessed in nude mice bearing tumor xenografts. Herein, we discuss the strategy we adopted to develop an optimized irreversible quinazoline or pyrido[3,4-<i>d</i>]pyrimidine pan-erbB inhibitor with improved pharmacokinetics, tumor pharmacodynamics, tumor efficacy in animal models, and potential toxicity profile in humans relative to canertinib itself.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71222" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71222" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of 6-amide substituted quinazolines, pyrido[3,4-<i>d</i>]pyrimidines, and quinoline-3-carbonitriles is well precedented,<a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24">(17-24)</a> and the present work proceeded along similar lines. The substituted acrylamides (<b>8</b>–<b>11</b>) of <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> were prepared by reaction of the 6-aminoquinazoline<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (<b>85</b>) with the respective acid chlorides (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Exploration of Substituted Acrylamides on the Canertinib Scaffold</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Concentration for 50% inhibition of phosphorylation of a Glu/Tyr copolymer (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). Values are the average of at least two separate determinations, with a CV of ±22%.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Inhibition of erbB1 autophosphorylation in NIH3T3 cells transfected with the full-length human erbB1 (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>).</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Inhibition of ligand-regulated erbB2 autophosphorylation in T24 NIH fibroblasts expressing a chimeric receptor with the extracellular binding domain of erbB1 and the intracellular kinase domain of erbB2 (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>).</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Percentage inhibition at a drug concentration of 0.5 μM.</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Percentage inhibition at a drug concentration of 1.0 μM.</p></div><div class="footnote" id="t1fn6"><sup>Table f</sup><p class="last">Length of drug exposure (minutes) required to provide 100% inhibition of erbB1 autophosphorylation in A431 cells, or conversely the percentage of inhibition after 2 h drug exposure (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). NA = data not available.</p></div></div><div></div></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) acid chloride, Et<sub>3</sub>N, THF, RT.</p></p></figure><div class="NLM_p">The 4-anilinoquinazolines (<b>12</b>–<b>43</b>) of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> were prepared by aniline displacement of the 4-chloro substituent of quinazoline <b>89</b>. This array substrate was prepared from 7-fluoro-6-nitroquinazolone<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> (<b>86</b>) by methoxide displacement of the activated fluorine to give <b>87</b>, followed by iron dust reduction of the nitro group and acylation with propionic anhydride to give propanamide <b>88</b>. Chlorination in refluxing POCl<sub>3</sub> then gave <b>89</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The majority of the anilines of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> were commercially available. The remainder were previously reported (A7–10, A12) or prepared (A6, A11, A13, A14, A31, and A32) by reduction of their nitro precursors, which were obtained by standard techniques (see <a href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_001.pdf" class="ext-link">Supporting Information</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Exploration of Pan-erbB Potency for Anilines on a Reversible Scaffold</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Concentration for 50% inhibition of phosphorylation of a Glu/Tyr copolymer (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). Values are the average of at least two separate determinations, with a CV of ±22%.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Percentage inhibition at a drug concentration of 1 μM. NA = data not available.</p></div></div><div></div></div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaOMe, MeOH, 100 °C, 18 h; (ii) (a) Fe, AcOH, EtOH, water, 100 °C, 1 h, (b) propionic anhydride, 120 °C, 2 h; (iii) POCl<sub>3</sub>, reflux, 90 min; (iv) subst aniline, <sup><i>i</i></sup>PrOH, c. HCl (cat.), 100 °C, 0.5–1 h.</p></p></figure><div class="NLM_p">The quinazolines (<b>44</b>–<b>52</b>) of <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> were prepared by ethoxide displacement on <b>86</b>, followed by POCl<sub>3</sub> mediated chlorination and displacement with 1-benzyl-1<i>H</i>-indazol-5-amine, to give <b>91</b>. Nitro group reduction via hydrogenation over Raney nickel then gave amine <b>92</b>, which was acylated with the freshly prepared acid chloride of <i>E</i>-4-bromobut-2-enoic acid to give bromide <b>93</b>. Low temperature displacement of the bromide with a range of secondary amines then gave compounds <b>44</b>–<b>52</b> of <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Investigation of Cyclic Amine Bearing Crotonamides on a Pan-erbB Scaffold</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0013.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0014.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Concentration for 50% inhibition of phosphorylation of a Glu/Tyr copolymer (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). Values are the average of at least two separate determinations, with a CV of ±22%.</p></div><div class="footnote" id="t3fn6"><sup>Table b</sup><p class="last">Inhibition of erbB1 autophosphorylation in NIH3T3 cells transfected with the full-length human erbB1 (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>).</p></div><div class="footnote" id="t3fn2"><sup>Table c</sup><p class="last">Concentration for 50% inhibition of phosphorylation of polyglutamic acid-tyrosine [PGT (4:1), Sigma catalogue no. P0275] by recombinant JAK3 (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). Values are the average of at least two separate determinations, with a CV of ±22%.</p></div><div class="footnote" id="t3fn3"><sup>Table d</sup><p class="last">Length of drug exposure (minutes) required to provide 100% inhibition of erbB1 autophosphorylation in A431 cells (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>).</p></div><div class="footnote" id="t3fn4"><sup>Table e</sup><p class="last">Length of rat liver microsome (RLM) or human liver microsome (HLM) exposure (minutes) required to give 50% loss of parent compound (starting concentration 5 μM) (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>).</p></div><div class="footnote" id="t3fn5"><sup>Table f</sup><p class="last">Length of rat hepatocyte (RH) or human hepatocyte (HH) exposure (minutes) required to give 50% loss of parent compound (starting concentration 1 μM) (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). NA = data not available.</p></div></div><div></div></div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0007.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaOEt, EtOH, 50 °C, 4 h; (ii) (a) POCl<sub>3</sub>, reflux, 3 h, (b) 1-benzyl-1<i>H</i>-indazol-5-amine, <sup><i>i</i></sup>PrOH/CH<sub>2</sub>Cl<sub>2</sub>, 50 °C, 15 h; (iii) Raney nickel, H<sub>2</sub>, EtOAc/MeOH; (iv) (a) <i>E</i>-4-bromobut-2-enoic acid, oxalyl chloride, cat. DMF, CH<sub>2</sub>Cl<sub>2</sub>, RT, (b) acid chloride from (a), THF, −20 °C, 075; (v) amine, DMA, −20 °C, 2 h.</p></p></figure><div class="NLM_p">The quinazolines (<b>53</b>–<b>69</b>) of <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> were prepared in an analogous manner to those of <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> described above. The pyrido[3,4-<i>d</i>]pyrimidines (<b>70</b>–<b>82</b>) of <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> were prepared similarly from 6-fluoropyrido[3,4-<i>d</i>]pyrimidin-4(3<i>H</i>)-one<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> (<b>95</b>) by chlorination with SOCl<sub>2</sub> and displacement with the respective anilines to give compounds <b>96</b>. Fluorine displacement with 4-methoxybenzylamine then gave the PMB-protected amines (<b>97</b>), which were deprotected using TFA to give the 6-amino derivatives (<b>98</b>). Acylation of these with the freshly prepared acid chloride of <i>E</i>-4-bromobut-2-enoic acid gave the bromides (<b>99</b>). Low temperature displacement of the bromides with a range of secondary amines then gave compounds <b>70</b>–<b>82</b> of <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Pan-erbB Anilines and Cyclic Amino Crotonamides on Quinazoline and Pyrido[3,4-<i>d</i>]pyrimidine Scaffolds</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0015.gif" alt="" id="fx7" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">kinase assays IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">kinase assays IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">erbB1</th><th class="rowsep1 colsep0" align="center" char=".">erbB2</th><th class="rowsep1 colsep0" align="center" char=".">erbB4</th><th class="rowsep1 colsep0" align="center">JAK3</th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">erbB1</th><th class="rowsep1 colsep0" align="center">erbB2</th><th class="rowsep1 colsep0" align="center" char=".">erbB4</th><th class="rowsep1 colsep0" align="center">JAK3</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">series</th><th class="colsep0 rowsep0" align="center">A</th><th class="colsep0 rowsep0" align="center">B</th><th class="colsep0 rowsep0" align="center">C</th><th class="colsep0 rowsep0" align="center" char=".">enzyme</th><th class="colsep0 rowsep0" align="center" char=".">cellular</th><th class="colsep0 rowsep0" align="center" char=".">enzyme</th><th class="colsep0 rowsep0" align="center" char=".">enzyme</th><th class="colsep0 rowsep0" align="center">enzyme</th><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">series</th><th class="colsep0 rowsep0" align="center">A</th><th class="colsep0 rowsep0" align="center">B</th><th class="colsep0 rowsep0" align="center">C</th><th class="colsep0 rowsep0" align="center" char=".">enzyme</th><th class="colsep0 rowsep0" align="center" char=".">cellular</th><th class="colsep0 rowsep0" align="center">enzyme</th><th class="colsep0 rowsep0" align="center" char=".">enzyme</th><th class="colsep0 rowsep0" align="center">enzyme</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="char" char=".">0.343</td><td class="colsep0 rowsep0" align="char" char=".">0.476</td><td class="colsep0 rowsep0" align="center">>1.0</td><td class="colsep0 rowsep0" align="center"><b>65</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">26</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.098</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="center">0.278</td><td class="colsep0 rowsep0" align="char" char=".">0.041</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.027</td><td class="colsep0 rowsep0" align="center">0 128</td><td class="colsep0 rowsep0" align="center"><b>66</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">26</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.164</td><td class="colsep0 rowsep0" align="char" char=".">0.061</td><td class="colsep0 rowsep0" align="center">>1.0</td><td class="colsep0 rowsep0" align="char" char=".">0.094</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.009</td><td class="colsep0 rowsep0" align="char" char=".">0.032</td><td class="colsep0 rowsep0" align="char" char=".">0.088</td><td class="colsep0 rowsep0" align="center">7.40</td><td class="colsep0 rowsep0" align="center"><b>67</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">30</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.021</td><td class="colsep0 rowsep0" align="char" char=".">0.061</td><td class="colsep0 rowsep0" align="center">0.045</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.046</td><td class="colsep0 rowsep0" align="char" char=".">0.074</td><td class="colsep0 rowsep0" align="center">3.57</td><td class="colsep0 rowsep0" align="center"><b>68</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">30</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.069</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="center">0.174</td><td class="colsep0 rowsep0" align="char" char=".">0.018</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="center">6.88</td><td class="colsep0 rowsep0" align="center"><b>69</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">30</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.082</td><td class="colsep0 rowsep0" align="char" char=".">0.390</td><td class="colsep0 rowsep0" align="center">0.290</td><td class="colsep0 rowsep0" align="char" char=".">0.029</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.019</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="center">4.96</td><td class="colsep0 rowsep0" align="center"><b>70</b></td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="center">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.028</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.019</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="center">7.15</td><td class="colsep0 rowsep0" align="center"><b>71</b></td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="center">0.014</td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="center">0.793</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.023</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td><td class="colsep0 rowsep0" align="char" char=".">0.023</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="center">8.75</td><td class="colsep0 rowsep0" align="center"><b>72</b></td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="center">0.035</td><td class="colsep0 rowsep0" align="char" char=".">0.043</td><td class="colsep0 rowsep0" align="center">1.71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="center">7.10</td><td class="colsep0 rowsep0" align="center"><b>73</b></td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.019</td><td class="colsep0 rowsep0" align="char" char=".">0.009</td><td class="colsep0 rowsep0" align="center">0.089</td><td class="colsep0 rowsep0" align="char" char=".">0.302</td><td class="colsep0 rowsep0" align="center">2.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="center">4.80</td><td class="colsep0 rowsep0" align="center"><b>74</b></td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.041</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="center">0.062</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="center">7.44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="char" char=".">0.016</td><td class="colsep0 rowsep0" align="char" char=".">0.026</td><td class="colsep0 rowsep0" align="char" char=".">0.019</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center"><b>75</b></td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.057</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="center">0.062</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="center">7.62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.038</td><td class="colsep0 rowsep0" align="char" char=".">0.016</td><td class="colsep0 rowsep0" align="char" char=".">0.038</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center"><b>76</b></td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">17</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.201</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="center">0.100</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="center">8.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.036</td><td class="colsep0 rowsep0" align="char" char=".">0.053</td><td class="colsep0 rowsep0" align="char" char=".">0.030</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="center">3.79</td><td class="colsep0 rowsep0" align="center"><b>77</b></td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">17</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.180</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td><td class="colsep0 rowsep0" align="center">0.102</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="center">5.97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">10</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.122</td><td class="colsep0 rowsep0" align="char" char=".">0.030</td><td class="colsep0 rowsep0" align="char" char=".">0.100</td><td class="colsep0 rowsep0" align="char" char=".">0.027</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center"><b>78</b></td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">21</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.304</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="center">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">17</td><td class="colsep0 rowsep0" align="center">4</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="char" char=".">0.132</td><td class="colsep0 rowsep0" align="char" char=".">0.016</td><td class="colsep0 rowsep0" align="char" char=".">0.073</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="center">7.1</td><td class="colsep0 rowsep0" align="center"><b>79</b></td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">21</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.405</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="center">0.017</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">21</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="char" char=".">0.148</td><td class="colsep0 rowsep0" align="char" char=".">0.029</td><td class="colsep0 rowsep0" align="char" char=".">0.413</td><td class="colsep0 rowsep0" align="char" char=".">0.013</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center"><b>80</b></td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">21</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.857</td><td class="colsep0 rowsep0" align="char" char=".">0.100</td><td class="colsep0 rowsep0" align="center">>1.0</td><td class="colsep0 rowsep0" align="char" char=".">0.094</td><td class="colsep0 rowsep0" align="center">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">25</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.060</td><td class="colsep0 rowsep0" align="char" char=".">0.023</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="center">6.45</td><td class="colsep0 rowsep0" align="center"><b>81</b></td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">25</td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.025</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="center">0.042</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="center">1.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">25</td><td class="colsep0 rowsep0" align="center">6</td><td class="colsep0 rowsep0" align="center">2</td><td class="colsep0 rowsep0" align="char" char=".">0.023</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="char" char=".">0.020</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="center">3.69</td><td class="colsep0 rowsep0" align="center"><b>82</b></td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">25</td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char=".">0.037</td><td class="colsep0 rowsep0" align="char" char=".">0.016</td><td class="colsep0 rowsep0" align="center">0.053</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="center">3.49</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Concentration for 50% inhibition of phosphorylation of a Glu/Tyr copolymer (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). Values are the average of at least two separate determinations, with a CV of ±22%.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Data repeated from <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> for clarity.</p></div></div></div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0008.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaO(CH<sub>2</sub>)<sub>2</sub>OCH<sub>3</sub>, THF, reflux; (ii) (a) SOCl<sub>2</sub>, cat. DMF, reflux, 2 h, (b) subst aniline, <sup><i>i</i></sup>PrOH/CH<sub>2</sub>Cl<sub>2</sub>, reflux, 0.75 h; (iii) 4-methoxybenzylamine, DMSO, 120 °C, 24 h; (iv) TFA, 6 h., RT; (v) (a) <i>E</i>-4-bromobut-2-enoic acid, oxalyl chloride, cat. DMF, CH<sub>2</sub>Cl<sub>2</sub>, RT, (b) acid chloride from (a), THF, −20 °C, 0.75 h; (vi) amine, DMA, −20 °C, 2 h.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38534" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38534" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Kinase and Reactivity Assays</h3><div class="NLM_p">The relative reactivity toward reduced glutathione for several Michael acceptors (A–E, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), on a common quinazoline scaffold, has been reported.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The dimethylamino crotonamide (A) was found to be more reactive than the acrylamide (B), which was in turn more reactive than the alkylacrylamides (C and D) and the morpholino crotonamide (E). The greater chemical reactivity of the dimethylamino crotonamide (A) toward reduced gluthathione relative to the acrylamide (B) intrigued us because pelitinib bears this Michael acceptor yet demonstrates a significantly longer human plasma half-life than canertinib (21.7 h<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> cf. 4 h<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a>). This led us to prioritize microsome and hepatocyte stability testing to predict compounds with improved first pass metabolism, oral bioavailability, and plasma half-life rather than chemical glutathione reactivity assays. With respect to alkylacrylamides (C and D), we reasoned that these Michael acceptors were understudied and further work was merited using the exact canertinib scaffold. With respect to the decreased reactivity of the morpholino crotonamide relative to the dimethylamino crotonamide (E cf. A), it was unclear whether this was due to changes in steric bulk, amine p<i>K</i><sub>a</sub>, or both. To investigate, we therefore targeted quinazolines and pyrido[3,4-<i>d</i>]pyrimidines substituted at the 6-position with crotonamides bearing cyclic amines of varying steric bulk and p<i>K</i><sub>a</sub>.</div><figure id="fig1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Reported relative reactivity of various Michael acceptors toward reduced glutathione.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> describes the structures and kinase inhibitory properties against erbB1, 2, and 4 of a subset of the compounds synthesized to explore alkylacrylamide (C and D, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) Michael acceptors on the canertinib scaffold. In previous publications, we<a onclick="showRef(event, 'ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19 ref20 ref21 ref22 ref23 ref24">(17-24)</a> and others<a onclick="showRef(event, 'ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24">(21-24)</a> have noted that care needs to be taken when interpreting IC<sub>50</sub> values for putative irreversible inhibitors. These values are essentially a composite of both the covalent interaction with the enzyme over the time frame of any particular assay and the reversible binding provided by the scaffold. As reference, we prepared the reversible propanamide <b>11</b> for comparative purposes. <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> also describes the results of a time-course washout assay where A431 cells were treated with potential irreversible inhibitors for 1, 5, 10, 30, 60, and 120 min before being washed free of drug, stimulated with EGF, lysed, and Western blotted for inhibition of erbB1 autophosphorylation. This determines the time required for the inhibitor to completely ablate autophosphorylation of erbB1 in A431 cells, providing an indication of the kinetics of alkylation of Cys 773 for each Michael acceptor.</div><div class="NLM_p">Relative to canertinib (<b>4</b>), compounds <b>8</b>–<b>10</b> showed a modest loss of potency (3–11-fold) for inhibition of erbB1 in the isolated enzyme assay and a greater loss of potency in the cellular erbB1 assay (13–38-fold). Compounds <b>8</b>–<b>10</b> further showed a considerable loss of potency against erbB2 (>31-fold) and erbB4 (>37-fold) in cellular and biochemical assays, respectively. Compounds <b>8</b> and <b>9</b> also gave incomplete inhibition of erbB1 autophosphorylation after 2 h drug exposure in the washout assay, although compound <b>10</b> was a little more encouraging in this regard. In general, the data for <b>8</b>–<b>10</b> was comparable to that for <b>11</b>, with the erbB1 selective nature of the compounds indicating inefficient alkylation of the target cysteines of erbB1, 2, and 4. It became apparent from this study that in order to reduce the reactivity of the Michael acceptor while retaining potent pan-erbB activity, it may first be preferable to increase the reversible binding affinity of the kinase inhibitor scaffold to erbB2 and 4. A study to investigate this was undertaken prior to an examination of the type E Michael acceptors (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).</div><div class="NLM_p">The SAR for erbB2 potency of 4-aniline substituents of quinazoline and quinoline-3-carbonitrile inhibitors has been reasonably well explored during the development of both lapatinib<a onclick="showRef(event, 'ref53 ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55 ref56">(53-56)</a> and neratinib.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> In this latter study, however, we felt it was difficult to separate the relative contribution made to the inhibitory potency of the test compounds from the aniline substituent versus that from the Michael acceptor. Further, to our knowledge, no erbB4 data has been reported for an SAR study around 4-aniline substituents. For these reasons, we undertook such a study in a reversible 7-methoxy-6-propanamide series. The aniline pharmacophore outlined in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a> was explored to determine its influence on pan-erbB potency. This approach had the added advantage that each aniline studied required only one synthetic step to provide final compounds for testing (aniline displacement of the 4-chloroquinazoline <b>89</b>). Approximately 95 anilines were explored in this series. <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> shows the erbB1, 2, and 4 isolated enzyme activities for the 32 that provided the most potent pan-erbB activity (compounds <b>12</b>–<b>43</b>). We reasoned that any compound with erbB1, 2, and 4 activity of <500 nM would be sufficiently interesting to synthesize comparative irreversible analogues (see <a class="ref internalNav" href="#tbl3" aria-label="Tables 3">Tables 3</a> and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Of the 32 compounds, six fitted this profile (A1, A4, A5, A10, A17, and A24 of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). A further eight of the 32 had erbB1, 2, and 4 activity of <1 μM (A6, A11, A12, A13, A25, A26, A30, and A32 of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><figure id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0004.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. General pharmacophore explored for anilines that provide pan-erbB activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The erbB1 selective nature of the 1<i>H</i>-indol-5-amine (A2) and the 1<i>H</i>-indazol-5-amine (A3) are readily apparent, while the 3-chloro-4-fluoroaniline (A1) is 203-fold erbB1 selective (over erbB2) but possesses acceptable erbB2 and 4 potency (<500 nM). As previously described<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> introduction of a benzyl substituent to the <i>N</i>-1 position of the indole (A4) and indazoleamines (A5) provided a significant improvement in the erbB2 and 4 potency giving a potent pan-erbB scaffold. <i>N</i>-1-Phenylsulfonylindole (A10) was also potent in this regard, while only the 2″-pyridomethyl substituted indole (A6) was tolerated by erbB1 and 4 (and to a lesser extent erbB2) with the 3″- and 4″-pyridine isomers (A7, A8), showing a considerable loss of erbB1 potency. The erbB1 preference for a 2″-pyridyl isomer is noted for the other pyridines in this study where a direct comparison could be made (A21, A22, A26, and A27), consistent with the preferred 2″-pyridomethyloxy substituent of neratinib (<b>6</b>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The 1-(2-Furylmethyl)-1<i>H</i>-indol-5-amine (A11) and indoline (A12, A13) analogues were detrimental to overall potency when compared to the analogous benzylindole (A4), and the need for an aromatic substituent at the indole <i>N</i>-1 position was confirmed by the lack of potency for the <i>N</i>-1-<i>iso</i>-butyl derivative (A14). The benzylamine (A15) and α-methylbenzylamine (A16) substituents were demonstrated to be erbB1 selective. The 4-phenoxyaniline (A17) showed pan-erbB potency as did the 4-(benzyloxy)aniline derivatives (A24, A25), typical of that present in lapatinib.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> The 4-phenylsulfonamide (A30) was also considered to be of interest. Several representative anilines with pan-erbB activity (erbB1, 2, and 4 mostly <500 nM) from <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> (A1, A5, A10, A17, A21, A25, A26, and A30) were selected for studies incorporating a range of Michael acceptors and 7-substituents (see <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>).</div><div class="NLM_p">Variations in the terminal dialkylamino group of the crotonamide Michael acceptor (e.g., A and E; <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) have been widely reported in the quinazoline<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and quinoline-3-carbonitrile<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> scaffolds. However, to our knowledge, only morpholine has been directly studied and determined to be less reactive toward reduced gluthathione.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> For this example, it is not clear if it is the reduced amine p<i>K</i><sub>a</sub> or increased steric demand of the cyclic amine that is responsible for this attenuated reactivity. To investigate the influence of amine structure on the reactivity of the crotonamide Michael acceptor, both metabolically and toward covalent reaction with the target Cys-773 of erbB1, we utilized the most potent pan-erbB <i>N</i>-1-benzylindazole (A5) scaffold of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> shows the erbB1, 2, and 4 isolated enzyme data, inhibition of erbB1 cellular autophosphorylation, time-course washout data, and rat and human liver microsome and hepatocyte stability for nine amine variations of the solubilized crotonamide Michael acceptor. Isolated enzyme inhibition of JAK3 kinase is included as an important off-target counterscreen. The most striking observation was that the dimethylamine (<b>44</b>), diisopropylamine (<b>45</b>), pyrrolidine (<b>46</b>), piperidine (<b>47</b>), morpholine (<b>49</b>), 4-methylpiperazine (<b>50</b>), and 3,5-dimethylpiperazine (<b>51</b>) crotonamides were all potent low nanomolar inhibitors of erbB1, 2, and 4 that irreversibly inhibited 100% of erbB1 cellular autophosphorylation after only 1 min of compound exposure. The 2,6-dimethyl substituted piperidine (<b>48</b>) and piperazine (<b>52</b>), possessing additional steric bulk around the amine nitrogen, showed an approximate 10-fold reduction in erbB1 and 2 isolated enzyme activity, consistent with reported observations of poorer performance.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> These compounds were not progressed to further studies. Of the compounds advanced to rat and human liver microsome and hepatocyte stability assays, only the diisopropylamine (<b>45</b>) was considered unstable. All of the compounds of <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a> showed a favorable selectivity profile for the erbB family relative to JAK3 (approximately 100–1000-fold). The cyclic amine crotonamides tested displayed excellent metabolic stability, and this in conjunction with rapid inhibition of cellular erbB1 and a favorable profile against JAK3 kinase indicated this class of Michael acceptor warranted further investigation in combination with preferred anilines of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>.</div><div class="NLM_p">To prepare an optimized 4-anilinoquinazoline or 4-anilinopyrido[3,4-<i>d</i>]pyrimidine, preferred 4-, 6-, and 7-substituents were selected. At the 4-position, the most potent pan-erbB anilines of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> (A1, A5, A10, A17, A21, A25, A26, and A30). At the key 6-position, optimized cyclic amine-bearing crotonamide Michael acceptors of <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, with a number of dimethylamino crotonamides prepared for comparison, while at the 7-position (where present), alkoxy substituents selected from those of gefitinib (OMe), neratinib (OEt), and erlotinib (OCH<sub>2</sub>CH<sub>2</sub>OMe) were included. <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> shows the erbB1, 2, and 4 isolated enzyme activity, erbB1 cellular autophosphorylation inhibitory activity, and JAK3 isolated enzyme inhibitory activity as an off-target counter screen for these compounds (<b>44</b>, <b>46</b>, <b>47</b>, <b>50</b>, <b>53</b>–<b>82</b>). A number of trends were apparent. The anilines that generally provided the best pan-erbB potency on either the quinazoline or pyrido[3,4-<i>d</i>]pyrimidine scaffolds, when prepared with a crotonamide Michael acceptor at the 6-position, were the 3-chloro-4-fluoroaniline (A1), the 1-benzyl-1<i>H</i>-indazol-5-amine (A5), and the lapatinib aniline (A25). Within this set of anilines ranging the dialkylamine substituted crotonamide had very little influence on the potencies against the isolated erbB1, 2, and 4 enzymes or the cellular erbB1 potency. The anilines that generally provided less potent pan-erbB activity when prepared with a crotonamide Michael acceptor at the 6-position were the 1-(phenylsulfonyl)-1<i>H</i>-indol-5-amine (A10), the 4-phenoxyaniline (A17), the 4-(2-pyridinylmethyl)aniline (A21), the 4-(2-pyridinylmethoxy)aniline (A26), and the <i>N</i>-(4-aminophenyl)benzenesulfonamide (A30). Within this set of anilines ranging the dialkylamine substituted crotonamide had more influence on the erbB1, 2, and 4 isolated enzyme potency and the cellular erbB1 potency, with the most basic amines (dimethylamine, piperidine, and pyrrolidine), providing the superior potency when compared to the less basic cyclic amines (morpholine and 4-methylpiperazine) (compare <b>58</b> and <b>59</b> with <b>60</b>, <b>65</b> with <b>66</b>, <b>67</b> and <b>68</b> with <b>69</b>, <b>78</b> and <b>79</b> with <b>80</b>). Where a comparison of 7-substituent could be made between 7-OEt and 7-OCH<sub>2</sub>CH<sub>2</sub>OMe, the overall potencies were comparable (compare <b>44</b>, <b>46</b>, and <b>50</b> with <b>55</b>, <b>56</b>, and <b>57</b>). With the exception of compound <b>71</b> (JAK3 IC<sub>50</sub> = 0.793 μM), all of the compounds of <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> were micromolar inhibitors of isolated JAK3.</div><div class="NLM_p">A selection of compounds from <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> were investigated in the erbB1 cellular autophosphorylation wash-out assay and the rat and human liver microsome and hepatocyte stability assays. The results are shown in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>. With the exception of compound <b>69</b>, all of the compounds gave rapid and complete shutdown of cellular erbB1 autophosphorylation after 1–5 min of drug exposure, indicating rapid alkylation of Cys-773. With the exception of compound <b>53</b>, all of the compounds tested were stable in rat and human microsomes for the duration of the assay (40 min) and gave comparable or improved rat and human hepatocyte stability relative to canertinib (<b>4</b>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Reactivity and Stability of Selected Compounds from <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center">reactivity assays<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">100% inhib (min)</th><th class="colsep0 rowsep0" align="center">RLM stability (min)</th><th class="colsep0 rowsep0" align="center">HLM stability (min)</th><th class="colsep0 rowsep0" align="center">RH stability (min)</th><th class="colsep0 rowsep0" align="center">HH stability (min)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="center">90% at 2 h</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">101</td><td class="colsep0 rowsep0" align="center">225</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">28.2</td><td class="colsep0 rowsep0" align="center">159</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">83.1</td><td class="colsep0 rowsep0" align="center">121</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">135</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">234</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="center">3</td><td class="colsep0 rowsep0" align="center">26.3</td><td class="colsep0 rowsep0" align="center">27</td><td class="colsep0 rowsep0" align="center">52.9</td><td class="colsep0 rowsep0" align="center">52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">143</td><td class="colsep0 rowsep0" align="center">249</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">86.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">53.1</td><td class="colsep0 rowsep0" align="center">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>67</b></td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">139</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69</b></td><td class="colsep0 rowsep0" align="center">30</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">329</td><td class="colsep0 rowsep0" align="center">273</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="center">1</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">>40</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Length of drug exposure (minutes) required to provide 100% inhibition of erbB1 autophosphorylation in A431 cells (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). Length of rat liver microsome (RLM) or human liver microsome (HLM) exposure (minutes) required to give 50% loss of parent compound (starting concentration 5 μM) (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). Length of rat hepatocyte (RH) or human hepatocyte (HH) exposure (minutes) required to give 50% loss of parent compound (starting concentration 1 μM) (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>). NA = data not available.</p></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Pharmacodynamic Testing in Vivo</h3><div class="NLM_p">The majority of the compounds of <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> demonstrated potent pan-erbB activity in enzyme and cellular assays, an acceptable counter-screening profile against JAK3, and good metabolic stability in microsome and hepatocycte assays. It appeared likely that physicochemical and pharmacokinetic differences between analogues would be the main determinant of in vivo efficacy. We therefore decided to advance most of the compounds of <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> to in vivo pharmacodynamic testing, where it was anticipated analogues optimal in this regard would show superior target modulation. Mice (three per cohort) bearing NIH3T3 tumors were dosed orally with each test compound of <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> at 30, 65, and 130 mg/kg once a day for two days (QDx2). Tumors were harvested 6 and 24 h after the final dose, digested, and Western blotted for the ability of each compound to inhibit the autophosphorylation of erbB1 (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). Gefitinib (<b>1</b>) and canertinib (<b>4</b>) were included in this assay as reference compounds. As expected, the irreversible inhibitor canertinib showed superior inhibition of erbB1 autophosphorylation when compared to gefitinib, which only gave complete inhibition at the earliest time point and highest dose (6 h after 130 mg/kg dose). In contrast, canertinib showed some return of phosphorylated erbB1 24 h after the lowest dose (30 mg/kg), while all other doses and time points gave complete inhibition.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Inhibition of erbB1 Phosphorylation in Vivo for Selected Compounds from <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0016.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">Western blots demonstrating inhibition of erbB1 autophosphorylation in NIH3T3 tumors 6 and 24 h following oral administration of the specified dose on a QDx2 schedule (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>).</p></div></div><div></div></div><div class="NLM_p">We sought to identify compounds of <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a> with pharmacodynamic profiles comparable to or better than canertinib for more advanced investigation. Very few compounds qualified despite being potent inhibitors of both isolated enzyme and cellular erbB1 (for example <b>44</b>, <b>46</b>, <b>47</b>, <b>50</b>, <b>58</b>, <b>59</b>, <b>60</b>, <b>62</b>, <b>67</b>, <b>74</b>, <b>75</b>, <b>79</b>, and <b>80</b>). We attribute this poor target modulation in vivo to a combination of factors including poor solubility, permeability, bioavailability, pharmacokinetics, and tissue penetration. We note that when dialkylamino crotonamide Michael acceptors are compared across scaffolds, the higher molecular weight compounds, bearing the more structurally complex anilines, are generally less effective at providing dose-potent and prolonged inhibition of erbB1 autophosphorylation. Quinazoline <b>54</b> and pyrido[3,4-<i>d</i>]pyrimidines <b>71</b> and <b>73</b> stood out as having superior activity to canertinib in the erbB1 pharmacodynamic assay, providing complete inhibition of phosphorylated erbB1 24 h after the lowest dose tested (30 mg/kg). These compounds possess the same 3-chloro-4-fluoroaniline (A1) of canertinib (gefitinib, peltinib, and afatinib) and a piperidine (<b>54</b>, <b>71</b>) or methylpiperazine (<b>73</b>) solubilized crotonamide Michael acceptor. We propose for simplicity that the common features of <b>54</b> and <b>71</b> represent the optimal 4- and 6-substituents for irreversible inhibition of erbB1 in vivo. These optimized substituents appear to be equally effective on a quinazoline or pyrido[3,4-<i>d</i>]pyrimidine scaffold.</div><div class="NLM_p last">An improvement in the duration of in vivo activity for a cyclic amine bearing crotonamide relative to a dimethylamino crotonamide is evident when comparing dimethylamine (<b>74)</b> and pyrrolidine (<b>75</b>). These compounds are identical in terms of reversible scaffold, isolated enzyme erbB1, 2, and 4 activity, and erbB1 cellular activity. Both compounds were effective inhibitors of erbB1 in vivo at the highest dose tested (130 mg/kg), while only the cyclic amine derivative <b>75</b> was effective 24 h after the middle and lower doses (65 and 30 mg/kg, respectively). It was, however, slow to inhibit erbB1 at the 30 mg/kg dose with 2 of 3 mice showing considerable erbB1 autophosphorylation at the 6 h time point which had been completely inhibited after 24 h.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Pharmacokinetic Comparison of Compounds <b>54</b> and <b>71</b> in Rat, Dog, and Monkey</h3><div class="NLM_p">A pharmacokinetic comparison of compounds <b>54</b> and <b>71</b> was undertaken in three preclinical species (rat, dog, and monkey) following a single oral and intravenous dose (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>). As previously described,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> compound <b>54</b> displayed an excellent pharmacokinetic profile across all three species, demonstrating high oral bioavailability (>50%), a long plasma half-life (<i>t</i><sub>1/2</sub> > 12 h), and a large volume of distribution (>17 L/kg). Indeed, compound <b>54</b> was determined to have significantly improved pharmacokinetics relative to canertinib.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Compound <b>71</b>, however, was considerably more variable across species, showing a volume of distribution (24.8 L/kg) and oral bioavailability that was acceptable in rat (60%) but with considerably poorer parameters in dog and particularly monkey, where plasma half-life following intravenous administration (0.7 h) and oral bioavailability (4%) were disappointing. This pharmacokinetic variability was deemed to be of concern, sufficiently so to recommend compound <b>54</b> to advance to human trial over compound <b>71</b>.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Mean Pharmacokinetic Parameters of Compounds <b>54</b> and <b>71</b> in Rat, Dog, and Monkey Following a Single Oral and Intraveneous Dose</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char=" " /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">dose (mg/kg/d)</th><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub>(μS/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC (μg·h/mL)</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/min/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>dss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=" "><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left">Compound <b>54</b><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="center">50</td><td class="colsep0 rowsep0" align="center">po</td><td class="colsep0 rowsep0" align="char" char=".">0.63</td><td class="colsep0 rowsep0" align="char" char=".">20.5</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=" ">19.4</td><td class="colsep0 rowsep0" align="char" char=".">80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="center">50<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">po</td><td class="colsep0 rowsep0" align="char" char=".">0.87</td><td class="colsep0 rowsep0" align="char" char=".">25.2</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=" ">20.9</td><td class="colsep0 rowsep0" align="char" char=".">74</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="center">25</td><td class="colsep0 rowsep0" align="center">po</td><td class="colsep0 rowsep0" align="char" char=".">0.22</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=" ">12.1</td><td class="colsep0 rowsep0" align="char" char=".">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">iv</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">49.1</td><td class="colsep0 rowsep0" align="char" char=".">34.2</td><td class="colsep0 rowsep0" align="char" char=" ">9.8</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">iv</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">24.4</td><td class="colsep0 rowsep0" align="char" char=".">28.0</td><td class="colsep0 rowsep0" align="char" char=" ">15.9</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">iv</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">44.1</td><td class="colsep0 rowsep0" align="char" char=".">17.3</td><td class="colsep0 rowsep0" align="char" char=" ">5.7</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="9" align="left">Compound <b>71</b></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="center">50</td><td class="colsep0 rowsep0" align="center">po</td><td class="colsep0 rowsep0" align="char" char=".">0.69</td><td class="colsep0 rowsep0" align="char" char=".">13.5</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=" ">9.8</td><td class="colsep0 rowsep0" align="char" char=".">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="center">40<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">po</td><td class="colsep0 rowsep0" align="char" char=".">1.04</td><td class="colsep0 rowsep0" align="char" char=".">11.0</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=" ">7.9</td><td class="colsep0 rowsep0" align="char" char=".">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="center">25</td><td class="colsep0 rowsep0" align="center">po</td><td class="colsep0 rowsep0" align="char" char=".">0.04</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=" ">NR</td><td class="colsep0 rowsep0" align="char" char=".">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">iv</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">62.0</td><td class="colsep0 rowsep0" align="char" char=".">24.8</td><td class="colsep0 rowsep0" align="char" char=" ">5.4</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="center">5</td><td class="colsep0 rowsep0" align="center">iv</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">10.3</td><td class="colsep0 rowsep0" align="char" char=".">9.0</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=" ">7.6</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="center">2.5</td><td class="colsep0 rowsep0" align="center">iv</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">69.8</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char=" ">0.7</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>a</sup><p class="last">As report in Gonzales et al., 2008 (ref <a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">57</a>).</p></div><div class="footnote" id="t7fn2"><sup>b</sup><p class="last">Fed condition, milled to reduce particle sizes; for further methods see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. NR: not reported due to insufficient data.</p></div></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47574" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47574" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We have described an approach to develop an irreversible inhibitor of erbB1, 2, and 4 with an improved pharmacokinetic and toxicity profile relative to canertinib. We have investigated the reactivity of alkyl substituted acrylamides and dialkylamino crotonamides in microsome and hepatocyte assays while ascertaining their relative rate of reaction with Cys-773 of erbB1. This has allowed identification of drug candidates with the potential for rapid irreversible inhibition of the target erbB family, minimized glutathione conjugation and therefore improved first-pass metabolism, oral bioavailability, plasma half-life, and tumor pharmacodynamics. We have counter-screened analogues against JAK3 kinase to identify compounds with minimized potency against this enzyme, an off-target event thought to contribute to the undesirable thrombocytopenia observed during human trials of canertinib.</div><div class="NLM_p">Cyclic amine solubilized crotonamides have been discovered to be optimal in terms of their rapid alkylation of erbB1 and desirable metabolic stability. We have characterized the pan-erbB potency imparted by a range of 4-aniline substituents to a reversible quinazoline scaffold and established one of the broadest SAR data sets for the inhibition of erbB4 reported to date. We have determined that 3-chloro-4-fluoroaniline, 5-amino-<i>N</i>-1-benzylindole, 5-amino-<i>N</i>-1-benzylindazole, 5-amino-<i>N</i>-1-phenylsulfonylindole, 4-phenoxyaniline, and 4-benzyloxyaniline all provide sufficiently potent pan-erbB isolated enzyme inhibition (IC<sub>50</sub> < 500 nM). Compounds with cyclic amine solubilized crotonamides and pan-erbB anilines on a quinazoline or pyrido[3,4-<i>d</i>]pyrimidine scaffold have been prepared. These compounds have been tested for their ability to inhibit erbB1, 2, and 4 isolated enzyme activity and erbB1 cellular activity. They have further been analyzed in functional assays to determine their erbB1 alkylation kinetics and pharmacodynamic inhibition of erbB1 in vivo. Compounds <b>54</b> and <b>71</b> were identified as clear lead candidates for advanced studies, having demonstrated selective, potent, irreversible inhibition of erbB1 in vitro and prolonged inhibition of erbB1 autophosphorylation in vivo. The sustained target modulation for <b>54</b> in vivo is consistent with dramatically improved pharmacokinetics relative to canertinib in rat, dog, and monkey,<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> a consequence of the metabolic stability of the piperidinyl crotonamide Michael acceptor. We propose that this Michael acceptor at the 6-position, particularly with a 3-chloro-4-fluoroanilino group at the 4-position, provides an optimum pharmacophore for irreversible inhibition of erbB1, 2, and 4 on both quinazoline and pyrido[3,4-<i>d</i>]pyrimidine scaffolds. Pharmacokinetic comparison of compounds <b>54</b> and <b>71</b> in rat, dog, and monkey identified compound <b>54</b> over (the more variable) compound <b>71</b> as the preferred clinical candidate.</div><div class="NLM_p">Compound <b>54</b> (PF-00299804) has now been widely studied in our laboratory and by several other groups. The irreversible nature of erbB1 inhibition was confirmed at the isolated enzyme level employing an ELISA-based enzyme assay and at the cellular level by assaying inhibition of erbB1autophosphorylation following drug exposure time course and extensive wash-out in A431 cells.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> This was further supported by solution state protein mass spectrometry experiments and an erbB1 T790M X-ray cocrystal structure at 1.8 Å resolution, clearly showing the presence of PF-00299804 covalently linked to the target cysteine.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> PF-00299804 has been screened against a panel of 38 protein kinases to assess off-target interactions and was found to be particularly selective for the erbB family with only Lck, Src, and JAK3 returning isolated enzyme inhibitory IC<sub>50</sub>s < 10 μM (IC<sub>50</sub> = 0.094, 0.110, and 3.57 μM, respectively).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></div><div class="NLM_p">Growth inhibitory activity has been observed for PF-00299804 in several cancer cell lines including models of squamous cell carcinoma of the head and neck that exhibit low response to cetuximab,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> biliary tract cancer cell lines either as a single agent or in combination with gemcitabine,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> erbB2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> and erbB2-amplified gastric cancer cell lines.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a></div><div class="NLM_p">PF-00299804 has shown excellent distribution to human tumor xenografts in nude mice and admirable pharmacokinetic properties across species.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Features resulting in efficacy superior to canertinib, demonstrating marked tumor regression in several xenograft models, including the wild-type erbB1 overexpressing A431 epidermoid carcinoma xenograft, the erbB2/3 expressing H125 nonsmall cell lung cancer xenograft, and the erbB2 overexpressing SKOV3 ovarian carcinoma xenograft.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> The striking erbB1 pharmacodynamics reported herein is matched by greater than 99% inhibition of phospho-erbB2 observed in SKOV3 tumor xenografts following a well tolerated dose.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> In addition, PF-00299804 has been shown preclinically to be a potent inhibitor of erbB1-activating mutations (L858R, exon 19 deletions) as well as the erbB1 T790M resistance mutation, both in vitro and in vivo. Robust antitumor activity is observed in the NCI-H1975 and engineered HCC827-del/T790M NSCLC xenograft models that are resistant to erlotinib/gefitinib.<a onclick="showRef(event, 'ref57 ref59'); return false;" href="javascript:void(0);" class="ref ref57 ref59">(57, 59)</a></div><div class="NLM_p">Phase I trials of PF-00299804 have now been conducted in the USA,<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> South Korea,<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> and Japan,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> providing broadly similar results. Dose-limiting toxicities include rash, diarrhea, paronychia, dehydration, and stomatitis. The maxium tolerated daily oral dose has been established to be 45 mg, and the mean human plasma half-life (<i>t</i><sub>1/2</sub>) was 59–85 h, with dosing ranging from 30 to 60 mg. The improved human half-life relative to canertinib (∼4 h) and the elimination of thrombocytopenia as a problematic toxicity validates the drug optimization approach reported herein.</div><div class="NLM_p">The efficacy of PF-00299804 has to date most widely been assessed in advanced or metastatic NSCLC.<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67, 68)</a> Phase II studies evaluating PF-00299804 as salvage therapy in advanced NSCLC patients who progressed following chemotherapy and erlotinib demonstrated preliminary evidence of activity,<a onclick="showRef(event, 'ref65 ref69'); return false;" href="javascript:void(0);" class="ref ref65 ref69">(65, 69)</a> however, a double-blind, randomized phase III trial (BR-26) in this setting determined PF-00299804 did not improve overall survival compared with placebo (NCT01000025).<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Phase II evaluation of PF-00299804 as a second-line therapy for NSCLC in comparison to erlotinib successfully met the primary end point of a statistically significant improvement in progression-free survival over erlotinib.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Unfortunately, the double-blind, randomized phase III trial (ARCHER 1009) comparing the efficacy of PF-00299804 to erlotinib as second- or third-line NSCLC therapy failed to establish superiority of PF-00299804 over erlotinib in this unselected patient population (NCT01360554).<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> A subanalysis of this trial has since demonstrated superiority of PF-00299804 over erlotinib among NSCLC patients harboring erbB1 mutations,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> while phase II evaluation of PF-00299804 in a first-line setting in this patient population has demonstrated significant activity with an objective response rate of 74%.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> A randomized phase III study of PF-00299804 versus gefitinib (ARCHER 1050) in this setting is ongoing (NCT01774721). Outside of lung cancer, PF-00299804 has also demonstrated promising efficacy in phase II trial as a first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck, where 12.7% of patients achieved a partial response and 57.1% of patients experienced stable disease.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a></div><div class="NLM_p last">In summary, PF-00299804, now assigned the nomenclature of dacomitinib, has demonstrated encouraging antitumor activity in human trials.<a onclick="showRef(event, 'ref73 ref76'); return false;" href="javascript:void(0);" class="ref ref73 ref76">(73, 76)</a> A large multicenter randomized phase III trial in the appropriately selected NSCLC EGFR mutant positive patient population is currently in progress. Only when this is complete will we further understand the role of this second-generation irreversible pan-erbB inhibitor for the treatment of NSCLC.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46071" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46071" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Combustion analyses were performed by the Microchemical Laboratory, University of Otago, Dunedin, NZ, or by the Analytical Department, Pfizer Global Research and Development, Michigan Laboratories. Purity of the compounds was confirmed to be ≥95% by combustion analysis, with found values for carbon, hydrogen, and nitrogen being within 0.4% of the calculated values for the proposed formula. The compounds were recrystallized from ethyl acetate unless otherwise stated. Melting points were determined using either an Electrothermal model 9200 or a Gallenkamp digital melting point apparatus and are as read. <sup>1</sup>H NMR spectra were measured either on a Bruker Avance-400 or a Varian INOVA 400 MHz spectrometer and are referenced to Me<sub>4</sub>Si. High resolution mass spectra were recorded on a Finnigan MAT 900Q or a Varian VG-70SE spectrometer at nominal 5000 resolution. Liquid chromatography–mass spectrometry (LCMS) was performed either on an Agilent 1100 LC system interfaced with an Agilent MSD mass detector or on a Micromass Platform LC mass spectrometer. In both cases, mass detection was performed with an APCI source, using simultaneous positive and negative ion acquisition. Unless otherwise indicated, compounds were purified by flash column chromatography on Silica gel 60 support (Scharlau, 230–400 mesh ASTM), using the indicated eluants.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Procedure <b>1</b>: Synthesis of Quinazolines of <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a></h3><div class="NLM_p">The appropriate acid chloride (1.25 equiv) was added to a solution of 6-aminoquinazoline<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (<b>85</b>) (1.0 equiv) and triethylamine (1.25 equiv) in THF. The reaction was stirred at room temperature until TLC indicated the reaction is complete. The reaction was then diluted with water and extracted into EtOAc. The organic extract was dried over MgSO<sub>4</sub>, filtered, concentrated, and purified by column chromatography eluting with a gradient of MeOH/CH<sub>2</sub>Cl<sub>2</sub>.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> <i>N</i>-{4-(3-Chloro-4-fluoroanilino)-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl}-2-methylacrylamide (<b>8</b>)</h4><div class="NLM_p last">Reaction of amine <b>85</b> with methacryloyl chloride according to general procedure 1, gave the title compound <b>8</b> as a cream solid (6%), mp 137–138 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.78 (s, 1 H), 9.19 (s, 1 H), 8.71 (s, 1 H), 8.51 (s, 1 H), 8.12 (dd, <i>J</i> = 2.7, 6.8 Hz, 1 H), 7.78 (m, 1 H), 7.39 (t, <i>J</i> = 9.3 Hz, 1 H), 7.25 (s, 1 H), 5.91 (s, 1 H), 5.56 (s, 1 H), 4.20 (t, <i>J</i> = 6.1 Hz, 2 H), 3.54 (t, <i>J</i> = 4.6 Hz, 4 H), 2.44 (m, 4 H), 2.33 (br s, 2 H), 1.99 (s, 3 H), 1.93 (m, 2 H). Anal. (C<sub>25</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub>FCl·1<sup>1</sup>/<sub>5</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> (2<i>E</i>)-<i>N</i>-{4-(3-Chloro-4-fluoroanilino)-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl}-2-butenamide (<b>9</b>)</h4><div class="NLM_p last">Reaction of amine <b>85</b> with crotonyl chloride according to general procedure 1 gave the title compound <b>9</b> as a cream solid (1%), mp 117–118 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.76 (s, 1 H), 9.33 (s, 1 H), 8.83 (s, 1 H), 8.49 (s, 1 H), 8.10 (dd, <i>J</i> = 2.6, 6.8 Hz, 1 H), 7.39 (t, <i>J</i> = 9.3 Hz, 1 H), 7.24 (s, 1 H), 6.70 (m, 1H), 6.39 (m, 1H), 4.20 (t, <i>J</i> = 6.3 Hz, 1 H), 3.54 (t, <i>J</i> = 4.6 Hz, 4 H), 2.44 (m, 4 H), 2.33 (br s, 2 H), 1.99 (s, 2 H), 1.85 (m, 3 H) (<sup>1</sup>H NMR contains 1 equiv of crotonic acid). Anal. (C<sub>25</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub>FCl·C<sub>4</sub>H<sub>6</sub>O<sub>2</sub>·1<sup>1</sup>/<sub>5</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> <i>N</i>-{4-(3-Chloro-4-fluoroanilino)-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl}-1-cyclopentene-1-carboxamide (<b>10</b>)</h4><div class="NLM_p last">Reaction of amine <b>85</b> with 1-cyclopentenecarboxylic acid chloride according to general procedure 1 gave the title compound <b>10</b> as a cream solid (42%), mp 165–166 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.76 (s, 1 H), 8.97 (s, 1 H), 8.74 (s, 1 H), 8.48 (s, 1 H), 8.07 (m, 1 H), 7.75 (m, 1 H), 7.38 (t, <i>J</i> = 9.0 Hz, 1 H), 7.20 (s, 1 H), 6.72 (s, 1 H), 4.19 (m, 2 H), 3.52 (m, 4 H), 2.57 (m, 2 H), 2.42 (m, 6 H), 1.93 (m, 4 H). Anal. (C<sub>27</sub>H<sub>29</sub>N<sub>5</sub>O<sub>3</sub>FCl·1<sup>1</sup>/<sub>10</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>N</i>-{4-(3-Chloro-4-fluoroanilino)-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl}propanamide (<b>11</b>)</h4><div class="NLM_p last">Reaction of amine <b>85</b> with propionyl chloride according to general procedure 1 gave the title compound <b>11</b> as a cream solid, mp 201–202 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.73 (s, 1 H), 9.24 (s, 1 H), 8.70 (s, 1 H), 8.47 (s, 1 H), 8.10 (m, 1 H), 7.75 (m, 1 H), 7.36 (t, <i>J</i> = 9.0 Hz, 1 H), 7.20 (s, 1 H), 4.19 (t, <i>J</i> = 6.3 Hz, 2 H), 3.54 (m, 4 H), 2.44 (m, 8 H), 1.90 (m, 2 H), 1.09 (t, <i>J</i> = 7.6 Hz, 3 H). Anal. (C<sub>24</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub>FCl) C, H, N.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Procedure <b>2</b>: Synthesis of Quinazolines of <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a></h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 7-Methoxy-6-nitro-4(3<i>H</i>)-quinazolinone (<b>87</b>)</h4><div class="NLM_p last">Sodium (2.3 g, 0.1 mol) was dissolved in methanol (150 mL). This solution was then added to 7-fluoro-6-nitro-4(3<i>H</i>)-quinazolinone<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a><b>86</b> (4.01 g, 19.1 mmol) in a sealed pressure vessel and heated to 100 °C overnight. The solution was neutralized with AcOH and diluted with water. The solid was filtered off to give the title compound <b>87</b> as light-brown solid (3.63 g, 86%), mp (EtOH) 287 °C (dec). <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 12.4 (br s, 1 H), 8.53 (s, 1 H), 8.23 (s, 1 H), 7.43 (s, 1 H), 4.05 (s, 3 H). Anal. (C<sub>9</sub>H<sub>7</sub>N<sub>3</sub>O<sub>4</sub>) C, H, N.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> <i>N</i>-(7-Methoxy-4-oxo-3,4-dihydro-6-quinazolinyl)propanamide (<b>88</b>)</h4><div class="NLM_p last">Compound <b>87</b> (5.1 g, 23.2 mmol) was suspended in EtOH (200 mL) and water (100 mL) and heated to 100 °C. After addition of glacial acetic acid (3 mL), Fe dust (activated by 1 N HCl wash, 6.8 g, 121 mmol) was added and the mixture was heated at 100 °C for 1 h. The hot solution was basified with 25% ammonia solution and filtered through a pad of Celite, then cooled to rt. The pH of the solution was adjusted to pH 6 (HCl) and basified again to pH 8 (NaHCO<sub>3</sub>). Ethanol was removed under reduced pressure, then water was added and the solid was collected by filtration to give the amine<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> as a brown solid (3.98 g, 90%). The amine was mixed with propionic anhydride (200 mL) and heated at 120 °C. Once the solution turned dark-brown, it was cooled down and water (250 mL) was added. The mixture was then heated to quench the excess anhydride. The cooled solution was neutralized with 25% ammonia solution followed by saturated NaHCO<sub>3</sub> solution. Filtration of the solid gave the title compound <b>88</b> as light-brown solid (4.63 g, 90%), mp (EtOH) 298–301 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 12.0 (br s, 1 H), 9.23 (s, 1 H), 8.76 (s, 1 H), 7.99 (s, 1 H), 7.17 (s, 1 H), 4.16 (s, 3 H), 2.45 (q, <i>J</i> = 7.5 Hz, 2 H), 1.09 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>12</sub>H<sub>13</sub>N<sub>3</sub>O<sub>3</sub>) C, H, N.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>N</i>-(4-Chloro-7-methoxy-6-quinazolinyl)propanamide (<b>89</b>)</h4><div class="NLM_p last">Compound <b>88</b> (6.14 g, 25 mmol) was suspended in POCl<sub>3</sub> (80 mL) and heated at reflux for 90 min. The POCl<sub>3</sub> was distilled off under reduced pressure and the resulting yellow-cream solid dissolved in EtOAc (700 mL), then treated with a mixture of ice and saturated NaHCO<sub>3</sub> solution. The aqueous layer was further extracted with EtOAc (100 mL), then the combined organic fractions were washed with brine (2 × 250 mL) and dried (Na<sub>2</sub>SO<sub>4</sub>). The solvent was removed under reduced pressure to afford the title compound <b>89</b> as a pale-yellow solid (5.64 g, 86%), mp 165–168 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.59 (s, 1 H), 9.08 (s, 1 H), 8.90 (s, 1 H), 7.52 (s, 1 H), 4.10 (s, 3 H), 2.55 (q, <i>J</i> = 7.5 Hz, 2 H), 1.11 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>12</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>N</i>-[4-(3-Chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]propanamide (<b>12</b>)</h4><div class="NLM_p last">Compound <b>89</b> (50 mg, 0.19 mmol) and 3-chloro-4-fluoroaniline (64 mg, 0.44 mmol) in 2-propanol (10 mL) with 1 drop of conc HCl was heated to 100 °C. After 45 min, TEA was added until the solution was pH 7–8, then the solvent was removed under reduced pressure. The resulting solid was purified by chromatography on silica gel (2–10% MeOH/EtOAc as eluant) to afford the title compound <b>12</b> as a white solid (64 mg, 90%), mp 253–256 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.78 (s, 1 H), 9.43 (s, 1 H), 8.84 (s, 1 H), 8.52 (s, 1 H), 8.12 (dd, <i>J</i> = 6.9, 2.5 Hz, 1 H), 7.79, (ddd, <i>J</i> = 9.0, 6.9, 2.5 Hz, 1 H), 7.42 (t, <i>J</i> = 9.1 Hz, 1 H), 7.39 (s, 1 H), 4.01 (s, 3 H), 2.48 (q, <i>J</i> = 7.5 Hz, 2 H), 1.13 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>18</sub>H<sub>16</sub>ClFN<sub>4</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-[4-(1<i>H</i>-Indol-5-ylamino)-7-methoxy-6-quinazolinyl]propanamide (<b>13</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 1<i>H</i>-indol-5-amine according to general procedure 2 gave the title compound <b>13</b> as a cream solid (62%), mp 256–258 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.89 (s, 1 H), 9.42 (s, 1 H), 9.22 (s, 1 H), 8.67 (s, 1 H), 8.24 (s, 1 H), 7.71 (d, <i>J</i> = 1.6 Hz, 1 H), 7.26–7.19 (m, 3 H), 7.08 (s, 1 H), 6.29 (m, 1 H), 3.86 (s, 3 H), 2.36 (q, <i>J</i> = 7.5 Hz, 2 H), 1.00 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>20</sub>H<sub>19</sub>N<sub>5</sub>O<sub>2</sub>·<sup>1</sup>/<sub>8</sub>MeOH) C, H, N.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N</i>-[4-(1<i>H</i>-Indazol-5-ylamino)-7-methoxy-6-quinazolinyl]propanamide (<b>14</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 5-aminoindazole according to general procedure 2, gave the title compound <b>14</b> as a cream solid (39%), mp 280–282 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 12.98 (s, 1 H), 9.70 (s, 1 H), 9.37 (s, 1 H), 8.81 (s, 1 H), 8.40 (s, 1 H), 8.09 (d, <i>J</i> = 1.8 Hz, 1 H), 8.04 (d, <i>J</i> = 1.4 Hz, 1 H), 7.60 (m, 1 H), 7.50 (d, <i>J</i> = 9.0 Hz, 1 H), 7.21 (s, 1 H), 3.98 (s, 3 H), 2.44 (q, <i>J</i> = 7.4 Hz, 2 H), 1.11 (t, <i>J</i> = 7.6 Hz, 3 H). Anal. (C<sub>19</sub>H<sub>18</sub>N<sub>6</sub>O<sub>2</sub>·1<sup>4</sup>/<sub>5</sub> H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-{4-[(1-Benzyl-1<i>H</i>-indol-5-yl)amino]-7-methoxy-6-quinazol0inyl}propanamide (<b>15</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 1-benzyl-1<i>H</i>-indol-5-amine according to general procedure 2 gave the title compound <b>15</b> as a cream solid (62%), mp 208–212 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.57 (s, 1 H), 9.34 (s, 1 H), 8.80 (s, 1 H), 8.36 (s, 1 H), 7.87 (d, <i>J</i> = 1.8 Hz, 1 H), 7.50 (d, <i>J</i> = 3.1 Hz, 1 H), 7.21–7.42 (m, 8 H), 6.48 (d, <i>J</i> = 3.1 Hz, 1 H), 5.42 (s, 2 H), 3.98 (s, 3 H), 2.45 (q, <i>J</i> = 7.5 Hz, 2 H), 1.12 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>27</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-{4-[(1-Benzyl-1<i>H</i>-indazol-5-yl)amino]-7-methoxy-6-quinazolinyl}propanamide (<b>16</b>)</h4><div class="NLM_p last">Reaction of <i>N</i><sup>4</sup>-(1-benzyl-1<i>H</i>-indazol-5-yl)-7-methoxy-4,6-quinazolinediamine<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> with propionyl chloride according to general procedure 1 gave the title compound <b>16</b> as a cream solid (26%), mp 211–212 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.69 (s, 1 H), 9.38 (s, 1 H), 8.77 (s, 1 H), 8.36 (s, 1 H), 8.05 (s, 2 H), 7.60 (m, 2 H), 7.29–7.18 (m, 6 H), 5.61 (s, 2 H), 3.94 (s, 3 H), 1.19 (d, <i>J</i> = 13.4 Hz, 2 H), 1.07 (t, <i>J</i> = 7.6 Hz, 3 H). Anal. (C<sub>25</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub>FCl·1<sup>1</sup>/<sub>5</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(7-Methoxy-4-{[1-(2-pyridinylmethyl)-1<i>H</i>-indol-5-yl]amino}-6-quinazolinyl)propanamide (<b>17</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 1-(2-pyridinylmethyl)-1<i>H</i>-indol-5-amine (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_001.pdf" class="ext-link">Supporting Information</a>) according to general procedure 2 gave the title compound <b>17</b> as a cream solid (91%), mp 219–221 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.57 (s, 1 H), 9.36 (s, 1 H), 8.79 (s, 1 H), 8.55 (m, 1 H), 8.36 (s, 1 H), 7.87 (d, <i>J</i> = 1.8 Hz, 1 H), 7.72 (dt, <i>J</i> = 7.7, 1.8 Hz, 1 H), 7.50 (d, <i>J</i> = 3.1 Hz, 1 H), 7.26–7.39 (m, 3 H), 7.19 (s, 1 H), 6.99 (d, <i>J</i> = 7.7 Hz, 1 H), 6.50 (d, <i>J</i> = 3.1 Hz, 1 H), 5.51 (s, 2 H), 3.98 (s, 3 H), 2.44 (q, <i>J</i> = 7.4 Hz, 2 H), 1.12 (t, <i>J</i> = 7.4 Hz, 3 H). Anal. (C<sub>26</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub>·<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> <i>N</i>-(7-Methoxy-4-{[1-(3-pyridinylmethyl)-1<i>H</i>-indol-5-yl]amino}-6-quinazolinyl)propanamide (<b>18</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 1-(3-pyridinylmethyl)-1<i>H</i>-indol-5-amine<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> according to general procedure 2 gave the title compound <b>18</b> as a cream solid (88%), mp 213–217 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.57 (s, 1 H), 9.35 (s, 1 H), 8.79 (s, 1 H), 8.54 (d, <i>J</i> = 1.7 Hz, 1 H), 8.46 (dd, <i>J</i> = 4.8, 1.6 Hz, 1 H), 8.37 (s, 1 H), 7.88 (d, <i>J</i> = 1.8 Hz, 1 H), 7.58 (m, 1 H), 7.54 (d, <i>J</i> = 3 0.1 Hz, 1 H), 7.47 (d, <i>J</i> = 8.8 Hz, 1 H), 7.32–7.38 (m, 2 H), 7.21 (s, 1 H), 6.50 (dd, <i>J</i> = 3.1, 0.7 Hz, 1 H), 5.47 (s, 2 H), 3.98 (s, 3 H), 2.45 (q, <i>J</i> = 7.6 Hz, 2 H), 1.13 (t, <i>J</i> = 7.6 Hz, 3 H). HRMS (FAB<sup>+</sup>) calcd for C<sub>26</sub>H<sub>25</sub>N<sub>6</sub>O<sub>2</sub>: 453.2039 (MH<sup>+</sup>); found, 453.2034.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>N</i>-(7-Methoxy-4-{[1-(4-pyridinylmethyl)-1<i>H</i>-indol-5-yl]amino}-6-quinazolinyl)propanamide (<b>19</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 1-(4-pyridinylmethyl)-1<i>H</i>-indol-5-amine<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> according to general procedure 2 gave the title compound <b>19</b> as a cream solid (92%), mp 168–171 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.58 (s, 1 H), 9.35 (s, 1 H), 8.79 (s, 1 H), 8.49 (m, 2 H), 8.37 (s, 1 H), 7.91 (m, 1 H), 7.51 (d, <i>J</i> = 3.1 Hz, 1 H), 7.36 (d, <i>J</i> = 1.3 Hz, 2 H), 7.21 (s, 1 H), 7.10 (m, 2 H), 6.53 (d, <i>J</i> = 3.1 Hz, 1 H), 5.50 (s, 2 H), 3.97 (s, 3 H), 2.45 (q, <i>J</i> = 7.6 Hz, 2 H), 1.12 (t, <i>J</i> = 7.6 Hz, 3 H). Anal. (C<sub>26</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub>·1<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>N</i>-(7-Methoxy-4-{[1-(2-pyridinylmethyl)-1<i>H</i>-indazol-5-yl]amino}-6-quinazolinyl)propanamide (<b>20</b>)</h4><div class="NLM_p last">Reaction of 7-methoxy-<i>N</i><sup>4</sup>-(1-(pyridin-2-ylmethyl)-1<i>H</i>-indazol-5-yl)quinazoline-4,6-diamine<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> with propionyl chloride according to general procedure 1 gave the title compound <b>20</b> as a cream solid (58%). <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 11.47 (s, 1 H), 9.65 (s, 1 H), 9.11 (s, 1 H), 8.55 (d, <i>J</i> = 4.1 Hz, 1 H), 8.17 (s, 1 H), 7.93 (d, <i>J</i> = 1.5 Hz, 1 H), 7.85 (t, <i>J</i> = 7.5 Hz, 1 H), 7.75 (d, <i>J</i> = 9.0 Hz, 1 H), 7.55 (dd, <i>J</i> = 1.7, 8.8 Hz, 2 H), 7.40 (t, <i>J</i> = 5.6 Hz, 2 H), 7.12 (d, <i>J</i> = 7.8 Hz, 1 H), 5.83 (s, 2 H), 4.01 (s, 3 H), 2.44 (q, <i>J</i> = 1.7 Hz, 2 H), 1.07 (t, <i>J</i> = 7.6 Hz, 3 H). Anal. (C<sub>25</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub>·3HCl) C, N, H: calcd, 4.7; found, 5.2.</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>N</i>-(7-Methoxy-4-{[1-(phenylsulfonyl)-1<i>H</i>-indol-5-yl]amino}-6-quinazolinyl)propanamide (<b>21</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 1-(phenylsulfonyl)-1<i>H</i>-indol-5-amine<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> according to general procedure 2 gave the title compound <b>21</b> as a cream solid (85%), mp 270–275 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.69 (s, 1 H), 9.37 (s, 1 H), 8.81 (s, 1 H), 8.42 (s, 1 H), 7.99 (m, 3 H), 7.91 (d, <i>J</i> = 8.9 Hz, 1 H), 7.79 (d, <i>J</i> = 3.7 Hz, 1 H), 7.70–7.59 (m, 4 H), 7.23 (s, 1 H), 6.86 (dd, <i>J</i> = 3.7, 0.6 Hz, 1 H), 3.99 (s, 3 H), 2.45 (q, <i>J</i> = 7.5 Hz, 2 H), 1.12 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>26</sub>H<sub>23</sub>N<sub>5</sub>O<sub>4</sub>S·<sup>1</sup>/<sub>2</sub>MeOH) C, H, N.</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>N</i>-(4-{[1-(2-Furylmethyl)-1<i>H</i>-indol-5-yl]amino}-7-methoxy-6-quinazolinyl)propanamide (<b>22</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 1-(2-furylmethyl)-1<i>H</i>-indol-5-amine (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_001.pdf" class="ext-link">Supporting Information</a>) according to general procedure 2 gave the title compound <b>22</b> as a cream solid (82%), mp 221–224 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.58 (s, 1 H), 9.36 (s, 1 H), 8.80 (s, 1 H), 8.37 (s, 1 H), 7.85 (d, <i>J</i> = 1.8 Hz, 1 H), 7.58 (m, 1 H), 7.53 (d, <i>J</i> = 8.8 Hz, 1 H), 7.39 (m, 2 H), 7.21 (s, 1 H), 6.40–6.47 (m, 3 H), 5.41 (s, 2 H), 3.99 (s, 3 H), 2.45 (q, <i>J</i> = 7.5 Hz, 2 H), 1.12 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>25</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>·<sup>1</sup>/<sub>3</sub>THF) C, H, N.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-{4-[(1-Benzyl-2,3-dihydro-1<i>H</i>-indol-5-yl)amino]-7-methoxy-6-quinazolinyl}propanamide (<b>23</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 1-benzyl-2,3-dihydro-1<i>H</i>-indol-5-ylamine<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> according to general procedure 2 gave the title compound <b>23</b> as a yellow solid (80%), mp 169–171 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.39 (s, 1 H), 9.33 (s, 1 H), 8.73 (s, 1 H), 8.35 (s, 1 H), 7.22–7.41 (m, 7 H), 7.19 (s, 1 H), 6.57 (d, <i>J</i> = 8.4 Hz, 1 H), 4.27 (s, 2 H), 3.97 (s, 3 H), 3.26 (t, <i>J</i> = 8.2 Hz, 2 H), 2.92 (t, <i>J</i> = 8.2 Hz, 2 H), 2.44 (q, <i>J</i> = 7.5 Hz, 2 H), 1.12 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>27</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub>·<sup>1</sup>/<sub>4</sub>EtOAc) C, H, N.</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(7-Methoxy-4-{[1-(2-pyridinylmethyl)-2,3-dihydro-1<i>H</i>-indol-5-yl]amino}-6-quinazolinyl)propanamide (<b>24</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 1-(2-pyridinylmethyl)-2,3-dihydro-1<i>H</i>-indol-5-ylamine (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_001.pdf" class="ext-link">Supporting Information</a>) according to general procedure 2 gave the title compound <b>24</b> as a brown solid (79%), mp 90–94 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.40 (s, 1 H), 9.34 (s, 1 H), 8.72 (s, 1 H), 8.54 (d, <i>J</i> = 4.0 Hz, 1 H), 8.35 (s, 1 H), 7.78 (dt, <i>J</i> = 7.7, 1.8 Hz, 1 H), 7.41 (m, 2 H), 7.30–7.15 (m, 3 H), 6.51 (d, <i>J</i> = 8.4 Hz, 1 H), 4.37 (s, 2 H), 3.97 (s, 3 H), 3.44 (m, 2 H), 2.96 (t, <i>J</i> = 8.2 Hz, 2 H), 2.45 (q, <i>J</i> = 7.5 Hz, 2 H), 1.12 (t, <i>J</i> = 7.5 Hz, 3 H). HRMS (FAB<sup>+</sup>) calcd for C<sub>26</sub>H<sub>26</sub>N<sub>6</sub>O<sub>2</sub>: 454.2117 (M<sup>+</sup>); found, 454.2110.</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-{4-[(1-Isobutyl-1<i>H</i>-indol-5-yl)amino]-7-methoxy-6-quinazolinyl}propanamide (<b>25</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 1-isobutyl-2,3-dihydro-1<i>H</i>-indol-5-ylamine (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_001.pdf" class="ext-link">Supporting Information</a>) according to general procedure 2 gave the title compound <b>25</b> as a cream solid (91%), mp 202–204 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.57 (s, 1 H), 9.35 (s, 1 H), 8.81 (s, 1 H), 8.37 (s, 1 H), 7.86 (d, <i>J</i> = 1.8 Hz, 1 H), 7.46–7.31 (m, 3 H), 7.21 (s, 1 H), 6.41 (d, <i>J</i> = 3.0 Hz, 1 H), 3.99 (s, 3 H), 3.96 (d, <i>J</i> = 5.7 Hz, 2 H), 2.45 (q, <i>J</i> = 7.5 Hz, 2 H), 2.13 (m, 1 H), 1.13 (t, <i>J</i> = 7.5 Hz, 3 H), 0.87 (d, <i>J</i> = 7.8 Hz, 6 H). Anal. (C<sub>24</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub>·<sup>2</sup>/<sub>9</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-[4-(Benzylamino)-7-methoxy-6-quinazolinyl]propanamide (<b>26</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with benzylamine according to general procedure 2, gave the title compound <b>26</b> as a cream solid (45%), mp 166–168 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.29 (s, 1 H), 8.61 (s, 1 H), 8.57 (t, <i>J</i> = 6.0 Hz, 1 H), 8.31 (s, 1 H), 7.34–7.25 (m, 4 H), 7.22–7.17 (m, 1 H), 7.14 (s, 1 H), 4.70 (d, <i>J</i> = 5.7 Hz, 1 H), 3.94 (s, 3 H), 2.41 (q, <i>J</i> = 7.4 Hz, 2 H), 1.08 (t, <i>J</i> = 7.6 Hz, 3 H). Anal. (C<sub>19</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>·H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-(7-Methoxy-4-{[(1<i>R</i>)-1-phenylethyl]amino}-6-quinazolinyl)propanamide (<b>27</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with α-methylbenzylamine according to general procedure 2 gave the title compound <b>27</b> as a cream solid (44%), mp 157–159 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.31 (s, 1 H), 8.62 (s, 1 H), 8.26 (m, 2 H), 7.42 (m, 2 H), 7.27 (t, <i>J</i> = 7.2 Hz, 2 H), 7.16 (m, 1 H), 7.11 (s, 1 H), 5.57 (m, 1 H), 3.92 (s, 3 H), 2.41 (q, <i>J</i> = 7.2 Hz, 2 H), 1.55 (d, <i>J</i> = 7.0 Hz, 3 H), 1.09 (t, <i>J</i> = 7.6 Hz, 3 H). Anal. (C<sub>20</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>·H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-[7-Methoxy-4-(4-phenoxyanilino)-6-quinazolinyl]propanamide (<b>28</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 4-phenoxyaniline according to general procedure 2, gave the title compound <b>28</b> as a cream solid (91%), mp 137–140 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.67 (s, 1 H), 9.38 (s, 1 H), 8.82 (s, 1 H), 8.46 (s, 1 H), 7.79 (m, 2 H), 7.39 (m, 2 H), 7.25 (s, 1 H), 7.12 (m, 1 H), 7.07–7.00 (m, 4 H), 4.00 (s, 3 H), 2.47 (q, <i>J</i> = 7.5 Hz, 2 H), 1.13 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>24</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>·<sup>1</sup>/<sub>2</sub>MeOH) C, H, N.</div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-{4-[4-(3-Fluorophenoxy)anilino]-7-methoxy-6-quinazolinyl}propanamide (<b>29</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 4-(3-fluorophenoxy)aniline according to general procedure 2 gave the title compound <b>29</b> as a cream solid (29%), mp 144–146 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.78 (s, 1 H), 9.42 (s, 1 H), 8.81 (s, 1 H), 8.46 (s, 1 H), 7.79 (d, <i>J</i> = 8.8 Hz, 2 H), 7.39 (q, <i>J</i> = 8.1 Hz, 1 H), 7.22 (s, 1 H), 7.08 (d, <i>J</i> = 8.8 Hz, 1 H), 6.92 (t, <i>J</i> = 8.1 Hz, 1 H), 6.81 (m, 2 H), 3.95 (s, 3 H), 2.42 (q, <i>J</i> = 8.0 Hz, 2 H, under DMSO peak), 1.09 (t, <i>J</i> = 7.6 Hz, 3 H). Anal. (C<sub>24</sub>H<sub>21</sub>N<sub>4</sub>O<sub>3</sub>F·H<sub>2</sub>O) C, H, N; calcd, 12.4; found, 13.2.</div></div><div id="sec5_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-{4-[4-(1,3-Benzodioxol-5-yloxy)anilino]-7-methoxy-6-quinazolinyl}propanamide (<b>30</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 4-(benzo[<i>d</i>][1,3]dioxol-5-yloxy)benzenamine according to general procedure 2 gave the title compound <b>30</b> as a cream solid (24%). <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.60 (s, 1 H), 9.35 (s, 1 H), 8.75 (s, 1 H), 8.38 (s, 1 H), 7.67 (d, <i>J</i> = 9.0 Hz, 2 H), 7.18 (s, 1 H), 6.93–6.84 (m, 3 H), 6.67 (d, <i>J</i> = 2.4 Hz, 1 H), 6.42 (m, 1 H), 5.98 (s, 2 H), 3.94 (s, 3 H), 2.41 (q, <i>J</i> = 7.3 Hz, 2 H under DMSO peak), 1.06 (t, <i>J</i> = 7.6 Hz, 3 H).</div></div><div id="sec5_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-{7-Methoxy-4-[4-(3-pyridinyloxy)anilino]-6-quinazolinyl}propanamide (<b>31</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 3-(4-aminophenoxy)pyridine according to general procedure 2 gave the title compound <b>31</b> as a cream solid (77%), mp 163–167 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.66 (s, 1 H), 9.36 (s, 1 H), 8.78 (s, 1 H), 8.42 (s, 1 H), 8.32 (d, <i>J</i> = 17.8 Hz, 2 H), 7.77 (d, <i>J</i> = 9.0 Hz, 2 H), 7.37 (d, <i>J</i> = 1.7 Hz, 1 H), 7.20 (s, 1 H), 7.05 (d, <i>J</i> = 9.0 Hz, 2 H), 3.94 (s, 3 H), 2.42 (q, <i>J</i> = 7.6 Hz, 2 H under DMSO peak), 1.07 (t, <i>J</i> = 7.6 Hz, 3 H). Anal. (C<sub>23</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub>·H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>-{7-Methoxy-4-[4-(2-pyridinylmethyl)anilino]-6-quinazolinyl}propanamide (<b>32</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 4-(2-pyridinylmethyl)aniline according to general procedure 2 gave the title compound <b>32</b> as a cream solid (94%), mp 195–198 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.62 (s, 1 H), 9.41 (s, 1 H), 8.80 (s, 1 H), 8.50 (m, 1 H), 8.43 (s, 1 H), 7.75–7.65 (m, 3 H), 7.32–7.18 (m, 5 H), 4.07 (s, 2 H), 3.99 (s, 3 H), 2.46 (q, <i>J</i> = 7.5 Hz, 2 H), 1.12 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>24</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>·<sup>1</sup>/<sub>4</sub>MeOH) C, H, N.</div></div><div id="sec5_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-{7-Methoxy-4-[4-(4-pyridinylmethyl)anilino]-6-quinazolinyl}propanamide (<b>33</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 4-(4-pyridinylmethyl)aniline according to general procedure 2 gave the title compound <b>33</b> as a yellow solid (85%), mp 227–230 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.61 (s, 1 H), 9.37 (s, 1 H), 8.80 (s, 1 H), 8.48–8.42 (m, 3 H), 7.71 (br d, <i>J</i> = 8.5 Hz, 2 H), 7.29–7.23 (m, 5 H), 3.99 (s, 3 H), 3.96 (s, 2 H), 2.46 (q, <i>J</i> = 7.5 Hz, 2 H), 1.12 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>24</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec5_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i>-(4-{4-[Hydroxy(phenyl)methyl]anilino}-7-methoxy-6-quinazolinyl)propanamide (<b>34</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with (4-aminophenyl) (phenyl)methanone according to general procedure 2, followed by reduction of the ketone with NaBH<sub>4</sub> in MeOH, gave the title compound <b>34</b> as a white solid (37%), mp 239–242 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.60 (s, 1 H), 9.36 (s, 1 H), 8.79 (s, 1 H), 8.42 (s, 1 H), 7.68 (br d, <i>J</i> = 8.6 Hz, 2 H), 7.40 (br d, <i>J</i> = 7.2 Hz, 2 H), 7.36–7.27 (m, 4 H), 7.25–7.17 (m, 2 H), 5.81 (d, <i>J</i> = 4.0 Hz, 1 H), 5.69 (d, <i>J</i> = 3.8 Hz, 1 H), 3.99 (s, 3 H), 2.45 (q, <i>J</i> = 7.5 Hz, 2 H), 1.12 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>25</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>) C, H, N.</div></div><div id="sec5_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> <i>N</i>-{4-[4-(Benzyloxy)anilino]-7-methoxy-6-quinazolinyl}propanamide (<b>35</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 4-(benzyloxy)aniline according to general procedure 2 gave the title compound <b>35</b> as a cream solid (96%), mp 189–192 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.54 (s, 1 H), 9.36 (s, 1 H), 8.77 (s, 1 H), 8.40 (s, 1 H), 7.63 (br d, <i>J</i> = 9.1 Hz, 2 H), 7.47 (m, 2 H), 7.44–7.37 (m, 2 H), 7.35–7.29 (m, 1 H), 7.22 (s, 1 H), 7.02 (br d, <i>J</i> = 9.1 Hz, 2 H), 5.12 (s, 2 H), 3.99 (s, 3 H), 2.46 (q, <i>J</i> = 7.5 Hz, 2 H), 1.12 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>25</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>) C, H, N.</div></div><div id="sec5_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> <i>N</i>-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}-7-methoxy-6-quinazolinyl)propanamide (<b>36</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 3-chloro-4-[(3-fluorobenzyl)oxy]aniline according to general procedure 2 gave the title compound <b>36</b> as a cream solid (95%), mp 240–243 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.65 (s, 1 H), 9.42 (s, 1 H), 8.80 (s, 1 H), 8.47 (s, 1 H), 7.96 (d, <i>J</i> = 2.6 Hz, 1 H), 7.69 (dd, <i>J</i> = 8.9, 2.6 Hz, 1 H), 7.47 (m, 1 H), 7.36–7.28 (m, 2 H), 7.26–7.22 (m, 2 H), 7.21–7.15 (m, 1 H), 5.25 (s, 2 H), 4.00 (s, 3 H), 2.47 (q, <i>J</i> = 7.5 Hz, 2 H), 1.12 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>25</sub>H<sub>22</sub>ClFN<sub>4</sub>O<sub>3</sub>) C, H, N.</div></div><div id="sec5_2_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>-{7-Methoxy-4-[4-(2-pyridinylmethoxy)anilino]-6-quinazolinyl}propanamide (<b>37</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 4-(2-pyridinylmethoxy)aniline according to general procedure 2 gave the title compound <b>37</b> as a white solid (64%), mp 216–218 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.55 (s, 1 H), 9.35 (s, 1 H), 8.78 (s, 1 H), 8.59 (ddd, <i>J</i> = 4.8, 1.7, 0.9 Hz, 1 H), 8.40 (s, 1 H), 7.85 (dt, <i>J</i> = 7.7, 1.8 Hz, 1 H), 7.64 (br d, <i>J</i> = 9.1 Hz, 2 H), 7.54 (d, <i>J</i> = 7.8 Hz, 1 H), 7.35 (ddd, <i>J</i> = 7.5, 4.8, 1.1 Hz, 1 H), 7.22 (s, 1 H), 7.04 (br d, <i>J</i> = 9.1 Hz, 2 H), 5.19 (s, 2 H), 3.99 (s, 3 H), 2.46 (q, <i>J</i> = 7.5 Hz, 2 H), 1.13 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>24</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>·<sup>1</sup>/<sub>4</sub>MeOH) C, H, N.</div></div><div id="sec5_2_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-{7-Methoxy-4-[4-(4-pyridinylmethoxy)anilino]-6-quinazolinyl}propanamide (<b>38</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 4-(4-pyridinylmethoxy)aniline according to general procedure 2 gave the title compound <b>38</b> as a white solid (20%), mp 212–214 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.55 (s, 1 H), 9.35 (s, 1 H), 8.78 (s, 1 H), 8.59 (dd, <i>J</i> = 4.4, 1.6 Hz, 2 H), 8.40 (s, 1 H), 7.65 (br d, <i>J</i> = 9.1 Hz, 2 H), 7.46 (br d, <i>J</i> = 6.0 Hz, 2 H), 7.22 (s, 1 H), 7.03 (br d, <i>J</i> = 9.1 Hz, 2 H), 5.20 (s, 2 H), 3.99 (s, 3 H), 2.46 (q, <i>J</i> = 7.5 Hz, 2 H), 1.12 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>24</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>·<sup>1</sup>/<sub>3</sub>MeOH) C, H, N.</div></div><div id="sec5_2_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>N</i>-{7-Methoxy-4-[4-(2-phenylethyl)anilino]-6-quinazolinyl}propanamide (<b>39</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with 4-(2-phenylethyl)aniline according to general procedure 2 gave the title compound <b>39</b> as a cream solid (65%), mp 170–172 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.56 (s, 1 H), 9.37 (s, 1 H), 8.80 (s, 1 H), 8.44 (s, 1 H), 7.67 (br d, <i>J</i> = 8.5 Hz, 2 H), 7.31–7.15 (m, 8 H), 3.99 (s, 3 H), 2.89 (m, 4 H), 2.46 (q, <i>J</i> = 7.5 Hz, 2 H), 1.13 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>26</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec5_2_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> <i>N</i>-{4-[4-(Benzylamino)anilino]-7-methoxy-6-quinazolinyl}propanamide (<b>40</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with <i>N</i><sup>1</sup>-benzyl-1,4-benzenediamine according to general procedure 2 gave the title compound <b>40</b> as a yellow solid (76%), mp 146–149 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.35 (s, 1 H), 9.32 (s, 1 H), 8.70 (s, 1 H), 8.32 (s, 1 H), 7.39 (br d, <i>J</i> = 7.0 Hz, 2 H), 7.35–7.28 (m, 4 H), 7.23 (m, 1 H), 7.17 (s, 1 H), 6.58 (br d, <i>J</i> = 8.9 Hz, 2 H), 6.13 (t, <i>J</i> = 6.2 Hz, 1 H), 4.28 (d, <i>J</i> = 6.0 Hz, 2 H), 3.97 (s, 3 H), 2.44 (q, <i>J</i> = 7.5 Hz, 2 H), 1.11 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>25</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec5_2_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>N</i>-(7-Methoxy-4-{4-[(phenylsulfonyl)amino]anilino}-6-quinazolinyl)propanamide (<b>41</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with <i>N</i>-(4-aminophenyl)benzenesulfonamide according to general procedure 2 gave the title compound <b>41</b> as a yellow solid (87%), mp 155–165 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.17 (s, 1 H), 9.83 (br s, 1 H), 9.40 (s, 1 H), 8.81 (s, 1 H), 8.47 (s, 1 H), 7.77 (br d, <i>J</i> = 7.0 Hz, 2 H), 7.65–7.52 (m, 5 H), 7.23 (s, 1 H), 7.08 (br d, <i>J</i> = 8.9 Hz, 2 H), 3.99 (s, 3 H), 2.46 (q, <i>J</i> = 7.5 Hz, 2 H), 1.11 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>24</sub>H<sub>23</sub>N<sub>5</sub>O<sub>4</sub>S·<sup>1</sup>/<sub>4</sub>EtOAc·<sup>1</sup>/<sub>2</sub>MeOH) C, H, N.</div></div><div id="sec5_2_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> <i>N</i>-(4-{3-Fluoro-4-[(phenylsulfonyl)amino]anilino}-7-methoxy-6-quinazolinyl)propanamide (<b>42</b>)</h4><div class="NLM_p last">Reaction of chloride <b>89</b> with <i>N</i>-(4-amino-2-fluorophenyl)benzenesulfonamide (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_001.pdf" class="ext-link">Supporting Information</a>) according to general procedure 2 gave the title compound <b>42</b> as a cream solid (78%), mp 157–162 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.98 (s, 1 H), 9.74 (s, 1 H), 9.41 (s, 1 H), 8.80 (s, 1 H), 8.51 (s, 1 H), 7.79 (dd, <i>J</i> = 13.0, 2.3 Hz, 1 H), 7.72 (br d, <i>J</i> = 7.1 Hz, 2 H), 7.64 (m, 1 H), 7.60–7.50 (m, 3 H), 7.26 (s, 1 H), 7.16 (t, <i>J</i> = 8.9 Hz, 1 H), 3.99 (s, 3 H), 2.46 (q, <i>J</i> = 7.5 Hz, 2 H), 1.12 (t, <i>J</i> = 7.5 Hz, 3 H). Anal. (C<sub>24</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>4</sub>S·<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O·<sup>1</sup>/<sub>4</sub>MeOH): C, H, N.</div></div><div id="sec5_2_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>-[7-Methoxy-4-({6-[(phenylsulfonyl)amino]-3-pyridinyl}amino)-6-quinazolinyl]propanamide Hydrochloride (<b>43</b>)</h4><div class="NLM_p last"><i>N</i>-(5-Nitro-2-pyridinyl)benzenesulfonamide (280 mg, 1.0 mmol) was dissolved in EtOH/EtOAc (80 mL, 1:1) to which a catalytic amount of Raney nickel was added. The reaction was stirred vigorously under an atmosphere of hydrogen (40 psi) for 2.5 h. The catalyst was removed by filtration (caution) and the residue concentrated under reduced pressure to give a quantative yield of <i>N</i>-(5-amino-2-pyridinyl)benzenesulfonamide (<b>A32</b>), which was used directly. Reaction of <b>A32</b> with chloride <b>89</b> according to general procedure 2 gave the title compound <b>43</b> as a brown solid (99%), mp 244–247 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 11.0 (br s, 1 H), 9.73 (s, 1 H), 9.39 (s, 1 H), 8.79 (s, 1 H), 8.49 (s, 1 H), 8.43 (s, 1 H), 8.07 (dd, <i>J</i> = 9.0, 2.6 Hz, 1 H), 7.91 (br d, <i>J</i> = 6.9 Hz, 2 H), 7.54–7.65 (m, 4 H), 7.24 (s, 1 H), 7.17 (d, <i>J</i> = 8.9 Hz, 1 H), 3.99 (s, 3 H), 2.46 (q, <i>J</i> = 7.5 Hz, 2 H), 1.12 (t, <i>J</i> = 7.5 Hz, 3 H). HRMS (FAB<sup>+</sup>) calcd for C<sub>23</sub>H<sub>23</sub>N<sub>6</sub>O<sub>4</sub>S: 479.1502 (MH<sup>+</sup>); found, 479.1499. Anal. (C<sub>23</sub>H<sub>22</sub>N<sub>6</sub>O<sub>4</sub>S·2.75HCl): C, H, N.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> General Procedure <b>3</b>: Synthesis of Quinazolines of <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a> and <a class="ref internalNav" href="#sch4" aria-label="4">4</a></h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-(1-Benzyl-1<i>H</i>-indazol-5-yl)-7-ethoxy-6-nitroquinazolin-4-amine (<b>91</b>)</h4><div class="NLM_p last">7-Ethoxy-6-nitroquinazolin-4(3<i>H</i>)-one (<b>90</b>) (2.50 g, 10.6 mmol), prepared using the same method as described for <b>87</b> (using ethanol at 50 °C for 4 h), was suspended in POCl<sub>3</sub> (50 mL) and heated at reflux for 3 h. The POCl<sub>3</sub> was distilled off under reduced pressure, and the resulting yellow-cream solid was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (100 mL) and then treated with a mixture of ice and saturated NaHCO<sub>3</sub> solution until the pH was slightly basic. The aqueous layer was further extracted with CH<sub>2</sub>Cl<sub>2</sub> (100 mL), then the combined organic fractions were washed with brine (200 mL) and dried (Na<sub>2</sub>SO<sub>4</sub>). The solvent was removed under reduced pressure to afford crude 4-chloro-7-ethoxy-6-nitroquinazoline. This solid was dissolved directly in a mixture of CH<sub>2</sub>Cl<sub>2</sub> (40 mL) and iPrOH (10 mL), then added to a suspension of 1-benzyl-1<i>H</i>-indazol-5-amine (2.61 g, 11.7 mmol) in iPrOH (50 mL) which contained 1 M HCl (5 drops). This mixture was heated at 50 °C for 15 h, resulting in precipitation of the desired product as the hydrochloride salt. The reaction was allowed to cool, concentrated in vacuo, then poured into saturated NaHCO<sub>3</sub> solution (300 mL) and stirred for 5 min. The resulting precipitate was collected by filtration and washed well with water and Et<sub>2</sub>O. This material was dried to give the title compound <b>91</b> as a yellow solid (4.59 g, 98%), mp 222–224 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.15 (br s, 1 H), 9.23 (s, 1 H), 8.56 (s, 1 H), 8.19–8.11 (m, 2 H), 7.74–7.68 (m, 1 H), 7.65 (dd, <i>J</i> = 8.8, 1.8 Hz, 1 H), 7.42 (s, 1 H), 7.35–7.21 (m, 5 H), 5.67 (s, 2 H), 4.36 (q, <i>J</i> = 6.9 Hz, 2 H), 1.41 (t, <i>J</i> = 6.9 Hz, 3 H). Anal. (C<sub>24</sub>H<sub>20</sub>N<sub>6</sub>O<sub>3</sub>) C, H, N.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> <i>N</i><sup>4</sup>-(1-Benzyl-1<i>H</i>-indazol-5-yl)-7-ethoxyquinazoline-4,6-diamine (<b>92</b>)</h4><div class="NLM_p last">Compound <b>91</b> (1.00 g, 2.27 mmol) was dissolved in a mixture of EtOAc (60 mL) and MeOH (60 mL), then Raney nickel (1.12 g wet from a 50% slurry in water) was added and the mixture stirred under a 40 psi atmosphere of hydrogen in a pressure vessel for 1.75 h. The Raney nickel was then carefully removed by filtration over Celite (<b><i>Caution</i>:</b> Raney nickel is highly flammable when dry) and the solvent removed from the filtrate under reduced pressure. The resulting solid was purified by chromatography on silica gel (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub> as eluant) to afford the title compound <b>92</b> as a crystalline pink–brown solid (556 mg, 60%), mp 210–212 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.25 (s, 1 H), 8.27 (s, 1 H), 8.21–8.19 (m, 1 H), 8.08 (d, <i>J</i> = 0.6 Hz, 1 H), 7.67 (dd, <i>J</i> = 9.0, 1.8 Hz, 1 H), 7.63 (d, <i>J</i> = 9.0 Hz, 1 H), 7.44 (s, 1 H), 7.34–7.21 (m, 5 H), 7.05 (s, 1 H), 5.65 (s, 2 H), 5.21 (br s, 2 H), 4.21 (q, <i>J</i> = 7.0 Hz, 2 H), 1.45 (t, <i>J</i> = 7.0 Hz, 3 H). LCMS (APCI<sup>+</sup>) 311. Anal. (C<sub>24</sub>H<sub>22</sub>N<sub>6</sub>O·<sup>1</sup>/<sub>4</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (<i>E</i>)-<i>N</i>-(4-(1-Benzyl-1<i>H</i>-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-bromobut-2-enamide (<b>93</b>)</h4><div class="NLM_p last">(<i>E</i>)-4-Bromobut-2-enoic acid (2.65 g, 15.9 mmol) was dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> (25 mL), to which was added oxalyl chloride (2.22 g, 17.5 mmol) and DMF (1 drop). This mixture was stirred at room temperature for 3 h, then all solvent was removed under reduced pressure to give a pale-yellow oil which was dissolved in THF (25 mL). Compound <b>92</b> (5.00 g, 12.1 mmol) was also dissolved in THF (350 mL), TEA (3.06 g, 30.3 mmol) added, and the flask sealed under nitrogen and cooled to −20 °C (ice/salt/water). The above THF solution of acid chloride was added dropwise over 0.25 h, then the reaction mixture was stirred for a further 0.5 h at this temperature. The mixture was then diluted with saturated NaHCO<sub>3</sub> solution (200 mL) and extracted with EtOAc (2 × 200 mL). The combined EtOAc fractions were washed with brine (200 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and the solvent removed under reduced pressure to give a crude solid which was purified by chromatography on silica gel (2% MeOH/CH<sub>2</sub>Cl<sub>2</sub> as eluant). The title compound <b>93</b> was isolated as an unstable orange foam (4.28 g, 63%). <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.75 (s, 1 H), 9.52 (s, 1 H), 8.80 (s, 1 H), 8.42 (s, 1 H), 8.10 (s, 2 H), 7.68 (d, <i>J</i> = 9.0 Hz, 1 H), 7.63 (dd, <i>J</i> = 9.0, 1.6 Hz, 1 H), 7.20–7.34 (m, 6 H), 6.62–6.67 (m, 1 H), 6.48–6.57 (m, 1 H), 5.66 (s, 2 H), 4.26 (q, <i>J</i> = 7.0 Hz, 2 H), 3.49–3.41 (m, 2 H; by D<sub>2</sub>O exchange), 1.45 (t, <i>J</i> = 6.9 Hz, 3 H). LCMS (APCI<sup>+</sup>) 557, 559.</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (<i>E</i>)-<i>N</i>-(4-(1-Benzyl-1<i>H</i>-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(dimethylamino)but-2-enamide (<b>44</b>)</h4><div class="NLM_p last">Compound <b>93</b> (500 mg, 0.90 mmol) was dissolved in DMA (10 mL) and cooled to −20 °C (ice/salt/water). Aqueous dimethylamine solution (40%, 1.01 mL) was added and the reaction monitored by TLC until complete reaction was achieved after 2 h. The reaction mixture was diluted with water (50 mL) and poured into saturated NaHCO<sub>3</sub> solution (100 mL). The resulting aqueous solution was extracted with EtOAc (2 × 100 mL) and the combined EtOAc fractions washed with brine (100 mL) and dried (Na<sub>2</sub>SO<sub>4</sub>). Filtration, followed by removal of the solvent under reduced pressure, afforded a crude residue which was purified by column chromatography on silica gel (2% MeOH/CH<sub>2</sub>Cl<sub>2</sub>) to give the title compound <b>44</b> as a pale-yellow solid (333 mg, 71%), mp (Et<sub>2</sub>O) 150–154 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.72 (s, 1 H), 9.47 (s, 1 H), 8.92 (s, 1 H), 8.41 (s, 1 H), 8.12 (br s, 1 H), 8.10 (s, 1 H), 7.69–7.63 (m, 2 H), 7.35–7.20 (m, 6 H), 6.80 (dt, <i>J</i> = 15.4, 6.0 Hz, 1 H), 6.57 (br d, <i>J</i> = 15.1 Hz, 1 H), 5.66 (s, 2 H), 4.28 (q, <i>J</i> = 7.0 Hz, 2 H), 3.09 (br d, <i>J</i> = 5.0 Hz, 2 H), 2.19 (s, 6 H), 1.46 (t, <i>J</i> = 7.0 Hz, 3 H). LCMS (APCI<sup>+</sup>) 522. Anal. (C<sub>30</sub>H<sub>31</sub>N<sub>7</sub>O<sub>2</sub>·1<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (<i>E</i>)-<i>N</i>-(4-(1-Benzyl-1<i>H</i>-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(diisopropylamino)but-2-enamide (<b>45</b>)</h4><div class="NLM_p last">Reaction of <b>93</b> with diisopropylamine, using the same method as described for <b>44</b>, afforded the title compound <b>45</b> as a pale-yellow solid (32%), mp 133–137 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.70 (s, 1 H), 9.42 (s, 1 H), 8.87 (br s, 1 H), 8.41 (s, 1 H), 8.13 (br s, 1 H), 8.10 (s, 1 H), 7.69–7.62 (m, 2 H), 7.35–7.19 (m, 6 H), 6.83 (dt, <i>J</i> = 15.2, 5.5 Hz, 1 H), 6.54 (br d, <i>J</i> = 15.4 Hz, 1 H), 5.66 (s, 2 H), 4.28 (q, <i>J</i> = 7.0 Hz, 2 H), 3.30–3.25 (m, 2 H; by D<sub>2</sub>O exchange), 3.01 (septet, <i>J</i> = 6.5 Hz, 2 H), 1.45 (t, <i>J</i> = 6.9 Hz, 3 H), 1.00 (d, <i>J</i> = 6.5 Hz, 12 H). LCMS (APCI<sup>+</sup>) 578. Anal. (C<sub>34</sub>H<sub>39</sub>N<sub>7</sub>O<sub>2</sub>·1<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (<i>E</i>)-<i>N</i>-(4-(1-Benzyl-1<i>H</i>-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(pyrrolidin-1-yl)but-2-enamide (<b>46</b>)</h4><div class="NLM_p last">Reaction of <b>93</b> with pyrrolidine, using the same method as described for <b>44</b>, afforded the title compound <b>46</b> as a pale-yellow solid (61%), mp 131–136 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.72 (s, 1 H), 9.47 (s, 1 H), 8.91 (s, 1 H), 8.41 (s, 1 H), 8.12 (s, 1 H), 8.10 (s, 1 H), 7.69–7.63 (m, 2 H), 7.35–7.21 (m, 6 H), 6.84 (dt, <i>J</i> = 15.5, 5.8 Hz, 1 H), 6.57 (br d, <i>J</i> = 15.4 Hz, 1 H), 5.66 (s, 2 H), 4.27 (q, <i>J</i> = 7.0 Hz, 2 H), 3.30–3.25 (m, 2 H; by D<sub>2</sub>O exchange), 2.51–2.49 (m, 4 H), 1.76–1.68 (br m, 4 H), 1.46 (t, <i>J</i> = 7.0 Hz, 3 H). LCMS (APCI<sup>+</sup>) 548. Anal. (C<sub>32</sub>H<sub>33</sub>N<sub>7</sub>O<sub>2</sub>·1<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (<i>E</i>)-<i>N</i>-(4-(1-Benzyl-1<i>H</i>-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide (<b>47</b>)</h4><div class="NLM_p last">Reaction of <b>93</b> with piperidine, using the same method as described for <b>44</b>, afforded the title compound <b>47</b> as a pale-yellow solid (69%), mp 140–144 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.71 (s, 1 H), 9.46 (s, 1 H), 8.89 (br s, 1 H), 8.41 (s, 1 H), 8.15–8.08 (m, 2 H), 7.69–7.63 (m, 2 H), 7.35–7.20 (m, 6 H), 6.79 (dt, <i>J</i> = 15.4, 6.1 Hz, 1 H), 6.54 (br d, <i>J</i> = 15.6 Hz, 1 H), 5.66 (s, 2 H), 4.28 (q, <i>J</i> = 7.0 Hz, 2 H), 3.11 (dd, <i>J</i> = 6.1, 1.2 Hz, 2 H), 2.40–2.30 (br m, 4 H), 1.56–1.48 (br m, 4 H), 1.45 (t, <i>J</i> = 7.0 Hz, 3 H), 1.43–1.35 (br m, 2 H). LCMS (APCI<sup>+</sup>) 562. Anal. (C<sub>33</sub>H<sub>35</sub>N<sub>7</sub>O<sub>2</sub>·H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (<i>E</i>)-<i>N</i>-(4-(1-Benzyl-1<i>H</i>-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-((2<i>R</i>,6<i>S</i>)-2,6-dimethylpiperidin-1-yl)but-2-enamide (<b>48</b>)</h4><div class="NLM_p last">Reaction of <b>93</b> with <i>cis</i>-2,6-dimethylpiperidine, using the same method as described for <b>44</b>, afforded the title compound <b>48</b> as a cream solid (62%), mp 143–146 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.70 (s, 1 H), 9.46 (s, 1 H), 8.89 (s, 1 H), 8.42 (s, 1 H), 8.13 (s, 1 H), 8.10 (s, 1 H), 7.69–7.63 (m, 2 H), 7.35–7.21 (m, 6 H), 6.98 (dt, <i>J</i> = 15.3, 6.1 Hz, 1 H), 6.59 (br d, <i>J</i> = 15.4 Hz, 1 H), 5.66 (s, 2 H), 4.28 (q, <i>J</i> = 7.0 Hz, 2 H), 3.48 (br d, <i>J</i> = 5.6 Hz, 2 H), 2.47–2.37 (br m, 2 H), 1.63–1.52 (br m, 4 H), 1.45 (t, <i>J</i> = 7.0 Hz, 3 H), 1.34–1.12 (br m, 2 H), 1.06 (d, <i>J</i> = 6.2 Hz, 6 H). LCMS (APCI<sup>+</sup>) 590. Anal. (C<sub>35</sub>H<sub>39</sub>N<sub>7</sub>O<sub>3</sub>·H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (<i>E</i>)-<i>N</i>-(4-(1-Benzyl-1<i>H</i>-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-morpholinobut-2-enamide (<b>49</b>)</h4><div class="NLM_p last">Reaction of <b>93</b> with morpholine, using the same method as described for <b>44</b>, afforded the title compound <b>49</b> as a cream solid (62%), mp 177–181 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.71 (s, 1 H), 9.48 (s, 1 H), 8.90 (s, 1 H), 8.42 (s, 1 H), 8.13 (s, 1 H), 8.10 (s, 1 H), 7.69–7.62 (m, 2 H), 7.35–7.21 (m, 6 H), 6.79 (dt, <i>J</i> = 15.4, 6.1 Hz, 1 H), 6.57 (br d, <i>J</i> = 15.4 Hz, 1 H), 5.66 (s, 2 H), 4.28 (q, <i>J</i> = 7.0 Hz, 2 H), 3.61 (t, <i>J</i> = 4.6 Hz, 4 H), 3.15 (dd, <i>J</i> = 6.1, 1.1 Hz, 2 H), 2.40 (t, <i>J</i> = 4.4 Hz, 4 H) 1.45 (t, <i>J</i> = 7.0 Hz, 3 H). LCMS (APCI<sup>+</sup>) 564. Anal. (C<sub>32</sub>H<sub>33</sub>N<sub>7</sub>O<sub>3</sub>·<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (<i>E</i>)-<i>N</i>-(4-(1-Benzyl-1<i>H</i>-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-(4-methylpiperazin-1-yl)but-2-enamide (<b>50</b>)</h4><div class="NLM_p last">Reaction of <b>93</b> with <i>N</i>-methylpiperazine, using the same method as described for <b>44</b>, afforded the title compound <b>50</b> as a pale-yellow solid (80%), mp 138–141 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.71 (s, 1 H), 9.47 (s, 1 H), 8.89 (s, 1 H), 8.42 (s, 1 H), 8.12 (s, 1 H), 8.10 (s, 1 H), 7.69–7.62 (m, 2 H), 7.35–7.21 (m, 6 H), 6.78 (dt, <i>J</i> = 15.4, 6.1 Hz, 1 H), 6.55 (br d, <i>J</i> = 15.5 Hz, 1 H), 5.66 (s, 2 H), 4.28 (q, <i>J</i> = 7.0 Hz, 2 H), 3.14 (br d, <i>J</i> = 5.0 Hz, 2 H), 2.46–2.26 (br m, 8 H), 2.16 (s, 3 H), 1.45 (t, <i>J</i> = 7.0 Hz, 3 H). LCMS (APCI<sup>+</sup>) 577. Anal. (C<sub>33</sub>H<sub>36</sub>N<sub>8</sub>O<sub>2</sub>·1<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (<i>E</i>)-<i>N</i>-(4-(1-Benzyl-1<i>H</i>-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-((3<i>S</i>,5<i>R</i>)-3,5-dimethylpiperazin-1-yl)but-2-enamide (<b>51</b>)</h4><div class="NLM_p last">Reaction of <b>93</b> with <i>cis</i>-2,6-dimethylpiperazine, using the same method as described for <b>44</b>, afforded the title compound <b>51</b> as a pale-yellow solid (45%), mp 140–144 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.71 (s, 1 H), 9.47 (s, 1 H), 8.89 (s, 1 H), 8.42 (s, 1 H), 8.12 (s, 1 H), 8.10 (s, 1 H), 7.69–7.62 (m, 2 H), 7.34–7.21 (m, 6 H), 6.79 (dt, <i>J</i> = 15.3, 6.2 Hz, 1 H), 6.55 (br d, <i>J</i> = 15.3 Hz, 1 H), 5.66 (s, 2 H), 4.28 (q, <i>J</i> = 7.0 Hz, 2 H), 3.13 (br d, <i>J</i> = 5.8 Hz, 2 H), 2.90–2.78 (br m, 2 H), 2.72 (br d, <i>J</i> = 9.9 Hz, 2 H), 1.59 (br t, <i>J</i> = 9.6 Hz, 2 H), 1.45 (t, <i>J</i> = 7.0 Hz, 3 H), 0.96 (br d, <i>J</i> = 6.2 Hz, 6 H). LCMS (APCI<sup>+</sup>) 591. Anal. (C<sub>34</sub>H<sub>38</sub>N<sub>8</sub>O<sub>2</sub>·1<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (<i>E</i>)-<i>N</i>-(4-(1-Benzyl-1<i>H</i>-indazol-5-ylamino)-7-ethoxyquinazolin-6-yl)-4-((2<i>R</i>,6<i>S</i>)-2,6-dimethylpiperazin-1-yl)but-2-enamide (<b>52</b>)</h4><div class="NLM_p last">Reaction of <b>93</b> with BOC-<i>cis</i>-2,6-dimethylpiperazine,<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> using the same method as described for <b>44</b>, gave the BOC-protected precursor of the title compound as a viscous oil which, without further purification, was deprotected with 1:1 CH<sub>2</sub>Cl<sub>2</sub>/TFA. The title compound <b>52</b> was isolated as a pale-yellow solid (25%), mp 240–244 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.70 (s, 1 H), 9.46 (s, 1 H), 8.88 (s, 1 H), 8.42 (s, 1 H), 8.14 (s, 1 H), 8.10 (s, 1 H), 7.69–7.62 (m, 2 H), 7.35–7.20 (m, 6 H), 6.98 (dt, <i>J</i> = 15.3, 6.2 Hz, 1 H), 6.58 (br d, <i>J</i> = 15.4 Hz, 1 H), 5.66 (s, 2 H), 4.29 (q, <i>J</i> = 7.0 Hz, 2 H), 3.46 (br d, <i>J</i> = 5.5 Hz, 2 H), 2.73 (dd, <i>J</i> = 12.0, 1.9 Hz, 2 H), 2.47–2.37 (m, 2 H), 2.27 (br t, <i>J</i> = 11.9 Hz, 2 H), 1.45 (t, <i>J</i> = 7.0 Hz, 3 H), 0.96 (d, <i>J</i> = 6.1 Hz, 6 H). HRMS (EI<sup>+</sup>) calcd. for C<sub>34</sub>H<sub>38</sub>N<sub>8</sub>O<sub>2</sub>: 590.3118; found, 590.3114. Anal. (C<sub>34</sub>H<sub>38</sub>N<sub>8</sub>O<sub>2</sub>·<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (2<i>E</i>)-<i>N</i>-[4-(3-Chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(diisopropylamino)-2-butenamide (<b>53</b>)</h4><div class="NLM_p last">Application of general procedure 3 to compound <b>87</b>, using 3-chloro-4-fluoroaniline as the aniline and diisopropylamine as the amine, gave the title compound <b>53</b>, mp 170–171 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.76 (s, 1 H), 9.60 (s, 1 H), 8.87 (s, 1 H), 8.51 (s, 1 H), 8.10 (m, 1 H), 7.77 (m, 1 H), 7.40 (t, <i>J</i> = 9.2 Hz, 1 H), 7.26 (s, 1 H), 6.80 (m, 1 H), 6.56 (m, 1 H), 3.99 (s, 3 H), 3.25 (d, <i>J</i> = 4.1 Hz, 2 H), 2.99 (m, 2 H), 0.97 (d, <i>J</i> = 6.6 Hz, 12 H). Anal. (C<sub>25</sub>H<sub>29</sub>N<sub>5</sub>O<sub>2</sub>FCl·1<sup>1</sup>/<sub>10</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (2<i>E</i>)-<i>N</i>-[4-(3-Chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide (<b>54</b>)</h4><div class="NLM_p last">Application of general procedure 3 to compound <b>87</b>, using 3-chloro-4-fluoroaniline as the aniline and piperidine as the amine, gave the title compound <b>54</b>, mp 149–151 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.76 (s, 1 H), 9.64 (s, 1 H), 8.87 (s, 1 H), 8.48 (s, 1 H), 8.07 (dd, <i>J</i> = 2.7, 6.8 Hz, 1 H), 7.74 (m, 1 H), 7.37 (t, <i>J</i> = 9.3 Hz, 1 H), 7.24 (s, 1 H), 6.74 (m, 1 H), 6.50 (m, 1 H), 3.96 (s, 3 H), 3.04 (d, <i>J</i> = 5.1 Hz, 2 H), 2.30 (m, 4 H), 1.46 (m, 4 H), 1.34 (m, 2 H). LCMS (APCI + ve) 470.1 (M + H). Anal. (C<sub>24</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub>FCl·H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> (2<i>E</i>)-<i>N</i>-[4-[(1-Benzyl-1<i>H</i>-indazol-5-yl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]-4-(dimethylamino)-2-butenamide (<b>55</b>)</h4><div class="NLM_p last">7-(2-Methoxyethoxy)-6-nitro-4(3<i>H</i>)-quinazolinone <b>94</b> (2.50 g, 10.6 mmol) was prepared using the same method as described for <b>87</b> (using THF as the solvent). General procedure 3 was then followed to give the title compound <b>55</b> as a pale-yellow solid, mp 123–127 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.73 (s, 1 H), 9.48 (s, 1 H), 8.90 (s, 1 H), 8.42 (s, 1 H), 8.13 (s, 1 H), 8.11 (s, 1 H), 7.67 (m, 2 H), 7.35–7.20 (m, 6 H), 6.80 (dt, <i>J</i> = 15.4, 6.0 Hz, 1 H), 6.55 (br d, <i>J</i> = 15.4 Hz, 1 H), 5.66 (s, 2 H), 4.36 (m, 2 H), 3.80 (m, 2 H), 3.35 (s, 3 H), 3.09 (br d, <i>J</i> = 5.2 Hz, 2 H), 2.20 (s, 6 H). Anal. (C<sub>31</sub>H<sub>33</sub>N<sub>7</sub>O<sub>3</sub>·1<sup>1</sup>/<sub>3</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> (2<i>E</i>)-<i>N</i>-[4-[(1-Benzyl-1<i>H</i>-indazol-5-yl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]-4-(1-pyrrolidinyl)-2-butenamide (<b>56</b>)</h4><div class="NLM_p last">Application of general procedure 3 to compound <b>94</b>, using pyrrolidine as the amine, gave the title compound <b>56</b> as a pale-yellow solid, mp 117–121 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.73 (s, 1 H), 9.48 (s, 1 H), 8.90 (s, 1 H), 8.42 (s, 1 H), 8.13 (s, 1 H), 8.10 (s, 1 H), 7.66 (m, 2 H), 7.35–7.20 (m, 6 H), 6.84 (dt, <i>J</i> = 15.4, 5.8 Hz, 1 H), 6.55 (br d, <i>J</i> = 15.4 Hz, 1 H), 5.66 (s, 2 H), 4.36 (m, 2 H), 3.80 (m, 2 H), 3.36 (s, 3 H), 3.17 (d, <i>J</i> = 5.3 Hz, 2 H), 2.52–2.48 (m, 4 H), 1.76–1.68 (br m, 4 H). Anal. (C<sub>33</sub>H<sub>35</sub>N<sub>7</sub>O<sub>3</sub>·2H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (2<i>E</i>)-<i>N</i>-[4-[(1-Benzyl-1<i>H</i>-indazol-5-yl)amino]-7-(2-methoxyethoxy)-6-quinazolinyl]-4-(4-methyl-1-piperazinyl)-2-butenamide (<b>57</b>)</h4><div class="NLM_p last">Application of general procedure 3 to compound <b>94</b>, using <i>N</i>-methylpiperazine as the amine, gave the title compound <b>57</b> as a pale-yellow solid, mp 123–127 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.73 (s, 1 H), 9.48 (s, 1 H), 8.88 (s, 1 H), 8.42 (s, 1 H), 8.13 (s, 1 H), 8.11 (s, 1 H), 7.66 (m, 2 H), 7.36–7.21 (m, 6 H), 6.78 (dt, <i>J</i> = 15.4, 6.1 Hz, 1 H), 6.53 (br d, <i>J</i> = 15.4 Hz, 1 H), 5.66 (s, 2 H), 4.36 (m, 2 H), 3.80 (m, 2 H), 3.35 (s, 3 H), 3.14 (br d, <i>J</i> = 5.3 Hz, 2 H), 2.50–2.30 (m, 8 H), 2.18 (s, 3 H). Anal. (C<sub>34</sub>H<sub>38</sub>N<sub>8</sub>O<sub>3</sub>·1<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (2<i>E</i>)-4-(Dimethylamino)-<i>N</i>-(7-ethoxy-4-{[1-(phenylsulfonyl)-1<i>H</i>-indol-5-yl]amino}-6-quinazolinyl)-2-butenamide (<b>58</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 3 using 1-(phenylsulfonyl)-1<i>H</i>-indol-5-amine<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> as the aniline, mp 154–158 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.71 (s, 1 H), 9.46 (s, 1 H), 8.91 (s, 1 H), 8.42 (s, 1 H), 8.03 (m, 3 H), 7.93 (d, <i>J</i> = 8.9 Hz, 1 H), 7.79 (d, <i>J</i> = 3.7 Hz, 1 H), 7.70–7.59 (m, 4 H), 7.22 (s, 1 H), 6.87 (dd, <i>J</i> = 3.7, 0.4 Hz, 1 H), 6.80 (m, 1 H), 6.56 (d, <i>J</i> = 15.5 Hz, 1 H), 4.27 (q, <i>J</i> = 7.0 Hz, 2 H), 3.09 (dd, <i>J</i> = 6.0, 1.1 Hz, 2 H), 2.19 (s, 6 H), 1.45 (t, <i>J</i> = 7.0 Hz, 3 H). Anal. (C<sub>30</sub>H<sub>30</sub>N<sub>6</sub>O<sub>4</sub>S·1<sup>3</sup>/<sub>4</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (2<i>E</i>)-<i>N</i>-(7-Ethoxy-4-{[1-(phenylsulfonyl)-1<i>H</i>-indol-5-yl]amino}-6-quinazolinyl)-4-(1-pyrrolidinyl)-2-butenamide (<b>59</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 3 using 1-(phenylsulfonyl)-1<i>H</i>-indol-5-amine<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> as the aniline and pyrrolidine as the amine, mp 158–162 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.71 (s, 1 H), 9.46 (s, 1 H), 8.90 (s, 1 H), 8.42 (s, 1 H), 8.02 (m, 3 H), 7.91 (d, <i>J</i> = 8.9 Hz, 1 H), 7.78 (d, <i>J</i> = 3.7 Hz, 1 H), 7.70–7.59 (m, 4 H), 7.22 (s, 1 H), 6.87 (dd, <i>J</i> = 3.7, 0.4 Hz, 1 H), 6.85 (m, 1 H), 6.56 (d, <i>J</i> = 15.4 Hz, 1 H), 4.27 (q, <i>J</i> = 7.0 Hz, 2 H), 3.25 (dd, <i>J</i> = 6.0, 1.1 Hz, 2 H), 2.47 (m, 4 H), 1.72 (m, 4 H), 1.45 (t, <i>J</i> = 7.0 Hz, 3 H). Anal. (C<sub>32</sub>H<sub>32</sub>N<sub>6</sub>O<sub>4</sub>S·1<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> (2<i>E</i>)-<i>N</i>-(7-Ethoxy-4-{[1-(phenylsulfonyl)-1<i>H</i>-indol-5-yl]amino}-6-quinazolinyl)-4-(4-morpholinyl)-2-butenamide (<b>60</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 3 using 1-(phenylsulfonyl)-1<i>H</i>-indol-5-amine<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> as the aniline and morpholine as the amine, mp 227–230 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.70 (s, 1 H), 9.48 (s, 1 H), 8.89 (s, 1 H), 8.42 (s, 1 H), 8.03 (m, 3 H), 7.91 (d, <i>J</i> = 8.9 Hz, 1 H), 7.78 (d, <i>J</i> = 3.7 Hz, 1 H), 7.70–7.59 (m, 4 H), 7.22 (s, 1 H), 6.87 (dd, <i>J</i> = 3.7, 0.4 Hz, 1 H), 6.76 (m, 1 H), 6.59 (d, <i>J</i> = 15.4 Hz, 1 H), 4.27 (q, <i>J</i> = 7.0 Hz, 2 H), 3.61 (t, <i>J</i> = 4.5 Hz, 4 H), 3.15 (dd, <i>J</i> = 6.0, 1.1 Hz, 2 H), 2.40 (t, <i>J</i> = 4.4 Hz, 4 H), 1.45 (t, <i>J</i> = 7.0 Hz, 3 H). Anal. (C<sub>32</sub>H<sub>32</sub>N<sub>6</sub>O<sub>5</sub>S·<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> (2<i>E</i>)-<i>N</i>-[7-Methoxy-4-(4-phenoxyanilino)-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide (<b>61</b>)</h4><div class="NLM_p last">Application of general procedure 3 to compound <b>87</b>, using 4-phenoxyaniline as the aniline and piperidine as the amine, gave the title compound <b>61</b>, mp 115–116 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.62 (d, <i>J</i> = 19.0 Hz, 2 H), 8.85 (s, 1 H), 8.41 (s, 1 H), 7.75 (m, 2 H), 7.32 (m, 2 H), 7.21 (s, 1 H), 7.05 (t, <i>J</i> = 7.3 Hz, 1 H), 7.00 (m, 4 H), 6.75 (m, 1 H), 6.48 (d, <i>J</i> = 15.4 Hz, 1 H), 3.95 (s, 3 H), 3.05 (d, <i>J</i> = 4.9 Hz, 2 H), 2.30 (m, 4 H), 1.47 (m, 4 H), 1.34 (m, 2 H). Anal. (C<sub>30</sub>H<sub>31</sub>N<sub>5</sub>O<sub>3</sub>·1<sup>1</sup>/<sub>5</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> (2<i>E</i>)-<i>N</i>-{7-Methoxy-4-[4-(2-pyridinylmethyl)anilino]-6-quinazolinyl}-4-(1-pyrrolidinyl)-2-butenamide Trihydrochloride (<b>62</b>)</h4><div class="NLM_p last">Application of general procedure 3 to compound <b>87</b> using 4-(2-pyridinylmethyl)aniline as the aniline and pyrrolidine as the amine, gave the title compound <b>62</b> as a yellow solid, mp 188–193 °C (dec). <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 15.2 (very br s, 1 H), 11.47 (br s, 1 H), 11.34 (s, 1 H), 10.16 (s, 1 H), 9.18 (s, 1 H), 8.81 (s, 1 H), 8.72 (br s, 1 H), 8.23 (br s, 1 H), 7.78–7.65 (m, 2 H), 7.61 (d, <i>J</i> = 8.4 Hz, 2 H), 7.50–7.43 (m, 3 H), 6.93 (dt, <i>J</i> = 15.4, 6.7 Hz, 1 H), 6.79 (br d, <i>J</i> = 15.5 Hz, 1 H), 4.37 (br s, 2 H), 4.07 (s, 3 H), 4.02 (m, 2 H), 3.54 (m, 2 H, by D<sub>2</sub>O exchange), 3.03 (m, 2 H), 2.04 (m, 2 H), 1.90 (m, 2 H). Anal. (C<sub>29</sub>H<sub>33</sub>Cl<sub>3</sub>N<sub>6</sub>O<sub>2</sub>.H<sub>2</sub>O·EtOAc) C, H, N.</div></div><div id="sec5_3_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> (2<i>E</i>)-<i>N</i>-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}-7-ethoxy-6-quinazolinyl)-4-(1-pyrrolidinyl)-2-butenamide Dihydrochloride (<b>63</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 3 using 3-chloro-4-[(3-fluorobenzyl)oxy]aniline as the aniline and pyrrolidine as the amine, mp 177–181 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 11.41 (br s, 1 H), 11.26 (br s, 1 H), 10.00 (s, 1 H), 9.14 (s, 1 H), 8.85 (s, 1 H), 7.83 (d, <i>J</i> = 2.5 Hz, 1 H), 7.57 (dd, <i>J</i> = 8.9, 2.5 Hz, 1 H), 7.51–7.46 (m, 1 H), 7.45 (s, 1 H), 7.36–7.29 (m, 3 H), 7.19 (ddd, <i>J</i> = 9.0, 8.9, 1.8 Hz, 1 H), 6.97–6.90 (m, 1 H), 6.79 (d, <i>J</i> = 15.4 Hz, 1 H), 5.30 (s, 2 H), 4.35 (q, <i>J</i> = 6.9 Hz, 2 H), 4.03 (t, <i>J</i> = 5.8 Hz, 2 H), 3.55–3.43 (m, 4 H), 3.08–2.97 (m, 2 H), 2.08–1.98 (m, 2 H), 1.96–1.85 (m, 2 H), 1.50 (t, <i>J</i> = 6.9 Hz, 3 H). LCMS (APCI<sup>+</sup>) 577 (100%). Anal. (C<sub>31</sub>H<sub>31</sub>ClFN<sub>5</sub>O<sub>3</sub>·2HCl·1<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> (2<i>E</i>)-<i>N</i>-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}-7-ethoxy-6-quinazolinyl)-4-(4-methyl-1-piperazinyl)-2-butenamide Dihydrochloride (<b>64</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 3 using 3-chloro-4-[(3-fluorobenzyl)oxy]aniline as the aniline and 4-methylpiperazine as the amine, mp 178–180 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 11.30 (br s, 1 H), 9.92 (s, 1 H), 9.15 (s, 1 H), 8.84 (s, 1 H), 7.82 (d, <i>J</i> = 2.5 Hz, 1 H), 7.57 (dd, <i>J</i> = 8.9, 2.5 Hz, 1 H), 7.51–7.46 (m, 1 H), 7.45 (s, 1 H), 7.36–7.29 (m, 3 H), 7.19 (ddd, <i>J</i> = 9.0, 8.9, 1.8 Hz, 1 H), 6.95–6.86 (m, 1 H), 6.75 (d, <i>J</i> = 15.4 Hz, 1 H), 5.30 (s, 2 H), 4.35 (q, <i>J</i> = 6.9 Hz, 2 H), 3.73 (m, obscured by water), 3.17 (s, 3 H), 2.80 (br s, 2 H), 1.50 (t, <i>J</i> = 6.9 Hz, 3 H). LCMS (APCI<sup>+</sup>) 606 (100%). Anal. (C<sub>32</sub>H<sub>34</sub>ClFN<sub>6</sub>O<sub>3</sub>·2HCl·4H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_3_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> (2<i>E</i>)-<i>N</i>-{7-Ethoxy-4-[4-(2-pyridinylmethoxy)anilino]-6-quinazolinyl}-4-(1-pyrrolidinyl)-2-butenamide (<b>65</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 3 using 4-(2-pyridinylmethoxy)aniline as the aniline and pyrrolidine as the amine, mp 169–172 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.57 (br s, 1 H), 9.47 (br s, 1 H), 8.86 (br s, 1 H), 8.59 (d, <i>J</i> = 4.1 Hz, 1 H), 8.40 (s, 1 H), 7.85 (ddd, <i>J</i> = 7.7, 7.7, 1.7 Hz, 1 H), 7.64 (d, <i>J</i> = 9.0 Hz, 2 H), 7.54 (d, <i>J</i> = 7.8 Hz, 1 H), 7.36 (dd, <i>J</i> = 5.1, 6.8 Hz, 1 H), 7.21 (s, 1 H), 7.04 (d, <i>J</i> = 9.0 Hz, 2 H), 6.84 (ddd, <i>J</i> = 5.8, 5.8, 15.4 Hz, 1 H), 6.57 (br d, <i>J</i> = 15.4 Hz, 1 H), 5.19 (s, 2 H), 4.27 (q, <i>J</i> = 6.9 Hz, 2 H), 3.3 (obscured d, <i>J</i> = 5.9 Hz, 2 H), 2.50 (br s, 4 H), 1.73 (br s, 4 H),1.45 (t, <i>J</i> = 6.9 Hz, 3 H). Anal. (C<sub>30</sub>H<sub>32</sub>N<sub>6</sub>O<sub>3</sub>·2<sup>1</sup>/<sub>5</sub>H<sub>2</sub>O) C, N, H: calcd, 6.50; found, 5.96.</div></div><div id="sec5_3_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> (2<i>E</i>)-<i>N</i>-{7-Ethoxy-4-[4-(2-pyridinylmethoxy)anilino]-6-quinazolinyl}-4-(4-methyl-1-piperazinyl)-2-butenamide Trihydrochloride (<b>66</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 3 using 4-(2-pyridinylmethoxy)aniline as the aniline and 4-methylpiperazine as the amine, mp 194–197 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ (free base): 9.56 (s, 1 H), 9.48 (s, 1 H), 8.85 (s, 1 H), 8.59 (d, <i>J</i> = 4.1 Hz, 1 H), 8.40 (s, 1 H), 7.85 (dt, <i>J</i> = 7.7, 1.7 Hz, 1 H), 7.64 (d, <i>J</i> = 9.0 Hz, 2 H), 7.54 (d, <i>J</i> = 7.8 Hz, 1 H), 7.35 (dd, <i>J</i> = 6.7, 4.9 Hz, 1 H), 7.21 (s, 1 H), 7.04 (d, <i>J</i> = 9.0 Hz, 2 H), 6.78 (dt, <i>J</i> = 15.4, 6.2 Hz, 1 H), 6.54 (br d, <i>J</i> = 15.3 Hz, 1 H), 5.19 (s, 2 H), 4.27 (q, <i>J</i> = 7.0 Hz, 2 H), 3.14 (br d, <i>J</i> = 5.5 Hz, 2 H), 2.46–2.26 (br m, 8 H), 2.16 (s, 3 H), 1.45 (t, <i>J</i> = 7.0 Hz, 3 H). Anal. (C<sub>31</sub>H<sub>38</sub>Cl<sub>3</sub>N<sub>7</sub>O<sub>3</sub>·2H<sub>2</sub>O·EtOAc) C, H, N.</div></div><div id="sec5_3_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> (2<i>E</i>)-<i>N</i>-(7-Ethoxy-4-{4-[(phenylsulfonyl)amino]anilino}-6-quinazolinyl)-4-(1-pyrrolidinyl)-2-butenamide (<b>67</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 3 using <i>N</i>-(4-aminophenyl)benzenesulfonamide as the aniline and pyrrolidine as the amine, mp 115–119 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.12 (s, 1 H), 9.57 (s, 1 H), 9.44 (s, 1 H), 8.85 (s, 1 H), 8.41 (s, 1 H), 7.76 (br d, <i>J</i> = 7.0 Hz, 2 H), 7.65–7.50 (m, 5 H), 7.21 (s, 1 H), 7.06 (br d, <i>J</i> = 8.9 Hz, 2 H), 6.83 (dt, <i>J</i> = 15.4, 5.8 Hz, 1 H), 6.56 (br d, <i>J</i> = 15.6 Hz, 1 H), 4.27 (q, <i>J</i> = 7.0 Hz, 2 H), 3.30 (d, <i>J</i> = 5.6 Hz, 2 H; by D<sub>2</sub>O exchange), 2.51–2.49 (m, 4 H), 1.76–1.68 (br m, 4 H), 1.45 (t, <i>J</i> = 7.0 Hz, 3 H). Anal. (C<sub>30</sub>H<sub>32</sub>N<sub>6</sub>O<sub>4</sub>S·<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O·1<sup>1</sup>/<sub>4</sub>MeOH) C, H, N.</div></div><div id="sec5_3_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> (2<i>E</i>)-<i>N</i>-(7-Ethoxy-4-{4-[(phenylsulfonyl)amino]anilino}-6-quinazolinyl)-4-(4-morpholinyl)-2-butenamide (<b>68</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 3 using <i>N</i>-(4-aminophenyl)benzenesulfonamide as the aniline and morpholine as the amine, mp 157–160 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.12 (br s, 1 H), 9.57 (s, 1 H), 9.46 (s, 1 H), 8.84 (s, 1 H), 8.41 (s, 1 H), 7.76 (m, 2 H), 7.66–7.50 (m, 5 H), 7.21 (s, 1 H), 7.06 (m, 2 H), 6.78 (dt, <i>J</i> = 15.4, 6.1 Hz, 1 H), 6.56 (br d, <i>J</i> = 15.3 Hz, 1 H), 4.27 (q, <i>J</i> = 7.0 Hz, 2 H), 3.61 (t, <i>J</i> = 4.6 Hz, 4 H), 3.15 (dd, <i>J</i> = 6.1, 1.2 Hz, 2 H), 2.40 (t, <i>J</i> = 4.4 Hz, 4 H) 1.44 (t, <i>J</i> = 7.0 Hz, 3 H). Anal. (C<sub>30</sub>H<sub>32</sub>N<sub>6</sub>O<sub>5</sub>S·<sup>1</sup>/<sub>2</sub>MeOH) C, H, N.</div></div><div id="sec5_3_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> (2<i>E</i>)-<i>N</i>-(7-Ethoxy-4-{4-[(phenylsulfonyl)amino]anilino}-6-quinazolinyl)-4-(4-methyl-1-piperazinyl)-2-butenamide (<b>69</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 3 using <i>N</i>-(4-aminophenyl)benzenesulfonamide as the aniline and 4-methylpiperazine as the amine, mp 151–155 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.12 (br s, 1 H), 9.56 (s, 1 H), 9.45 (s, 1 H), 8.84 (s, 1 H), 8.41 (s, 1 H), 7.76 (m, 2 H), 7.66–7.52 (m, 5 H), 7.21 (s, 1 H), 7.06 (br d, <i>J</i> = 8.8 Hz, 2 H), 6.77 (dt, <i>J</i> = 15.4, 6.1 Hz, 1 H), 6.54 (br d, <i>J</i> = 15.4 Hz, 1 H), 4.27 (q, <i>J</i> = 7.0 Hz, 2 H), 3.13 (br d, <i>J</i> = 5.1 Hz, 2 H), 2.45–2.25 (br m, 8 H), 2.16 (s, 3 H), 1.44 (t, <i>J</i> = 7.0 Hz, 3 H). Anal. (C<sub>31</sub>H<sub>35</sub>N<sub>7</sub>O<sub>4</sub>S·1<sup>3</sup>/<sub>4</sub>H<sub>2</sub>O·<sup>3</sup>/<sub>4</sub>MeOH) C, H, N.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> General Procedure <b>4</b>: Synthesis of Pyrido[3,4-<i>d</i>]pyrimidines of <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a></h3><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> <i>N</i>-(1-Benzyl-1<i>H</i>-indazol-5-yl)-6-fluoropyrido[3,4-<i>d</i>]pyrimidin-4-amine (<b>96A5</b>)</h4><div class="NLM_p last">6-Fluoropyrido[3,4-<i>d</i>]pyrimidin-4(3<i>H</i>)-one (<b>95</b>)<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> (1.00 g, 6.06 mmol) was suspended in SOCl<sub>2</sub> (80 mL), to which was added DMF (1 drop). The mixture was heated at reflux for 2 h, then the solvent was distilled off under reduced pressure. The resulting crude 4-chloro-6-fluoropyrido[3,4-<i>d</i>]pyrimidine was then dissolved in a mixture of iPrOH (80 mL) and CH<sub>2</sub>Cl<sub>2</sub> (50 mL), 1-benzyl-1<i>H</i>-indazol-5-amine (1.62 g, 7.27 mmol) was added, and the mixture heated at reflux for 0.75 h. After cooling, the reaction mixture was concentrated under reduced pressure, then the suspension was poured into saturated NaHCO<sub>3</sub> solution (400 mL). The resulting solid was extracted with 10% MeOH/CH<sub>2</sub>Cl<sub>2</sub> (4 × 100 mL) then the combined organic extracts were washed with brine (200 mL) and dried (Na<sub>2</sub>SO<sub>4</sub>). Filtration, followed by removal of the solvent under reduced pressure, afforded a crude solid which was purified by chromatography on silica gel (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub> as eluant). The title compound <b>96A5</b> was isolated as yellow–orange plates (1.94 g, 87%), mp 202–205 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.15 (br s, 1 H), 8.92 (s, 1 H), 8.63 (s, 1 H), 8.27 (s, 2 H), 8.16 (s, 1 H), 7.75 (d, <i>J</i> = 9.0 Hz, 1 H), 7.69 (dd, <i>J</i> = 9.0, 1.8 Hz, 1 H), 7.35–7.22 (m, 5 H), 5.68 (s, 2 H). LCMS (APCI<sup>+</sup>) 371. Anal. (C<sub>21</sub>H<sub>15</sub>FN<sub>6</sub>) C, H, N.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> <i>N</i><sup>4</sup>-(1-Benzyl-1<i>H</i>-indazol-5-yl)-<i>N</i><sup>6</sup>-(4-methoxybenzyl)pyrido[3,4-<i>d</i>]pyrimidine-4,6-diamine (<b>97A5</b>)</h4><div class="NLM_p last">Compound <b>96A5</b> (3.85 g, 10.4 mmol) was dissolved in DMSO (50 mL), to which was added 4-methoxybenzylamine (7.14 g, 52.0 mmol). The mixture was heated to 120 °C with stirring for 24 h. The reaction was allowed to cool, then partitioned between water (200 mL) and EtOAc (200 mL). A bright-yellow solid crystallized out of this mixture and was collected by filtration and dried, affording the title compound <b>97A5</b> (3.21 g, 63%), mp 204–206 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.68 (s, 1 H), 8.71 (s, 1 H), 8.28 (s, 1 H), 8.20 (d, <i>J</i> = 1.2 Hz, 1 H), 8.12 (d, <i>J</i> = 0.8 Hz, 1 H), 7.71 (d, <i>J</i> = 9.0 Hz, 1 H), 7.66 (dd, <i>J</i> = 9.0, 1.9 Hz, 1 H), 7.37–7.16 (m, 9 H), 6.91–6.85 (m, 2 H), 5.67 (s, 2 H), 4.49 (d, <i>J</i> = 6.4 Hz, 2 H), 3.71 (s, 3 H). LCMS (APCI<sup>+</sup>) 488. Anal. (C<sub>29</sub>H<sub>25</sub>N<sub>7</sub>O) C, H, N.</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> <i>N</i><sup>4</sup>-(1-Benzyl-1<i>H</i>-indazol-5-yl)pyrido[3,4-<i>d</i>]pyrimidine-4,6-diamine (<b>98A5</b>)</h4><div class="NLM_p last">Compound <b>97A5</b> (1.46 g, 3.00 mmol) was dissolved in TFA (15 mL) and stirred at room temperature for 6 h. The TFA was then evaporated off under a stream of nitrogen to give an oil which was dissolved in EtOAc (200 mL) and washed with saturated NaHCO<sub>3</sub> solution (2 × 200 mL), brine (200 mL), and dried (Na<sub>2</sub>SO<sub>4</sub>). Filtration, followed by removal of the solvent under reduced pressure, afforded a residue which was purified by chromatography on silica gel (10% MeOH/CH<sub>2</sub>Cl<sub>2</sub> as eluant) to give the title compound <b>98A5</b> as a yellow crystalline solid (763 mg, 69%), mp 231–234 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 9.72 (s, 1 H), 8.67 (s, 1 H), 8.29 (s, 1 H), 8.25 (t, <i>J</i> = 1.2 Hz, 1 H), 8.12 (s, 1 H), 7.68 (d, <i>J</i> = 1.1 Hz, 2 H), 7.34–7.22 (m, 5 H), 7.17 (d, <i>J</i> = 0.6 Hz, 1 H), 6.20 (br s, 2 H), 5.66 (s, 2 H). Anal. (C<sub>21</sub>H<sub>17</sub>N<sub>7</sub>) C, H, N.</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> (<i>E</i>)-<i>N</i>-(4-(1-Benzyl-1<i>H</i>-indazol-5-ylamino)pyrido[3,4-<i>d</i>]pyrimidin-6-yl)-4-bromobut-2-enamide (<b>99A5</b>)</h4><div class="NLM_p last">(<i>E</i>)-4-Bromobut-2-enoic acid (420 mg, 2.51 mmol) was converted to the corresponding acid chloride using the same method as described for <b>93</b>. The resulting oil was dissolved in dry THF (10 mL) and added dropwise to a solution of <b>98A5</b> (710 mg, 1.93 mmol) and TEA (390 mg, 3.86 mmol) in THF (50 mL), which had been previously cooled to −20 °C (ice/salt/water) under nitrogen. The resulting reaction mixture was stirred at this temperature for 4 h, then partitioned between EtOAc (100 mL) and saturated NaHCO<sub>3</sub> solution (100 mL). One further extraction was performed with EtOAc, then the organic extracts combined, washed with brine (100 mL), and dried (Na<sub>2</sub>SO<sub>4</sub>). Filtration, followed by removal of the solvent under reduced pressure, afforded a residue which was purified by filtration through a plug of silica gel (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub> as eluant). The title compound <b>99A5</b> was isolated as an unstable orange foam (707 mg, 71%), which was used immediately in the next step. LCMS (APCI<sup>+</sup>) 514, 516.</div></div><div id="sec5_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> (2<i>E</i>)-<i>N</i>-{4-[(1-Benzyl-1<i>H</i>-indazol-5-yl)amino]pyrido[3,4-<i>d</i>]pyrimidin-6-yl}-4-(dimethylamino)-2-butenamide (<b>74</b>)</h4><div class="NLM_p last">Compound <b>99A5</b> (324 mg, 0.63 mmol) was dissolved in DMA (10 mL), cooled to −20 °C (ice/salt/water), and then 40% aqueous dimethylamine added (709 mg, 6.30 mmol) and stirring continued at this temperature for 1 h. The reaction mixture was diluted with water (50 mL) and poured into saturated NaHCO<sub>3</sub> solution (100 mL). The resulting yellow precipitate was extracted into EtOAc (3 × 80 mL) and the combined EtOAc fractions washed with brine (100 mL) and dried (Na<sub>2</sub>SO<sub>4</sub>). Filtration, followed by removal of the solvent under reduced pressure, afforded a residue which was purified by chromatography on silica gel (5% MeOH/CH<sub>2</sub>Cl<sub>2</sub> as eluant) to give the title compound <b>74</b> as a pale-yellow solid (218 mg, 72%), mp 237–240 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.88 (s, 1 H), 10.29 (s, 1 H), 9.00 (d, 1 H), 8.98 (s, 1 H), 8.52 (s, 1 H), 8.18 (d, 1 H), 8.13 (s, 1 H), 7.73–7.66 (m, 2 H), 7.36–7.23 (m, 5 H), 6.87 (dt, <i>J</i> = 15.4, 6.0 Hz, 1 H), 6.52 (dt, <i>J</i> = 15.4, 1.5 Hz, 1 H), 5.69 (s, 2 H), 3.09 (dd, <i>J</i> = 6.0, 1.3 Hz, 2 H), 2.19 (s, 6 H). Anal. (C<sub>27</sub>H<sub>26</sub>N<sub>8</sub>O·<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> (2<i>E</i>)-<i>N</i>-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-<i>d</i>]pyrimidin-6-yl]-4-(dimethylamino)-2-butenamide (<b>70</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 4 using 3-chloro-4-fluoroaniline as the aniline, mp 182–186 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.90 (s, 1 H), 10.30 (s, 1 H), 9.01 (s, 1 H), 8.97 (s, 1 H), 8.62 (s, 1 H), 8.12 (s, 1 H), 7.81 (s, 1 H), 7.45 (t, <i>J</i> = 9.1 Hz, 1 H), 6.88 (dt, <i>J</i> = 15.4, 6.1 Hz, 1 H), 6.51 (d, <i>J</i> = 15.4 Hz, 1 H), 3.09 (d, <i>J</i> = 6.4 Hz, 2 H), 2.18 (s, 6 H). LCMS (APCI<sup>+</sup>) 401 (100%). HRMS (FAB<sup>+</sup>) calcd for C<sub>19</sub>H<sub>19</sub>ClFN<sub>6</sub>O, 401.1293 (M<sup>+</sup>); found, 401.1294.</div></div><div id="sec5_4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> (2<i>E</i>)-<i>N</i>-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-<i>d</i>]pyrimidin-6-yl]-4-(1-piperidinyl)-2-butenamide (<b>71</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 4 using 3-chloro-4-fluoroaniline as the aniline and piperidine as the amine, mp 187–190 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.93 (s, 1 H), 10.31 (s, 1 H), 8.99 (s, 1 H), 8.95 (s, 1 H), 8.60 (s, 1 H), 8.10 (d, <i>J</i> = 5.4 Hz, 1 H), 7.79 (m, 1 H), 7.43 (t, <i>J</i> = 9.0 Hz, 1 H), 6.83 (m, 1 H), 6.48 (d, <i>J</i> = 15.4 Hz, 1 H), 3.0 (d, <i>J</i> = 5.4 Hz, 2 H), 2.32 (br s, 4 H), 1.49 (t, <i>J</i> = 5.1 Hz, 4 H), 1.36 (m, 2 H). MS (APCI+) 441.1 (M + H). Anal. (C<sub>22</sub>H<sub>22</sub>N<sub>6</sub>OFCl·H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> (2<i>E</i>)-<i>N</i>-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-<i>d</i>]pyrimidin-6-yl]-4-(4-morpholinyl)-2-butenamide (<b>72</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 4 using 3-chloro-4-fluoroaniline as the aniline and morpholine as the amine, mp 218–220 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.93 (s, 1 H), 10.32 (s, 1 H), 9.01 (s, 1 H), 8.97 (s, 1 H), 8.62 (s, 1 H), 8.13 (br s, 1 H), 7.82 (br s, 1 H), 7.46 (t, <i>J</i> = 9.1 Hz, 1 H), 6.86 (dt, <i>J</i> = 15.4, 5.8 Hz, 1 H), 6.55 (d, <i>J</i> = 15.4 Hz, 1 H), 3.61 (t, <i>J</i> = 4.5 Hz, 4 H), 3.16 (d, <i>J</i> = 5.8 Hz, 2 H), 2.41 (t, <i>J</i> = 4.3 Hz, 4 H). LCMS (APCI<sup>+</sup>) 443 (100%). Anal. (C<sub>21</sub>H<sub>20</sub>ClFN<sub>6</sub>O<sub>2</sub>·H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> (2<i>E</i>)-<i>N</i>-[4-(3-Chloro-4-fluoroanilino)pyrido[3,4-<i>d</i>]pyrimidin-6-yl]-4-(4-methyl-1-piperazinyl)-2-butenamide (<b>73</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 4 using 3-chloro-4-fluoroaniline as the aniline and 4-methylpiperazine as the amine, mp 138–141 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.93 (s, 1 H), 10.31 (s, 1 H), 9.02 (s, 1 H), 8.97 (s, 1 H), 8.63 (s, 1 H), 8.17–8.11 (m, 1 H), 7.87–7.80 (m, 1 H), 7.45 (t, <i>J</i> = 9.1 Hz, 1 H), 6.86 (td, <i>J</i> = 15.4, 5.9 Hz, 1 H), 5.53 (d, <i>J</i> = 15.4 Hz, 1 H), 3.15 (d, <i>J</i> = 5.9 Hz, 2 H), 2.41–2.36 (m, 8 H), 1.99 (s, 3 H). LCMS (APCI<sup>+</sup>) 456 (100%). Anal. (C<sub>22</sub>H<sub>23</sub>ClFN<sub>7</sub>O·<sup>1</sup>/<sub>2</sub>MeOH·<sup>1</sup>/<sub>4</sub>CH<sub>2</sub>Cl<sub>2</sub>) C, H, N.</div></div><div id="sec5_4_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> (2<i>E</i>)-<i>N</i>-{4-[(1-Benzyl-1<i>H</i>-indazol-5-yl)amino]pyrido[3,4-<i>d</i>]pyrimidin-6-yl}-4-(1-pyrrolidinyl)-2-butenamide (<b>75</b>)</h4><div class="NLM_p last">Reaction of bromide <b>99A5</b> with pyrrolidine, using the same method as described for <b>74</b>, afforded the title compound <b>75</b> as a pale-yellow solid (30%), mp 224–226 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.86 (s, 1 H), 10.29 (s, 1 H), 9.00 (s, 1 H) 8.98 (s, 1 H), 8.52 (s, 1 H), 8.16 (s, 1 H), 8.14 (d, 1 H), 7.73–7.65 (m, 2 H), 7.35–7.23 (m, 5 H), 6.92 (dt, <i>J</i> = 15.4, 5.8 Hz, 1 H), 6.53 (d, <i>J</i> = 15.4 Hz, 1 H), 5.67 (s, 2 H), 3.24 (d, <i>J</i> = 5.1 Hz, 2 H by D<sub>2</sub>O exchange), 2.46 (br s, 4 H by D<sub>2</sub>O exchange), 1.69 (br s, 4 H). Anal. (C<sub>29</sub>H<sub>28</sub>N<sub>8</sub>O·<sup>1</sup>/<sub>2</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_4_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> (2<i>E</i>)-4-(Dimethylamino)-<i>N</i>-[4-(4-phenoxybenzyl)pyrido[3,4-<i>d</i>]pyrimidin-6-yl]-2-butenamide dihydrochloride (<b>76</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 4 using 4-phenoxyaniline as the aniline, mp 229–235 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 11.57 (br, 1H), 11.41 (s, 1 H), 11.12 (br, 1H), 9.16 (s, 1 H), 9.15 (s, 1 H), 8.82 (s, 1H), 7.73 (d, <i>J</i> = 6.7 Hz, 2H), 7.45–7.41 (m, 2H), 7.20–6.95 (m, 6H), 6.70 (d, <i>J</i> = 15.4 Hz, 1H), 3.97 (dd, <i>J</i> = 7.0, 5.5 Hz, 2H), 2.77, 2.76 (2s, 6H). LCMS (APCI<sup>+</sup>) 440 (100%). Anal. (C<sub>26</sub>H<sub>25</sub>N<sub>5</sub>O<sub>2</sub>·2HCl·H<sub>2</sub>O·MeOH) C, H, N.</div></div><div id="sec5_4_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> (2<i>E</i>)-<i>N</i>-[4-(4-Phenoxybenzyl)pyrido[3,4-<i>d</i>]pyrimidin-6-yl]-4-(1-pyrrolidinyl)-2-butenamide Dihydrochloride (<b>77</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 4 using 4-phenoxyaniline as the aniline and pyrrolidine as the amine, mp 200–205 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 11.64 (br, 2H), 11.43 (s, 1 H), 9.21 (s, 1 H), 9.16 (s, 1 H), 8.85 (s, 1H), 7.73 (d, <i>J</i> = 6.8 Hz, 2H), 7.45–7.40 (m, 2H), 7.20–6.97 (m, 6H), 6.71 (d, <i>J</i> = 15.5 Hz, 1H), 4.04 (dd, <i>J</i> = 6.6, 5.8 Hz, 2H), 3.48 (m, 2H), 3.02 (m, 2H), 2.02 (m, 2H), 1.91 (m, 2H). LCMS (APCI<sup>+</sup>) 466 (100%). Anal. (C<sub>28</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub>·2HCl·2H<sub>2</sub>O·<sup>1</sup>/<sub>2</sub>Et<sub>2</sub>O) C, H, N.</div></div><div id="sec5_4_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> (2<i>E</i>)-4-(Dimethylamino)-<i>N</i>-{4-[4-(2-pyridinylmethyl)anilino]pyrido[3,4-<i>d</i>]pyrimidin-6-yl}-2-butenamide (<b>78</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 4 using 4-(2-pyridinylmethyl)aniline as the aniline, mp 196–199 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.92 (s, 1 H), 10.20 (s, 1 H), 8.98 (s, 1 H), 8.97 (s, 1 H), 8.53 (s, 1 H), 8.49 (ddd, <i>J</i> = 4.9, 1.8, 0.9 Hz, 1 H), 7.75–7.65 (m, 3 H), 7.35–7.25 (m, 3 H), 7.22 (ddd, <i>J</i> = 7.5, 4.9, 1.0 Hz, 1 H), 6.86 (dt, <i>J</i> = 15.4, 6.0 Hz, 1 H), 6.50 (d, <i>J</i> = 15.4 Hz, 1 H), 4.09 (s, 2 H), 3.08 (br d, <i>J</i> = 5.6 Hz, 2 H), 2.17 (s, 6 H). LCMS (APCI<sup>+</sup>) 440 (100%). Anal. (C<sub>25</sub>H<sub>25</sub>N<sub>7</sub>O·<sup>1</sup>/<sub>3</sub>H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_4_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> (2<i>E</i>)-<i>N</i>-{4-[4-(2-Pyridinylmethyl)anilino]pyrido[3,4-<i>d</i>]pyrimidin-6-yl}-4-(1-pyrrolidinyl)-2-butenamide (<b>79</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 4 using 4-(2-pyridinylmethyl)aniline as the aniline and pyrrolidine as the amine, mp 159–163 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.90 (s, 1 H), 10.20 (s, 1 H), 8.98 (s, 1 H), 8.97 (s, 1 H), 8.53 (s, 1 H), 8.49 (ddd, <i>J</i> = 4.9, 1.8, 0.8 Hz, 1 H), 7.75–7.65 (m, 3 H), 7.35–7.25 (m, 3 H), 7.22 (ddd, <i>J</i> = 7.5, 4.9, 1.1 Hz, 1 H), 6.90 (dt, <i>J</i> = 15.4, 5.8 Hz, 1 H), 6.52 (d, <i>J</i> = 15.4 Hz, 1 H), 4.09 (s, 2 H), 3.25 (dd, <i>J</i> = 5.8, 1.4 Hz, 2 H), 2.48 (br s, 4 H), 1.71 (br s, 4 H). LCMS (APCI<sup>+</sup>) 466 (100%). Anal. (C<sub>27</sub>H<sub>27</sub>N<sub>7</sub>O·H<sub>2</sub>O) C, H, N.</div></div><div id="sec5_4_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> (2<i>E</i>)-4-(4-Methyl-1-piperazinyl)-<i>N</i>-{4-[4-(2-pyridinylmethyl)anilino]pyrido[3,4-<i>d</i>]pyrimidin-6-yl}-2-butenamide (<b>80</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 4 using 4-(2-pyridinylmethyl)aniline as the aniline and 4-methylpiperazine as the amine, mp 176–180 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.88 (s, 1 H), 10.17 (s, 1 H), 8.97 (s, 1 H), 8.96 (s, 1 H), 8.53 (s, 1 H), 8.50 (ddd, <i>J</i> = 4.9, 1.8, 0.9 Hz, 1 H), 7.75–7.65 (m, 3 H), 7.35–7.25 (m, 3 H), 7.22 (ddd, <i>J</i> = 7.5, 4.9, 1.0 Hz, 1 H), 6.86 (dt, <i>J</i> = 15.4, 6.0 Hz, 1 H), 6.50 (d, <i>J</i> = 15.4 Hz, 1 H), 4.09 (s, 2 H), 3.13 (br d, <i>J</i> = 5.6 Hz, 2 H), 2.41 (br s, 4 H), 2.35 (br s, 4 H), 2.16 (s, 3 H). LCMS (APCI<sup>+</sup>) 495 (100%). Anal. (C<sub>28</sub>H<sub>30</sub>N<sub>8</sub>O·<sup>3</sup>/<sub>5</sub>CH<sub>2</sub>Cl<sub>2</sub>) C, H, N.</div></div><div id="sec5_4_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> (2<i>E</i>)-<i>N</i>-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}pyrido[3,4-<i>d</i>]pyrimidin-6-yl)-4-(dimethylamino)-2-butenamide (<b>81</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 4 using 3-chloro-4-[(3-fluorobenzyl)oxy]aniline as the aniline, mp 210–214 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.88 (s, 1 H), 10.19 (s, 1 H), 8.99 (s, 1 H), 8.96 (s, 1 H), 8.58 (s, 1 H), 7.98 (s, 1 H), 7.72 (d, <i>J</i> = 7.3 Hz, 1 H), 7.50–7.43 (m, 1 H), 7.35–7.25 (m, 3 H), 7.21–7.14 (m, 1 H), 6.87 (dt, <i>J</i> = 15.4, 6.0 Hz, 1 H), 6.51 (d, <i>J</i> = 15.4 Hz, 1 H), 5.26 (s, 2 H), 3.09 (dd, <i>J</i> = 6.0, 1.3 Hz, 2 H), 2.19 (s, 6 H). LCMS (APCI<sup>+</sup>) 507 (100%). Anal. (C<sub>26</sub>H<sub>24</sub>ClFN<sub>6</sub>O<sub>2</sub>) C, H, N.</div></div><div id="sec5_4_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> (2<i>E</i>)-<i>N</i>-(4-{3-Chloro-4-[(3-fluorobenzyl)oxy]anilino}pyrido[3,4-<i>d</i>]pyrimidin-6-yl)-4-(1-pyrrolidinyl)-2-butenamide (<b>82</b>)</h4><div class="NLM_p last">The title compound was prepared according to general procedure 4 using 3-chloro-4-[(3-fluorobenzyl)oxy]aniline as the aniline and pyrrolidine as the amine, mp 188–192 °C. <sup>1</sup>H NMR [(CD<sub>3</sub>)<sub>2</sub>SO] δ 10.87 (s, 1 H), 10.20 (s, 1 H), 8.99 (s, 1 H), 8.96 (s, 1 H), 8.58 (s, 1 H), 7.99 (d, <i>J</i> = 2.6 Hz, 1 H), 7.73 (dd, <i>J</i> = 8.9, 2.6 Hz, 1 H), 7.51–7.44 (m, 1 H), 7.35–7.25 (m, 3 H), 7.21–7.15 (m, 1 H), 6.91 (dt, <i>J</i> = 15.4, 5.8 Hz, 1 H), 6.53 (d, <i>J</i> = 15.4 Hz, 1 H), 5.27 (s, 2 H), 3.23 (d, <i>J</i> = 5.3 Hz, 2 H), 1.72 (p, <i>J</i> = 3.1 Hz, 4 H) (other 4 H peak under DMSO-<i>d</i><sub>6</sub>). LCMS (APCI<sup>+</sup>) 533 (100%). Anal. (C<sub>28</sub>H<sub>26</sub>ClFN<sub>6</sub>O<sub>2</sub>·H<sub>2</sub>O) C, H, N.</div></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> ELISA-Based erbB and JAK3 Kinase Assays</h3><div class="NLM_p last">Inhibitory activity against the catalytic domains of erbB1, erbB2, erbB4, and JAK3 was assessed using ELISA-based receptor tyrosine kinase assays, as described previously.<a onclick="showRef(event, 'ref20 ref83'); return false;" href="javascript:void(0);" class="ref ref20 ref83">(20, 83)</a></div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> Inhibition of erbB1 and erbB2 Autophosphorylation in Cells</h3><div class="NLM_p last">Inhibition of erbB1 tyrosine kinase activity was evaluated in NIH3T3 cells transfected with the full-length human erbB1 receptor, and inhibition of erbB2 tyrosine kinase activity was evaluated in T24 NIH 3T3 cells transfected with a chimeric receptor with the extracellular binding domain of erbB1 and the intracellular kinase domain of erbB2. These lines were a gift from Dr. Bruce Cohen (National Cancer Institute, Bethesda, MD), and the derivation of these lines has been previously described.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Inhibition of erbB1 and erbB2 autophosphorylation was detected using BioVeris technology, as previously described.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> Inhibition of EGF-Stimulated erbB1 Autophosphorylation in A431 Cells</h3><div class="NLM_p last">To determine the rate at which test compounds could irreversibly inhibit EGF-induced phosphorylation of erbB1 in cells, A431 cells were incubated with 2 μmol/L of test compound for varying lengths of time (1, 5, 30, 60, or 120 min). Medium was removed, and cells were repeatedly washed thrice with serum-free and inhibitor-free medium every hour for 2 h. After the last wash, cells were stimulated with 100 ng/mL of EGF (Sigma) for 5 min at 37 °C. Medium was removed, and cells were immediately lysed in buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol, 1 mM EDTA, 1% Triton, 10 mM β-glycerophosphate, 0.1 mM NaVa, 1 mM NaF, 0.25% deoxycholic acid, 10 μg/mL aprotinin, 10 μg/mL leupeptin) for 15 min at room temperature, mixing gently. Inhibition of erbB1 phosphorylation was assessed using a sandwich ELISA approach employing the BioVeris technology as previously described.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> Human and Rat Liver Microsome and Hepatocyte Stability Assessment</h3><div class="NLM_p last">Cryopreserved rat and human hepatocytes were obtained from XenoTech, LLC (Lenexa, Kansas). Liver microsomes were obtained from BD Gentest (Woburn, Massachusetts). Test compoundss were incubated at 37 °C with hepatocytes in Leibovitz’s L-15 medium (Invitrogen, Carlsbad, California) and with liver microsomes in a shaking water bath. Aliquots (100 μL) from incubations were harvested at various time points thereafter, where 100 μL of sample was dried down under a steady stream of nitrogen before being reconstituted with 100 μL of mobile phase and analyzed with mass spectrometric detection.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> In Vivo Assessment of erbB1 Pharmacodynamic Effects</h3><div class="NLM_p last">Test compounds were given orally to mice implanted subcutaneously with NIH 3T3 cells transfected with the full-length human erbB1 receptor (described above). Modulation of erbB1 autophosphorylation was assessed in tumors after dosing using Western blotting techniques. Briefly, mice (3 per cohort) were dosed once a day for 2 days with test compounds at a dose of 30, 65, and 130 mg/kg. Tumor samples were harvested at 6 or 24 h after the last dose. Excised tumors were immediately frozen in liquid nitrogen and ground into a powder over liquid nitrogen using a mortar and pestle. Powders (100–500 mg) were suspended in 0.1–1.5 mL of ice-cold cell lysis buffer [50 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 5 mmol/L EDTA, 50 mmol/L β-glycerophosphate, 0.1% SDS, 1% Triton, 0.2% deoxycholate, 1 mmol/L sodium vanadate, and 1 EDTA-free Complete protease inhibitor tablet from Roche] and homogenized with a Polytron hand-held tissue homogenizer. Protein concentrations were determined on clarified lysates using a Bradford protein assay (Bio-Rad) or BCA reagents (Pierce Biotechnology). For each sample, 50 μg of protein were denatured and separated by SDS PAGE. Proteins were transferred to 0.2 μm nitrocellulose membranes (Invitrogen). Antiphosphorylated erbB1 (Tyr<sup>1068</sup>) from Sigma-Aldrich, Co. was used to detect phosphorylated erbB1.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> Pharmacokinetics</h3><div class="NLM_p last">Male Sprague–Dawley or Wistar rats (Charles River Laboratories), male purebred beagle dogs (Covance), and male cynomolgus monkeys (Biomedical Resources Foundation/Charles River Laboratories) were used for pharmacokinetic assessments. Animals were housed and maintained in accordance with Pfizer Institutional Animal Care and Use Committee, State, and Federal guidelines for the humane treatment and care of laboratory animals. All protocols involving animals were approved by the Pfizer Research and Development Institutional Animal Care and Use Committee. All animals were fasted overnight prior to dosing the next morning, and food was withheld until 4 h following dosing. Water was allowed ad libitum throughout the studies. For each study, blood samples were collected from a jugular cannula into EDTA/ascorbic acid tubes. Sampling occurred prior to dosing and at time points up to 144 h after the iv and the po dose. To assess the concentration of <b>54</b> or <b>71</b> in plasma, protein was precipitated with acetonitrile (50 μL of), and 100 μL of sample was dried down under a steady stream of nitrogen. Samples were reconstituted with 100 μL of mobile phase [40:60 acetonitrile/10 mmol/L ammonium formate (pH 3.5) with formic acid]. Liquid chromatography-tandem mass spectrometry was conducted using a Sciex API 4000 equipped with a Leap Technologies CTCPAL autosampler and a Shimadzu LC-10Avp pump. Drug concentration below the limit of quantitation (<5 ng/mL) was treated as zero for pharmacokinetic and statistical calculations.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i111"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00883">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67044" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67044" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b00883" class="ext-link">10.1021/acs.jmedchem.6b00883</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic procedures for the synthesis of anilines (A6, A11, A13, A14, A31, A32) of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> and combustion analytical data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_001.pdf">jm6b00883_si_001.pdf (237.56 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_002.csv">jm6b00883_si_002.csv (7.11 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b00883" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33840" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33840" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeff B. Smaill</span> - <span class="hlFld-Affiliation affiliation">Auckland
Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span>; 
    <span class="hlFld-Affiliation affiliation">Maurice
Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2f45015c424e4643436f4e5a4c44434e414b014e4c014155"><span class="__cf_email__" data-cfemail="d1bbffa2bcb0b8bdbd91b0a4b2babdb0bfb5ffb0b2ffbfab">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea J. Gonzales</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julie A. Spicer</span> - <span class="hlFld-Affiliation affiliation">Auckland
Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span>; 
    <span class="hlFld-Affiliation affiliation">Maurice
Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Helen Lee</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jessica E. Reed</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Sexton</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Irene W. Althaus</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tong Zhu</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shannon L. Black</span> - <span class="hlFld-Affiliation affiliation">Auckland
Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adrian Blaser</span> - <span class="hlFld-Affiliation affiliation">Auckland
Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William A. Denny</span> - <span class="hlFld-Affiliation affiliation">Auckland
Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span>; 
    <span class="hlFld-Affiliation affiliation">Maurice
Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul A. Ellis</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Fakhoury</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patricia J. Harvey</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ken Hook</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florence O. J. McCarthy</span> - <span class="hlFld-Affiliation affiliation">Auckland
Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian D. Palmer</span> - <span class="hlFld-Affiliation affiliation">Auckland
Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span>; 
    <span class="hlFld-Affiliation affiliation">Maurice
Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Freddy Rivault</span> - <span class="hlFld-Affiliation affiliation">Auckland
Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Schlosser</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Teresa Ellis</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrew M. Thompson</span> - <span class="hlFld-Affiliation affiliation">Auckland
Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erin Trachet</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">R. Thomas Winters</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haile Tecle</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexander Bridges</span> - <span class="hlFld-Affiliation affiliation">Pfizer
Global Research and Development, Michigan
Laboratories, 2800 Plymouth
Road, Ann Arbor, Michigan 48105-1047, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e9746-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i113">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08186" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08186" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was partially supported by the Auckland Division of the Cancer Society of New Zealand and the Maurice Wilkins Centre for Molecular Biodiscovery.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i114" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i114"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i115" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i115"> Abbreviations Used</h2><tr><td class="NLM_term">APCI</td><td class="NLM_def"><p class="first last">Atmospheric pressure chemical ionization</p></td></tr><tr><td class="NLM_term">BLK</td><td class="NLM_def"><p class="first last">B lymphocyte kinase</p></td></tr><tr><td class="NLM_term">BMX</td><td class="NLM_def"><p class="first last">Bone marrow kinase in chromosome X</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term"><i>C</i><sub>max</sub></td><td class="NLM_def"><p class="first last">maximum serum concentration</p></td></tr><tr><td class="NLM_term">GAK</td><td class="NLM_def"><p class="first last">cyclin G associated kinase</p></td></tr><tr><td class="NLM_term">HEPES</td><td class="NLM_def"><p class="first last">4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid</p></td></tr><tr><td class="NLM_term">JAK3</td><td class="NLM_def"><p class="first last">Janus kinase 3</p></td></tr><tr><td class="NLM_term">LCK</td><td class="NLM_def"><p class="first last">lymphocyte-specific protein tyrosine kinase</p></td></tr><tr><td class="NLM_term">MKNK1</td><td class="NLM_def"><p class="first last">MAP kinase-interacting serine/threonine-protein kinase 1</p></td></tr><tr><td class="NLM_term">RIPK2</td><td class="NLM_def"><p class="first last">receptor-interacting serine/threonine–protein kinase 2</p></td></tr><tr><td class="NLM_term">T790M</td><td class="NLM_def"><p class="first last">mutation of threonine 790 to methionine</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>obs</sub></td><td class="NLM_def"><p class="first last">apparent volume of distribution</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i116">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62173" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62173" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 84 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Reid, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J.</span><span> </span><span class="NLM_article-title">Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">489</span><span class="refDoi"> DOI: 10.1016/j.ejca.2006.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.ejca.2006.11.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2007&pages=481-489&author=A.+Reidauthor=L.+Vidalauthor=H.+Shawauthor=J.+de+Bono&title=Dual+inhibition+of+ErbB1+%28EGFR%2FHER1%29+and+ErbB2+%28HER2%2Fneu%29&doi=10.1016%2Fj.ejca.2006.11.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2006.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2006.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DReid%26aufirst%3DA.%26aulast%3DVidal%26aufirst%3DL.%26aulast%3DShaw%26aufirst%3DH.%26aulast%3Dde%2BBono%26aufirst%3DJ.%26atitle%3DDual%2520inhibition%2520of%2520ErbB1%2520%2528EGFR%252FHER1%2529%2520and%2520ErbB2%2520%2528HER2%252Fneu%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2007%26volume%3D43%26spage%3D481%26epage%3D489%26doi%3D10.1016%2Fj.ejca.2006.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Nyati, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, T. S.</span><span> </span><span class="NLM_article-title">Integration of EGFR inhibitors with radiochemotherapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span><span class="refDoi"> DOI: 10.1038/nrc1953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnrc1953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=17036041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=876-885&author=M.+K.+Nyatiauthor=M.+A.+Morganauthor=F.+Y.+Fengauthor=T.+S.+Lawrence&title=Integration+of+EGFR+inhibitors+with+radiochemotherapy&doi=10.1038%2Fnrc1953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of EGFR inhibitors with radiochemotherapy</span></div><div class="casAuthors">Nyati, Mukesh K.; Morgan, Meredith A.; Feng, Felix Y.; Lawrence, Theodore S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">876-885</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lab. studies that led to the development of epidermal growth factor receptor (EGFR) inhibitors indicated that such inhibitors would be effective when given to patients with tumors that are driven by activated EGFR.  However, initial clin. studies have shown modest responses to EGFR inhibitors when used alone, and it has not yet been possible to clearly identify which tumors will respond to this therapy.  As a result, EGFR inhibitors are now used in combination with radiation therapy, chemotherapy and, more recently, with concurrent radiochemotherapy.  In general, these clin. trials have been designed without much preclin. data.  What do we need to know to make these combinations successful in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnHPTAiQOacLVg90H21EOLACvtfcHk0licYrjzyZ6UKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhs7bK&md5=e67a50e83fcac4a146695188b16cdc8f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1953%26sid%3Dliteratum%253Aachs%26aulast%3DNyati%26aufirst%3DM.%2BK.%26aulast%3DMorgan%26aufirst%3DM.%2BA.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DLawrence%26aufirst%3DT.%2BS.%26atitle%3DIntegration%2520of%2520EGFR%2520inhibitors%2520with%2520radiochemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D876%26epage%3D885%26doi%3D10.1038%2Fnrc1953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Mendelsohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor targeting in cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span><span class="refDoi"> DOI: 10.1053/j.seminoncol.2006.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1053%2Fj.seminoncol.2006.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16890793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVersLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2006&pages=369-385&author=J.+Mendelsohnauthor=J.+Baselga&title=Epidermal+growth+factor+receptor+targeting+in+cancer&doi=10.1053%2Fj.seminoncol.2006.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor targeting in cancer</span></div><div class="casAuthors">Mendelsohn, John; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">369-385</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family that is abnormally activated in many epithelial tumors.  Several mechanisms lead to the receptor's aberrant activation that is obsd. in cancer, including receptor overexpression, mutation, ligand-dependent receptor dimerization, and ligand-independent activation.  Two classes of anti-EGFR agents are currently approved for the treatment of patients with cancer: cetuximab, a monoclonal antibody directed at the extracellular domain of the receptor, and gefitinib and erlotinib, oral, low-mol.-wt. (MW), ATP-competitive inhibitors of the receptor's tyrosine kinase.  Anti-EGFR monoclonal antibodies have demonstrated activity in the therapy of advanced colorectal carcinoma and in a variety of epithelial tumor types, including head and neck cancer and non-small cell lung cancer (NSCLC).  The development of low MW, anti-EGFR tyrosine kinase inhibitors (TKIs) has been focused until recently on NSCLC, although responses have been reported for other types of cancer.  Erlotinib was the only agent approved based on demonstrating improved survival, which was obsd. in patients with advanced NSCLC who previously had been treated with chemotherapy.  Recent major advances in the EGFR field include the discovery of EGFR somatic mutations in NSCLC that have important implications for biol., treatment, clin. trial design, and methods for mutation detection.  Clin. and survival benefits with anti-EGFR agents have been demonstrated in addnl. tumor types such as head and neck and pancreatic carcinomas.  New agents with clin. activity are entering the clinic and new combinatorial approaches with anti-EGFR agents are being explored.  Major efforts are, belatedly, attempting to identify mol. markers that can predict patients more likely to respond to anti-EGFR therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkawbwoHPfpLVg90H21EOLACvtfcHk0lh2GSkjuiqYoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVersLk%253D&md5=68ddafac141c8351630137c8b28ca74e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2006.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2006.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520targeting%2520in%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2006%26volume%3D33%26spage%3D369%26epage%3D385%26doi%3D10.1053%2Fj.seminoncol.2006.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ErbB receptors and cancer: the complexity of targeted inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span><span class="refDoi"> DOI: 10.1038/nrc1609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ErbB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors&doi=10.1038%2Fnrc1609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0lh2GSkjuiqYoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DErbB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354%26doi%3D10.1038%2Fnrc1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Landi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span> </span><span class="NLM_article-title">Front-line therapy in lung cancer with mutations in EGFR</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">571</span><span class="NLM_x">–</span> <span class="NLM_lpage">573</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2011.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnrclinonc.2011.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=21878894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Gitb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=571-573&author=L.+Landiauthor=F.+Cappuzzo&title=Front-line+therapy+in+lung+cancer+with+mutations+in+EGFR&doi=10.1038%2Fnrclinonc.2011.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Front-line therapy in lung cancer with mutations in EGFR</span></div><div class="casAuthors">Landi, Lorenza; Cappuzzo, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">571-573</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Large randomized phase III trials conducted in patients with non-small-cell lung cancer (NSCLC) harboring activating mutations in EGFR have demonstrated that erlotinib or gefitinib are superior to platinum-based chemotherapy.  Zhou et al. have now confirmed that these agents represent the best treatment we can offer today as front-line therapy for EGFR-mutant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13q42VvvUE7Vg90H21EOLACvtfcHk0lh2GSkjuiqYoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Gitb%252FO&md5=8a3ced52ebc1d1ac268dd98fbdabd5be</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2011.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2011.135%26sid%3Dliteratum%253Aachs%26aulast%3DLandi%26aufirst%3DL.%26aulast%3DCappuzzo%26aufirst%3DF.%26atitle%3DFront-line%2520therapy%2520in%2520lung%2520cancer%2520with%2520mutations%2520in%2520EGFR%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26spage%3D571%26epage%3D573%26doi%3D10.1038%2Fnrclinonc.2011.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, N.</span><span> </span><span class="NLM_article-title">Where next for gefitinib in patients with lung cancer?</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">499</span><span class="NLM_x">–</span> <span class="NLM_lpage">507</span><span class="refDoi"> DOI: 10.1016/S1470-2045(06)70725-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS1470-2045%2806%2970725-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16750500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28XltFClsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=499-507&author=F.+Blackhallauthor=M.+Ransonauthor=N.+Thatcher&title=Where+next+for+gefitinib+in+patients+with+lung+cancer%3F&doi=10.1016%2FS1470-2045%2806%2970725-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Where next for gefitinib in patients with lung cancer?</span></div><div class="casAuthors">Blackhall, Fiona; Ranson, Malcolm; Thatcher, Nick</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">499-507</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Gefitinib belongs to the small-mol. class of epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors.  It was given conditional approval by the US Food and Drug Administration (FDA) in 2003 for treatment of advanced, chemorefractory non-small-cell lung cancer (NSCLC), but was relabeled for restricted use for patients that were already receiving and benefiting from it after the neg. result of the phase III Iressa Survival Evaluation in Advanced Lung Cancer (ISEL) trial.  By contrast, erlotinib, another EGFR tyrosine-kinase inhibitor, showed an overall survival benefit compared with placebo and best supportive care in the National Cancer Institute of Canada's BR21 trial, and now has full FDA approval for treatment of patients with NSCLC who have progressed after treatment with chemotherapy.  Although the ISEL trial result was neg. overall, preplanned subgroup analyses showed a significant overall survival benefit for gefitinib treatment in never-smokers and in patients of Asian origin.  Here, we review the clin. experience with gefitinib and, in light of the licensing of erlotinib, address the lessons learned, the ongoing trials, and whether scope remains for clin. development of gefitinib in selected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8yvRqJ5czKrVg90H21EOLACvtfcHk0litXJKDW2L5vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltFClsLg%253D&md5=37ef22f3279b3383c7c3abef0918e9a1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2806%2970725-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252806%252970725-2%26sid%3Dliteratum%253Aachs%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DThatcher%26aufirst%3DN.%26atitle%3DWhere%2520next%2520for%2520gefitinib%2520in%2520patients%2520with%2520lung%2520cancer%253F%26jtitle%3DLancet%2520Oncol.%26date%3D2006%26volume%3D7%26spage%3D499%26epage%3D507%26doi%3D10.1016%2FS1470-2045%2806%2970725-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Goodin, S.</span><span> </span><span class="NLM_article-title">Erlotinib: Optimizing therapy with predictors of response?</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2961</span><span class="NLM_x">–</span> <span class="NLM_lpage">2963</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-0426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1078-0432.CCR-06-0426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16707589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28Xks1Cisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=2961-2963&author=S.+Goodin&title=Erlotinib%3A+Optimizing+therapy+with+predictors+of+response%3F&doi=10.1158%2F1078-0432.CCR-06-0426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib: Optimizing therapy with predictors of response?</span></div><div class="casAuthors">Goodin, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2961-2963</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review on FDA-approved oral EGFR tyrosine kinase inhibitors, with emphasis on erlotinib, its clin. pharmacol., clin. trials, predictors of response and resistance, adverse effects, dose and administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ZFTUllYfnLVg90H21EOLACvtfcHk0litXJKDW2L5vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xks1Cisbw%253D&md5=8f0b10030d5df5935b63edbfebb04f21</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0426%26sid%3Dliteratum%253Aachs%26aulast%3DGoodin%26aufirst%3DS.%26atitle%3DErlotinib%253A%2520Optimizing%2520therapy%2520with%2520predictors%2520of%2520response%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D2961%26epage%3D2963%26doi%3D10.1158%2F1078-0432.CCR-06-0426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Gorden, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesbah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesar, J. M.</span><span> </span><span class="NLM_article-title">EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC</span> <span class="citation_source-journal">J. Oncol. Pharm. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span><span class="refDoi"> DOI: 10.1177/1078155211408373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1177%2F1078155211408373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=21733906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOitL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=245-249&author=K.+J.+Gordenauthor=P.+Mesbahauthor=J.+M.+Kolesar&title=EGFR+inhibitors+as+first-line+therapy+in+EGFR+mutation-positive+patients+with+NSCLC&doi=10.1177%2F1078155211408373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC</span></div><div class="casAuthors">Gorden, Kimberly J.; Mesbah, Parvin; Kolesar, Jill M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Oncology Pharmacy Practice</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-249</span>CODEN:
                <span class="NLM_cas:coden">JOPPFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-1552</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Purpose: The purpose of this review article is to describe the recent data supporting the use of epidermal growth factor receptor (EGFR) receptor tyrosine kinase inhibitors (TKIs) in the first-line setting of EGFR mutation-pos. non-small cell lung cancer (NSCLC).  Summary: EGFR receptor TKIs were originally developed in unselected NSCLC patients and demonstrated modest clin. benefit compared to placebo.  With the discovery of improved benefits in the approx. 16% of NSCLC patients with an EGFR mutation, trials in selected populations were undertaken, demonstrating comparable efficacy to std. chemotherapy with an improved toxicity profile.  The most common toxicity is rash, sometimes requiring dose adjustment and discontinuation and the most serious toxicity is interstitial lung disease, which occurs in about 1% of patients treated with EGFR receptor TKIs and is fatal in 30% who develop this toxicity.  Conclusion: The EGFR receptor TKIs are an effective therapy in EGFR-mutated NSCLC and are recommended as first-line therapy for those with advanced or metastatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLSjBZ6cSdtbVg90H21EOLACvtfcHk0litXJKDW2L5vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOitL3E&md5=cb0b7855867165378d7abd93d3c0bf21</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1177%2F1078155211408373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1078155211408373%26sid%3Dliteratum%253Aachs%26aulast%3DGorden%26aufirst%3DK.%2BJ.%26aulast%3DMesbah%26aufirst%3DP.%26aulast%3DKolesar%26aufirst%3DJ.%2BM.%26atitle%3DEGFR%2520inhibitors%2520as%2520first-line%2520therapy%2520in%2520EGFR%2520mutation-positive%2520patients%2520with%2520NSCLC%26jtitle%3DJ.%2520Oncol.%2520Pharm.%2520Pract.%26date%3D2012%26volume%3D18%26spage%3D245%26epage%3D249%26doi%3D10.1177%2F1078155211408373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eYDsjjg4RvIxbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Factors underlying sensitivity of cancers to small-molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">723</span><span class="refDoi"> DOI: 10.1038/nrd2871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnrd2871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=19629074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFylur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=709-723&author=P.+A.+J%C3%A4nneauthor=N.+Grayauthor=J.+Settleman&title=Factors+underlying+sensitivity+of+cancers+to+small-molecule+kinase+inhibitors&doi=10.1038%2Fnrd2871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Factors underlying sensitivity of cancers to small-molecule kinase inhibitors</span></div><div class="casAuthors">Janne, Pasi A.; Gray, Nathanael; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">709-723</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Selective small-mol. kinase inhibitors have emerged over the past decade as an important class of anti-cancer agents, and have demonstrated impressive clin. efficacy in several different diseases, including relatively common malignancies such as breast and lung cancer.  However, clin. benefit is typically limited to a fraction of treated patients.  Genomic features of individual tumors contribute significantly to such clin. responses, and these seem to vary tremendously across patients.  Addnl. factors, including pharmacogenomics, the tumor microenvironment and rapidly acquired drug resistance, also contribute to the clin. sensitivity of various cancers, and should be considered and applied in the development and use of new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ6L91RJfWIrVg90H21EOLACvtfcHk0lhr8oDCWT2lpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFylur4%253D&md5=7deddcb339b6e6047a9a11f9cb408d1a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd2871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2871%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DFactors%2520underlying%2520sensitivity%2520of%2520cancers%2520to%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D709%26epage%3D723%26doi%3D10.1038%2Fnrd2871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Nass, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahm, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, N. E.</span><span> </span><span class="NLM_article-title">Breast cancer biology blossoms in the clinic</span> <span class="citation_source-journal">Nat. Med. (N. Y., NY, U. S.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span><span class="refDoi"> DOI: 10.1038/nm0798-761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnm0798-761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=9662357" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=761-762&author=S.+J.+Nassauthor=H.+A.+Hahmauthor=N.+E.+Davidson&title=Breast+cancer+biology+blossoms+in+the+clinic&doi=10.1038%2Fnm0798-761"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnm0798-761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0798-761%26sid%3Dliteratum%253Aachs%26aulast%3DNass%26aufirst%3DS.%2BJ.%26aulast%3DHahm%26aufirst%3DH.%2BA.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26atitle%3DBreast%2520cancer%2520biology%2520blossoms%2520in%2520the%2520clinic%26jtitle%3DNat.%2520Med.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D1998%26volume%3D4%26spage%3D761%26epage%3D762%26doi%3D10.1038%2Fnm0798-761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Lessons from the drug discovery of Lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span><span class="refDoi"> DOI: 10.2174/156802606776743156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.2174%2F156802606776743156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16719802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtV2juro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=435-460&author=K.+E.+Lackey&title=Lessons+from+the+drug+discovery+of+Lapatinib%2C+a+dual+ErbB1%2F2+tyrosine+kinase+inhibitor&doi=10.2174%2F156802606776743156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from the drug discovery of Lapatinib, a dual ErbB1/2 tyrosine Kinase inhibitor</span></div><div class="casAuthors">Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">435-460</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein Kinases offer many opportunities for drug intervention points since phosphorylation is the most common post-translational modification.  Phosphorylation regulates activity, location, degrdn., and conformation and the aberrant activity is implicated in many diseases, including cancer, inflammation, cardiovascular, and central nervous system diseases.  The focus of this review will be on the generation of highly effective signaling inhibitors targeting members of the erbB family of receptor tyrosine kinases, EGFR and ErbB-2, also known as transmembrane Type 1 receptor tyrosine kinases of the HER family of receptors.  Ligand binding to the receptor causes a conformational change which activates the tyrosine kinase domain leading to autophosphorylation.  This autophosphorylation activates the RAS/mitogen-activated protein (MAP) kinase and phosphoinositol-3-kinase (PI3K) pathways leading to a myriad of signaling and cellular activities.  Type 1 receptors are overexpressed in a variety of cancers and generally correlate with poor prognosis.  For this reason, scientists at GlaxoSmithKline and many others in the scientific community target the ATP binding site of the intracellular portion of the protein to block the aberrant signaling event.  This review intends to cover the lessons learned in the discovery of Lapatinib (GW572016, GW2016) by pulling together the various different publications that have been generated in distinct disciplines on aspects of the drug discovery program.  Data analyses and correlation of assay data to help with the design of drug-like mols. are included and demonstrate a break from the traditional focus on abs. potency as a guiding factor in lead compd. selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnKhQE45WWsbVg90H21EOLACvtfcHk0lgxCfsQxwhv1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtV2juro%253D&md5=5bb70c03abc1fb8c301cac0f5f713fbe</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F156802606776743156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802606776743156%26sid%3Dliteratum%253Aachs%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DLessons%2520from%2520the%2520drug%2520discovery%2520of%2520Lapatinib%252C%2520a%2520dual%2520ErbB1%252F2%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2006%26volume%3D6%26spage%3D435%26epage%3D460%26doi%3D10.2174%2F156802606776743156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Tsang, R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadeghi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Lapatinib, a dual-targeted small molecule inhibitor of EGFR and HER2, in HER2-amplified breast cancer: from bench to bedside</span> <span class="citation_source-journal">Clin. Med. Insights: Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.4137/CMT.S3783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.4137%2FCMT.S3783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyjtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1-13&author=R.+Y.+Tsangauthor=S.+Sadeghiauthor=R.+S.+Finn&title=Lapatinib%2C+a+dual-targeted+small+molecule+inhibitor+of+EGFR+and+HER2%2C+in+HER2-amplified+breast+cancer%3A+from+bench+to+bedside&doi=10.4137%2FCMT.S3783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib, a dual-targeted small molecule inhibitor of EGFR and HER2, in HER2-amplified breast cancer: from bench to bedside</span></div><div class="casAuthors">Tsang, Roger Y.; Sadeghi, Saeed; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Medicine Insights: Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">CMITB2</span>;
        ISSN:<span class="NLM_cas:issn">1179-559X</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica</span>)
        </div><div class="casAbstract">A review.  The HER-2/neu gene product is a 185 kDa Type I receptor tyrosine kinase which consists of an extracellular domain, transmembrane domain, kinase domain, and cytoplasmic tail.  The initial discovery that amplification and subsequent overexpression of the HER-2/neu oncogene plays a pivotal role in the pathogenesis of 20%-25% of breast cancers has since led to significant clin. advances in the management of this subtype of breast cancer.  The first approved HER2-targeted therapy, trastuzumab, is a humanized monoclonal antibody against the extracellular domain of HER2 and has demonstrated survival benefits in both the metastatic and adjuvant settings.  Lapatinib, a small mol. tyrosine kinase inhibitor of both the epidermal growth factor receptor (EGFR) and HER2 is now also approved for advanced HER2-amplified breast cancer and is currently being evaluated in the adjuvant setting.  Importantly, lapatinib has been shown to have activity in women with HER2-amplified breast cancer that is refractory to trastuzumab.  In addn., it has been shown to extend survival in the front-line setting in combination with letrozole for estrogen receptor (ER) pos., HER2-pos. breast cancer.  Here we will review the biol. rationale and pre-clin. data that drove its initial clin. development as well as current clin. data and ongoing studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV28DyXQ6Q-7Vg90H21EOLACvtfcHk0lgxCfsQxwhv1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyjtL8%253D&md5=f3b89fd99ad860e54295a844c9f29502</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.4137%2FCMT.S3783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FCMT.S3783%26sid%3Dliteratum%253Aachs%26aulast%3DTsang%26aufirst%3DR.%2BY.%26aulast%3DSadeghi%26aufirst%3DS.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DLapatinib%252C%2520a%2520dual-targeted%2520small%2520molecule%2520inhibitor%2520of%2520EGFR%2520and%2520HER2%252C%2520in%2520HER2-amplified%2520breast%2520cancer%253A%2520from%2520bench%2520to%2520bedside%26jtitle%3DClin.%2520Med.%2520Insights%253A%2520Ther.%26date%3D2011%26volume%3D3%26spage%3D1%26epage%3D13%26doi%3D10.4137%2FCMT.S3783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Hurvitz, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Current approaches and future directions in the treatment of HER2-positive breast cancer</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2012.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.ctrv.2012.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=22658319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVSqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=219-229&author=S.+A.+Hurvitzauthor=Y.+Huauthor=N.+O%E2%80%99Brienauthor=R.+S.+Finn&title=Current+approaches+and+future+directions+in+the+treatment+of+HER2-positive+breast+cancer&doi=10.1016%2Fj.ctrv.2012.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Current approaches and future directions in the treatment of HER2-positive breast cancer</span></div><div class="casAuthors">Hurvitz, Sara A.; Hu, Yufang; O'Brien, Neil; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-229</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Human epidermal growth factor receptor 2 (HER2), a member of the ErbB family of transmembrane receptor tyrosine kinases, is amplified in 20-30% of invasive breast cancers.  HER2 amplification is assocd. with metastasis and reduced survival.  Two HER2-directed therapies have been approved by the United States Food and Drug Administration for the treatment of HER2-overexpressing breast cancer: trastuzumab, a humanized monoclonal antibody against the extracellular portion of HER2; and lapatinib, a dual HER2- and epidermal growth factor receptor-specific tyrosine kinase inhibitor.  Despite the improvement in overall survival with the addn. of HER2-targeted agents to chemotherapy, many patients do not benefit from these agents because of inherent resistance.  In addn., many patients who achieve an initial response eventually acquire drug resistance.  Currently, several mechanisms of resistance have been described, including mutations in other signaling pathways, expression of a truncated form of HER2, receptor crosstalk, and autophagy.  There are several approaches under study to target these pathways of resistance, including blocking PI3 kinase and mammalian target of rapamycin signaling, blocking neoangiogenesis and the vascular endothelial growth factor axis, using monoclonal antibody targeting of the HER2 dimerization site, and using HER2 monoclonal antibody-drug conjugates.  Here we will review the current scientific rationale for these agents and how combinations of these agents may yield additive or synergistic effects and lead to improved outcomes for patients with HER2-amplified breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Y-gBEc20hLVg90H21EOLACvtfcHk0lgxCfsQxwhv1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVSqsro%253D&md5=4a664c8a6e359cc85a7bb188416f49bd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2012.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2012.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DN.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DCurrent%2520approaches%2520and%2520future%2520directions%2520in%2520the%2520treatment%2520of%2520HER2-positive%2520breast%2520cancer%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2013%26volume%3D39%26spage%3D219%26epage%3D229%26doi%3D10.1016%2Fj.ctrv.2012.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span><span class="refDoi"> DOI: 10.1073/pnas.95.20.12022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor&doi=10.1073%2Fpnas.95.20.12022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0lhaQWR7NwRGKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027%26doi%3D10.1073%2Fpnas.95.20.12022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Mechanism of action of erbB tyrosine kinase inhibitors</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span><span class="refDoi"> DOI: 10.1016/S0014-4827(02)00095-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS0014-4827%2802%2900095-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=12648472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitVyltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2003&pages=131-139&author=D.+W.+Fry&title=Mechanism+of+action+of+erbB+tyrosine+kinase+inhibitors&doi=10.1016%2FS0014-4827%2802%2900095-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of erbB tyrosine kinase inhibitors</span></div><div class="casAuthors">Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-139</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">A review.  Over the last decade, drug discovery efforts have generated a myriad of compds. that inhibit the activity of the erbB family of tyrosine kinases with potencies and selectivity that have surpassed original expectations.  These characteristics, along with improved pharmaceutical properties, have enabled inhibitors from this class of agents to finally realize their therapeutic potential, and indeed, some are currently producing significant clin. responses.  Interestingly, those properties that are essential for a clin. active inhibitor of the erbB family are most readily attained with compds. that bind at the ATP site, and the most successful compds. have shown a distinct convergence to certain common chem. features.  The reasons for this trend are beginning to be realized through the generation of an increasing array of cryst. structures for protein kinases as well as advances in mol. modeling.  This has allowed a more complete understanding of the precise phys. interactions that occur between erbB tyrosine kinase inhibitors and their target(s), which, in turn, has begun to shed light on the mechanism by which these mols. attain their remarkable affinity and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-o5XCjZZQdLVg90H21EOLACvtfcHk0lhaQWR7NwRGKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitVyltL8%253D&md5=09c10abfc9a8e91617f468393b2d449a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0014-4827%2802%2900095-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-4827%252802%252900095-2%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DMechanism%2520of%2520action%2520of%2520erbB%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2003%26volume%3D284%26spage%3D131%26epage%3D139%26doi%3D10.1016%2FS0014-4827%2802%2900095-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slintak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliot, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patmore, S. J.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[<i>d</i>]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1803</span><span class="NLM_x">–</span> <span class="NLM_lpage">1815</span><span class="refDoi"> DOI: 10.1021/jm9806603</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9806603" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=1803-1815&author=J.+B.+Smaillauthor=B.+D.+Palmerauthor=G.+W.+Rewcastleauthor=W.+A.+Dennyauthor=D.+J.+McNamaraauthor=E.+M.+Dobrusinauthor=A.+J.+Bridgesauthor=H.+Zhouauthor=H.+D.+H.+Showalterauthor=R.+T.+Wintersauthor=W.+R.+Leopoldauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=V.+Slintakauthor=W.+L.+Elliotauthor=B.+J.+Robertsauthor=P.+W.+Vincentauthor=S.+J.+Patmore&title=Tyrosine+kinase+inhibitors.+15.+4-%28Phenylamino%29quinazoline+and+4-%28phenylamino%29pyrido%5Bd%5Dpyrimidine+acrylamides+as+irreversible+inhibitors+of+the+ATP+binding+site+of+the+epidermal+growth+factor+receptor&doi=10.1021%2Fjm9806603"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm9806603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9806603%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSlintak%26aufirst%3DV.%26aulast%3DElliot%26aufirst%3DW.%2BL.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DPatmore%26aufirst%3DS.%2BJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252015.%25204-%2528Phenylamino%2529quinazoline%2520and%25204-%2528phenylamino%2529pyrido%255Bd%255Dpyrimidine%2520acrylamides%2520as%2520irreversible%2520inhibitors%2520of%2520the%2520ATP%2520binding%2520site%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D1803%26epage%3D1815%26doi%3D10.1021%2Fjm9806603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges,  A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeJohn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span><span class="refDoi"> DOI: 10.1021/jm990482t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=+Bridgesauthor=H.+Zhouauthor=H.+D.+H.+Showalterauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=W.+L.+Elliottauthor=P.+W.+Vincentauthor=D.+DeJohnauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions&doi=10.1021%2Fjm990482t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions</span></div><div class="casAuthors">Smaill, Jeff B.; Rewcastle, Gordon W.; Loo, Joseph A.; Greis, Kenneth D.; Chan, O. Helen; Reyner, Eric L.; Lipka, Elke; Showalter, H. D. Hollis; Vincent, Patrick W.; Elliott, William L.; Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1380-1397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-Anilinoquinazoline- and 4-anilinopyrido[3,2-d]pyrimidine-6-acrylamides substituted with solubilizing 7-alkylamine or 7-alkoxyamine side chains were prepd. by reaction of the corresponding 6-amines with acrylic acid or acrylic acid anhydrides.  In the pyrido[3,2-d]pyrimidine series, the intermediate 6-amino-7-alkylamines were prepd. from 7-bromo-6-fluoropyrido[3,2-d]pyrimidine via Stille coupling with the appropriate stannane under palladium(0) catalysis.  This proved a versatile method for the introduction of cationic solubilizing side chains.  The compds. were evaluated for their inhibition of phosphorylation of the isolated EGFR enzyme and for inhibition of EGF-stimulated autophosphorylation of EGFR in A431 cells and of heregulin-stimulated autophosphorylation of erbB2 in MDA-MB 453 cells.  Quinazoline analogs with 7-alkoxyamine solubilizing groups were potent irreversible inhibitors of the isolated EGFR enzyme, with IC50[app] values from 2 to 4 nM, and potently inhibited both EGFR and erbB2 autophosphorylation in cells. 7-Alkylamino- and 7-alkoxyaminopyrido[3,2-d]pyrimidines were also irreversible inhibitors with equal or superior potency against the isolated enzyme but were less effective in the cellular autophosphorylation assays.  Both quinazoline- and pyrido[3,2-d]pyrimidine-6-acrylamides bound at the ATP site alkylating cysteine 773, as shown by electrospray ionization mass spectrometry, and had similar rates of absorptive and secretory transport in Caco-2 cells.  A comparison of two 7-propoxymorpholide analogs showed that the pyrido[3,2-d]pyrimidine-6-acrylamide had greater amide instability and higher acrylamide reactivity, being converted to glutathione adducts in cells more rapidly than the corresponding quinazoline.  This difference may contribute to the obsd. lower cellular potency of the pyrido[3,2-d]pyrimidine-6-acrylamides.  Selected compds. showed high in vivo activity against A431 xenografts on oral dosing, with the quinazolines being superior to the pyrido[3,2-d]pyrimidines. Overall, the quinazolines proved superior to previous analogs in terms of aq. soly., potency, and in vivo antitumor activity, and one example (CI 1033) has been selected for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF5L1nBGlu6rVg90H21EOLACvtfcHk0liGHuqJPHXrUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D&md5=6c569a822c398df08559abde31a1d4ac</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DBridges%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DDeJohn%26aufirst%3DD.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397%26doi%3D10.1021%2Fjm990482t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-<i>d</i>]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span><span class="refDoi"> DOI: 10.1021/jm000372i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000372i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=429-440&author=J.+B.+Smaillauthor=H.+D.+H.+Showalterauthor=H.+Zhouauthor=A.+J.+Bridgesauthor=D.+J.+McNamaraauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=P.+W.+Vincentauthor=B.+J.+Robertsauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+18.+6-Substituted+4-anilinoquinazolines+and+4-anilinopyrido%5B3%2C4-d%5Dpyrimidines+as+soluble%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor&doi=10.1021%2Fjm000372i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm000372i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000372i%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252018.%25206-Substituted%25204-anilinoquinazolines%2520and%25204-anilinopyrido%255B3%252C4-d%255Dpyrimidines%2520as%2520soluble%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D429%26epage%3D440%26doi%3D10.1021%2Fjm000372i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Klutchko, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amato, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meade, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pace, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-<i>d</i>]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1475</span><span class="NLM_x">–</span> <span class="NLM_lpage">1485</span><span class="refDoi"> DOI: 10.1021/jm050936o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050936o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1475-1485&author=S.+R.+Klutchkoauthor=H.+Zhouauthor=R.+T.+Wintersauthor=T.+P.+Tranauthor=A.+J.+Bridgesauthor=I.+W.+Althausauthor=D.+M.+Amatoauthor=W.+L.+Elliottauthor=P.+A.+Ellisauthor=M.+A.+Meadeauthor=B.+J.+Robertsauthor=D.+W.+Fryauthor=A.+J.+Gonzalesauthor=P.+J.+Harveyauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=H.+K.+Hanauthor=G.+Paceauthor=J.+B.+Smaillauthor=W.+A.+Dennyauthor=H.+D.+H.+Showalter&title=Tyrosine+kinase+inhibitors.+19.+6-Alkynamides+of+4-anilinoquinazolines+and+4-anilinopyrido%5B3%2C4-d%5Dpyrimidines+as+irreversible+inhibitors+of+the+erbB+family+of+tyrosine+kinase+receptors&doi=10.1021%2Fjm050936o"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm050936o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050936o%26sid%3Dliteratum%253Aachs%26aulast%3DKlutchko%26aufirst%3DS.%2BR.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DTran%26aufirst%3DT.%2BP.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DAmato%26aufirst%3DD.%2BM.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DMeade%26aufirst%3DM.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DH.%2BK.%26aulast%3DPace%26aufirst%3DG.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252019.%25206-Alkynamides%2520of%25204-anilinoquinazolines%2520and%25204-anilinopyrido%255B3%252C4-d%255Dpyrimidines%2520as%2520irreversible%2520inhibitors%2520of%2520the%2520erbB%2520family%2520of%2520tyrosine%2520kinase%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1475%26epage%3D1485%26doi%3D10.1021%2Fjm050936o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitchen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnick, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span> </span><span class="NLM_article-title">Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)</span> <span class="citation_source-journal">Biochem. Pharmacol. (Amsterdam, Neth.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span><span class="refDoi"> DOI: 10.1016/S0006-2952(98)00356-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS0006-2952%2898%2900356-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1999&pages=917-925&author=C.+M.+Discafaniauthor=M.+L.+Carrollauthor=M.+B.+Floydauthor=I.+J.+Hollanderauthor=Z.+Husainauthor=B.+D.+Johnsonauthor=D.+Kitchenauthor=M.+K.+Mayauthor=M.+S.+Maloauthor=A.+A.+Minnickauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.-F.+Wangauthor=A.+Wissnerauthor=L.+M.+Greenberger&title=Irreversible+inhibition+of+epidermal+growth+factor+receptor+tyrosine+kinase+with+in+vivo+activity+by+N-%5B4-%283-bromophenyl%29amino%5D-6-quinazolinyl%5D-2-butynamide+%28CL-387%2C785%29&doi=10.1016%2FS0006-2952%2898%2900356-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2898%2900356-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252898%252900356-6%26sid%3Dliteratum%253Aachs%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DCarroll%26aufirst%3DM.%2BL.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DHollander%26aufirst%3DI.%2BJ.%26aulast%3DHusain%26aufirst%3DZ.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DKitchen%26aufirst%3DD.%26aulast%3DMay%26aufirst%3DM.%2BK.%26aulast%3DMalo%26aufirst%3DM.%2BS.%26aulast%3DMinnick%26aufirst%3DA.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26atitle%3DIrreversible%2520inhibition%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520with%2520in%2520vivo%2520activity%2520by%2520N-%255B4-%25283-bromophenyl%2529amino%255D-6-quinazolinyl%255D-2-butynamide%2520%2528CL-387%252C785%2529%26jtitle%3DBiochem.%2520Pharmacol.%2520%2528Amsterdam%252C%2520Neth.%2529%26date%3D1999%26volume%3D57%26spage%3D917%26epage%3D925%26doi%3D10.1016%2FS0006-2952%2898%2900356-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeBlanc, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehn, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2734</span><span class="refDoi"> DOI: 10.1021/jm0005555</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0005555" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFChsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2719-2734&author=H.-R.+Tsouauthor=N.+Mamuyaauthor=B.+D.+Johnsonauthor=M.+F.+Reichauthor=B.+C.+Gruberauthor=F.+Yeauthor=R.+Nilakantanauthor=R.+Shenauthor=C.+Discafaniauthor=R.+DeBlancauthor=R.+Davisauthor=F.+E.+Koehnauthor=L.+M.+Greenbergerauthor=Y.+F.+Wangauthor=A.+Wissner&title=6-Substituted-4-%283-bromophenylamino%29quinazolines+as+putative+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+human+epidermal+growth+factor+receptor+%28HER-2%29+tyrosine+kinases+with+enhanced+antitumor+activity&doi=10.1021%2Fjm0005555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity</span></div><div class="casAuthors">Tsou, Hwei-Ru; Mamuya, Nellie; Johnson, Bernard D.; Reich, Marvin F.; Gruber, Brian C.; Ye, Fei; Nilakantan, Ramaswamy; Shen, Ru; Discafani, Carolyn; DeBlanc, Ronald; Davis, Rachel; Koehn, Frank E.; Greenberger, Lee M.; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2719-2734</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of new 6-substituted-4-(3-bromophenylamino)quinazoline derivs. that may function as irreversible inhibitors of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases have been prepd.  These inhibitors have, at the C-6 position, butynamide, crotonamide, and methacrylamide Michael acceptors bearing water-solubilizing substituents.  These compds. were prepd. by acylation of 6-amino-4-(3-bromophenylamino)quinazoline with unsatd. acid chlorides or mixed anhydrides.  We show that attaching a basic functional group onto the Michael acceptor results in greater reactivity, due to intramol. catalysis of the Michael addn. and/or an inductive effect of the protonated basic group. This, along with improved water soly., results in compds. with enhanced biol. properties.  We present mol. modeling and exptl. evidence that these inhibitors interact covalently with the target enzymes.  One compd., (I) was shown to have excellent oral activity in a human epidermoid carcinoma (A431) xenograft model in nude mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVl-zt4kiGDrVg90H21EOLACvtfcHk0lgF8QjpWP6Nlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFChsb8%253D&md5=989e6e77195324d92e70ca13f532e1cf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm0005555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0005555%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDeBlanc%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DKoehn%26aufirst%3DF.%2BE.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3D6-Substituted-4-%25283-bromophenylamino%2529quinazolines%2520as%2520putative%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520%2528HER-2%2529%2520tyrosine%2520kinases%2520with%2520enhanced%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2719%26epage%3D2734%26doi%3D10.1021%2Fjm0005555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of 6, 7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1021/jm020241c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.-F.+Wangauthor=L.+M.+Greenbergerauthor=H.-R.+Tsou&title=Synthesis+and+structure-activity+relationships+of+6%2C+7-disubstituted+4-anilinoquinoline-3-carbonitriles.+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29&doi=10.1021%2Fjm020241c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.-R.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%25206%252C%25207-disubstituted%25204-anilinoquinoline-3-carbonitriles.%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63%26doi%3D10.1021%2Fjm020241c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6, 7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span><span class="refDoi"> DOI: 10.1021/jm040159c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C+7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity&doi=10.1021%2Fjm040159c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C%25207-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131%26doi%3D10.1021%2Fjm040159c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brignola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brashear, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caferro, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donaldson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reno, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadepalli, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulrich, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderwall, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehling, D. E.</span><span> </span><span class="NLM_article-title">6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of erbB kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2773</span><span class="NLM_x">–</span> <span class="NLM_lpage">2778</span><span class="refDoi"> DOI: 10.1073/pnas.0708281105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1073%2Fpnas.0708281105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=18287036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2773-2778&author=E.+R.+Woodauthor=L.+M.+Shewchukauthor=B.+Ellisauthor=P.+Brignolaauthor=R.+L.+Brashearauthor=T.+R.+Caferroauthor=S.+H.+Dickersonauthor=H.+D.+Dicksonauthor=K.+H.+Donaldsonauthor=M.+Gaulauthor=R.+J.+Griffinauthor=A.+M.+Hassellauthor=B.+Keithauthor=R.+Mullinauthor=K.+G.+Petrovauthor=M.+J.+Renoauthor=D.+W.+Rusnakauthor=S.+M.+Tadepalliauthor=J.+C.+Ulrichauthor=C.+D.+Wagnerauthor=D.+E.+Vanderwallauthor=A.+G.+Watersonauthor=J.+D.+Williamsauthor=W.+L.+Whiteauthor=D.+E.+Uehling&title=6-Ethynylthieno%5B3%2C2-d%5D-+and+6-ethynylthieno%5B2%2C3-d%5Dpyrimidin-4-anilines+as+tunable+covalent+modifiers+of+erbB+kinases&doi=10.1073%2Fpnas.0708281105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases</span></div><div class="casAuthors">Wood, Edgar R.; Shewchuk, Lisa M.; Ellis, Byron; Brignola, Perry; Brashear, Ronald L.; Caferro, Thomas R.; Dickerson, Scott H.; Dickson, Hamilton D.; Donaldson, Kelly H.; Gaule, Michael; Griffin, Robert J.; Hassell, Anne M.; Keith, Barry; Mullin, Robert; Petrov, Kimberly G.; Reno, Michael J.; Rusnak, David W.; Tadepalli, Sarva M.; Ulrich, John C.; Wagner, Craig D.; Vanderwall, Dana E.; Waterson, Alex G.; Williams, Jon D.; White, Wendy L.; Uehling, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2773-2778</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Anal. of the x-ray crystal structure of mono-substituted acetylenic thienopyrimidine 6 complexed with the ErbB family enzyme ErbB-4 revealed a covalent bond between the terminal carbon of the acetylene moiety and the sulfhydryl group of Cys-803 at the solvent interface.  The identification of this covalent adduct suggested that acetylenic thienopyrimidine 6 and related analogs might also be capable of forming an analogous covalent adduct with EGFR, which has a conserved cysteine (797) near the ATP binding pocket.  To test this hypothesis, we treated a truncated, catalytically competent form of EGFR (678-1020) with a structurally related propargylic amine (8).  An investigation of the resulting complex by mass spectrometry revealed the formation of a covalent complex of thienopyrimidine 8 with Cys-797 of EGFR.  This finding enabled us to readily assess the irreversibility of various inhibitors and also facilitated a structure-activity relation understanding of the covalent modifying potential and biol. activity of a series of acetylenic thienopyrimidine compds. with potent antitumor activity.  Several ErbB family enzyme and cell potent 6-ethynyl thienopyrimidine kinase inhibitors were found to form covalent adducts with EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNoM38Ky48ELVg90H21EOLACvtfcHk0lioVnYhUSMNsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSjtbw%253D&md5=fbfeeff1f03e8f7fb2c9e228231ff92e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0708281105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0708281105%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DShewchuk%26aufirst%3DL.%2BM.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DBrignola%26aufirst%3DP.%26aulast%3DBrashear%26aufirst%3DR.%2BL.%26aulast%3DCaferro%26aufirst%3DT.%2BR.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DDickson%26aufirst%3DH.%2BD.%26aulast%3DDonaldson%26aufirst%3DK.%2BH.%26aulast%3DGaul%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DKeith%26aufirst%3DB.%26aulast%3DMullin%26aufirst%3DR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DReno%26aufirst%3DM.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DTadepalli%26aufirst%3DS.%2BM.%26aulast%3DUlrich%26aufirst%3DJ.%2BC.%26aulast%3DWagner%26aufirst%3DC.%2BD.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26aulast%3DWhite%26aufirst%3DW.%2BL.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3D6-Ethynylthieno%255B3%252C2-d%255D-%2520and%25206-ethynylthieno%255B2%252C3-d%255Dpyrimidin-4-anilines%2520as%2520tunable%2520covalent%2520modifiers%2520of%2520erbB%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2773%26epage%3D2778%26doi%3D10.1073%2Fpnas.0708281105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Carmi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vezzosi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacondio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Monica, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardizzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronini, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span> </span><span class="NLM_article-title">Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2038</span><span class="NLM_x">–</span> <span class="NLM_lpage">2050</span><span class="refDoi"> DOI: 10.1021/jm901558p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901558p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2038-2050&author=C.+Carmiauthor=A.+Cavazzoniauthor=S.+Vezzosiauthor=F.+Bordiauthor=F.+Vacondioauthor=C.+Silvaauthor=S.+Rivaraauthor=A.+Lodolaauthor=R.+R.+Alfieriauthor=S.+La+Monicaauthor=M.+Galettiauthor=A.+Ardizzoniauthor=P.+G.+Petroniniauthor=M.+Mor&title=Novel+irreversible+epidermal+growth+factor+receptor+inhibitors+by+chemical+modulation+of+the+cysteine-trap+portion&doi=10.1021%2Fjm901558p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm901558p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901558p%26sid%3Dliteratum%253Aachs%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DVezzosi%26aufirst%3DS.%26aulast%3DBordi%26aufirst%3DF.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%2BR.%26aulast%3DLa%2BMonica%26aufirst%3DS.%26aulast%3DGaletti%26aufirst%3DM.%26aulast%3DArdizzoni%26aufirst%3DA.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DNovel%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520by%2520chemical%2520modulation%2520of%2520the%2520cysteine-trap%2520portion%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2038%26epage%3D2050%26doi%3D10.1021%2Fjm901558p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Cha, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span> </span><span class="NLM_article-title">Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6880</span><span class="NLM_x">–</span> <span class="NLM_lpage">6888</span><span class="refDoi"> DOI: 10.1021/jm901146p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901146p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6880-6888&author=M.+Y.+Chaauthor=K.-O.+Leeauthor=J.+W.+Kimauthor=C.+G.+Leeauthor=J.+Y.+Songauthor=Y.+H.+Kimauthor=G.+S.+Leeauthor=S.+B.+Parkauthor=M.+S.+Kim&title=Discovery+of+a+novel+Her-1%2FHer-2+dual+tyrosine+kinase+inhibitor+for+the+treatment+of+Her-1+selective+inhibitor-resistant+non-small+cell+lung+cancer&doi=10.1021%2Fjm901146p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm901146p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901146p%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DK.-O.%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DC.%2BG.%26aulast%3DSong%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DG.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520Her-1%252FHer-2%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Her-1%2520selective%2520inhibitor-resistant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6880%26epage%3D6888%26doi%3D10.1021%2Fjm901146p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leou, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chittimalla, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Fastforwarding hit to lead: Aurora and epidermal growth factor receptor kinase inhibitor lead identification</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4980</span><span class="NLM_x">–</span> <span class="NLM_lpage">4988</span><span class="refDoi"> DOI: 10.1021/jm1000198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1000198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4980-4988&author=M.+S.+Coumarauthor=C.-Y.+Chuauthor=C.-W.+Linauthor=H.-Y.+Shiaoauthor=Y.-L.+Hoauthor=R.+Reddyauthor=W.-H.+Linauthor=C.-H.+Chenauthor=Y.-H.+Pengauthor=J.-S.+Leouauthor=T.-W.+Lienauthor=C.-T.+Huangauthor=M.-Y.+Fangauthor=S.-H.+Wuauthor=J.-S.+Wuauthor=S.+K.+Chittimallaauthor=J.-S.+Songauthor=J.+T.-A.+Hsuauthor=S.-Y.+Wuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Fastforwarding+hit+to+lead%3A+Aurora+and+epidermal+growth+factor+receptor+kinase+inhibitor+lead+identification&doi=10.1021%2Fjm1000198"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm1000198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1000198%26sid%3Dliteratum%253Aachs%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DC.-W.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DHo%26aufirst%3DY.-L.%26aulast%3DReddy%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DLeou%26aufirst%3DJ.-S.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DHuang%26aufirst%3DC.-T.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DWu%26aufirst%3DS.-H.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DChittimalla%26aufirst%3DS.%2BK.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DFastforwarding%2520hit%2520to%2520lead%253A%2520Aurora%2520and%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520inhibitor%2520lead%2520identification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4980%26epage%3D4988%26doi%3D10.1021%2Fjm1000198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Wu, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Design and synthesis of tetrahydropyridothieno-[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7316</span><span class="NLM_x">–</span> <span class="NLM_lpage">7326</span><span class="refDoi"> DOI: 10.1021/jm100607r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100607r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7316-7326&author=C.-H.+Wuauthor=M.+S.+Coumarauthor=C.-Y.+Chuauthor=W.-H.+Linauthor=Y.-R.+Chenauthor=C.-T.+Chenauthor=H.-Y.+Shiaoauthor=S.+Rafiauthor=S.-Y.+Wangauthor=H.+Hsuauthor=C.-H.+Chenauthor=C.-Y.+Changauthor=T.-Y.+Changauthor=T.-W.+Lienauthor=M.-Y.+Fangauthor=K.-C.+Yehauthor=C.-P.+Chenauthor=T.-K.+Yehauthor=S.-H.+Hsiehauthor=J.+T.-A.+Hsuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Design+and+synthesis+of+tetrahydropyridothieno-%5B2%2C3-d%5Dpyrimidine+scaffold+based+epidermal+growth+factor+receptor+%28EGFR%29+kinase+inhibitors%3A+the+role+of+side+chain+chirality+and+Michael+acceptor+group+for+maximal+potency&doi=10.1021%2Fjm100607r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm100607r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100607r%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.-H.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DY.-R.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DRafi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DHsu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DChang%26aufirst%3DT.-Y.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DYeh%26aufirst%3DK.-C.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DHsieh%26aufirst%3DS.-H.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tetrahydropyridothieno-%255B2%252C3-d%255Dpyrimidine%2520scaffold%2520based%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520kinase%2520inhibitors%253A%2520the%2520role%2520of%2520side%2520chain%2520chirality%2520and%2520Michael%2520acceptor%2520group%2520for%2520maximal%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7316%26epage%3D7326%26doi%3D10.1021%2Fjm100607r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Allen, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span> </span><span class="NLM_article-title">CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 16</span><span class="NLM_x">) </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span><span class="refDoi"> DOI: 10.1053/j.seminoncol.2003.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1053%2Fj.seminoncol.2003.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=14613028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2003&pages=65-78&issue=Suppl+16&author=L.+F.+Allenauthor=I.+A.+Eisemanauthor=D.+W.+Fryauthor=P.+F.+Lenehan&title=CI-1033%2C+an+irreversible+pan-erbB+receptor+inhibitor+and+its+potential+application+for+the+treatment+of+breast+cancer&doi=10.1053%2Fj.seminoncol.2003.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer</span></div><div class="casAuthors">Allen, Lee F.; Eiseman, Irene A.; Fry, David W.; Lenehan, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  The erbB family of cell surface receptor proteins consists of four members, all of which play a role in the development and growth of the normal breast.  The activity of this signaling pathway is normally tightly controlled, and dysregulation has been shown to play a significant role in the pathogenesis and progression of breast and other cancers.  The potent transforming potential of these receptors is further enhanced by the coexpression of multiple members of this receptor family, which worsens prognosis.  Therapeutic blockade of erbB-2 receptor signaling has to date been shown to be effective in only a subset of chemotherapy-resistant breast cancer patients.  CI-1033 is a highly potent and selective pan-erbB inhibitor that efficiently blocks signal transduction through all four members of the erbB receptor family.  In addn., it covalently binds to these receptors, irreversibility inhibiting them, and thereby provides for prolonged suppression of erbB receptor-mediated signaling.  Clin., it has been shown to have an acceptable side effect profile at potentially therapeutic doses and schedules.  Biomarker studies have shown target inhibition in patients, and evidence of antitumor activity has also been obsd. in phase I studies.  Given the broad expression pattern of the erbB family of receptors in solid tumors, and the important proliferative effect of co-expression of multiple erbB receptors, CI-1033, as an irreversible, pan-erbB inhibitor, has the potential to have an important role in the future treatment of breast and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnHJoa4ri9ObVg90H21EOLACvtfcHk0lh0SjleJTFrRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrF&md5=13e9d00d8a20f3c79b4f7fe1032f07b5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2003.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2003.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DL.%2BF.%26aulast%3DEiseman%26aufirst%3DI.%2BA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26atitle%3DCI-1033%252C%2520an%2520irreversible%2520pan-erbB%2520receptor%2520inhibitor%2520and%2520its%2520potential%2520application%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2003%26volume%3D30%26issue%3DSuppl%252016%26spage%3D65%26epage%3D78%26doi%3D10.1053%2Fj.seminoncol.2003.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Calvo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreery, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">7112</span><span class="NLM_x">–</span> <span class="NLM_lpage">7120</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-1187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1078-0432.CCR-04-1187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=15534081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVKltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=7112-7120&author=E.+Calvoauthor=A.+W.+Tolcherauthor=L.+A.+Hammondauthor=A.+Patnaikauthor=J.+S.+de+Bonoauthor=I.+A.+Eisemanauthor=S.+C.+Olsonauthor=P.+F.+Lenehanauthor=H.+McCreeryauthor=P.+LoRussoauthor=E.+K.+Rowinsky&title=Administration+of+CI-1033%2C+an+irreversible+pan-erbB+tyrosine+kinase+inhibitor%2C+is+feasible+on+a+7-day+on%2C+7-day+off+schedule%3A+a+phase+I+pharmacokinetic+and+food+effect+study&doi=10.1158%2F1078-0432.CCR-04-1187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study</span></div><div class="casAuthors">Calvo, Emiliano; Tolcher, Anthony W.; Hammond, Lisa A.; Patnaik, Amita; de Bono, Johan S.; Eiseman, Irene A.; Olson, Stephen C.; Lenehan, Peter F.; McCreery, Heather; LoRusso, Patricia; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7112-7120</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To det. the max. tolerated dose of administrating CI-1033, an oral 4-anilinoquinazoline that irreversibly inhibits the tyrosine kinase domain of all erbB subfamilies, on an intermittent schedule, and assess the interaction of CI-1033 with food on the pharmacokinetic behavior.  Escalating doses of CI-1033 from a dose level of 300 mg/day for 7 days every other week were administered to patients with advanced solid malignancies.  Plasma concn.-time data sets from all evaluable patients were used to develop a population pharmacokinetic model.  Noncompartmental methods were used to independently assess the effect of a high-fat meal on CI-1033 absorption and bioavailability.  Twenty-four patients were treated with 69 twenty-eight day courses.  The incidence of unacceptable toxicity, principally diarrhea and skin rash, was obsd. at the 300 mg/day dose level.  At the 250 mg/day level, toxicity was manageable, and protracted administration was feasible.  A one-compartment linear model with first-order absorption and elimination adequately described the pharmacokinetic disposition.  CL/F, apparent vol. of distribution (Vd/F), and ka (mean ± relative SD) were 280 L/h ± 33%, 684 L ± 20%, and 0.35 h-1± 69%, resp.  Cmax values were achieved in 2 to 4 h.  Systemic CI-1033 exposure was largely unaffected by administration of a high-fat meal.  At 250 mg, concn. values exceeded IC50 values required for prolonged pan-erbB tyrosine kinase inhibition in preclin. assays.  The recommended dose on this schedule is 250 mg/day.  Its tolerability and the biol. relevance of concns. achieved at the maximal tolerated dose warrant consideration of disease-directed evaluations.  This intermittent treatment schedule can be used without regard to meals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6W_Q3OL3jkrVg90H21EOLACvtfcHk0lh0SjleJTFrRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVKltL4%253D&md5=6950bba7fc378f6c7ae7b0b1a643dedf</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1187%26sid%3Dliteratum%253Aachs%26aulast%3DCalvo%26aufirst%3DE.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DHammond%26aufirst%3DL.%2BA.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DEiseman%26aufirst%3DI.%2BA.%26aulast%3DOlson%26aufirst%3DS.%2BC.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26aulast%3DMcCreery%26aufirst%3DH.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DAdministration%2520of%2520CI-1033%252C%2520an%2520irreversible%2520pan-erbB%2520tyrosine%2520kinase%2520inhibitor%252C%2520is%2520feasible%2520on%2520a%25207-day%2520on%252C%25207-day%2520off%2520schedule%253A%2520a%2520phase%2520I%2520pharmacokinetic%2520and%2520food%2520effect%2520study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D7112%26epage%3D7120%26doi%3D10.1158%2F1078-0432.CCR-04-1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Nunes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span> </span><span class="NLM_article-title">Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.4161%2Fcbt.3.1.538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=14749472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFajtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=21-27&author=M.+Nunesauthor=C.+Shiauthor=L.+M.+Greenberger&title=Phosphorylation+of+extracellular+signal-regulated+kinase+1+and+2%2C+protein+kinase+B%2C+and+signal+transducer+and+activator+of+transcription+3+are+differently+inhibited+by+an+epidermal+growth+factor+receptor+inhibitor%2C+EKB-569%2C+in+tumor+cells+and+normal+human+keratinocytes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes</span></div><div class="casAuthors">Nunes, Maria; Shi, Celine; Greenberger, Lee M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-27</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">EKB-569 is an irreversible inhibitor of epidermal growth factor receptor (EGF-R) tyrosine kinase.  It inhibits EGF-induced phosphorylation of EGF-R and the growth of tumors that overexpress EGF-R in animal models.  In clin. trials, EKB-569 and all other EGF-R inhibitors cause skin rashes.  To understand the latter phenomenon, the effect of EKB-569 on EGF-R as well as downstream signaling to phosphoinositide 3-kinase-protein kinase B (AKT), extracellular signal-regulated kinase 1 and 2 (ERK1/2), or signal transducer and activator of transcription 3 (STAT3) pathways were compared in tumor cell lines and normal human keratinocytes (NHEK) grown in tissue culture.  Tumor cell lines that have high (A431 epidermoid and MDA-468 breast carcinomas) and low (MCF-7 breast carcinoma) expression of EGF-R were used.  NHEK cells express at least 15-fold less EGF-R than A431 cells.  EKB-569 was a potent inhibitor of proliferation in NHEK, A431, and MDA-468 cells (IC50 = 61, 125, and 260 nM, resp.) but not MCF-7 cells (IC50 = 3600 nM).  EKB-569 was also a potent inhibitor of EGF-induced phosphorylated EGF-R (pEGF-R) in A431 and NHEK cells (IC50 = 20-80 nM).  The redn. in pEGF-R paralleled inhibition of phosphotyrosine-705 STAT3, while the inhibition of phosphorylated AKT and phosphorylated ERK1/2 occurred at higher concns. of EKB-569 (75-500 nM) in both A431 and NHEK cells.  The effects were specific because EKB-569 did not inhibit the nuclear factor-κB pathway.  It is proposed that skin toxicity assocd. with EKB-569 is due to inhibition of EGF-R signaling.  Downstream signal transduction markers, particularly the activation status of STAT3, may be useful surrogate markers to guide clin. development of EGF-R inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyN4PdUKYOdbVg90H21EOLACvtfcHk0lh0SjleJTFrRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFajtA%253D%253D&md5=a54cd8d19e1806fca4174afebd0da642</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.4161%2Fcbt.3.1.538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.3.1.538%26sid%3Dliteratum%253Aachs%26aulast%3DNunes%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DC.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26atitle%3DPhosphorylation%2520of%2520extracellular%2520signal-regulated%2520kinase%25201%2520and%25202%252C%2520protein%2520kinase%2520B%252C%2520and%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520are%2520differently%2520inhibited%2520by%2520an%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%252C%2520EKB-569%252C%2520in%2520tumor%2520cells%2520and%2520normal%2520human%2520keratinocytes%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D21%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Chan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaloge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silovski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokmen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Minckwitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ejlertsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chia, S. K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gnant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryce, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span> </span><span class="NLM_article-title">Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span><span class="NLM_issue">suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">33</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=33&issue=suppl&author=A.+Chanauthor=S.+Delalogeauthor=F.+A.+Holmesauthor=B.+Moyauthor=H.+Iwataauthor=V.+J.+Harveyauthor=N.+J.+Robertauthor=T.+Silovskiauthor=E.+Gokmenauthor=G.+Von+Minckwitzauthor=B.+Ejlertsenauthor=S.+K.+L.+Chiaauthor=J.+Mansiauthor=C.+H.+Barriosauthor=M.+Gnantauthor=A.+Wongauthor=R.+Bryceauthor=B.+Yaoauthor=M.+Martin&title=Neratinib+after+adjuvant+chemotherapy+and+trastuzumab+in+HER2-positive+early+breast+cancer%3A+Primary+analysis+at+2+years+of+a+phase+3%2C+randomized%2C+placebo-controlled+trial+%28ExteNET%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DA.%26aulast%3DDelaloge%26aufirst%3DS.%26aulast%3DHolmes%26aufirst%3DF.%2BA.%26aulast%3DMoy%26aufirst%3DB.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DHarvey%26aufirst%3DV.%2BJ.%26aulast%3DRobert%26aufirst%3DN.%2BJ.%26aulast%3DSilovski%26aufirst%3DT.%26aulast%3DGokmen%26aufirst%3DE.%26aulast%3DVon%2BMinckwitz%26aufirst%3DG.%26aulast%3DEjlertsen%26aufirst%3DB.%26aulast%3DChia%26aufirst%3DS.%2BK.%2BL.%26aulast%3DMansi%26aufirst%3DJ.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DBryce%26aufirst%3DR.%26aulast%3DYao%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DM.%26atitle%3DNeratinib%2520after%2520adjuvant%2520chemotherapy%2520and%2520trastuzumab%2520in%2520HER2-positive%2520early%2520breast%2520cancer%253A%2520Primary%2520analysis%2520at%25202%2520years%2520of%2520a%2520phase%25203%252C%2520randomized%252C%2520placebo-controlled%2520trial%2520%2528ExteNET%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26issue%3Dsuppl%26spage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoephel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraemer, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haaksma, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span> </span><span class="NLM_article-title">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible erbB family blocker</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">350</span><span class="refDoi"> DOI: 10.1124/jpet.112.197756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1124%2Fjpet.112.197756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=22888144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2012&pages=342-350&author=F.+Solcaauthor=G.+Dahlauthor=A.+Zoephelauthor=G.+Baderauthor=M.+Sandersonauthor=C.+Kleinauthor=O.+Kraemerauthor=F.+Himmelsbachauthor=E.+Haaksmaauthor=G.+R.+Adolf&title=Target+binding+properties+and+cellular+activity+of+afatinib+%28BIBW+2992%29%2C+an+irreversible+erbB+family+blocker&doi=10.1124%2Fjpet.112.197756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker</span></div><div class="casAuthors">Solca, Flavio; Dahl, Goeran; Zoephel, Andreas; Bader, Gerd; Sanderson, Michael; Klein, Christian; Kraemer, Oliver; Himmelsbach, Frank; Haaksma, Eric; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">342-350</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain) receptor network is well recognized as an oncogenic driver in epithelial cancers.  Several targeted drugs have been developed, including antibodies and small-mol. kinase inhibitors, each of them characterized by distinct patterns of ErbB receptor interactions.  Understanding the precise pharmacol. properties of these compds. is important for optimal use in clin. practice.  Afatinib [BIBW 2992; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide] is an ATP-competitive anilinoquinazoline deriv. harboring a reactive acrylamide group.  It was designed to covalently bind and irreversibly block enzymically active ErbB receptor family members.  Here, we show by X-ray crystallog. the covalent binding of afatinib to wild-type epidermal growth factor receptor (EGFR) and by mass spectrometry the covalent interaction with EGFR, EGFRL858R/T790M, human epidermal growth factor receptor 2 (HER2), and ErbB-4.  Afatinib potently inhibits the enzymatic activity of ErbB-4 (EC50 = 1 nM) and the proliferation of cancer cell lines driven by multiple ErbB receptor aberrations at concns. below 100 nM.  N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butanamide (BI 37781), a close analog of afatinib lacking the acrylamide group and thus incapable of covalent bond formation, had similar potency on cells driven by EGFR or EGFRL858R, but less or no detectable activity on cells expressing EGFRL858R/T790M HER2 or ErbB-4.  These results stress the importance of the acrylamide group and show that afatinib differs from approved ErbB targeting agents by irreversibly inhibiting the kinase activity of all ErbB family members.  They provide a mechanistic rationale for the distinct pharmacol. features of this compd. and explain the clin. activity seen in some patients who are resistant to antibody or kinase inhibitor therapy because of secondary mutations or ErbB receptor "reprogramming.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofXgQqaKXv-bVg90H21EOLACvtfcHk0liYOkyD5h-gQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE&md5=4a57df32abe8101f287fc6251f63f92d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.197756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.197756%26sid%3Dliteratum%253Aachs%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSanderson%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DKraemer%26aufirst%3DO.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DHaaksma%26aufirst%3DE.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DTarget%2520binding%2520properties%2520and%2520cellular%2520activity%2520of%2520afatinib%2520%2528BIBW%25202992%2529%252C%2520an%2520irreversible%2520erbB%2520family%2520blocker%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D343%26spage%3D342%26epage%3D350%26doi%3D10.1124%2Fjpet.112.197756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Sanderson, K.</span><span> </span><span class="NLM_article-title">Irreversible kinase inhibitors gain traction</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">649</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span><span class="refDoi"> DOI: 10.1038/nrd4103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnrd4103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=649-651&author=K.+Sanderson&title=Irreversible+kinase+inhibitors+gain+traction&doi=10.1038%2Fnrd4103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnrd4103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4103%26sid%3Dliteratum%253Aachs%26aulast%3DSanderson%26aufirst%3DK.%26atitle%3DIrreversible%2520kinase%2520inhibitors%2520gain%2520traction%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D649%26epage%3D651%26doi%3D10.1038%2Fnrd4103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span><span class="refDoi"> DOI: 10.1073/pnas.0502860102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1073%2Fpnas.0502860102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=15897464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib&doi=10.1073%2Fpnas.0502860102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span></div><div class="casAuthors">Kwak, Eunice L.; Sordella, Raffaella; Bell, Daphne W.; Godin-Heymann, Nadia; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Driscoll, David R.; Fidias, Panos; Lynch, Thomas J.; Rabindran, Sridhar K.; McGinnis, John P.; Wissner, Allan; Sharma, Sreenath V.; Isselbacher, Kurt J.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7665-7670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonsmall cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to the reversible tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva).  Some recurrent tumors have a common secondary mutation in the EGFR kinase domain, T790M, conferring drug resistance, but in other cases the mechanism underlying acquired resistance is unknown.  In studying multiple sites of recurrent NSCLCs, the authors detected T790M in only a small percentage of tumor cells.  To identify addnl. mechanisms of acquired resistance to gefitinib, the authors used NSCLC cells harboring an activating EGFR mutation to generate multiple resistant clones in vitro.  These drug-resistant cells demonstrate continued dependence on EGFR and ERBB2 signaling for their viability and have not acquired secondary EGFR mutations.  However, they display increased internalization of ligand-activated EGFR, consistent with altered receptor trafficking.  Although gefitinib-resistant clones are cross-resistant to related anilinoquinazolines, they demonstrate sensitivity to a class of irreversible inhibitors of EGFR.  These inhibitors also show effective inhibition of signaling by T790M-mutant EGFR and killing of NSCLC cells with the T790M mutation.  Both mechanisms of gefitinib resistance are therefore circumvented by irreversible tyrosine kinase inhibitors.  Our findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW5BSM8yaZe7Vg90H21EOLACvtfcHk0liSk_MyvB-h3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D&md5=f3fb866c3673fd4dff8a3f0a8c9be65b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502860102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502860102%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670%26doi%3D10.1073%2Fpnas.0502860102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">Inhibition of drug- resistant mutants of ABL, KIT, and EGF receptor kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">11011</span><span class="NLM_x">–</span> <span class="NLM_lpage">11016</span><span class="refDoi"> DOI: 10.1073/pnas.0504952102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1073%2Fpnas.0504952102" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11011-11016&author=T.+A.+Carterauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=D.+K.+Treiberauthor=Z.+V.+Milanovauthor=C.+E.+Atteridgeauthor=W.+H.+Biggsauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=S.+A.+Mehtaauthor=H.+K.+Patelauthor=W.+Paoauthor=C.+L.+Sawyersauthor=H.+Varmusauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=Inhibition+of+drug-+resistant+mutants+of+ABL%2C+KIT%2C+and+EGF+receptor+kinases&doi=10.1073%2Fpnas.0504952102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0504952102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0504952102%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVarmus%26aufirst%3DH.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520drug-%2520resistant%2520mutants%2520of%2520ABL%252C%2520KIT%252C%2520and%2520EGF%2520receptor%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D11011%26epage%3D11016%26doi%3D10.1073%2Fpnas.0504952102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0liSk_MyvB-h3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.-H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+profiling+provides+insights+into+the+limited+activity+of+irreversible+EGFR+inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation&doi=10.1158%2F0008-5472.CAN-09-3106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0lj9nUesbpgIaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.-H.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520profiling%2520provides%2520insights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874%26doi%3D10.1158%2F0008-5472.CAN-09-3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Z.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abolhoda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span> </span><span class="NLM_article-title">The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">784</span><span class="NLM_x">–</span> <span class="NLM_lpage">791</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1535-7163.MCT-11-0750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=22228822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=784-791&author=Y.+Kimauthor=J.+Koauthor=Z.-Y.+Cuiauthor=A.+Abolhodaauthor=J.+S.+Ahnauthor=S.-H.+Ouauthor=M.-Y.+Ahnauthor=K.+Park&title=The+EGFR+T790M+mutation+in+acquired+resistance+to+an+irreversible+second-generation+EGFR+inhibitor&doi=10.1158%2F1535-7163.MCT-11-0750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor</span></div><div class="casAuthors">Kim, Youngwook; Ko, Jeonghun; Cui, ZhengYun; Abolhoda, Amir; Ahn, Jin Seok; Ou, Sai-Hong; Ahn, Myung-Ju; Park, Keunchil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">784-791</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mol. target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR.  However, these patients eventually develop resistance to the reversible TKIs, and this has led to the development of second-generation, irreversible EGFR inhibitors.  Currently, the mechanism of acquired resistance to irreversible EGFR inhibitors is not clear.  Using an in vitro cell culture system, we modeled the acquired resistance to first-line treatment with second-generation EGFR-TKIs using an EGFR-mutant NSCLC cell line.  Here, we report a mechanism of resistance involving T790M secondary mutation as well as a corresponding clin. case.  The results of these findings suggest that inhibition of EGFR by currently available second-generation EGFR-TKIs may not be sufficient to physiol. prevent the emergence of cells that are still dependent on EGFR signaling.  This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs.  Mol Cancer Ther; 11(3); 784-91.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhUxzW64OFLVg90H21EOLACvtfcHk0lj9nUesbpgIaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D&md5=3cd09bb1dd73f8045b93b054c79480d3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0750%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DKo%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DZ.-Y.%26aulast%3DAbolhoda%26aufirst%3DA.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DOu%26aufirst%3DS.-H.%26aulast%3DAhn%26aufirst%3DM.-Y.%26aulast%3DPark%26aufirst%3DK.%26atitle%3DThe%2520EGFR%2520T790M%2520mutation%2520in%2520acquired%2520resistance%2520to%2520an%2520irreversible%2520second-generation%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D784%26epage%3D791%26doi%3D10.1158%2F1535-7163.MCT-11-0750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M&doi=10.1016%2Fj.bmcl.2010.12.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0ljPjIeGCmK-BQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643%26doi%3D10.1016%2Fj.bmcl.2010.12.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.,  St</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M mediated resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=A.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M+mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M%2520mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Cross, D. A. E</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+E+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lhGw7IPLHR_Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Mitsudomi, T.; Tsai, C.; Shepherd, F.; Bazhenova, L.; Lee, J.; Chang, G.; Crino, L.; Satouchi, M.; Chu, Q.; Lawrance, R.; Cantarini, M.; Ghiorghiu, S.; Goss, G.</span><span> </span><span class="NLM_article-title">MINI16.08: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 phase II study</span>.  <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span>, <span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">1406</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1406&issue=Suppl.+2&author=T.+Mitsudomi&author=C.+Tsai&author=F.+Shepherd&author=L.+Bazhenova&author=J.+Lee&author=G.+Chang&author=L.+Crino&author=M.+Satouchi&author=Q.+Chu&author=R.+Lawrance&author=M.+Cantarini&author=S.+Ghiorghiu&author=G.+Goss&title=MINI16.08%3A+AZD9291+in+pre-treated+T790M+positive+advanced+NSCLC%3A+AURA2+phase+II+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitsudomi%26aufirst%3DT.%26atitle%3DMINI16.08%253A%2520AZD9291%2520in%2520pre-treated%2520T790M%2520positive%2520advanced%2520NSCLC%253A%2520AURA2%2520phase%2520II%2520study%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26issue%3DSuppl.%25202%26spage%3D1406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Zinner, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemunaitis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H. J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donato, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, D. M.</span><span> </span><span class="NLM_article-title">Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in Patients with refractory cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3006</span><span class="NLM_x">–</span> <span class="NLM_lpage">3014</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-1958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1078-0432.CCR-06-1958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=17505003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Krt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=3006-3014&author=R.+G.+Zinnerauthor=J.+Nemunaitisauthor=I.+Eisemanauthor=H.+J.+C.+Shinauthor=S.+C.+Olsonauthor=J.+Christensenauthor=X.+Huangauthor=P.+F.+Lenehanauthor=N.+J.+Donatoauthor=D.+M.+Shin&title=Phase+I+clinical+and+pharmacodynamic+evaluation+of+oral+CI-1033+in+Patients+with+refractory+cancer&doi=10.1158%2F1078-0432.CCR-06-1958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer</span></div><div class="casAuthors">Zinner, Ralph G.; Nemunaitis, John; Eiseman, Irene; Shin, Hyung Ju C.; Olson, Stephen C.; Christensen, James; Huang, Xin; Lenehan, Peter F.; Donato, Nicholas J.; Shin, Dong M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3006-3014</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To det. the tolerability and pharmacokinetics of CI-1033 given daily for 7 days of a 21-day cycle.  Tumor response and changes in erbB receptor tyrosine kinase activity in tumor and skin tissue were examd., and modulation of potential biomarkers in plasma was explored.  Design: This was a dose-finding phase I study in patients with advanced solid malignancies.  Patients were evaluated for safety, pharmacokinetics, and tumor response.  Pharmacodynamic markers, such as Ki67, p27, and erbB receptor status, were assessed in tumor and skin tissue using immunohistochem. and immunopptn. methodologies.  Plasma biomarkers HER2, vascular endothelial growth factor, interleukin-8, and matrix metalloproteinase-9 were evaluated using immunol. techniques.  Results: Fifty-three patients were enrolled in the study.  Dose-limiting toxicity (emesis, persistent rash, and mouth ulcer) was obsd. at 750 mg.  The max. tolerated dose was 650 mg.  There were no confirmed objective responses.  CI-1033 treatment showed down-regulation of epidermal growth factor receptor, HER2, and Ki67 in a variety of tumor tissues and up regulation of p27 in skin tissue.  Plasma HER2 was reduced following CI-1033 administration, but no consistent change in vascular endothelial growth factor, interleukin-8, or matrix metalloproteinase-9 was noted.  CI-1033 plasma concns. were proportional to dose.  Conclusion: The safety and pharmacokinetic profile of CI-1033 was favorable for multidose oral administration.  Evidence of modulation of erbB receptor activity in tumor and skin tissue was accompanied by changes in markers of proliferation and cell cycle inhibition.  Addnl. clin. trials are warranted in defining the role of CI-1033 in the treatment of cancer and further assessing the utility of antitumor markers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPny5s9HKAYLVg90H21EOLACvtfcHk0lhGw7IPLHR_Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Krt7w%253D&md5=d7cbd945bb7242152a2afe580dc4f0bf</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1958%26sid%3Dliteratum%253Aachs%26aulast%3DZinner%26aufirst%3DR.%2BG.%26aulast%3DNemunaitis%26aufirst%3DJ.%26aulast%3DEiseman%26aufirst%3DI.%26aulast%3DShin%26aufirst%3DH.%2BJ.%2BC.%26aulast%3DOlson%26aufirst%3DS.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26aulast%3DDonato%26aufirst%3DN.%2BJ.%26aulast%3DShin%26aufirst%3DD.%2BM.%26atitle%3DPhase%2520I%2520clinical%2520and%2520pharmacodynamic%2520evaluation%2520of%2520oral%2520CI-1033%2520in%2520Patients%2520with%2520refractory%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D3006%26epage%3D3014%26doi%3D10.1158%2F1078-0432.CCR-06-1958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Nemunaitis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senzer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bycott, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlicht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zentgraff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinner, R. G.</span><span> </span><span class="NLM_article-title">Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3846</span><span class="NLM_x">–</span> <span class="NLM_lpage">3853</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-1950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1078-0432.CCR-04-1950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=15897585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFyru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=3846-3853&author=J.+Nemunaitisauthor=I.+Eisemanauthor=C.+Cunninghamauthor=N.+Senzerauthor=A.+Williamsauthor=P.+F.+Lenehanauthor=S.+C.+Olsonauthor=P.+Bycottauthor=M.+Schlichtauthor=R.+Zentgraffauthor=D.+M.+Shinauthor=R.+G.+Zinner&title=Phase+1+clinical+and+pharmacokinetics+evaluation+of+oral+CI-1033+in+patients+with+refractory+cancer&doi=10.1158%2F1078-0432.CCR-04-1950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer</span></div><div class="casAuthors">Nemunaitis, John; Eiseman, Irene; Cunningham, Casey; Senzer, Neil; Williams, Adrienne; Lenehan, Peter F.; Olson, Stephen C.; Bycott, Paul; Schlicht, Michael; Zentgraff, Rebecca; Shin, Dong M.; Zinner, Ralph G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3846-3853</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To det. the tolerability and pharmacokinetics of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, administered over 14 consecutive days of a 21-day cycle.  Design: Phase 1, multicenter trial involving patients with solid tumors that are refractory to std. therapy.  CI-1033 was administered initially at 300 mg/day to a min. cohort of three patients.  Dose escalation proceeded at ≤40% increments.  Patients were evaluated for toxicity, pharmacokinetic profile, and evidence of response.  Results: Thirty-two patients entered the trial and were evaluable for safety assessment.  Dose-limiting toxicity (diarrhea, rash, and/or anorexia) occurred at the 560 mg dose level; the max. tolerated dose was 450 mg.  No patients achieved objective responses and six patients achieved stable disease.  Plasma CI-1033 concns. increased with increasing dose.  CI-1033 was not eliminated in urine to any appreciable extent.  Conclusions: CI-1033 is suitable for phase 2 testing at the 450 mg/day dose level when administered for 14 days in a 21-day cycle.  The pharmacokinetic profile is consistent with biol. relevant plasma concns. over the dosing interval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyQ3ltoWKM9rVg90H21EOLACvtfcHk0ljb0qsMi8Uh7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFyru7Y%253D&md5=efeb265dd0a8eba66ce6dd9308bd3123</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1950%26sid%3Dliteratum%253Aachs%26aulast%3DNemunaitis%26aufirst%3DJ.%26aulast%3DEiseman%26aufirst%3DI.%26aulast%3DCunningham%26aufirst%3DC.%26aulast%3DSenzer%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DA.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26aulast%3DOlson%26aufirst%3DS.%2BC.%26aulast%3DBycott%26aufirst%3DP.%26aulast%3DSchlicht%26aufirst%3DM.%26aulast%3DZentgraff%26aufirst%3DR.%26aulast%3DShin%26aufirst%3DD.%2BM.%26aulast%3DZinner%26aufirst%3DR.%2BG.%26atitle%3DPhase%25201%2520clinical%2520and%2520pharmacokinetics%2520evaluation%2520of%2520oral%2520CI-1033%2520in%2520patients%2520with%2520refractory%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D3846%26epage%3D3853%26doi%3D10.1158%2F1078-0432.CCR-04-1950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velentza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatauer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagorska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiDonato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balk, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5916</span><span class="NLM_x">–</span> <span class="NLM_lpage">5919</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.bmcl.2008.07.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=18667312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5916-5919&author=W.+Hurauthor=A.+Velentzaauthor=S.+Kimauthor=L.+Flatauerauthor=X.+Jiangauthor=D.+Valenteauthor=D.+E.+Masonauthor=M.+Suzukiauthor=B.+Larsonauthor=J.+Zhangauthor=A.+Zagorskaauthor=M.+DiDonatoauthor=A.+Nagleauthor=M.+Warmuthauthor=S.+P.+Balkauthor=E.+C.+Petersauthor=N.+S.+Gray&title=Clinical+stage+EGFR+inhibitors+irreversibly+alkylate+Bmx+kinase&doi=10.1016%2Fj.bmcl.2008.07.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase</span></div><div class="casAuthors">Hur, Wooyoung; Velentza, Anastasia; Kim, Sungjoon; Flatauer, Laura; Jiang, Xinnong; Valente, David; Mason, Daniel E.; Suzuki, Melissa; Larson, Brad; Zhang, Jianming; Zagorska, Anna; DiDonato, Michael; Nagle, Advait; Warmuth, Markus; Balk, Steven P.; Peters, Eric C.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5916-5919</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Irreversible HER/erbB inhibitors selectively inhibit HER-family kinases by targeting a unique cysteine residue located within the ATP-binding pocket.  Sequence alignment reveals that this rare cysteine is also present in ten other protein kinases including all five Tec-family members.  We demonstrate that the Tec-family kinase Bmx is potently inhibited by irreversible modification at Cys496 by clin. stage EGFR inhibitors such as CI-1033.  This cross-reactivity may have significant clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_hlFgn2jwY7Vg90H21EOLACvtfcHk0ljb0qsMi8Uh7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7vM&md5=2f704e42920d0a18f9dfdcc688347f0a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.062%26sid%3Dliteratum%253Aachs%26aulast%3DHur%26aufirst%3DW.%26aulast%3DVelentza%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DFlatauer%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DValente%26aufirst%3DD.%26aulast%3DMason%26aufirst%3DD.%2BE.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DLarson%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZagorska%26aufirst%3DA.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DPeters%26aufirst%3DE.%2BC.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DClinical%2520stage%2520EGFR%2520inhibitors%2520irreversibly%2520alkylate%2520Bmx%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5916%26epage%3D5919%26doi%3D10.1016%2Fj.bmcl.2008.07.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lipQe0RGQ8ZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Campos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiden, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plante, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potkul, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldjian, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varterasian, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charbonneau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirte, H.</span><span> </span><span class="NLM_article-title">Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5597</span><span class="NLM_x">–</span> <span class="NLM_lpage">5604</span><span class="refDoi"> DOI: 10.1200/JCO.2005.08.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1200%2FJCO.2005.08.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16110019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVersr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5597-5604&author=S.+Camposauthor=O.+Hamidauthor=M.+V.+Seidenauthor=A.+Ozaauthor=M.+Planteauthor=R.+K.+Potkulauthor=P.+F.+Lenehanauthor=E.+P.+Kaldjianauthor=M.+L.+Varterasianauthor=C.+Jordanauthor=C.+Charbonneauauthor=H.+Hirte&title=Multicenter%2C+randomized+phase+II+trial+of+oral+CI-1033+for+previously+treated+advanced+ovarian+cancer&doi=10.1200%2FJCO.2005.08.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer</span></div><div class="casAuthors">Campos, Susana; Hamid, Oday; Seiden, Michael V.; Oza, Amit; Plante, Marie; Potkul, Ronald K.; Lenehan, Peter F.; Kaldjian, Eric P.; Varterasian, Mary L.; Jordan, Cheryl; Charbonneau, Claudie; Hirte, Hal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5597-5604</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To evaluate the antitumor activity and toxicity of two doses of CI-1033 in patients with platinum-refractory or recurrent ovarian cancer, and to det. baseline expression of epidermal growth factor receptor in tumor cells.  Patients and Methods: This phase II, open-label clin. trial evaluated CI-1033 in patients with ovarian cancer who failed prior platinum-based therapy.  Two oral doses of CI-1033 were evaluated-a 50-mg and a 200-mg oral dose administered daily for 21 days in a 28-day cycle.  Patients were evaluated for tumor response and toxicity; in addn., archival baseline tumor samples were analyzed by immunohistochem. for erbB1 to erbB4 status.  Results: One hundred five eligible patients were treated.  Baseline demog. characteristics were balanced in this heavily pretreated patient population.  The median no. of prior chemotherapy regimens received was four.  The most commonly encountered drug-related adverse events for both dose arms were gastrointestinal (diarrhea, nausea, stomatitis) toxicity, asthenia, and rash.  No responses were obsd.  Stable disease was confirmed in 34% and 26% of patients in the 200-mg and 50-mg arms, resp., and 1-yr survival rates were 38.5% and 37.7%, resp.  Baseline erbB3 and erbB4 revealed the highest frequencies of expression, while erbB2 was the lowest.  Conclusion: CI-1033 did not show activity in unscreened patients with advanced ovarian cancer.  At 50 mg/d, CI-1033 had a more favorable adverse events profile than at 200 mg/d.  ErbB3 and erbB4 receptors showed the highest expression in tumor samples while erbB2 revealed the least.  There appears to be no assocn. between baseline erbB expression and disease stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQbgq5slTwJLVg90H21EOLACvtfcHk0lipQe0RGQ8ZLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVersr%252FL&md5=35cb9a35e064461ad1bbf3097ee09de8</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.08.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.08.091%26sid%3Dliteratum%253Aachs%26aulast%3DCampos%26aufirst%3DS.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSeiden%26aufirst%3DM.%2BV.%26aulast%3DOza%26aufirst%3DA.%26aulast%3DPlante%26aufirst%3DM.%26aulast%3DPotkul%26aufirst%3DR.%2BK.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26aulast%3DKaldjian%26aufirst%3DE.%2BP.%26aulast%3DVarterasian%26aufirst%3DM.%2BL.%26aulast%3DJordan%26aufirst%3DC.%26aulast%3DCharbonneau%26aufirst%3DC.%26aulast%3DHirte%26aufirst%3DH.%26atitle%3DMulticenter%252C%2520randomized%2520phase%2520II%2520trial%2520of%2520oral%2520CI-1033%2520for%2520previously%2520treated%2520advanced%2520ovarian%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5597%26epage%3D5604%26doi%3D10.1200%2FJCO.2005.08.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogs as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">–</span> <span class="NLM_lpage">928</span><span class="refDoi"> DOI: 10.1021/jm950692f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm950692f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=918-928&author=G.+W.+Rewcastleauthor=B.+D.+Palmerauthor=A.+J.+Bridgesauthor=H.+D.+H.+Showalterauthor=L.+Sunauthor=J.+Nelsonauthor=A.+McMichaelauthor=A.+J.+Krakerauthor=D.+W.+Fryauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+9.+Synthesis+and+evaluation+of+fused+tricyclic+quinazoline+analogs+as+ATP+site+inhibitors+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor&doi=10.1021%2Fjm950692f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm950692f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950692f%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DNelson%26aufirst%3DJ.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%25209.%2520Synthesis%2520and%2520evaluation%2520of%2520fused%2520tricyclic%2520quinazoline%2520analogs%2520as%2520ATP%2520site%2520inhibitors%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D918%26epage%3D928%26doi%3D10.1021%2Fjm950692f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cody, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-Bromophenyl)amino]pyrido[<i>d</i>]pyrimidines Are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1823</span><span class="NLM_x">–</span> <span class="NLM_lpage">1835</span><span class="refDoi"> DOI: 10.1021/jm9508651</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9508651" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=1823-1835&author=G.+W.+Rewcastleauthor=B.+D.+Palmerauthor=A.+M.+Thompsonauthor=A.+J.+Bridgesauthor=D.+R.+Codyauthor=H.+Zhouauthor=D.+W.+Fryauthor=A.+McMichaelauthor=W.+A.+Denny&title=Tyrosine+Kinase+Inhibitors.+10.+Isomeric+4-%5B%283-Bromophenyl%29amino%5Dpyrido%5Bd%5Dpyrimidines+Are+Potent+ATP+Binding+Site+Inhibitors+of+the+Tyrosine+Kinase+Function+of+the+Epidermal+Growth+Factor+Receptor&doi=10.1021%2Fjm9508651"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm9508651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9508651%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DCody%26aufirst%3DD.%2BR.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520Kinase%2520Inhibitors.%252010.%2520Isomeric%25204-%255B%25283-Bromophenyl%2529amino%255Dpyrido%255Bd%255Dpyrimidines%2520Are%2520Potent%2520ATP%2520Binding%2520Site%2520Inhibitors%2520of%2520the%2520Tyrosine%2520Kinase%2520Function%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D1823%26epage%3D1835%26doi%3D10.1021%2Fjm9508651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boni, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amorusi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2252</span><span class="NLM_x">–</span> <span class="NLM_lpage">2260</span><span class="refDoi"> DOI: 10.1200/JCO.2005.01.8960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1200%2FJCO.2005.01.8960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16710023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvV2ksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=2252-2260&author=C.+Erlichmanauthor=M.+Hidalgoauthor=J.+P.+Boniauthor=P.+Martinsauthor=S.+E.+Quinnauthor=C.+Zacharchukauthor=P.+Amorusiauthor=A.+A.+Adjeiauthor=E.+K.+Rowinsky&title=Phase+I+study+of+EKB-569%2C+an+irreversible+inhibitor+of+the+epidermal+growth+factor+receptor%2C+in+patients+with+advanced+solid+tumors&doi=10.1200%2FJCO.2005.01.8960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors</span></div><div class="casAuthors">Erlichman, Charles; Hidalgo, Manuel; Boni, Joseph P.; Martins, Patricia; Quinn, Susan E.; Zacharchuk, Charles; Amorusi, Peter; Adjei, Alex A.; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2252-2260</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The max. tolerated dose (MTD) and the dose-limiting toxicities of EKB-569, a selective, irreversible inhibitor of the epidermal growth factor receptor (EGFR), when administered orally once daily on an intermittent-dose schedule (14 days of a 28-day cycle) or on a continuous-dose schedule (each day of a 28-day cycle), were detd. in patients with advanced solid tumors.  Planned dose escalation was 25, 50, 75, 125, 175, and 225 mg.  Pharmacokinetic sampling was performed on days 1 and 14 for the intermittent-dose cohort and on days 1 and 15 for the continuous-dose cohort.  Thirty patients received a median of two cycles (range, one to 10 cycles) in the intermittent-dose cohort; 29 patients received a median of three cycles (range, one to eight cycles) in the continuous-dose cohort.  Dose-limiting toxicity was grade 3 diarrhea, and the MTD was 75 mg EKB-569 per day for both cohorts.  Other common toxicities included rash, nausea, and asthenia.  Exposure to EKB-569 was dose proportional.  At the MTD, the mean ± std. deviation terminal half-life was 21.7 ± 4.2 h and peak concn. increased 1.2-fold from day 1 to day 14/15.  No major antitumor responses were obsd.  However, one patient with non-small-cell lung cancer and one with cutaneous squamous cell carcinoma had stable disease for 33 and 24 wk, resp.  The MTD of once-daily oral EKB-569 is 75 mg.  The tolerable toxicity profile and long half-life of this irreversible EGFR inhibitor warrant its further evaluation as a single agent and in combination with other drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoWU_wd20ORbVg90H21EOLACvtfcHk0liq9olWUwJvBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvV2ksLk%253D&md5=3a7766538e63808314fe4ea73b5f766d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.01.8960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.01.8960%26sid%3Dliteratum%253Aachs%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DBoni%26aufirst%3DJ.%2BP.%26aulast%3DMartins%26aufirst%3DP.%26aulast%3DQuinn%26aufirst%3DS.%2BE.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DAmorusi%26aufirst%3DP.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DPhase%2520I%2520study%2520of%2520EKB-569%252C%2520an%2520irreversible%2520inhibitor%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D2252%26epage%3D2260%26doi%3D10.1200%2FJCO.2005.01.8960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Cockerill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubberfield, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stables, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guntrip, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeown, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jowett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woollard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spalding, D.</span><span> </span><span class="NLM_article-title">Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1401</span><span class="NLM_x">–</span> <span class="NLM_lpage">1405</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00219-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS0960-894X%2801%2900219-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1401-1405&author=S.+Cockerillauthor=C.+Stubberfieldauthor=J.+Stablesauthor=M.+Carterauthor=S.+Guntripauthor=K.+Smithauthor=S.+McKeownauthor=R.+Shawauthor=P.+Topleyauthor=L.+Thomsenauthor=K.+Affleckauthor=A.+Jowettauthor=D.+Hayesauthor=M.+Willsonauthor=P.+Woollardauthor=D.+Spalding&title=Indazolylamino+quinazolines+and+pyridopyrimidines+as+inhibitors+of+the+EGFr+and+c-erbB-2&doi=10.1016%2FS0960-894X%2801%2900219-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900219-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900219-0%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DS.%26aulast%3DStubberfield%26aufirst%3DC.%26aulast%3DStables%26aufirst%3DJ.%26aulast%3DCarter%26aufirst%3DM.%26aulast%3DGuntrip%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DMcKeown%26aufirst%3DS.%26aulast%3DShaw%26aufirst%3DR.%26aulast%3DTopley%26aufirst%3DP.%26aulast%3DThomsen%26aufirst%3DL.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DJowett%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DD.%26aulast%3DWillson%26aufirst%3DM.%26aulast%3DWoollard%26aufirst%3DP.%26aulast%3DSpalding%26aufirst%3DD.%26atitle%3DIndazolylamino%2520quinazolines%2520and%2520pyridopyrimidines%2520as%2520inhibitors%2520of%2520the%2520EGFr%2520and%2520c-erbB-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1401%26epage%3D1405%26doi%3D10.1016%2FS0960-894X%2801%2900219-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Gaul, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guntrip, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadepalli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span> </span><span class="NLM_article-title">Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">–</span> <span class="NLM_lpage">640</span><span class="refDoi"> DOI: 10.1016/S0960-894X(02)01047-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS0960-894X%2802%2901047-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=637-640&author=M.+D.+Gaulauthor=Y.+Guoauthor=K.+Affleckauthor=G.+S.+Cockerillauthor=T.+M.+Gilmerauthor=R.+J.+Griffinauthor=S.+Guntripauthor=B.+R.+Keithauthor=W.+B.+Knightauthor=R.+J.+Mullinauthor=D.+M.+Murrayauthor=D.+W.+Rusnakauthor=K.+Smithauthor=S.+Tadepalliauthor=E.+R.+Woodauthor=K.+Lackey&title=Discovery+and+Biological+Evaluation+of+Potent+Dual+ErbB-2%2FEGFR+Tyrosine+Kinase+Inhibitors%3A+6-Thiazolylquinazolines&doi=10.1016%2FS0960-894X%2802%2901047-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2901047-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252901047-8%26sid%3Dliteratum%253Aachs%26aulast%3DGaul%26aufirst%3DM.%2BD.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DGuntrip%26aufirst%3DS.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DKnight%26aufirst%3DW.%2BB.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DMurray%26aufirst%3DD.%2BM.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DTadepalli%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DLackey%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520Biological%2520Evaluation%2520of%2520Potent%2520Dual%2520ErbB-2%252FEGFR%2520Tyrosine%2520Kinase%2520Inhibitors%253A%25206-Thiazolylquinazolines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D637%26epage%3D640%26doi%3D10.1016%2FS0960-894X%2802%2901047-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Zhang, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guntrip, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderwall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span> </span><span class="NLM_article-title">Synthesis and SAR of potent EGFR/erbB2 dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.bmcl.2003.10.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=111-114&author=Y.-M.+Zhangauthor=S.+Cockerillauthor=S.+B.+Guntripauthor=D.+Rusnakauthor=K.+Smithauthor=D.+Vanderwallauthor=E.+Woodauthor=K.+Lackey&title=Synthesis+and+SAR+of+potent+EGFR%2FerbB2+dual+inhibitors&doi=10.1016%2Fj.bmcl.2003.10.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.-M.%26aulast%3DCockerill%26aufirst%3DS.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DRusnak%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DVanderwall%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520potent%2520EGFR%252FerbB2%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D111%26epage%3D114%26doi%3D10.1016%2Fj.bmcl.2003.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Optimization and SAR for dual erbB-1/erbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4686</span><span class="NLM_x">–</span> <span class="NLM_lpage">4691</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.05.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.bmcl.2006.05.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16777410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4686-4691&author=K.+G.+Petrovauthor=Y.-M.+Zhangauthor=M.+Carterauthor=G.+S.+Cockerillauthor=S.+Dickersonauthor=C.+A.+Gauthierauthor=Y.+Guoauthor=R.+A.+Mookauthor=D.+W.+Rusnakauthor=A.+L.+Walkerauthor=E.+R.+Woodauthor=K.+E.+Lackey&title=Optimization+and+SAR+for+dual+erbB-1%2FerbB-2+tyrosine+kinase+inhibition+in+the+6-furanylquinazoline+series&doi=10.1016%2Fj.bmcl.2006.05.090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span></div><div class="casAuthors">Petrov, Kimberly G.; Zhang, Yue-Mei; Carter, Malcolm; Cockerill, G. Stuart; Dickerson, Scott; Gauthier, Cassandra A.; Guo, Yu; Mook, Robert A.; Rusnak, David W.; Walker, Ann L.; Wood, Edgar R.; Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4686-4691</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino structure provided the best enzyme potency and cellular selectivity.  Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy.  The discovery of lapatinib emerged from this work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtejUjyH9in7Vg90H21EOLACvtfcHk0liX6OuY0Qmoxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D&md5=946712927ab1a7940ea3ef2fea7574b5</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.05.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.05.090%26sid%3Dliteratum%253Aachs%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DZhang%26aufirst%3DY.-M.%26aulast%3DCarter%26aufirst%3DM.%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DDickerson%26aufirst%3DS.%26aulast%3DGauthier%26aufirst%3DC.%2BA.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DOptimization%2520and%2520SAR%2520for%2520dual%2520erbB-1%252FerbB-2%2520tyrosine%2520kinase%2520inhibition%2520in%2520the%25206-furanylquinazoline%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4686%26epage%3D4691%26doi%3D10.1016%2Fj.bmcl.2006.05.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amato, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhoury, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lettiere, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span> </span><span class="NLM_article-title">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1880</span><span class="NLM_x">–</span> <span class="NLM_lpage">1889</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1535-7163.MCT-07-2232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=18606718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1880-1889&author=A.+J.+Gonzalesauthor=K.+E.+Hookauthor=I.+W.+Althausauthor=P.+A.+Ellisauthor=E.+Trachetauthor=A.+M.+Delaneyauthor=P.+J.+Harveyauthor=T.+A.+Ellisauthor=D.+M.+Amatoauthor=J.+M.+Nelsonauthor=D.+W.+Fryauthor=T.+Zhuauthor=C.-M.+Loiauthor=S.+A.+Fakhouryauthor=K.+M.+Schlosserauthor=K.+E.+Sextonauthor=R.+T.+Wintersauthor=J.+E.+Reedauthor=A.+J.+Bridgesauthor=D.+J.+Lettiereauthor=D.+A.+Bakerauthor=J.+Yangauthor=H.+T.+Leeauthor=H.+Tecleauthor=P.+W.+Vincent&title=Antitumor+activity+and+pharmacokinetic+properties+of+PF-00299804%2C+a+second-generation+irreversible+pan-erbB+receptor+tyrosine+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-07-2232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Gonzales, Andrea J.; Hook, Kenneth E.; Althaus, Irene W.; Ellis, Paul A.; Trachet, Erin; Delaney, Amy M.; Harvey, Patricia J.; Ellis, Teresa A.; Amato, Danielle M.; Nelson, James M.; Fry, David W.; Zhu, Tong; Loi, Cho-Ming; Fakhoury, Stephen A.; Schlosser, Kevin M.; Sexton, Karen E.; Winters, R. Thomas; Reed, Jessica E.; Bridges, Alex J.; Lettiere, Daniel J.; Baker, Deborah A.; Yang, Jianxin; Lee, Helen T.; Tecle, Haile; Vincent, Patrick W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1880-1889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types.  Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments.  PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor currently in phase I clin. trials.  PF-00299804 is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members.  Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) assocd. with resistance to gefitinib and erlotinib.  Furthermore, PF-00299804 shows exceptional distribution to human tumor xenografts and excellent pharmacokinetic properties across species. [Mol Cancer Ther 2008;7(7):1880-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbL0hP8K2G37Vg90H21EOLACvtfcHk0liX6OuY0Qmoxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D&md5=3392275d1e4f4d5d70e3b22d4893e3c8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2232%26sid%3Dliteratum%253Aachs%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DEllis%26aufirst%3DT.%2BA.%26aulast%3DAmato%26aufirst%3DD.%2BM.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DLoi%26aufirst%3DC.-M.%26aulast%3DFakhoury%26aufirst%3DS.%2BA.%26aulast%3DSchlosser%26aufirst%3DK.%2BM.%26aulast%3DSexton%26aufirst%3DK.%2BE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DLettiere%26aufirst%3DD.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacokinetic%2520properties%2520of%2520PF-00299804%252C%2520a%2520second-generation%2520irreversible%2520pan-erbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1880%26epage%3D1889%26doi%3D10.1158%2F1535-7163.MCT-07-2232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span> </span><span class="NLM_article-title">Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1016/j.str.2012.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.str.2012.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=23273428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFeq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=209-219&author=K.+S.+Gajiwalaauthor=J.+Fengauthor=R.+Ferreauthor=K.+Ryanauthor=O.+Brodskyauthor=S.+Weinrichauthor=J.+C.+Kathauthor=A.+Stewart&title=Insights+into+the+aberrant+activity+of+mutant+EGFR+kinase+domain+and+drug+recognition&doi=10.1016%2Fj.str.2012.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition</span></div><div class="casAuthors">Gajiwala, Ketan S.; Feng, Junli; Ferre, RoseAnn; Ryan, Kevin; Brodsky, Oleg; Weinrich, Scott; Kath, John C.; Stewart, Al</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-219</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The oncogenicity of the L858R mutant form of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer is thought to be due to the constitutive activation of its kinase domain.  The selectivity of the marketed drugs gefitinib and erlotinib for L858R mutant is attributed to their specific recognition of the active kinase and to weaker ATP binding by L858R EGFR.  We present crystal structures showing that neither L858R nor the drug-resistant L858R+T790M EGFR kinase domain is in the constitutively active conformation.  Addnl. co-crystal structures show that gefitinib and dacomitinib, an irreversible anilinoquinazoline deriv. currently in clin. development, may not be conformation specific for the active state of the enzyme.  Structural data further reveal the potential mode of recognition of one of the autophosphorylation sites in the C-terminal tail, Tyr-1016, by the kinase domain.  Biochem. and biophys. evidence suggest that the oncogenic mutations impact the conformational dynamics of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi6kAQLM6h7LVg90H21EOLACvtfcHk0ljM4d4po0Fu3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFeq&md5=439bfda2e4e33786a15742e53cc271bc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DWeinrich%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DStewart%26aufirst%3DA.%26atitle%3DInsights%2520into%2520the%2520aberrant%2520activity%2520of%2520mutant%2520EGFR%2520kinase%2520domain%2520and%2520drug%2520recognition%26jtitle%3DStructure%26date%3D2013%26volume%3D21%26spage%3D209%26epage%3D219%26doi%3D10.1016%2Fj.str.2012.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an irreversible pan-erbB inhibitor, is effective in lung cancer models with EGFR and erbB2 mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F0008-5472.CAN-07-1885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=18089823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjs7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+irreversible+pan-erbB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+erbB2+mutations+that+are+resistant+to+gefitinib&doi=10.1158%2F0008-5472.CAN-07-1885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Gale, Christopher-Michael; Lifshits, Eugene; Gonzales, Andrea J.; Shimamura, Takeshi; Zhao, Feng; Vincent, Patrick W.; Naumov, George N.; Bradner, James E.; Althaus, Irene W.; Gandhi, Leena; Shapiro, Geoffrey I.; Nelson, James M.; Heymach, John V.; Meyerson, Matthew; Wong, Kwok-Kin; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11924-11932</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective treatments for a subset of non-small cell lung cancers.  In particular, cancers with specific EGFR-activating mutations seem to be the most sensitive to these agents.  However, despite their initial response, such cancers almost invariably develop resistance.  In 50% of such cancers, a secondary EGFR mutation, T790M, has been identified that renders gefitinib and erlotinib ineffective inhibitors of EGFR kinase activity.  Thus, there is a clin. need to develop novel EGFR inhibitors that can effectively inactivate T790M-contg. EGFR proteins.  In this study, we evaluate the effectiveness of a novel compd., PF00299804, an irreversible pan-ERBB inhibitor.  The results from these studies show that PF00299804 is a potent inhibitor of EGFR-activating mutations as well as the EGFR T790M resistance mutation both in vitro and in vivo.  Addnl., PF00299804 is a highly effective inhibitor of both the wild-type ERBB2 and the gefitinib-resistant oncogenic ERBB2 mutation identified in lung cancers.  These preclin. evaluations support further clin. development of PF00299804 for cancers with mutations and/or amplifications of ERBB family members. [Cancer Res 2007;67(24):11924-32].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq02Cx_x26RirVg90H21EOLACvtfcHk0ljM4d4po0Fu3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjs7nL&md5=c210cf2fb3d1479df5915d317259696f</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1885%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520irreversible%2520pan-erbB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520erbB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932%26doi%3D10.1158%2F0008-5472.CAN-07-1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Ather, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamidi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fejzo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrent, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span> </span><span class="NLM_article-title">Dacomitinib, an irreversible pan-erbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e56112</span><span class="refDoi"> DOI: 10.1371/journal.pone.0056112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1371%2Fjournal.pone.0056112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e56112&author=F.+Atherauthor=H.+Hamidiauthor=M.+S.+Fejzoauthor=S.+Letrentauthor=R.+S.+Finnauthor=F.+Kabbinavarauthor=C.+Headauthor=S.+G.+Wong&title=Dacomitinib%2C+an+irreversible+pan-erbB+inhibitor+significantly+abrogates+growth+in+head+and+neck+cancer+models+that+exhibit+low+response+to+cetuximab&doi=10.1371%2Fjournal.pone.0056112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0056112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0056112%26sid%3Dliteratum%253Aachs%26aulast%3DAther%26aufirst%3DF.%26aulast%3DHamidi%26aufirst%3DH.%26aulast%3DFejzo%26aufirst%3DM.%2BS.%26aulast%3DLetrent%26aufirst%3DS.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DKabbinavar%26aufirst%3DF.%26aulast%3DHead%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DS.%2BG.%26atitle%3DDacomitinib%252C%2520an%2520irreversible%2520pan-erbB%2520inhibitor%2520significantly%2520abrogates%2520growth%2520in%2520head%2520and%2520neck%2520cancer%2520models%2520that%2520exhibit%2520low%2520response%2520to%2520cetuximab%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De56112%26doi%3D10.1371%2Fjournal.pone.0056112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Nam, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Min, A.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span> </span><span class="NLM_article-title">The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2148</span><span class="NLM_x">–</span> <span class="NLM_lpage">2160</span><span class="refDoi"> DOI: 10.1007/s10637-011-9782-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1007%2Fs10637-011-9782-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2148-2160&author=H.-J.+Namauthor=H.-P.+Kimauthor=Y.-K.+Yoonauthor=S.-H.+Songauthor=A.-R.+Minauthor=S.-W.+Hanauthor=S.-A.+Imauthor=T.-Y.+Kimauthor=D.-Y.+Ohauthor=Y.-J.+Bang&title=The+irreversible+pan-HER+inhibitor+PF00299804+alone+or+combined+with+gemcitabine+has+an+antitumor+effect+in+biliary+tract+cancer+cell+lines&doi=10.1007%2Fs10637-011-9782-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1007%2Fs10637-011-9782-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-011-9782-6%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DH.-J.%26aulast%3DKim%26aufirst%3DH.-P.%26aulast%3DYoon%26aufirst%3DY.-K.%26aulast%3DSong%26aufirst%3DS.-H.%26aulast%3DMin%26aufirst%3DA.-R.%26aulast%3DHan%26aufirst%3DS.-W.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DBang%26aufirst%3DY.-J.%26atitle%3DThe%2520irreversible%2520pan-HER%2520inhibitor%2520PF00299804%2520alone%2520or%2520combined%2520with%2520gemcitabine%2520has%2520an%2520antitumor%2520effect%2520in%2520biliary%2520tract%2520cancer%2520cell%2520lines%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D2148%26epage%3D2160%26doi%3D10.1007%2Fs10637-011-9782-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Kalous, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Dacomitinib (PF-00299804), an irreversible pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1978</span><span class="NLM_x">–</span> <span class="NLM_lpage">1987</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1535-7163.MCT-11-0730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=22761403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1978-1987&author=O.+Kalousauthor=D.+Conklinauthor=A.+J.+Desaiauthor=N.+A.+O%E2%80%99Brienauthor=C.+Gintherauthor=L.+Andersonauthor=D.+J.+Cohenauthor=C.+D.+Brittenauthor=I.+Taylorauthor=J.+G.+Christensenauthor=D.+J.+Slamonauthor=R.+S.+Finn&title=Dacomitinib+%28PF-00299804%29%2C+an+irreversible+pan-HER+inhibitor%2C+inhibits+proliferation+of+HER2-amplified+breast+cancer+cell+lines+resistant+to+trastuzumab+and+lapatinib&doi=10.1158%2F1535-7163.MCT-11-0730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib</span></div><div class="casAuthors">Kalous, Ondrej; Conklin, Dylan; Desai, Amrita J.; O'Brien, Neil A.; Ginther, Charles; Anderson, Lee; Cohen, David J.; Britten, Carolyn D.; Taylor, Ian; Christensen, James G.; Slamon, Dennis J.; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1978-1987</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The human EGF (HER) family of receptors has been pursued as therapeutic targets in breast cancer and other malignancies.  Trastuzumab and lapatinib are std. treatments for HER2-amplified breast cancer, but a significant no. of patients do not respond or develop resistance to these drugs.  Here we evaluate the in vitro activity of dacomitinib (PF-00299804), an irreversible small mol. pan-HER inhibitor, in a large panel of human breast cancer cell lines with variable expression of the HER family receptors and ligands, and with variable sensitivity to trastuzumab and lapatinib.  Forty-seven human breast cancer and immortalized breast epithelial lines representing the known mol. subgroups of breast cancer were treated with dacomitinib to det. IC50 values.  HER2-amplified lines were far more likely to respond to dacomitinib than nonamplified lines (RR, 3.39; P < 0.0001).  Furthermore, HER2 mRNA and protein expression were quant. assocd. with response.  Dacomitinib reduced the phosphorylation of HER2, EGFR, HER4, AKT, and ERK in the majority of sensitive lines.  Dacomitinib exerted its antiproliferative effect through a combined G0-G1 arrest and an induction of apoptosis.  Dacomitinib inhibited growth in several HER2-amplified lines with de novo and acquired resistance to trastuzumab.  Dacomitinib maintained a high activity in lines with acquired resistance to lapatinib.  This study identifies HER2-amplified breast cancer lines as most sensitive to the antiproliferative effect of dacomitinib and provides a strong rationale for its clin. testing in HER2-amplified breast cancers resistant to trastuzumab and lapatinib.  Mol Cancer Ther; 11(9); 1978-87. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp55-QHIJqDk7Vg90H21EOLACvtfcHk0liZqPACCisIBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrvI&md5=b2b0677cbecb66e1e629742adffb0782</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0730%26sid%3Dliteratum%253Aachs%26aulast%3DKalous%26aufirst%3DO.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DN.%2BA.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DD.%2BJ.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DDacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520pan-HER%2520inhibitor%252C%2520inhibits%2520proliferation%2520of%2520HER2-amplified%2520breast%2520cancer%2520cell%2520lines%2520resistant%2520to%2520trastuzumab%2520and%2520lapatinib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1978%26epage%3D1987%26doi%3D10.1158%2F1535-7163.MCT-11-0730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Nam, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ching, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span> </span><span class="NLM_article-title">Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1535-7163.MCT-11-0494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=22135232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=439-451&author=H.-J.+Namauthor=K.+A.+Chingauthor=J.+Kanauthor=H.-P.+Kimauthor=S.-W.+Hanauthor=S.-A.+Imauthor=T.-Y.+Kimauthor=J.+G.+Christensenauthor=D.-Y.+Ohauthor=Y.-J.+Bang&title=Evaluation+of+the+antitumor+effects+and+mechanisms+of+PF00299804%2C+a+pan-HER+inhibitor%2C+alone+or+in+combination+with+chemotherapy+or+targeted+agents+in+gastric+cancer&doi=10.1158%2F1535-7163.MCT-11-0494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer</span></div><div class="casAuthors">Nam, Hyun-Jin; Ching, Keith A.; Kan, Julie; Kim, Hwang-Phill; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Christensen, James G.; Oh, Do-Youn; Bang, Yung-Jue</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">439-451</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recently, HER2-directed treatment, such as trastuzumab, has shown clin. benefit in HER2-amplified gastric cancer.  On the basis of recent studies about epidermal growth factor receptor (EGFR) or HER2-targeting agents (including gefitinib, lapatinib, and trastuzumab) in gastric cancer, the potent effects of pan-HER inhibitors targeting the HER family are anticipated.  In this study, we evaluated the activity and mechanisms of PF00299804, an irreversible pan-HER inhibitor, in gastric cancer in vitro and in vivo models.  PF00299804 showed significant growth-inhibitory effects in HER2-amplified gastric cancer cells (SNU216, N87), and it had lower 50% inhibitory concn. values compared with other EGFR tyrosine kinase inhibitors, including gefitinib, lapatinib, BIBW-2992, and CI-1033.  PF00299804 induced apoptosis and G1 arrest and inhibited phosphorylation of receptors in the HER family and downstream signaling pathways including STAT3, AKT, and extracellular signal-regulated kinases (ERK) in HER2-amplified gastric cancer cells.  PF00299804 also blocked EGFR/HER2, HER2/HER3, and HER3/HER4 heterodimer formation as well as the assocn. of HER3 with p85α in SNU216 cells.  The combination of PF00299804 with clin. relevant chemotherapeutic agents or mol.-targeted agents including trastuzumab (an anti-HER2 monoclonal antibody), CP751871 (an IGF1R inhibitor), PD0325901 (an ERK1/2 inhibitor), and PF04691502 (a PI3K/mTOR inhibitor) produced synergistic effects.  These findings indicate that PF00299804 can be used as a targeted therapy for the treatment of HER2-amplified gastric cancer through inhibition of HER family heterodimer formation and may augment antitumor efficacy of chemotherapeutic and/or mol.-targeted agents.  Mol Cancer Ther; 11(2); 439-51.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVUhH4_Ser5LVg90H21EOLACvtfcHk0lhPPxgri5ZbCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksr8%253D&md5=36d48e8853974378c8d5477fe76b2260</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0494%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DH.-J.%26aulast%3DChing%26aufirst%3DK.%2BA.%26aulast%3DKan%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.-P.%26aulast%3DHan%26aufirst%3DS.-W.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DBang%26aufirst%3DY.-J.%26atitle%3DEvaluation%2520of%2520the%2520antitumor%2520effects%2520and%2520mechanisms%2520of%2520PF00299804%252C%2520a%2520pan-HER%2520inhibitor%252C%2520alone%2520or%2520in%2520combination%2520with%2520chemotherapy%2520or%2520targeted%2520agents%2520in%2520gastric%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D439%26epage%3D451%26doi%3D10.1158%2F1535-7163.MCT-11-0494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">15 Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">8027</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=8027&issue=15+Suppl&author=P.+A.+J%C3%A4nneauthor=J.+H.+Schellensauthor=J.+A.+Engelmanauthor=S.+G.+Eckhardtauthor=R.+Millhamauthor=L.+J.+Denisauthor=C.+D.+Brittenauthor=S.+G.+Wongauthor=D.+S.+Bossauthor=D.+R.+Camidge&title=Preliminary+activity+and+safety+results+from+a+phase+I+clinical+trial+of+PF-00299804%2C+an+irreversible+pan-HER+inhibitor%2C+in+patients+%28pts%29+with+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DMillham%26aufirst%3DR.%26aulast%3DDenis%26aufirst%3DL.%2BJ.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DPreliminary%2520activity%2520and%2520safety%2520results%2520from%2520a%2520phase%2520I%2520clinical%2520trial%2520of%2520PF-00299804%252C%2520an%2520irreversible%2520pan-HER%2520inhibitor%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520NSCLC%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26issue%3D15%2520Suppl%26spage%3D8027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millham, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span> </span><span class="NLM_article-title">PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">15 Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">7599</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=7599&issue=15+Suppl&author=K.+Parkauthor=D.+S.+Heoauthor=B.+Choauthor=D.+Kimauthor=M.+Ahnauthor=S.+Leeauthor=R.+D.+Millhamauthor=A.+Campbellauthor=H.+Zhangauthor=J.+Kim&title=PF-00299804+%28PF299%29+in+Asian+patients+%28pts%29+with+non-small+cell+lung+cancer+%28NSCLC%29+refractory+to+chemotherapy+%28CT%29+and+erlotinib+%28E%29+or+gefitinib+%28G%29%3A+A+phase+%28P%29+I%2FII+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DK.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCho%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DAhn%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DMillham%26aufirst%3DR.%2BD.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DPF-00299804%2520%2528PF299%2529%2520in%2520Asian%2520patients%2520%2528pts%2529%2520with%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520refractory%2520to%2520chemotherapy%2520%2528CT%2529%2520and%2520erlotinib%2520%2528E%2529%2520or%2520gefitinib%2520%2528G%2529%253A%2520A%2520phase%2520%2528P%2529%2520I%252FII%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3D15%2520Suppl%26spage%3D7599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boku, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machida, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohki, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span> </span><span class="NLM_article-title">Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, −2, and −4 tyrosine kinases, in Japanese patients with advanced solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2352</span><span class="NLM_x">–</span> <span class="NLM_lpage">2363</span><span class="refDoi"> DOI: 10.1007/s10637-011-9789-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1007%2Fs10637-011-9789-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2352-2363&author=T.+Takahashiauthor=N.+Bokuauthor=H.+Murakamiauthor=T.+Naitoauthor=A.+Tsuyaauthor=Y.+Nakamuraauthor=A.+Onoauthor=N.+Machidaauthor=K.+Yamazakiauthor=J.+Watanabeauthor=A.+Ruiz-Garciaauthor=K.+Imaiauthor=E.+Ohkiauthor=N.+Yamamoto&title=Phase+I+and+pharmacokinetic+study+of+dacomitinib+%28PF-00299804%29%2C+an+oral+irreversible%2C+small+molecule+inhibitor+of+human+epidermal+growth+factor+receptor-1%2C+%E2%88%922%2C+and+%E2%88%924+tyrosine+kinases%2C+in+Japanese+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-011-9789-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs10637-011-9789-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-011-9789-z%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DBoku%26aufirst%3DN.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DT.%26aulast%3DTsuya%26aufirst%3DA.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DOno%26aufirst%3DA.%26aulast%3DMachida%26aufirst%3DN.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DRuiz-Garcia%26aufirst%3DA.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DOhki%26aufirst%3DE.%26aulast%3DYamamoto%26aufirst%3DN.%26atitle%3DPhase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520dacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520oral%2520irreversible%252C%2520small%2520molecule%2520inhibitor%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-1%252C%2520%25E2%2588%25922%252C%2520and%2520%25E2%2588%25924%2520tyrosine%2520kinases%252C%2520in%2520Japanese%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D2352%26epage%3D2363%26doi%3D10.1007%2Fs10637-011-9789-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Brzezniak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span> </span><span class="NLM_article-title">Dacomitinib, a new therapy for the treatment of non-small cell lung cancer</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1517/14656566.2013.758714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1517%2F14656566.2013.758714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=23294134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVamt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=247-253&author=C.+Brzezniakauthor=C.+A.+Carterauthor=G.+Giaccone&title=Dacomitinib%2C+a+new+therapy+for+the+treatment+of+non-small+cell+lung+cancer&doi=10.1517%2F14656566.2013.758714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">, a new therapy for the treatment of non-small cell lung cancer</span></div><div class="casAuthors">Brzezniak, Christina; Carter, Corey A.; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">247-253</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Advanced or metastatic non-small cell lung cancer (NSCLC) is characterized by a poor prognosis and few second- or third-line treatments.  First-generation reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibition (TKI) has paved the way for targeted treatment in lung cancer.  These drugs result in excellent responses in patients with activating EGFR mutations.  Unfortunately, resistance often develops.  Second-generation irreversible inhibitors hope to prevent mutational progression to a resistant clone or delay the use of alternative non-targeted therapies.Areas covered: This article focuses on the current published ongoing research using the second-generation irreversible TKI, .  The use of dacomitinib, a pan inhibitor of the HER family of tyrosine kinases, will be reviewed along with its efficacy in the advanced or metastatic NSCLC population.Expert opinion: Data available suggest dacomitinib is effective in NSCLC patients both in initial treatment and after failure of first-generation inhibitors.  Furthermore, preclin. data suggest dacomitinib can achieve responses in tumors harboring the T790M, gatekeeper mutation, present in up to 50% of tumors that have acquired resistant to first-generation inhibitors.  Its usefulness in potentially delaying development of resistant clones as well as in combination with other targeting strategies is under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWPg2gU0zXXbVg90H21EOLACvtfcHk0lhzQVUyjD32iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVamt7o%253D&md5=bd5088b56d16f6880d3b1254182a3864</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1517%2F14656566.2013.758714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2013.758714%26sid%3Dliteratum%253Aachs%26aulast%3DBrzezniak%26aufirst%3DC.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DDacomitinib%252C%2520a%2520new%2520therapy%2520for%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2013%26volume%3D14%26spage%3D247%26epage%3D253%26doi%3D10.1517%2F14656566.2013.758714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, L.</span><span> </span><span class="NLM_article-title">Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">822</span><span class="refDoi"> DOI: 10.2217/fon.14.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.2217%2Ffon.14.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=24799062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsVSktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=813-822&author=T.+Mokauthor=K.+Leeauthor=M.+Tangauthor=L.+Leung&title=Dacomitinib+for+the+treatment+of+advanced+or+metastatic+non-small-cell+lung+cancer&doi=10.2217%2Ffon.14.22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer</span></div><div class="casAuthors">Mok, Tony; Lee, Kirsty; Tang, Michael; Leung, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">813-822</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Dacomitinib (PF-00299804) is a second-generation irreversible HER tyrosine kinase inhibitor (TKI).  In preclin. studies, dacomitinib has demonstrated anti-tumor activity in lung cancer cell lines with sensitive and resistant EGFR mutations (including the T790 mutation).  Safety and well tolerability of dacomitinib were demonstrated in Phase I studies with stomatitis, diarrhea and skin toxicities being the dose-limiting toxicities.  The max. tolerated dose was established to be 45 mg/day.  In Phase II and III studies, dacomitinib has shown clin. activity in both HER tyrosine kinase-naive and HER tyrosine kinase failure settings.  Further clin. trials are underway to evaluate the efficacy of dacomitinib in non-small-cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGjhkbZZr1U7Vg90H21EOLACvtfcHk0lhzQVUyjD32iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsVSktbw%253D&md5=9a5abeca52e35070d4d63b57e9512c76</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.22%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DLeung%26aufirst%3DL.%26atitle%3DDacomitinib%2520for%2520the%2520treatment%2520of%2520advanced%2520or%2520metastatic%2520non-small-cell%2520lung%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D813%26epage%3D822%26doi%3D10.2217%2Ffon.14.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckamp, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">15 Suppl</span><span class="NLM_x">–</span> <span class="NLM_lpage">7596</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=15+Suppl-7596&author=A.+Campbellauthor=K.+L.+Reckampauthor=D.+R.+Camidgeauthor=G.+Giacconeauthor=S.+M.+Gadgeelauthor=F.+R.+Khuriauthor=J.+A.+Engelmanauthor=L.+J.+Denisauthor=J.+P.+O%E2%80%99Connellauthor=P.+A.+J%C3%A4nne&title=PF-00299804+%28PF299%29+patient+%28pt%29-reported+outcomes+%28PROs%29+and+efficacy+in+adenocarcinoma+%28adeno%29+and+nonadeno+non-small+cell+lung+cancer+%28NSCLC%29%3A+A+phase+%28P%29+II+trial+in+advanced+NSCLC+after+failure+of+chemotherapy+%28CT%29+and+erlotinib+%28E%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DReckamp%26aufirst%3DK.%2BL.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DDenis%26aufirst%3DL.%2BJ.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%2BP.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF-00299804%2520%2528PF299%2529%2520patient%2520%2528pt%2529-reported%2520outcomes%2520%2528PROs%2529%2520and%2520efficacy%2520in%2520adenocarcinoma%2520%2528adeno%2529%2520and%2520nonadeno%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%253A%2520A%2520phase%2520%2528P%2529%2520II%2520trial%2520in%2520advanced%2520NSCLC%2520after%2520failure%2520of%2520chemotherapy%2520%2528CT%2529%2520and%2520erlotinib%2520%2528E%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D15%2520Suppl%26epage%3D7596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Ellis, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrone, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morabito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighl, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockler, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierzbicki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blais, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangha, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favaretto, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, M.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goss, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, P. A.</span><span> </span><span class="NLM_article-title">Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomized, phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1379</span><span class="NLM_x">–</span> <span class="NLM_lpage">1388</span><span class="refDoi"> DOI: 10.1016/S1470-2045(14)70472-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS1470-2045%2814%2970472-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=25439692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKjtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1379-1388&author=P.+M.+Ellisauthor=F.+A.+Shepherdauthor=M.+Millwardauthor=F.+Perroneauthor=L.+Seymourauthor=G.+Liuauthor=S.+Sunauthor=B.+C.+Choauthor=A.+Morabitoauthor=N.+B.+Leighlauthor=M.+R.+Stocklerauthor=C.+W.+Leeauthor=R.+Wierzbickiauthor=V.+Cohenauthor=N.+Blaisauthor=R.+S.+Sanghaauthor=A.+G.+Favarettoauthor=J.+H.+Kangauthor=M.-S.+Tsaoauthor=C.+F.+Wilsonauthor=Z.+Goldbergauthor=K.+Dingauthor=G.+D.+Gossauthor=P.+A.+Bradbury&title=Dacomitinib+compared+with+placebo+in+pretreated+patients+with+advanced+or+metastatic+non-small-cell+lung+cancer+%28NCIC+CTG+BR.26%29%3A+a+double-blind%2C+randomized%2C+phase+3+trial&doi=10.1016%2FS1470-2045%2814%2970472-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial</span></div><div class="casAuthors">Ellis, Peter M.; Shepherd, Frances A.; Millward, Michael; Perrone, Francesco; Seymour, Lesley; Liu, Geoffrey; Sun, Sophie; Cho, Byoung Chul; Morabito, Alessandro; Leighl, Natasha B.; Stockler, Martin R.; Lee, Christopher W.; Wierzbicki, Rafal; Cohen, Victor; Blais, Normand; Sangha, Randeep S.; Favaretto, Adolfo G.; Kang, Jin Hyoung; Tsao, Ming-Sound; Wilson, Carolyn F.; Goldberg, Zelanna; Ding, Keyue; Goss, Glenwood D.; Bradbury, Penelope Ann</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1379-1388</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclin. and clin. evidence of activity in non-small-cell lung cancer.  We designed BR.26 to assess whether dacomitinib improved overall survival in heavily pretreated patients with this disease.  In this double-blind, randomised, placebo-controlled, phase 3 trial, we enrolled adults (aged ≥18 years) with advanced or metastatic non-small-cell lung cancer from 75 centers in 12 countries.  Eligible patients had received up to three previous lines of chemotherapy and either gefitinib or erlotinib, and had assessable disease (RECIST 1.1) and tumor tissue samples for translational studies.  Patients were stratified according to center, performance status, tobacco use, best response to previous EGFR tyrosine-kinase inhibitor, wt. loss within the previous 3 mo, and ethnicity, and were then randomly allocated 2:1 to oral dacomitinib 45 mg once-daily or matched placebo centrally via a web-based system.  Treatment continued until disease progression or unacceptable toxicity.  The primary outcome was overall survival in the intention-to-treat population; secondary outcomes included overall survival in predefined mol. subgroups, progression-free survival, the proportion of patients who achieved an objective response, safety, and quality of life.  This study is completed, although follow-up is ongoing for patients on treatment.  This study is registered with ClinicalTrials.gov, no. NCT01000025.  Between Dec 23, 2009, and June 11, 2013, we randomly assigned 480 patients to dacomitinib and 240 patients to placebo.  At the final anal. (Jan., 2014), median follow-up was 23·4 mo (IQR 15·6-29·6) for patients in the dacomitinib group and 24·4 mo (11·5-38·9) for those in the placebo group.  Dacomitinib did not improve overall survival compared with placebo (median 6·83 mo [95% CI 6·08-7·49] for dacomitinib vs 6·31 mo [5·32-7·52] for placebo; hazard ratio [HR] 1·00 [95% CI 0·83-1·21]; p=0·506).  However, patients in the dacomitinib group had longer progression-free survival than those in the placebo group (median 2·66 mo [1·91-3·32] vs 1·38 mo [0·99-1·74], resp.; HR 0·66 [95% CI 0·55-0·79]; p<0·0001), and a significantly greater proportion of patients in the dacomitinb group achieved an objective response than in the placebo group (34 [7%] of 480 patients vs three [1%] of 240 patients, resp.; p=0·001).  Compared with placebo, the effect of dacomitinib on overall survival seemed similar in patients with EGFR-mutation-pos. tumors (HR 0·98, 95% CI 0·67-1·44) and EGFR wild-type tumors (0·93, 0·71-1·21; pinteraction=0·69).  However, we noted qual. differences in the effect of dacomitinib on overall survival for patients with KRAS-mutation-pos. tumors (2·10, 1·05-4·22) and patients with KRAS wild-type tumors (0·79, 0·61-1·03; pinteraction=0·08).  Compared with placebo, patients allocated dacomitinib had significantly longer time to deterioration of cough (p<0·0001), dyspnoea (p=0·049), and pain (p=0·041). 185 (39%) of 477 patients who received dacomitinib and 86 (36%) of 239 patients who received placebo had serious adverse events.  The most common grade 3-4 adverse events were diarrhoea (59 [12%] patients on dacomitinib vs no controls), acneiform rash (48 [10%] vs one [<1%]), oral mucositis (16 [3%] vs none), and fatigue (13 [3%] vs four [2%]).  Dacomitinib did not increase overall survival and cannot be recommended for treatment of patients with advanced non-small-cell lung cancer previously treated with chemotherapy and an EGFR tyrosine-kinase inhibitor.  Canadian Cancer Society Research Institute and Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSa-G6JOVCebVg90H21EOLACvtfcHk0lgEBdaazP-5Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKjtrbI&md5=69185e91537e35ff7c45b737ed1d0ad7</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970472-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970472-3%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DP.%2BM.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DF.%26aulast%3DSeymour%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DMorabito%26aufirst%3DA.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26aulast%3DStockler%26aufirst%3DM.%2BR.%26aulast%3DLee%26aufirst%3DC.%2BW.%26aulast%3DWierzbicki%26aufirst%3DR.%26aulast%3DCohen%26aufirst%3DV.%26aulast%3DBlais%26aufirst%3DN.%26aulast%3DSangha%26aufirst%3DR.%2BS.%26aulast%3DFavaretto%26aufirst%3DA.%2BG.%26aulast%3DKang%26aufirst%3DJ.%2BH.%26aulast%3DTsao%26aufirst%3DM.-S.%26aulast%3DWilson%26aufirst%3DC.%2BF.%26aulast%3DGoldberg%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DGoss%26aufirst%3DG.%2BD.%26aulast%3DBradbury%26aufirst%3DP.%2BA.%26atitle%3DDacomitinib%2520compared%2520with%2520placebo%2520in%2520pretreated%2520patients%2520with%2520advanced%2520or%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520%2528NCIC%2520CTG%2520BR.26%2529%253A%2520a%2520double-blind%252C%2520randomized%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1379%26epage%3D1388%26doi%3D10.1016%2FS1470-2045%2814%2970472-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seog Heo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talbot, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrent, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, M.</span><span> </span><span class="NLM_article-title">Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan–human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3337</span><span class="NLM_x">–</span> <span class="NLM_lpage">3344</span><span class="refDoi"> DOI: 10.1200/JCO.2011.40.9433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1200%2FJCO.2011.40.9433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=22753918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3337-3344&author=S.+S.+Ramalingamauthor=F.+Blackhallauthor=M.+Krzakowskiauthor=C.+H.+Barriosauthor=K.+Parkauthor=I.+Boverauthor=D.+Seog+Heoauthor=R.+Rosellauthor=D.+C.+Talbotauthor=R.+Frankauthor=S.+P.+Letrentauthor=A.+Ruiz-Garciaauthor=I.+Taylorauthor=J.+L.+Liangauthor=A.+K.+Campbellauthor=J.+O%E2%80%99Connellauthor=M.+Boyer&title=Randomized+phase+II+study+of+dacomitinib+%28PF-00299804%29%2C+an+irreversible+pan%E2%80%93human+epidermal+growth+factor+receptor+inhibitor%2C+versus+erlotinib+in+patients+with+advanced+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2011.40.9433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study of dacomitinib (PF-00299804), and irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Ramalingam, Suresh S.; Blackhall, Fiona; Krzakowski, Maciej; Barrios, Carlos H.; Park, Keunchil; Bover, Isabel; Heo, Dae Seog; Rosell, Rafael; Talbot, Denis C.; Frank, Richard; Letrent, Stephen P.; Ruiz-Garcia, Ana; Taylor, Ian; Liang, Jane Q.; Campbell, Alicyn K.; O'Connell, Joseph; Boyer, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3337-3344</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR1/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC).  Patients and Methods Patients with NSCLC, Eastern Cooperative Oncol. Group performance status 0 to 2, no prior HER-directed therapy, and one/two prior chemotherapy regimens received dacomitinib 45 mg or erlotinib 150 mg once daily.  Results One hundred eighty-eight patients were randomly assigned.  Treatment arms were balanced for most clin. and mol. characteristics.  Median progression-free survival (PFS; primary end point) was 2.86 mo for patients treated with dacomitinib and 1.91 mo for patients treated with erlotinib (hazard ratio [HR] = 0.66; 95% CI, 0.47 to 0.91; two-sided P = .012); in patients with KRAS wild-type tumors, median PFS was 3.71 mo for patients treated with dacomitinib and 1.91 mo for patients treated with erlotinib (HR = 0.55; 95% CI, 0.35 to 0.85; two-sided P = .006); and in patients with KRAS wild-type/EGFR wild-type tumors, median PFS was 2.21 mo for patients treated with dacomitinib and 1.84 mo for patients treated with erlotinib (HR = 0.61; 95% CI, 0.37 to 0.99; two-sided P = .043).  Median overall survival was 9.53 mo for patients treated with dacomitinib and 7.44 mo for patients treated with erlotinib (HR = 0.80; 95% CI, 0.56 to 1.13; two-sided P = .205).  Adverse event-related discontinuations were uncommon in both arms.  Common treatment-related adverse events were dermatol. and gastrointestinal, predominantly grade 1 to 2, and more frequent with dacomitinib.  Conclusion Dacomitinib demonstrated significantly improved PFS vs. erlotinib, with acceptable toxicity.  PFS benefit was obsd. in most clin. and mol. subsets, notably KRAS wild-type/EGFR any status, KRAS wild-type/EGFR wild-type, and EGFR mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHl-bReesXsbVg90H21EOLACvtfcHk0lgEBdaazP-5Aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FK&md5=bdc76102e0ae37fb3f5307c285f952d4</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.40.9433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.40.9433%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DKrzakowski%26aufirst%3DM.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DSeog%2BHeo%26aufirst%3DD.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DTalbot%26aufirst%3DD.%2BC.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DLetrent%26aufirst%3DS.%2BP.%26aulast%3DRuiz-Garcia%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DLiang%26aufirst%3DJ.%2BL.%26aulast%3DCampbell%26aufirst%3DA.%2BK.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DM.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520dacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520pan%25E2%2580%2593human%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%252C%2520versus%2520erlotinib%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3337%26epage%3D3344%26doi%3D10.1200%2FJCO.2011.40.9433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Pawel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pluzanski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shtivelband, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Docampo, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennouna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mather, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span> </span><span class="NLM_article-title">Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomized, double-blind, phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1369</span><span class="NLM_x">–</span> <span class="NLM_lpage">1378</span><span class="refDoi"> DOI: 10.1016/S1470-2045(14)70452-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS1470-2045%2814%2970452-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=25439691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKjtrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1369-1378&author=S.+S.+Ramalingamauthor=P.+A.+J%C3%A4nneauthor=T.+Mokauthor=K.+O%E2%80%99Byrneauthor=M.+J.+Boyerauthor=J.+Von+Pawelauthor=A.+Pluzanskiauthor=M.+Shtivelbandauthor=L.+I.+Docampoauthor=J.+Bennounaauthor=H.+Zhangauthor=J.+Q.+Liangauthor=J.+P.+Dohertyauthor=I.+Taylorauthor=C.+B.+Matherauthor=Z.+Goldbergauthor=J.+O%E2%80%99Connellauthor=L.+Paz-Ares&title=Dacomitinib+versus+erlotinib+in+patients+with+advanced-stage%2C+previously+treated+non-small-cell+lung+cancer+%28ARCHER+1009%29%3A+a+randomized%2C+double-blind%2C+phase+3+trial&doi=10.1016%2FS1470-2045%2814%2970452-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial</span></div><div class="casAuthors">Ramalingam, Suresh S.; Janne, Pasi A.; Mok, Tony; O'Byrne, Kenneth; Boyer, Michael J.; Von Pawel, Joachim; Pluzanski, Adam; Shtivelband, Mikhail; Docampo, Lara Iglesias; Bennouna, Jaafar; Zhang, Hui; Liang, Jane Q.; Doherty, Jim P.; Taylor, Ian; Mather, Cecile B.; Goldberg, Zelanna; O'Connell, Joseph; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1369-1378</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor.  Findings from a phase 2 study in non-small cell lung cancer showed favorable efficacy for dacomitinib compared with erlotinib.  We aimed to compare dacomitinib with erlotinib in a phase 3 study.  In a randomised, multicentre, double-blind phase 3 trial in 134 centers in 23 countries, we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer, progression after one or two previous regimens of chemotherapy, Eastern Cooperative Oncol. Group (ECOG) performance status of 0-2, and presence of measurable disease.  We randomly assigned patients in a 1:1 ratio to dacomitinib (45 mg/day) or erlotinib (150 mg/day) with matching placebo.  Treatment allocation was masked to the investigator, patient, and study funder.  Randomisation was stratified by histol. (adenocarcinoma vs non-adenocarcinoma), ethnic origin (Asian vs non-Asian and Indian sub-continent), performance status (0-1 vs 2), and smoking status (never-smoker vs ever-smoker).  The coprimary endpoints were progression-free survival per independent review for all randomly assigned patients, and for all randomly assigned patients with KRAS wild-type tumors.  The study has completed accrual and is registered with ClinicalTrials.gov, no. NCT01360554.  Between June 22, 2011, and March 12, 2013, we enrolled 878 patients and randomly assigned 439 to dacomitinib (256 KRAS wild type) and 439 (263 KRAS wild type) to erlotinib.  Median progression-free survival was 2·6 mo (95% CI 1·9-2·8) in both the dacomitinib group and the erlotinib group (stratified hazard ratio [HR] 0·941, 95% CI 0·802-1·104, one-sided log-rank p=0·229).  For patients with wild-type KRAS, median progression-free survival was 2·6 mo for dacomitinib (95% CI 1·9-2·9) and erlotinib (95% CI 1·9-3·0; stratified HR 1·022, 95% CI 0·834-1·253, one-sided p=0·587).  In patients who received at least one dose of study drug, the most frequent grade 3-4 adverse events were diarrhoea (47 [11%] patients in the dacomitinib group vs ten [2%] patients in the erlotinib group), rash (29 [7%] vs 12 [3%]), and stomatitis (15 [3%] vs two [<1%]).  Serious adverse events were reported in 52 (12%) patients receiving dacomitinib and 40 (9%) patients receiving erlotinib.  Irreversible EGFR inhibition with dacomitinib was not superior to erlotinib in an unselected patient population with advanced non-small-cell lung cancer or in patients with KRAS wild-type tumors.  Further study of irreversible EGFR inhibitors should be restricted to patients with activating EGFR mutations.Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS7UYIyeysF7Vg90H21EOLACvtfcHk0livO746o6WQVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKjtrbK&md5=4c28096b12811da70e4a158efd512462</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970452-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970452-8%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DBoyer%26aufirst%3DM.%2BJ.%26aulast%3DVon%2BPawel%26aufirst%3DJ.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DShtivelband%26aufirst%3DM.%26aulast%3DDocampo%26aufirst%3DL.%2BI.%26aulast%3DBennouna%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%2BQ.%26aulast%3DDoherty%26aufirst%3DJ.%2BP.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DMather%26aufirst%3DC.%2BB.%26aulast%3DGoldberg%26aufirst%3DZ.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DDacomitinib%2520versus%2520erlotinib%2520in%2520patients%2520with%2520advanced-stage%252C%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%2520%2528ARCHER%25201009%2529%253A%2520a%2520randomized%252C%2520double-blind%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1369%26epage%3D1378%26doi%3D10.1016%2FS1470-2045%2814%2970452-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sbar, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span> </span><span class="NLM_article-title">Dacomitinib versus erlotinib in patients with EGFR mutated advanced non small-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span><span class="refDoi"> DOI: 10.1093/annonc/mdv593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1093%2Fannonc%2Fmdv593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=26768165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A280%3ADC%252BC28ngtFGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=423-429&author=S.+S.+Ramalingamauthor=K.+O%E2%80%99Byrneauthor=M.+Boyerauthor=T.+Mokauthor=P.+A.+J%C3%A4nneauthor=H.+Zhangauthor=J.+Liangauthor=I.+Taylorauthor=E.+I.+Sbarauthor=L.+Paz-Ares&title=Dacomitinib+versus+erlotinib+in+patients+with+EGFR+mutated+advanced+non+small-cell+lung+cancer+%28NSCLC%29%3A+pooled+subset+analyses+from+two+randomized+trials&doi=10.1093%2Fannonc%2Fmdv593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials</span></div><div class="casAuthors">Ramalingam S S; O'Byrne K; Boyer M; Mok T; Janne P A; Zhang H; Liang J; Taylor I; Sbar E I; Paz-Ares L</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">423-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The irreversible epidermal growth factor receptor (EGFR) inhibitors have demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown if they are superior to the reversible inhibitors.  Dacomitinib is an oral, small-molecule irreversible inhibitor of all enzymatically active HER family tyrosine kinases.  METHODS:  The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067) studies randomized patients with locally advanced/metastatic NSCLC following progression with one or two prior chemotherapy regimens to dacomitinib or erlotinib.  EGFR mutation testing was performed centrally on archived tumor samples.  We pooled patients with exon 19 deletion and L858R EGFR mutations from both studies to compare the efficacy of dacomitinib to erlotinib.  RESULTS:  One hundred twenty-one patients with any EGFR mutation were enrolled; 101 had activating mutations in exon 19 or 21.  For patients with exon19/21 mutations, the median progression-free survival was 14.6 months [95% confidence interval (CI) 9.0-18.2] with dacomitinib and 9.6 months (95% CI 7.4-12.7) with erlotinib [unstratified hazard ratio (HR) 0.717 (95% CI 0.458-1.124), two-sided log-rank, P = 0.146].  The median survival was 26.6 months (95% CI 21.6-41.5) with dacomitinib versus 23.2 months (95% CI 16.0-31.8) with erlotinib [unstratified HR 0.737 (95% CI 0.431-1.259), two-sided log-rank, P = 0.265].  Dacomitinib was associated with a higher incidence of diarrhea and mucositis in both studies compared with erlotinib.  CONCLUSIONS:  Dacomitinib is an active agent with comparable efficacy to erlotinib in the EGFR mutated patients.  The subgroup with exon 19 deletion had favorable outcomes with dacomitinib.  An ongoing phase III study will compare dacomitinib to gefitinib in first-line therapy of patients with NSCLC harboring common activating EGFR mutations (ARCHER 1050; NCT01774721).  CLINICAL TRIALS NUMBER:  ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3TTXce8SicyXXDYhVZBdlfW6udTcc2eahWs7fTXnAm7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28ngtFGqsQ%253D%253D&md5=f686fa296e6f5adf345bd81bde5ec664</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv593%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DBoyer%26aufirst%3DM.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DSbar%26aufirst%3DE.%2BI.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DDacomitinib%2520versus%2520erlotinib%2520in%2520patients%2520with%2520EGFR%2520mutated%2520advanced%2520non%2520small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%253A%2520pooled%2520subset%2520analyses%2520from%2520two%2520randomized%2520trials%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26spage%3D423%26epage%3D429%26doi%3D10.1093%2Fannonc%2Fmdv593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, I. S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrent, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">15 Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">7530</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=7530&issue=15+Suppl&author=M.+G.+Krisauthor=T.+Mokauthor=I.+S.-H.+Ouauthor=R.+Martinsauthor=D.-W.+Kimauthor=Z.+Goldbergauthor=H.+Zhangauthor=I.+Taylorauthor=S.+P.+Letrentauthor=P.+A.+J%C3%A4nne&title=First-line+dacomitinib+%28PF-00299804%29%2C+an+irreversible+pan-HER+tyrosine+kinase+inhibitor%2C+for+patients+with+EGFR-mutant+lung+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DOu%26aufirst%3DI.%2BS.-H.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DGoldberg%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DLetrent%26aufirst%3DS.%2BP.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DFirst-line%2520dacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520pan-HER%2520tyrosine%2520kinase%2520inhibitor%252C%2520for%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26issue%3D15%2520Suppl%26spage%3D7530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Abdul Razak, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soulieres, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurie, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hotte, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winquist, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Tourneau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen-Tan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, E. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mormont, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, L. L.</span><span> </span><span class="NLM_article-title">A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span><span class="refDoi"> DOI: 10.1093/annonc/mds503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1093%2Fannonc%2Fmds503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=23108949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FptFGiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=761-769&author=A.+R.+Abdul+Razakauthor=D.+Soulieresauthor=S.+A.+Laurieauthor=S.+J.+Hotteauthor=S.+Singhauthor=E.+Winquistauthor=S.+Chiaauthor=C.+Le+Tourneauauthor=P.+F.+Nguyen-Tanauthor=E.+X.+Chenauthor=K.+K.+Chanauthor=T.+Wangauthor=N.+Giriauthor=C.+Mormontauthor=S.+Quinnauthor=L.+L.+Siu&title=A+phase+II+trial+of+dacomitinib%2C+an+oral+pan-human+EGF+receptor+%28HER%29+inhibitor%2C+as+first-line+treatment+in+recurrent+and%2For+metastatic+squamous-cell+carcinoma+of+the+head+and+neck&doi=10.1093%2Fannonc%2Fmds503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck</span></div><div class="casAuthors">Abdul Razak A R; Soulieres D; Laurie S A; Hotte S J; Singh S; Winquist E; Chia S; Le Tourneau C; Nguyen-Tan P-F; Chen E X; Chan K K; Wang T; Giri N; Mormont C; Quinn S; Siu L L</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">761-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  An open-label, multicenter, single-arm phase II trial was conducted to investigate the clinical activity of dacomitinib in recurrent/metastatic squamous-cell carcinoma of the head and neck (RM-SCCHN).  PATIENTS AND METHODS:  Eligible patients were administered dacomitinib at 45 mg orally daily, in 21-day cycles.  Primary end point was objective response rate.  RESULTS:  Sixty-nine patients were enrolled with a median age of 62 years.  Among response-evaluable patients, 8 [12.7%, 95% confidence interval (CI) 5.6% to 23.5%] achieved a partial response and 36 (57.1%) had stable disease, lasting ≥24 weeks in 9 patients (14.3%).  The median progression-free survival (PFS) was 12.1 weeks and the median overall survival (OS) was 34.6 weeks.  Most adverse events (AEs) were tolerable.  The most common grade 3 or higher treatment-related AEs were diarrhea (15.9%), acneiform dermatitis (8.7%), and fatigue (8.7%).  Treatment-related AEs led to at least one dose interruption in 28 (40.6%) patients and dose reductions in 26 (37.7%).  Permanent treatment discontinuation occurred in 8 (11.6%) patients due to treatment-related AEs.  CONCLUSIONS:  Dacomitinib demonstrated clinical activity in RM-SCCHN, and the primary end point of this study was met.  The toxicity profile of this agent was generally manageable with dose interruptions and adjustments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRASc6h49NT8EloaUqgkFHkfW6udTcc2ebtYPZRHRrvY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FptFGiuw%253D%253D&md5=30a57108c19363bd3d4c764ff0d723b0</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds503%26sid%3Dliteratum%253Aachs%26aulast%3DAbdul%2BRazak%26aufirst%3DA.%2BR.%26aulast%3DSoulieres%26aufirst%3DD.%26aulast%3DLaurie%26aufirst%3DS.%2BA.%26aulast%3DHotte%26aufirst%3DS.%2BJ.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DWinquist%26aufirst%3DE.%26aulast%3DChia%26aufirst%3DS.%26aulast%3DLe%2BTourneau%26aufirst%3DC.%26aulast%3DNguyen-Tan%26aufirst%3DP.%2BF.%26aulast%3DChen%26aufirst%3DE.%2BX.%26aulast%3DChan%26aufirst%3DK.%2BK.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DGiri%26aufirst%3DN.%26aulast%3DMormont%26aufirst%3DC.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520dacomitinib%252C%2520an%2520oral%2520pan-human%2520EGF%2520receptor%2520%2528HER%2529%2520inhibitor%252C%2520as%2520first-line%2520treatment%2520in%2520recurrent%2520and%252For%2520metastatic%2520squamous-cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DAnn.%2520Oncol.%26date%3D2013%26volume%3D24%26spage%3D761%26epage%3D769%26doi%3D10.1093%2Fannonc%2Fmds503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunphy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span> </span><span class="NLM_article-title">Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">1433</span><span class="NLM_x">–</span> <span class="NLM_lpage">1441</span><span class="refDoi"> DOI: 10.1016/S1470-2045(14)70461-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS1470-2045%2814%2970461-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=25456362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVOktLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1433-1441&issue=13&author=P.+A.+J%C3%A4nneauthor=S.+H.+Ouauthor=D.+W.+Kimauthor=G.+R.+Oxnardauthor=R.+Martinsauthor=M.+G.+Krisauthor=F.+Dunphyauthor=M.+Nishioauthor=J.+O%E2%80%99Connellauthor=C.+Paweletzauthor=I.+Taylorauthor=H.+Zhangauthor=Z.+Goldbergauthor=T.+Mok&title=Dacomitinib+as+first-line+treatment+in+patients+with+clinically+or+molecularly+selected+advanced+non-small-cell+lung+cancer%3A+a+multicentre%2C+open-label%2C+phase+2+trial&doi=10.1016%2FS1470-2045%2814%2970461-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial</span></div><div class="casAuthors">Janne, Pasi A.; Ou, Sai-Hong I.; Kim, Dong-Wan; Oxnard, Geoffrey R.; Martins, Renato; Kris, Mark G.; Dunphy, Frank; Nishio, Makoto; O'Connell, Joseph; Paweletz, Cloud; Taylor, Ian; Zhang, Hui; Goldberg, Zelanna; Mok, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1433-1441</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with EGFR-mutant non-small-cell lung cancer generally have a progression-free survival of 9-13 mo while being treated with the EGFR tyrosine-kinase inhibitors gefitinib or erlotinib.  However, resistance inevitably develops, and more effective EGFR inhibitors are needed.  Dacomitinib is a covalent pan-HER inhibitor that has shown clin. activity in patients previously treated with gefitinib or erlotinib.  We did a trial of dacomitinib as initial systemic therapy in clin. and molecularly selected patients with advanced non-small-cell lung cancer.  In this open-label, multicentre, phase 2 trial, we enrolled treatment-naive patients with advanced lung cancer who had clin. (never-smokers [<100 cigarettes per lifetime] or former light smokers [<10 pack-years per lifetime] and ≥15 years since last cigarette) or mol. (EGFR mutation, regardless of smoking status) characteristics assocd. with response to EGFR inhibitors.  We gave dacomitinib orally once daily (45 mg or 30 mg) until progressive disease, unacceptable toxicity, or patient withdrawal.  We used Response Evaluation Criteria in Solid Tumors criteria (version 1.0) to investigate the activity of dacomitinib in all patients with a baseline scan and at least one post-treatment scan, with investigator assessment of response and progression.  The primary endpoint was progression-free survival at 4 mo in the as-enrolled population, with a null hypothesis of progression-free survival at 4 mo of 50% or less.  The study is registered with ClinicalTrials.gov, no. NCT00818441, and is no longer accruing patients.  Between March 11, 2009, and Apr. 1, 2011, we enrolled 89 patients from 25 centers, including 45 (51%) with EGFR-activating mutations in exon 19 (n=25) or exon 21 (n=20).  Progression-free survival at 4 mo was 76·8% (95% CI 66·4-84·4) in the as-enrolled population, and was 95·5% (95% CI 83·2-98·9) in the EGFR-mutant population.  The most common all-grade treatment-related adverse events were diarrhoea in 83 (93%) patients, dermatitis acneiform in 69 (78%) patients, dry skin in 39 (44%) patients, and stomatitis in 36 (40%) patients.  Two patients (2%) had grade 4 treatment-related events (one with hypokalemia and one with dyspnoea).  No grade 5 toxicities were recorded.  Dacomitinib had encouraging clin. activity as initial systemic treatment in clin. or molecularly selected patients with advanced non-small-cell lung cancer.Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9kNWlD10i2bVg90H21EOLACvtfcHk0ljiyXPHOQRDNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVOktLjL&md5=1f221dd93d690a832357db14d762efd7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970461-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970461-9%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DDunphy%26aufirst%3DF.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DPaweletz%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGoldberg%26aufirst%3DZ.%26aulast%3DMok%26aufirst%3DT.%26atitle%3DDacomitinib%2520as%2520first-line%2520treatment%2520in%2520patients%2520with%2520clinically%2520or%2520molecularly%2520selected%2520advanced%2520non-small-cell%2520lung%2520cancer%253A%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26issue%3D13%26spage%3D1433%26epage%3D1441%26doi%3D10.1016%2FS1470-2045%2814%2970461-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cody, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: 8. An unusually steep structure-activity relationship for analogs of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span><span class="refDoi"> DOI: 10.1021/jm9503613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9503613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=267-276&author=A.+J.+Bridgesauthor=H.+Zhouauthor=D.+R.+Codyauthor=G.+W.+Rewcastleauthor=A.+McMichaelauthor=H.+D.+H.+Showalterauthor=D.+W.+Fryauthor=A.+J.+Krakerauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors%3A+8.+An+unusually+steep+structure-activity+relationship+for+analogs+of+4-%283-bromoanilino%29-6%2C7-dimethoxyquinazoline+%28PD+153035%29%2C+a+potent+inhibitor+of+the+epidermal+growth+factor+receptor&doi=10.1021%2Fjm9503613"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fjm9503613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9503613%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DCody%26aufirst%3DD.%2BR.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%25208.%2520An%2520unusually%2520steep%2520structure-activity%2520relationship%2520for%2520analogs%2520of%25204-%25283-bromoanilino%2529-6%252C7-dimethoxyquinazoline%2520%2528PD%2520153035%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D267%26epage%3D276%26doi%3D10.1021%2Fjm9503613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Nomoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teranishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span> </span><span class="NLM_article-title">Studies on cardiotonic agents. I. Synthesis of some quinazoline derivatives</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1591</span><span class="NLM_x">–</span> <span class="NLM_lpage">1595</span><span class="refDoi"> DOI: 10.1248/cpb.38.1591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1248%2Fcpb.38.1591" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1990&pages=1591-1595&author=Y.+Nomotoauthor=H.+Obaseauthor=H.+Takaiauthor=T.+Hirataauthor=M.+Teranishiauthor=J.+Nakamuraauthor=K.+Kubo&title=Studies+on+cardiotonic+agents.+I.+Synthesis+of+some+quinazoline+derivatives&doi=10.1248%2Fcpb.38.1591"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1248%2Fcpb.38.1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.38.1591%26sid%3Dliteratum%253Aachs%26aulast%3DNomoto%26aufirst%3DY.%26aulast%3DObase%26aufirst%3DH.%26aulast%3DTakai%26aufirst%3DH.%26aulast%3DHirata%26aufirst%3DT.%26aulast%3DTeranishi%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DKubo%26aufirst%3DK.%26atitle%3DStudies%2520on%2520cardiotonic%2520agents.%2520I.%2520Synthesis%2520of%2520some%2520quinazoline%2520derivatives%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1990%26volume%3D38%26spage%3D1591%26epage%3D1595%26doi%3D10.1248%2Fcpb.38.1591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Ham, Y. J.; Gong, J. H.; Cha, M. Y.; Kim, J. W.; Kim, M. S.; Kim, E. Y.; Song, J. Y.; Kim, C. I.; Kim, S. Y.; Lee, G. S.</span><span> </span><span class="NLM_article-title">Preparation of quinazoline derivatives as inhibitors of epidermal growth factor receptor and growth of cancer cells</span>. PCT Int. Appl. WO 2006071017 A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=Y.+J.+Ham&author=J.+H.+Gong&author=M.+Y.+Cha&author=J.+W.+Kim&author=M.+S.+Kim&author=E.+Y.+Kim&author=J.+Y.+Song&author=C.+I.+Kim&author=S.+Y.+Kim&author=G.+S.+Lee&title=Preparation+of+quinazoline+derivatives+as+inhibitors+of+epidermal+growth+factor+receptor+and+growth+of+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHam%26aufirst%3DY.%2BJ.%26atitle%3DPreparation%2520of%2520quinazoline%2520derivatives%2520as%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520growth%2520of%2520cancer%2520cells%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Gaster, L. M.; Wyman, P. A.; Mulholland, K. R.; Davies, D. T.; Duckworth, D. M.; Forbes, I. T.; Jones, G. E.</span><span> </span><span class="NLM_article-title">Preparation of indolines as 5-HT2B/2C receptor antagonists</span>. PCT Int. Appl. WO 9623783 A1,<span class="NLM_x"> </span><span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=L.+M.+Gaster&author=P.+A.+Wyman&author=K.+R.+Mulholland&author=D.+T.+Davies&author=D.+M.+Duckworth&author=I.+T.+Forbes&author=G.+E.+Jones&title=Preparation+of+indolines+as+5-HT2B%2F2C+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGaster%26aufirst%3DL.%2BM.%26atitle%3DPreparation%2520of%2520indolines%2520as%25205-HT2B%252F2C%2520receptor%2520antagonists%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Cockerill, G. S.; Carter, M. C.; Guntrip, S. B.; Smith, K. J.</span><span> </span><span class="NLM_article-title">Preparation of azolylquinazolines and related compounds as protein tyrosine kinase inhibitors</span>. PCT Int. Appl. WO 9802434 A1,<span class="NLM_x"> </span><span class="NLM_year">1998</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=G.+S.+Cockerill&author=M.+C.+Carter&author=S.+B.+Guntrip&author=K.+J.+Smith&title=Preparation+of+azolylquinazolines+and+related+compounds+as+protein+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26atitle%3DPreparation%2520of%2520azolylquinazolines%2520and%2520related%2520compounds%2520as%2520protein%2520tyrosine%2520kinase%2520inhibitors%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stelzer, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TenBrink, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belonga, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sethy, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VonVoigtlander, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petke, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mickelson, J. W.</span><span> </span><span class="NLM_article-title">Piperazine imidazo[1,5-<i>a</i>]quinoxaline ureas as high-affinity GABAA ligands of dual functionality</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1123</span><span class="NLM_x">–</span> <span class="NLM_lpage">1144</span><span class="refDoi"> DOI: 10.1021/jm9801307</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9801307" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=1123-1144&author=E.+J.+Jacobsenauthor=L.+S.+Stelzerauthor=R.+E.+TenBrinkauthor=K.+L.+Belongaauthor=D.+B.+Carterauthor=H.+K.+Imauthor=W.+B.+Imauthor=V.+H.+Sethyauthor=A.+H.+Tangauthor=P.+F.+VonVoigtlanderauthor=J.+D.+Petkeauthor=W.+Z.+Zhongauthor=J.+W.+Mickelson&title=Piperazine+imidazo%5B1%2C5-a%5Dquinoxaline+ureas+as+high-affinity+GABAA+ligands+of+dual+functionality&doi=10.1021%2Fjm9801307"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fjm9801307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9801307%26sid%3Dliteratum%253Aachs%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DStelzer%26aufirst%3DL.%2BS.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DBelonga%26aufirst%3DK.%2BL.%26aulast%3DCarter%26aufirst%3DD.%2BB.%26aulast%3DIm%26aufirst%3DH.%2BK.%26aulast%3DIm%26aufirst%3DW.%2BB.%26aulast%3DSethy%26aufirst%3DV.%2BH.%26aulast%3DTang%26aufirst%3DA.%2BH.%26aulast%3DVonVoigtlander%26aufirst%3DP.%2BF.%26aulast%3DPetke%26aufirst%3DJ.%2BD.%26aulast%3DZhong%26aufirst%3DW.%2BZ.%26aulast%3DMickelson%26aufirst%3DJ.%2BW.%26atitle%3DPiperazine%2520imidazo%255B1%252C5-a%255Dquinoxaline%2520ureas%2520as%2520high-affinity%2520GABAA%2520ligands%2520of%2520dual%2520functionality%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D1123%26epage%3D1144%26doi%3D10.1021%2Fjm9801307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">–</span> <span class="NLM_lpage">8484</span><span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+A+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lh9QLWIQQkHWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520A%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Cohen, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutledge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vass, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowy, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, J. T.</span><span> </span><span class="NLM_article-title">Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">5303</span><span class="NLM_x">–</span> <span class="NLM_lpage">5311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=8394451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADyaK3sXms1Oksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=5303-5311&author=B.+D.+Cohenauthor=D.+J.+Goldsteinauthor=L.+Rutledgeauthor=W.+C.+Vassauthor=D.+R.+Lowyauthor=R.+Schlegelauthor=J.+T.+Schiller&title=Transformation-specific+interaction+of+the+bovine+papillomavirus+E5+oncoprotein+with+the+platelet-derived+growth+factor+receptor+transmembrane+domain+and+the+epidermal+growth+factor+receptor+cytoplasmic+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain</span></div><div class="casAuthors">Cohen, Bruce D.; Goldstein, David J.; Rutledge, Laura; Vass, William C.; Lowy, Douglas R.; Schlegel, Richard; Schiller, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5303-11</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">The bovine papillomavirus E5 transforming protein appears to activate both the epidermal growth factor receptor (EGF-R) and the platelet-derived growth factor receptor (PDGF-R) by a ligand-independent mechanism.  To further investigate the ability of E5 to activate receptors of different classes and to det. whether this stimulation occurs through the extracellular domains required for ligand activation, the authors constructed chimeric genes encoding PDGF-R and EGF-R by interchanging the extracellular, membrane, and cytoplasmic coding domains.  Chimeras were transfected into NIH 3T3 and CHO(LR73) cells.  All chimeras expressed stable protein which, upon addn. of the appropriate ligand, could be activated as assayed by tyrosine autophosphorylation and biol. transformation.  Co-transfection of E5 with the wild-type and chimeric receptors resulted in the ligand-independent activation of receptors, provided that a receptor contained either the transmembrane domain of the PDGF-R or the cytoplasmic domain of the EGF-R.  Chimeric receptors that contained both of these domains exhibited the highest level of E5-induced biochem. and biol. stimulation.  These results imply that E3 activates the PDGF-R and EGR-R by two distinct mechanisms, neither of which specifically involves the extracellular domain of the receptor.  Consistent with the biochem. and biol. activation data, co-immunopptn. studies demonstrated that E5 formed a complex with any chimera that contained a PDGF-R transmembrane domain or an EGF-R cytoplasmic domain, with those chimeras contg. both domains demonstrating the greatest efficiency of complex formation.  These results suggest that although different domains of the PDGF-R and EGF-R are required for E5 activation, both receptors are activated directly by formation of an E5-contg. complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohxDkN9Ekd9rVg90H21EOLACvtfcHk0lh9QLWIQQkHWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXms1Oksbo%253D&md5=30bc0a89087eb4396fe5f40dc71bcc13</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DB.%2BD.%26aulast%3DGoldstein%26aufirst%3DD.%2BJ.%26aulast%3DRutledge%26aufirst%3DL.%26aulast%3DVass%26aufirst%3DW.%2BC.%26aulast%3DLowy%26aufirst%3DD.%2BR.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DSchiller%26aufirst%3DJ.%2BT.%26atitle%3DTransformation-specific%2520interaction%2520of%2520the%2520bovine%2520papillomavirus%2520E5%2520oncoprotein%2520with%2520the%2520platelet-derived%2520growth%2520factor%2520receptor%2520transmembrane%2520domain%2520and%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520cytoplasmic%2520domain%26jtitle%3DJ.%2520Virol.%26date%3D1993%26volume%3D67%26spage%3D5303%26epage%3D5311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 29 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Tamer A. Elwaie, Safinaz E. Abbas, Enayat I. Aly, Riham F. George, Hamdy Ali, Nikolai Kraiouchkine, Khaldoun S. Abdelwahed, Tamer E. Fandy, Khalid A. El Sayed, Zakaria Y. Abd Elmageed, <span class="NLM_string-name hlFld-ContribAuthor">Hamed I. Ali</span>. </span><span class="cited-content_cbyCitation_article-title">HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (24)
                                     , 15906-15945. <a href="https://doi.org/10.1021/acs.jmedchem.0c01647" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01647</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01647%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHER2%252BKinase-Targeted%252BBreast%252BCancer%252BTherapy%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BIn%252BVitro%252Band%252BIn%252BVivo%252BEvaluation%252Bof%252BNovel%252BLapatinib%252BCongeners%252Bas%252BSelective%252Band%252BPotent%252BHER2%252BInhibitors%252Bwith%252BFavorable%252BMetabolic%252BStability%26aulast%3DElwaie%26aufirst%3DTamer%2BA.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D21092020%26date%3D14122020%26volume%3D63%26issue%3D24%26spage%3D15906%26epage%3D15945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jonas Lategahn, Julia Hardick, Tobias Grabe, Janina Niggenaber, Kirujan Jeyakumar, Marina Keul, Hannah L. Tumbrink, Christian Becker, Luke Hodson, Tonia Kirschner, Philip Klövekorn, Julia Ketzer, Matthias Baumann, Susanne Terheyden, Anke Unger, Jörn Weisner, Matthias P. Müller, Willem A. L. van Otterlo, Sebastian Bauer, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Her2-insYVMA with Covalent Inhibitors—A Focused Compound Screening and Structure-Based Design Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11725-11755. <a href="https://doi.org/10.1021/acs.jmedchem.0c00870" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00870</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00870%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BHer2-insYVMA%252Bwith%252BCovalent%252BInhibitors%2525E2%252580%252594A%252BFocused%252BCompound%252BScreening%252Band%252BStructure-Based%252BDesign%252BApproach%26aulast%3DLategahn%26aufirst%3DJonas%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D22052020%26date%3D30092020%26date%3D15092020%26volume%3D63%26issue%3D20%26spage%3D11725%26epage%3D11755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Christopher J. Helal, Jacob C. DeForest, Peter D. Morse, Subham Mahapatra, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to New Drugs Approved during 2018. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10652-10704. <a href="https://doi.org/10.1021/acs.jmedchem.0c00345" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00345</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00345%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252BNew%252BDrugs%252BApproved%252Bduring%252B2018%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26022020%26date%3D22052020%26date%3D27042020%26volume%3D63%26issue%3D19%26spage%3D10652%26epage%3D10704" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Janina Niggenaber, Julia Hardick, Jonas Lategahn, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (1)
                                     , 40-51. <a href="https://doi.org/10.1021/acs.jmedchem.9b00964" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00964</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00964%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%252BDefines%252BFunction%25253A%252BClinically%252BRelevant%252BMutations%252Bin%252BErbB%252BKinases%26aulast%3DNiggenaber%26aufirst%3DJanina%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D17062019%26date%3D28082019%26date%3D15082019%26volume%3D63%26issue%3D1%26spage%3D40%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jiayi Shen, Tao Zhang, Su-Jie Zhu, Min Sun, Linjiang Tong, Mengzhen Lai, Rong Zhang, Wei Xu, Ruibo Wu, Jian Ding, Cai-Hong Yun, Hua Xie, Xiaoyun Lu, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (15)
                                     , 7302-7308. <a href="https://doi.org/10.1021/acs.jmedchem.9b00576" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00576</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00576&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00576%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Based%252BDesign%252Bof%252B5-Methylpyrimidopyridone%252BDerivatives%252Bas%252BNew%252BWild-Type%252BSparing%252BInhibitors%252Bof%252Bthe%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BTriple%252BMutant%252B%252528EGFRL858R%25252FT790M%25252FC797S%252529%26aulast%3DShen%26aufirst%3DJiayi%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08042019%26date%3D23072019%26date%3D12072019%26volume%3D62%26issue%3D15%26spage%3D7302%26epage%3D7308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Douglas C.  Behenna</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Theodore O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">T. Eric  Ballard</span>, <span class="hlFld-ContribAuthor ">Louise  Bernier</span>, <span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Judith G.  Deal</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle  Hemkens</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">John C.  Kath</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Neal W.  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Manli  Shi</span>, <span class="hlFld-ContribAuthor ">James  Solowiej</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">Paolo  Vicini</span>, <span class="hlFld-ContribAuthor ">Yuli  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Longqing  Liu</span>, <span class="hlFld-ContribAuthor ">Yiqin  Luo</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Chengyi  Zhang</span>, and <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (7)
                                     , 3002-3019. <a href="https://doi.org/10.1021/acs.jmedchem.6b01894" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01894</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01894%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN-%252528%2525283R%25252C4R%252529-4-Fluoro-1-%2525286-%252528%2525283-methoxy-1-methyl-1H-pyrazol-4-yl%252529amino%252529-9-methyl-9H-purin-2-yl%252529pyrrolidine-3-yl%252529acrylamide%252B%252528PF-06747775%252529%252Bthrough%252BStructure-Based%252BDrug%252BDesign%25253A%252BA%252BHigh%252BAffinity%252BIrreversible%252BInhibitor%252BTargeting%252BOncogenic%252BEGFR%252BMutants%252Bwith%252BSelectivity%252Bover%252BWild-Type%252BEGFR%26aulast%3DPlanken%26aufirst%3DSimon%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11012017%26date%3D29032017%26date%3D13042017%26date%3D13032017%26volume%3D60%26issue%3D7%26spage%3D3002%26epage%3D3019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jingbing  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Next‐Generation Kinase Inhibitors Targeting Specific Biomarkers in Non‐Small Cell Lung Cancer (NSCLC): A Recent Overview. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>71 </em><a href="https://doi.org/10.1002/cmdc.202100166" title="DOI URL">https://doi.org/10.1002/cmdc.202100166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100166%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DNext%2525E2%252580%252590Generation%252BKinase%252BInhibitors%252BTargeting%252BSpecific%252BBiomarkers%252Bin%252BNon%2525E2%252580%252590Small%252BCell%252BLung%252BCancer%252B%252528NSCLC%252529%25253A%252BA%252BRecent%252BOverview%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2021%26date%3D2021%26volume%3D71" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Seung‐Hwan  Shim</span>, <span class="hlFld-ContribAuthor ">Hyejun  Park</span>, <span class="hlFld-ContribAuthor ">Neeraj Kumar  Mishra</span>, <span class="hlFld-ContribAuthor ">In Su  Kim</span>, <span class="hlFld-ContribAuthor ">Jae Kyun  Lee</span>, <span class="hlFld-ContribAuthor ">Kiho  Lee</span>, <span class="hlFld-ContribAuthor ">Hitesh B.  Jalani</span>, <span class="hlFld-ContribAuthor ">Yongseok  Choi</span>. </span><span class="cited-content_cbyCitation_article-title">Catalyst‐Free One‐Pot Multi‐Component Synthesis of 2‐Substituted Quinazolin‐4‐carboxamides from 2‐Aminophenyl‐2‐oxoacetamides, Aldehydes, and Ammonium Acetate. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (22)
                                     , 5446-5450. <a href="https://doi.org/10.1002/slct.202100534" title="DOI URL">https://doi.org/10.1002/slct.202100534</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202100534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202100534%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DCatalyst%2525E2%252580%252590Free%252BOne%2525E2%252580%252590Pot%252BMulti%2525E2%252580%252590Component%252BSynthesis%252Bof%252B2%2525E2%252580%252590Substituted%252BQuinazolin%2525E2%252580%2525904%2525E2%252580%252590carboxamides%252Bfrom%252B2%2525E2%252580%252590Aminophenyl%2525E2%252580%2525902%2525E2%252580%252590oxoacetamides%25252C%252BAldehydes%25252C%252Band%252BAmmonium%252BAcetate%26aulast%3DShim%26aufirst%3DSeung%25E2%2580%2590Hwan%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D22%26spage%3D5446%26epage%3D5450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhao</span>, <span class="hlFld-ContribAuthor ">Tingting  Fan</span>, <span class="hlFld-ContribAuthor ">Zhichao  Shi</span>, <span class="hlFld-ContribAuthor ">Chao  Ding</span>, <span class="hlFld-ContribAuthor ">Cunlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Qinsheng  Sun</span>, <span class="hlFld-ContribAuthor ">Chunyan  Tan</span>, <span class="hlFld-ContribAuthor ">Bizhu  Chu</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFRT790M mutant cell lines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113173. <a href="https://doi.org/10.1016/j.ejmech.2021.113173" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113173</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113173%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252BErbB%25252FHDAC%252Bmultitargeted%252Binhibitors%252Bwith%252Bselectivity%252Bin%252BEGFRT790M%252Bmutant%252Bcell%252Blines%26aulast%3DZhao%26aufirst%3DLei%26date%3D2021%26volume%3D213%26spage%3D113173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs). </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2021,</strong> <em>165 </em>, 105422. <a href="https://doi.org/10.1016/j.phrs.2021.105422" title="DOI URL">https://doi.org/10.1016/j.phrs.2021.105422</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2021.105422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2021.105422%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DOrally%252Beffective%252BFDA-approved%252Bprotein%252Bkinase%252Btargeted%252Bcovalent%252Binhibitors%252B%252528TCIs%252529%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2021%26volume%3D165%26spage%3D105422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiu  Gu</span>, <span class="hlFld-ContribAuthor ">Zi-Xue  Zhang</span>, <span class="hlFld-ContribAuthor ">Min-Ru  Jiao</span>, <span class="hlFld-ContribAuthor ">Xin-Yan  Peng</span>, <span class="hlFld-ContribAuthor ">Jian-Qi  Li</span>, <span class="hlFld-ContribAuthor ">Qing-Wei  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of SIPI6473, a New, Potent, and Orally Bioavailable Multikinase Inhibitor for the Treatment of Non-small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Fronts</span><span> <strong>2021,</strong> <em>03 </em>
                                    (01)
                                     , e1-e7. <a href="https://doi.org/10.1055/s-0041-1731081" title="DOI URL">https://doi.org/10.1055/s-0041-1731081</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0041-1731081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0041-1731081%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Fronts%26atitle%3DDiscovery%252Bof%252BSIPI6473%25252C%252Ba%252BNew%25252C%252BPotent%25252C%252Band%252BOrally%252BBioavailable%252BMultikinase%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-small%252BCell%252BLung%252BCancer%26aulast%3DGu%26aufirst%3DXiu%26date%3D2021%26date%3D2021%26volume%3D03%26issue%3D01%26spage%3De1%26epage%3De7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmet Sureyya  Rifaioglu</span>, <span class="hlFld-ContribAuthor ">Esra  Nalbat</span>, <span class="hlFld-ContribAuthor ">Volkan  Atalay</span>, <span class="hlFld-ContribAuthor ">Maria Jesus  Martin</span>, <span class="hlFld-ContribAuthor ">Rengul  Cetin-Atalay</span>, <span class="hlFld-ContribAuthor ">Tunca  Doğan</span>. </span><span class="cited-content_cbyCitation_article-title">DEEPScreen: high performance drug–target interaction prediction with convolutional neural networks using 2-D structural compound representations. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2020,</strong> <em>11 </em>
                                    (9)
                                     , 2531-2557. <a href="https://doi.org/10.1039/C9SC03414E" title="DOI URL">https://doi.org/10.1039/C9SC03414E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9SC03414E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9SC03414E%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DDEEPScreen%25253A%252Bhigh%252Bperformance%252Bdrug%2525E2%252580%252593target%252Binteraction%252Bprediction%252Bwith%252Bconvolutional%252Bneural%252Bnetworks%252Busing%252B2-D%252Bstructural%252Bcompound%252Brepresentations%26aulast%3DRifaioglu%26aufirst%3DAhmet%2BSureyya%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D9%26spage%3D2531%26epage%3D2557" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Gehringer</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Kinase Inhibitors: An Overview. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 43-94. <a href="https://doi.org/10.1007/7355_2020_103" title="DOI URL">https://doi.org/10.1007/7355_2020_103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_103%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252BKinase%252BInhibitors%25253A%252BAn%252BOverview%26aulast%3DGehringer%26aufirst%3DMatthias%26date%3D2020%26date%3D2020%26spage%3D43%26epage%3D94%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed  Elkamhawy</span>, <span class="hlFld-ContribAuthor ">Sora  Paik</span>, <span class="hlFld-ContribAuthor ">Hyeon Jeong  Kim</span>, <span class="hlFld-ContribAuthor ">Jong-Hyun  Park</span>, <span class="hlFld-ContribAuthor ">Ashwini M.  Londhe</span>, <span class="hlFld-ContribAuthor ">Kyeong  Lee</span>, <span class="hlFld-ContribAuthor ">Ae Nim  Pae</span>, <span class="hlFld-ContribAuthor ">Ki Duk  Park</span>, <span class="hlFld-ContribAuthor ">Eun Joo  Roh</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of
              N
              -(1-(3-fluorobenzoyl)-1
              H
              -indol-5-yl)pyrazine-2-carboxamide: a novel, selective, and competitive indole-based lead inhibitor for human monoamine oxidase B. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2020,</strong> <em>35 </em>
                                    (1)
                                     , 1568-1580. <a href="https://doi.org/10.1080/14756366.2020.1800666" title="DOI URL">https://doi.org/10.1080/14756366.2020.1800666</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2020.1800666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2020.1800666%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN%252B-%2525281-%2525283-fluorobenzoyl%252529-1%252BH%252B-indol-5-yl%252529pyrazine-2-carboxamide%25253A%252Ba%252Bnovel%25252C%252Bselective%25252C%252Band%252Bcompetitive%252Bindole-based%252Blead%252Binhibitor%252Bfor%252Bhuman%252Bmonoamine%252Boxidase%252BB%26aulast%3DElkamhawy%26aufirst%3DAhmed%26date%3D2020%26date%3D2020%26volume%3D35%26issue%3D1%26spage%3D1568%26epage%3D1580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haibo  Mei</span>, <span class="hlFld-ContribAuthor ">Jianlin  Han</span>, <span class="hlFld-ContribAuthor ">Santos  Fustero</span>, <span class="hlFld-ContribAuthor ">Mercedes  Medio‐Simon</span>, <span class="hlFld-ContribAuthor ">Daniel M.  Sedgwick</span>, <span class="hlFld-ContribAuthor ">Claudio  Santi</span>, <span class="hlFld-ContribAuthor ">Renzo  Ruzziconi</span>, <span class="hlFld-ContribAuthor ">Vadim A.  Soloshonok</span>. </span><span class="cited-content_cbyCitation_article-title">Fluorine‐Containing Drugs Approved by the FDA in 2018. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (51)
                                     , 11797-11819. <a href="https://doi.org/10.1002/chem.201901840" title="DOI URL">https://doi.org/10.1002/chem.201901840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201901840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201901840%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DFluorine%2525E2%252580%252590Containing%252BDrugs%252BApproved%252Bby%252Bthe%252BFDA%252Bin%252B2018%26aulast%3DMei%26aufirst%3DHaibo%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D51%26spage%3D11797%26epage%3D11819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maud  Bollenbach</span>, <span class="hlFld-ContribAuthor ">Claire  Lugnier</span>, <span class="hlFld-ContribAuthor ">Mélanie  Kremer</span>, <span class="hlFld-ContribAuthor ">Eric  Salvat</span>, <span class="hlFld-ContribAuthor ">Salim  Megat</span>, <span class="hlFld-ContribAuthor ">Frédéric  Bihel</span>, <span class="hlFld-ContribAuthor ">Jean-Jacques  Bourguignon</span>, <span class="hlFld-ContribAuthor ">Michel  Barrot</span>, <span class="hlFld-ContribAuthor ">Martine  Schmitt</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>177 </em>, 269-290. <a href="https://doi.org/10.1016/j.ejmech.2019.05.026" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.026%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B3-aminophthalazine%252Bderivatives%252Band%252Bstructural%252Banalogues%252Bas%252BPDE5%252Binhibitors%25253A%252Banti-allodynic%252Beffect%252Bagainst%252Bneuropathic%252Bpain%252Bin%252Ba%252Bmouse%252Bmodel%26aulast%3DBollenbach%26aufirst%3DMaud%26date%3D2019%26volume%3D177%26spage%3D269%26epage%3D290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Properties of FDA-approved small molecule protein kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2019,</strong> <em>144 </em>, 19-50. <a href="https://doi.org/10.1016/j.phrs.2019.03.006" title="DOI URL">https://doi.org/10.1016/j.phrs.2019.03.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2019.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2019.03.006%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DProperties%252Bof%252BFDA-approved%252Bsmall%252Bmolecule%252Bprotein%252Bkinase%252Binhibitors%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2019%26volume%3D144%26spage%3D19%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Debasis  Das</span>, <span class="hlFld-ContribAuthor ">Jian  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>170 </em>, 55-72. <a href="https://doi.org/10.1016/j.ejmech.2019.03.004" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.004%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvancements%252Bof%252B4-aminoquinazoline%252Bderivatives%252Bas%252Bkinase%252Binhibitors%252Band%252Btheir%252Bapplications%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DDas%26aufirst%3DDebasis%26date%3D2019%26volume%3D170%26spage%3D55%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Clinton G. L.  Veale</span>. </span><span class="cited-content_cbyCitation_article-title">Unpacking the Pathogen Box—An Open Source Tool for Fighting Neglected Tropical Disease. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (4)
                                     , 386-453. <a href="https://doi.org/10.1002/cmdc.201800755" title="DOI URL">https://doi.org/10.1002/cmdc.201800755</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800755%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DUnpacking%252Bthe%252BPathogen%252BBox%2525E2%252580%252594An%252BOpen%252BSource%252BTool%252Bfor%252BFighting%252BNeglected%252BTropical%252BDisease%26aulast%3DVeale%26aufirst%3DClinton%2BG.%2BL.%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D4%26spage%3D386%26epage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saeed  Bahadorikhalili</span>, <span class="hlFld-ContribAuthor ">Golnaz  Rahimzadeh</span>, <span class="hlFld-ContribAuthor ">Ebrahim  Kianmehr</span>, <span class="hlFld-ContribAuthor ">Samira  Ansari</span>, <span class="hlFld-ContribAuthor ">Haleh  Hamedifar</span>, <span class="hlFld-ContribAuthor ">Mohammad  Mahdavi</span>. </span><span class="cited-content_cbyCitation_article-title">Facile Non-Transition Metal-Catalyzed Synthesis of 2-Thioxo-2,3-dihydroquinazolin-4(1
              H
              )-one Derivatives via One-Pot Multicomponent Reactions. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2019,</strong> <em>4 </em>
                                    (1)
                                     , 100-104. <a href="https://doi.org/10.1002/slct.201802861" title="DOI URL">https://doi.org/10.1002/slct.201802861</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201802861&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201802861%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DFacile%252BNon-Transition%252BMetal-Catalyzed%252BSynthesis%252Bof%252B2-Thioxo-2%25252C3-dihydroquinazolin-4%2525281%252BH%252B%252529-one%252BDerivatives%252Bvia%252BOne-Pot%252BMulticomponent%252BReactions%26aulast%3DBahadorikhalili%26aufirst%3DSaeed%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D1%26spage%3D100%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammad Hosein  Sayahi</span>, <span class="hlFld-ContribAuthor ">Seyyed Jafar  Saghanezhad</span>, <span class="hlFld-ContribAuthor ">Saeed  Bahadorikhalili</span>, <span class="hlFld-ContribAuthor ">Mohammad  Mahdavi</span>. </span><span class="cited-content_cbyCitation_article-title">CuBr-catalysed one-pot multicomponent synthesis of 3-substituted 2-thioxo-2,3-dihydroquinazolin-4(1
              H
              )-one derivatives. </span><span class="cited-content_cbyCitation_journal-name">Applied Organometallic Chemistry</span><span> <strong>2019,</strong> <em>33 </em>
                                    (1)
                                     , e4635. <a href="https://doi.org/10.1002/aoc.4635" title="DOI URL">https://doi.org/10.1002/aoc.4635</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/aoc.4635&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Faoc.4635%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Organometallic%2520Chemistry%26atitle%3DCuBr-catalysed%252Bone-pot%252Bmulticomponent%252Bsynthesis%252Bof%252B3-substituted%252B2-thioxo-2%25252C3-dihydroquinazolin-4%2525281%252BH%252B%252529-one%252Bderivatives%26aulast%3DSayahi%26aufirst%3DMohammad%2BHosein%26date%3D2019%26date%3D2018%26volume%3D33%26issue%3D1%26spage%3De4635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches in the Development of Covalent Irreversible EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 45-128. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00003-2" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00003-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00003-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00003-2%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BApproaches%252Bin%252Bthe%252BDevelopment%252Bof%252BCovalent%252BIrreversible%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D45%26epage%3D128%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2019,</strong> <em>139 </em>, 395-411. <a href="https://doi.org/10.1016/j.phrs.2018.11.014" title="DOI URL">https://doi.org/10.1016/j.phrs.2018.11.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2018.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2018.11.014%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DSmall%252Bmolecule%252Binhibitors%252Btargeting%252Bthe%252BEGFR%25252FErbB%252Bfamily%252Bof%252Bprotein-tyrosine%252Bkinases%252Bin%252Bhuman%252Bcancers%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2019%26volume%3D139%26spage%3D395%26epage%3D411" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">András György  Németh</span>, <span class="hlFld-ContribAuthor ">György Miklós  Keserű</span>, <span class="hlFld-ContribAuthor ">Péter  Ábrányi-Balogh</span>. </span><span class="cited-content_cbyCitation_article-title">A novel three-component reaction between isocyanides, alcohols or thiols and elemental sulfur: a mild, catalyst-free approach towards
              O
              -thiocarbamates and dithiocarbamates. </span><span class="cited-content_cbyCitation_journal-name">Beilstein Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>15 </em>, 1523-1533. <a href="https://doi.org/10.3762/bjoc.15.155" title="DOI URL">https://doi.org/10.3762/bjoc.15.155</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3762/bjoc.15.155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3762%2Fbjoc.15.155%26sid%3Dliteratum%253Aachs%26jtitle%3DBeilstein%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DA%252Bnovel%252Bthree-component%252Breaction%252Bbetween%252Bisocyanides%25252C%252Balcohols%252Bor%252Bthiols%252Band%252Belemental%252Bsulfur%25253A%252Ba%252Bmild%25252C%252Bcatalyst-free%252Bapproach%252Btowards%252BO%252B-thiocarbamates%252Band%252Bdithiocarbamates%26aulast%3DN%25C3%25A9meth%26aufirst%3DAndr%25C3%25A1s%2BGy%25C3%25B6rgy%26date%3D2019%26date%3D2019%26volume%3D15%26spage%3D1523%26epage%3D1533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EGFR
              L858R/T790M
              and EGFR
              L858R/T790M/C797S
              resistance mutations in NSCLC: Current developments in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5)
                                     , 1550-1581. <a href="https://doi.org/10.1002/med.21488" title="DOI URL">https://doi.org/10.1002/med.21488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21488%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252BEGFR%252BL858R%25252FT790M%252Band%252BEGFR%252BL858R%25252FT790M%25252FC797S%252Bresistance%252Bmutations%252Bin%252BNSCLC%25253A%252BCurrent%252Bdevelopments%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1550%26epage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">V.  Alagarsamy</span>, <span class="hlFld-ContribAuthor ">K.  Chitra</span>, <span class="hlFld-ContribAuthor ">G.  Saravanan</span>, <span class="hlFld-ContribAuthor ">V. Raja  Solomon</span>, <span class="hlFld-ContribAuthor ">M.T.  Sulthana</span>, <span class="hlFld-ContribAuthor ">B.  Narendhar</span>. </span><span class="cited-content_cbyCitation_article-title">An overview of quinazolines: Pharmacological significance and recent developments. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>151 </em>, 628-685. <a href="https://doi.org/10.1016/j.ejmech.2018.03.076" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.076%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAn%252Boverview%252Bof%252Bquinazolines%25253A%252BPharmacological%252Bsignificance%252Band%252Brecent%252Bdevelopments%26aulast%3DAlagarsamy%26aufirst%3DV.%26date%3D2018%26volume%3D151%26spage%3D628%26epage%3D685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongjun  Fan</span>, <span class="hlFld-ContribAuthor ">Weikang  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Zhao</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Acceptorless Dehydrogenative Cyclization of
              o
              -Aminobenzylamines and Aldehydes to Quinazolines in Water Catalyzed by a Water-Soluble Metal-Ligand Bifunctional Catalyst. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2017,</strong> <em>2 </em>
                                    (20)
                                     , 5735-5739. <a href="https://doi.org/10.1002/slct.201700871" title="DOI URL">https://doi.org/10.1002/slct.201700871</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201700871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201700871%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DAcceptorless%252BDehydrogenative%252BCyclization%252Bof%252Bo%252B-Aminobenzylamines%252Band%252BAldehydes%252Bto%252BQuinazolines%252Bin%252BWater%252BCatalyzed%252Bby%252Ba%252BWater-Soluble%252BMetal-Ligand%252BBifunctional%252BCatalyst%26aulast%3DFan%26aufirst%3DHongjun%26date%3D2017%26date%3D2017%26volume%3D2%26issue%3D20%26spage%3D5735%26epage%3D5739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xinshan  Deng</span>, <span class="hlFld-ContribAuthor ">Jiaofeng  Wu</span>, <span class="hlFld-ContribAuthor ">Guangpeng  Meng</span>, <span class="hlFld-ContribAuthor ">Congchong  Liu</span>, <span class="hlFld-ContribAuthor ">Guzhou  Chen</span>, <span class="hlFld-ContribAuthor ">Qingchun  Zhao</span>, <span class="hlFld-ContribAuthor ">Chun  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological activities of N-(furan-2-ylmethyl)-1H-indole-3-carboxamide derivatives as epidemal growth factor receptor inhibitors and anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Chinese Universities</span><span> <strong>2017,</strong> <em>33 </em>
                                    (3)
                                     , 365-372. <a href="https://doi.org/10.1007/s40242-017-7041-x" title="DOI URL">https://doi.org/10.1007/s40242-017-7041-x</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40242-017-7041-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40242-017-7041-x%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Chinese%2520Universities%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bactivities%252Bof%252BN-%252528furan-2-ylmethyl%252529-1H-indole-3-carboxamide%252Bderivatives%252Bas%252Bepidemal%252Bgrowth%252Bfactor%252Breceptor%252Binhibitors%252Band%252Banticancer%252Bagents%26aulast%3DZhang%26aufirst%3DLan%26date%3D2017%26date%3D2017%26volume%3D33%26issue%3D3%26spage%3D365%26epage%3D372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dirk  Theile</span>, <span class="hlFld-ContribAuthor ">Gal  Lenz</span>, <span class="hlFld-ContribAuthor ">Jamil A.  Momand</span>, <span class="hlFld-ContribAuthor ">Susan E.  Kane</span>. </span><span class="cited-content_cbyCitation_article-title">Resistance to HER2-Targeted Therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 35-88. <a href="https://doi.org/10.1007/978-3-319-70142-4_2" title="DOI URL">https://doi.org/10.1007/978-3-319-70142-4_2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-70142-4_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-70142-4_2%26sid%3Dliteratum%253Aachs%26atitle%3DResistance%252Bto%252BHER2-Targeted%252BTherapy%26aulast%3DTheile%26aufirst%3DDirk%26date%3D2017%26date%3D2017%26spage%3D35%26epage%3D88%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DResistance%252Bto%252BTargeted%252BTherapies%252Bin%252BBreast%252BCancer%26aulast%3DProsperi%26aufirst%3DJenifer%2BR.%26date%3D2017%26volume%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="cht1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Chart 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0002.jpeg" id="rightTab-GRAPHIC-d7e486-autogenerated" class="rightTab-fig internalNav" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=cht1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) acid chloride, Et<sub>3</sub>N, THF, RT.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaOMe, MeOH, 100 °C, 18 h; (ii) (a) Fe, AcOH, EtOH, water, 100 °C, 1 h, (b) propionic anhydride, 120 °C, 2 h; (iii) POCl<sub>3</sub>, reflux, 90 min; (iv) subst aniline, <sup><i>i</i></sup>PrOH, c. HCl (cat.), 100 °C, 0.5–1 h.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0007.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 3. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaOEt, EtOH, 50 °C, 4 h; (ii) (a) POCl<sub>3</sub>, reflux, 3 h, (b) 1-benzyl-1<i>H</i>-indazol-5-amine, <sup><i>i</i></sup>PrOH/CH<sub>2</sub>Cl<sub>2</sub>, 50 °C, 15 h; (iii) Raney nickel, H<sub>2</sub>, EtOAc/MeOH; (iv) (a) <i>E</i>-4-bromobut-2-enoic acid, oxalyl chloride, cat. DMF, CH<sub>2</sub>Cl<sub>2</sub>, RT, (b) acid chloride from (a), THF, −20 °C, 075; (v) amine, DMA, −20 °C, 2 h.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0008.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) NaO(CH<sub>2</sub>)<sub>2</sub>OCH<sub>3</sub>, THF, reflux; (ii) (a) SOCl<sub>2</sub>, cat. DMF, reflux, 2 h, (b) subst aniline, <sup><i>i</i></sup>PrOH/CH<sub>2</sub>Cl<sub>2</sub>, reflux, 0.75 h; (iii) 4-methoxybenzylamine, DMSO, 120 °C, 24 h; (iv) TFA, 6 h., RT; (v) (a) <i>E</i>-4-bromobut-2-enoic acid, oxalyl chloride, cat. DMF, CH<sub>2</sub>Cl<sub>2</sub>, RT, (b) acid chloride from (a), THF, −20 °C, 0.75 h; (vi) amine, DMA, −20 °C, 2 h.</p></p></figure><figure data-id="fig1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Reported relative reactivity of various Michael acceptors toward reduced glutathione.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/medium/jm-2016-00883c_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0004.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. General pharmacophore explored for anilines that provide pan-erbB activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-17/acs.jmedchem.6b00883/20160901/images/large/jm-2016-00883c_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b00883&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i116">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11858" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11858" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 84 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Reid, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J.</span><span> </span><span class="NLM_article-title">Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)</span> <span class="citation_source-journal">Eur. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">481</span><span class="NLM_x">–</span> <span class="NLM_lpage">489</span><span class="refDoi"> DOI: 10.1016/j.ejca.2006.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.ejca.2006.11.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2007&pages=481-489&author=A.+Reidauthor=L.+Vidalauthor=H.+Shawauthor=J.+de+Bono&title=Dual+inhibition+of+ErbB1+%28EGFR%2FHER1%29+and+ErbB2+%28HER2%2Fneu%29&doi=10.1016%2Fj.ejca.2006.11.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2006.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2006.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DReid%26aufirst%3DA.%26aulast%3DVidal%26aufirst%3DL.%26aulast%3DShaw%26aufirst%3DH.%26aulast%3Dde%2BBono%26aufirst%3DJ.%26atitle%3DDual%2520inhibition%2520of%2520ErbB1%2520%2528EGFR%252FHER1%2529%2520and%2520ErbB2%2520%2528HER2%252Fneu%2529%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2007%26volume%3D43%26spage%3D481%26epage%3D489%26doi%3D10.1016%2Fj.ejca.2006.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Nyati, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawrence, T. S.</span><span> </span><span class="NLM_article-title">Integration of EGFR inhibitors with radiochemotherapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">876</span><span class="NLM_x">–</span> <span class="NLM_lpage">885</span><span class="refDoi"> DOI: 10.1038/nrc1953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnrc1953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=17036041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWhs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=876-885&author=M.+K.+Nyatiauthor=M.+A.+Morganauthor=F.+Y.+Fengauthor=T.+S.+Lawrence&title=Integration+of+EGFR+inhibitors+with+radiochemotherapy&doi=10.1038%2Fnrc1953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of EGFR inhibitors with radiochemotherapy</span></div><div class="casAuthors">Nyati, Mukesh K.; Morgan, Meredith A.; Feng, Felix Y.; Lawrence, Theodore S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">876-885</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Lab. studies that led to the development of epidermal growth factor receptor (EGFR) inhibitors indicated that such inhibitors would be effective when given to patients with tumors that are driven by activated EGFR.  However, initial clin. studies have shown modest responses to EGFR inhibitors when used alone, and it has not yet been possible to clearly identify which tumors will respond to this therapy.  As a result, EGFR inhibitors are now used in combination with radiation therapy, chemotherapy and, more recently, with concurrent radiochemotherapy.  In general, these clin. trials have been designed without much preclin. data.  What do we need to know to make these combinations successful in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnHPTAiQOacLVg90H21EOLACvtfcHk0lhfUqjJFoPqpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWhs7bK&md5=e67a50e83fcac4a146695188b16cdc8f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc1953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1953%26sid%3Dliteratum%253Aachs%26aulast%3DNyati%26aufirst%3DM.%2BK.%26aulast%3DMorgan%26aufirst%3DM.%2BA.%26aulast%3DFeng%26aufirst%3DF.%2BY.%26aulast%3DLawrence%26aufirst%3DT.%2BS.%26atitle%3DIntegration%2520of%2520EGFR%2520inhibitors%2520with%2520radiochemotherapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2006%26volume%3D6%26spage%3D876%26epage%3D885%26doi%3D10.1038%2Fnrc1953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Mendelsohn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor targeting in cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">369</span><span class="NLM_x">–</span> <span class="NLM_lpage">385</span><span class="refDoi"> DOI: 10.1053/j.seminoncol.2006.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1053%2Fj.seminoncol.2006.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16890793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28XpsVersLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2006&pages=369-385&author=J.+Mendelsohnauthor=J.+Baselga&title=Epidermal+growth+factor+receptor+targeting+in+cancer&doi=10.1053%2Fj.seminoncol.2006.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor targeting in cancer</span></div><div class="casAuthors">Mendelsohn, John; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">369-385</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase of the ErbB family that is abnormally activated in many epithelial tumors.  Several mechanisms lead to the receptor's aberrant activation that is obsd. in cancer, including receptor overexpression, mutation, ligand-dependent receptor dimerization, and ligand-independent activation.  Two classes of anti-EGFR agents are currently approved for the treatment of patients with cancer: cetuximab, a monoclonal antibody directed at the extracellular domain of the receptor, and gefitinib and erlotinib, oral, low-mol.-wt. (MW), ATP-competitive inhibitors of the receptor's tyrosine kinase.  Anti-EGFR monoclonal antibodies have demonstrated activity in the therapy of advanced colorectal carcinoma and in a variety of epithelial tumor types, including head and neck cancer and non-small cell lung cancer (NSCLC).  The development of low MW, anti-EGFR tyrosine kinase inhibitors (TKIs) has been focused until recently on NSCLC, although responses have been reported for other types of cancer.  Erlotinib was the only agent approved based on demonstrating improved survival, which was obsd. in patients with advanced NSCLC who previously had been treated with chemotherapy.  Recent major advances in the EGFR field include the discovery of EGFR somatic mutations in NSCLC that have important implications for biol., treatment, clin. trial design, and methods for mutation detection.  Clin. and survival benefits with anti-EGFR agents have been demonstrated in addnl. tumor types such as head and neck and pancreatic carcinomas.  New agents with clin. activity are entering the clinic and new combinatorial approaches with anti-EGFR agents are being explored.  Major efforts are, belatedly, attempting to identify mol. markers that can predict patients more likely to respond to anti-EGFR therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkawbwoHPfpLVg90H21EOLACvtfcHk0lhfUqjJFoPqpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XpsVersLk%253D&md5=68ddafac141c8351630137c8b28ca74e</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2006.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2006.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520targeting%2520in%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2006%26volume%3D33%26spage%3D369%26epage%3D385%26doi%3D10.1053%2Fj.seminoncol.2006.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hynes, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, H. A.</span><span> </span><span class="NLM_article-title">ErbB receptors and cancer: the complexity of targeted inhibitors</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">341</span><span class="NLM_x">–</span> <span class="NLM_lpage">354</span><span class="refDoi"> DOI: 10.1038/nrc1609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnrc1609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=15864276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=341-354&author=N.+E.+Hynesauthor=H.+A.+Lane&title=ErbB+receptors+and+cancer%3A+the+complexity+of+targeted+inhibitors&doi=10.1038%2Fnrc1609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">ERBB receptors and cancer: the complexity of targeted inhibitors</span></div><div class="casAuthors">Hynes, Nancy E.; Lane, Heidi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">341-354</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  ERBB receptor tyrosine kinases have important roles in human cancer.  In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumors, and clin. studies indicate that they have important roles in tumor etiol. and progression.  Accordingly, these receptors have been intensely studied to understand their importance in cancer biol. and as therapeutic targets, and many ERBB inhibitors are now used in the clinic.  We will discuss the significance of these receptors as clin. targets, in particular the mol. mechanisms underlying response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrimBiy4bn4LrVg90H21EOLACvtfcHk0lhfUqjJFoPqpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslertb0%253D&md5=54a45e004711da7017ee0f016696a36e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc1609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1609%26sid%3Dliteratum%253Aachs%26aulast%3DHynes%26aufirst%3DN.%2BE.%26aulast%3DLane%26aufirst%3DH.%2BA.%26atitle%3DErbB%2520receptors%2520and%2520cancer%253A%2520the%2520complexity%2520of%2520targeted%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D341%26epage%3D354%26doi%3D10.1038%2Fnrc1609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Landi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cappuzzo, F.</span><span> </span><span class="NLM_article-title">Front-line therapy in lung cancer with mutations in EGFR</span> <span class="citation_source-journal">Nat. Rev. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">571</span><span class="NLM_x">–</span> <span class="NLM_lpage">573</span><span class="refDoi"> DOI: 10.1038/nrclinonc.2011.135</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnrclinonc.2011.135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=21878894" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Gitb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=571-573&author=L.+Landiauthor=F.+Cappuzzo&title=Front-line+therapy+in+lung+cancer+with+mutations+in+EGFR&doi=10.1038%2Fnrclinonc.2011.135"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Front-line therapy in lung cancer with mutations in EGFR</span></div><div class="casAuthors">Landi, Lorenza; Cappuzzo, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">571-573</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Large randomized phase III trials conducted in patients with non-small-cell lung cancer (NSCLC) harboring activating mutations in EGFR have demonstrated that erlotinib or gefitinib are superior to platinum-based chemotherapy.  Zhou et al. have now confirmed that these agents represent the best treatment we can offer today as front-line therapy for EGFR-mutant NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo13q42VvvUE7Vg90H21EOLACvtfcHk0lgdWdWtdMJcPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Gitb%252FO&md5=8a3ced52ebc1d1ac268dd98fbdabd5be</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2011.135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2011.135%26sid%3Dliteratum%253Aachs%26aulast%3DLandi%26aufirst%3DL.%26aulast%3DCappuzzo%26aufirst%3DF.%26atitle%3DFront-line%2520therapy%2520in%2520lung%2520cancer%2520with%2520mutations%2520in%2520EGFR%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26spage%3D571%26epage%3D573%26doi%3D10.1038%2Fnrclinonc.2011.135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thatcher, N.</span><span> </span><span class="NLM_article-title">Where next for gefitinib in patients with lung cancer?</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">499</span><span class="NLM_x">–</span> <span class="NLM_lpage">507</span><span class="refDoi"> DOI: 10.1016/S1470-2045(06)70725-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS1470-2045%2806%2970725-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16750500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28XltFClsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=499-507&author=F.+Blackhallauthor=M.+Ransonauthor=N.+Thatcher&title=Where+next+for+gefitinib+in+patients+with+lung+cancer%3F&doi=10.1016%2FS1470-2045%2806%2970725-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Where next for gefitinib in patients with lung cancer?</span></div><div class="casAuthors">Blackhall, Fiona; Ranson, Malcolm; Thatcher, Nick</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">499-507</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Summary: Gefitinib belongs to the small-mol. class of epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors.  It was given conditional approval by the US Food and Drug Administration (FDA) in 2003 for treatment of advanced, chemorefractory non-small-cell lung cancer (NSCLC), but was relabeled for restricted use for patients that were already receiving and benefiting from it after the neg. result of the phase III Iressa Survival Evaluation in Advanced Lung Cancer (ISEL) trial.  By contrast, erlotinib, another EGFR tyrosine-kinase inhibitor, showed an overall survival benefit compared with placebo and best supportive care in the National Cancer Institute of Canada's BR21 trial, and now has full FDA approval for treatment of patients with NSCLC who have progressed after treatment with chemotherapy.  Although the ISEL trial result was neg. overall, preplanned subgroup analyses showed a significant overall survival benefit for gefitinib treatment in never-smokers and in patients of Asian origin.  Here, we review the clin. experience with gefitinib and, in light of the licensing of erlotinib, address the lessons learned, the ongoing trials, and whether scope remains for clin. development of gefitinib in selected patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8yvRqJ5czKrVg90H21EOLACvtfcHk0lgdWdWtdMJcPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltFClsLg%253D&md5=37ef22f3279b3383c7c3abef0918e9a1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2806%2970725-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252806%252970725-2%26sid%3Dliteratum%253Aachs%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DRanson%26aufirst%3DM.%26aulast%3DThatcher%26aufirst%3DN.%26atitle%3DWhere%2520next%2520for%2520gefitinib%2520in%2520patients%2520with%2520lung%2520cancer%253F%26jtitle%3DLancet%2520Oncol.%26date%3D2006%26volume%3D7%26spage%3D499%26epage%3D507%26doi%3D10.1016%2FS1470-2045%2806%2970725-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Goodin, S.</span><span> </span><span class="NLM_article-title">Erlotinib: Optimizing therapy with predictors of response?</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2961</span><span class="NLM_x">–</span> <span class="NLM_lpage">2963</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-0426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1078-0432.CCR-06-0426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16707589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28Xks1Cisbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=2961-2963&author=S.+Goodin&title=Erlotinib%3A+Optimizing+therapy+with+predictors+of+response%3F&doi=10.1158%2F1078-0432.CCR-06-0426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib: Optimizing therapy with predictors of response?</span></div><div class="casAuthors">Goodin, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2961-2963</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review on FDA-approved oral EGFR tyrosine kinase inhibitors, with emphasis on erlotinib, its clin. pharmacol., clin. trials, predictors of response and resistance, adverse effects, dose and administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2ZFTUllYfnLVg90H21EOLACvtfcHk0lgdWdWtdMJcPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xks1Cisbw%253D&md5=8f0b10030d5df5935b63edbfebb04f21</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-0426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-0426%26sid%3Dliteratum%253Aachs%26aulast%3DGoodin%26aufirst%3DS.%26atitle%3DErlotinib%253A%2520Optimizing%2520therapy%2520with%2520predictors%2520of%2520response%253F%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D2961%26epage%3D2963%26doi%3D10.1158%2F1078-0432.CCR-06-0426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Gorden, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesbah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesar, J. M.</span><span> </span><span class="NLM_article-title">EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC</span> <span class="citation_source-journal">J. Oncol. Pharm. Pract.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">245</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span><span class="refDoi"> DOI: 10.1177/1078155211408373</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1177%2F1078155211408373" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=21733906" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFOitL3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=245-249&author=K.+J.+Gordenauthor=P.+Mesbahauthor=J.+M.+Kolesar&title=EGFR+inhibitors+as+first-line+therapy+in+EGFR+mutation-positive+patients+with+NSCLC&doi=10.1177%2F1078155211408373"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC</span></div><div class="casAuthors">Gorden, Kimberly J.; Mesbah, Parvin; Kolesar, Jill M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Oncology Pharmacy Practice</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">245-249</span>CODEN:
                <span class="NLM_cas:coden">JOPPFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-1552</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Purpose: The purpose of this review article is to describe the recent data supporting the use of epidermal growth factor receptor (EGFR) receptor tyrosine kinase inhibitors (TKIs) in the first-line setting of EGFR mutation-pos. non-small cell lung cancer (NSCLC).  Summary: EGFR receptor TKIs were originally developed in unselected NSCLC patients and demonstrated modest clin. benefit compared to placebo.  With the discovery of improved benefits in the approx. 16% of NSCLC patients with an EGFR mutation, trials in selected populations were undertaken, demonstrating comparable efficacy to std. chemotherapy with an improved toxicity profile.  The most common toxicity is rash, sometimes requiring dose adjustment and discontinuation and the most serious toxicity is interstitial lung disease, which occurs in about 1% of patients treated with EGFR receptor TKIs and is fatal in 30% who develop this toxicity.  Conclusion: The EGFR receptor TKIs are an effective therapy in EGFR-mutated NSCLC and are recommended as first-line therapy for those with advanced or metastatic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLSjBZ6cSdtbVg90H21EOLACvtfcHk0lgAGFsdDcTjFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFOitL3E&md5=cb0b7855867165378d7abd93d3c0bf21</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1177%2F1078155211408373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1078155211408373%26sid%3Dliteratum%253Aachs%26aulast%3DGorden%26aufirst%3DK.%2BJ.%26aulast%3DMesbah%26aufirst%3DP.%26aulast%3DKolesar%26aufirst%3DJ.%2BM.%26atitle%3DEGFR%2520inhibitors%2520as%2520first-line%2520therapy%2520in%2520EGFR%2520mutation-positive%2520patients%2520with%2520NSCLC%26jtitle%3DJ.%2520Oncol.%2520Pharm.%2520Pract.%26date%3D2012%26volume%3D18%26spage%3D245%26epage%3D249%26doi%3D10.1177%2F1078155211408373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Somwar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span> <span class="citation_source-journal">PLoS Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">e73</span><span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2ear13nS9mtMZLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Factors underlying sensitivity of cancers to small-molecule kinase inhibitors</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">723</span><span class="refDoi"> DOI: 10.1038/nrd2871</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnrd2871" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=19629074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovFylur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=709-723&author=P.+A.+J%C3%A4nneauthor=N.+Grayauthor=J.+Settleman&title=Factors+underlying+sensitivity+of+cancers+to+small-molecule+kinase+inhibitors&doi=10.1038%2Fnrd2871"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Factors underlying sensitivity of cancers to small-molecule kinase inhibitors</span></div><div class="casAuthors">Janne, Pasi A.; Gray, Nathanael; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">709-723</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Selective small-mol. kinase inhibitors have emerged over the past decade as an important class of anti-cancer agents, and have demonstrated impressive clin. efficacy in several different diseases, including relatively common malignancies such as breast and lung cancer.  However, clin. benefit is typically limited to a fraction of treated patients.  Genomic features of individual tumors contribute significantly to such clin. responses, and these seem to vary tremendously across patients.  Addnl. factors, including pharmacogenomics, the tumor microenvironment and rapidly acquired drug resistance, also contribute to the clin. sensitivity of various cancers, and should be considered and applied in the development and use of new kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ6L91RJfWIrVg90H21EOLACvtfcHk0ljoPgt_qzb7BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovFylur4%253D&md5=7deddcb339b6e6047a9a11f9cb408d1a</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd2871&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2871%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DFactors%2520underlying%2520sensitivity%2520of%2520cancers%2520to%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2009%26volume%3D8%26spage%3D709%26epage%3D723%26doi%3D10.1038%2Fnrd2871" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Nass, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hahm, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, N. E.</span><span> </span><span class="NLM_article-title">Breast cancer biology blossoms in the clinic</span> <span class="citation_source-journal">Nat. Med. (N. Y., NY, U. S.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">762</span><span class="refDoi"> DOI: 10.1038/nm0798-761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnm0798-761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=9662357" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=761-762&author=S.+J.+Nassauthor=H.+A.+Hahmauthor=N.+E.+Davidson&title=Breast+cancer+biology+blossoms+in+the+clinic&doi=10.1038%2Fnm0798-761"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnm0798-761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm0798-761%26sid%3Dliteratum%253Aachs%26aulast%3DNass%26aufirst%3DS.%2BJ.%26aulast%3DHahm%26aufirst%3DH.%2BA.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26atitle%3DBreast%2520cancer%2520biology%2520blossoms%2520in%2520the%2520clinic%26jtitle%3DNat.%2520Med.%2520%2528N.%2520Y.%252C%2520NY%252C%2520U.%2520S.%2529%26date%3D1998%26volume%3D4%26spage%3D761%26epage%3D762%26doi%3D10.1038%2Fnm0798-761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Lessons from the drug discovery of Lapatinib, a dual ErbB1/2 tyrosine kinase inhibitor</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">435</span><span class="NLM_x">–</span> <span class="NLM_lpage">460</span><span class="refDoi"> DOI: 10.2174/156802606776743156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.2174%2F156802606776743156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16719802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28XmtV2juro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=435-460&author=K.+E.+Lackey&title=Lessons+from+the+drug+discovery+of+Lapatinib%2C+a+dual+ErbB1%2F2+tyrosine+kinase+inhibitor&doi=10.2174%2F156802606776743156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons from the drug discovery of Lapatinib, a dual ErbB1/2 tyrosine Kinase inhibitor</span></div><div class="casAuthors">Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">435-460</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein Kinases offer many opportunities for drug intervention points since phosphorylation is the most common post-translational modification.  Phosphorylation regulates activity, location, degrdn., and conformation and the aberrant activity is implicated in many diseases, including cancer, inflammation, cardiovascular, and central nervous system diseases.  The focus of this review will be on the generation of highly effective signaling inhibitors targeting members of the erbB family of receptor tyrosine kinases, EGFR and ErbB-2, also known as transmembrane Type 1 receptor tyrosine kinases of the HER family of receptors.  Ligand binding to the receptor causes a conformational change which activates the tyrosine kinase domain leading to autophosphorylation.  This autophosphorylation activates the RAS/mitogen-activated protein (MAP) kinase and phosphoinositol-3-kinase (PI3K) pathways leading to a myriad of signaling and cellular activities.  Type 1 receptors are overexpressed in a variety of cancers and generally correlate with poor prognosis.  For this reason, scientists at GlaxoSmithKline and many others in the scientific community target the ATP binding site of the intracellular portion of the protein to block the aberrant signaling event.  This review intends to cover the lessons learned in the discovery of Lapatinib (GW572016, GW2016) by pulling together the various different publications that have been generated in distinct disciplines on aspects of the drug discovery program.  Data analyses and correlation of assay data to help with the design of drug-like mols. are included and demonstrate a break from the traditional focus on abs. potency as a guiding factor in lead compd. selection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnKhQE45WWsbVg90H21EOLACvtfcHk0ljoPgt_qzb7BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmtV2juro%253D&md5=5bb70c03abc1fb8c301cac0f5f713fbe</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.2174%2F156802606776743156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802606776743156%26sid%3Dliteratum%253Aachs%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DLessons%2520from%2520the%2520drug%2520discovery%2520of%2520Lapatinib%252C%2520a%2520dual%2520ErbB1%252F2%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2006%26volume%3D6%26spage%3D435%26epage%3D460%26doi%3D10.2174%2F156802606776743156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Tsang, R. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadeghi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Lapatinib, a dual-targeted small molecule inhibitor of EGFR and HER2, in HER2-amplified breast cancer: from bench to bedside</span> <span class="citation_source-journal">Clin. Med. Insights: Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.4137/CMT.S3783</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.4137%2FCMT.S3783" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyjtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=1-13&author=R.+Y.+Tsangauthor=S.+Sadeghiauthor=R.+S.+Finn&title=Lapatinib%2C+a+dual-targeted+small+molecule+inhibitor+of+EGFR+and+HER2%2C+in+HER2-amplified+breast+cancer%3A+from+bench+to+bedside&doi=10.4137%2FCMT.S3783"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Lapatinib, a dual-targeted small molecule inhibitor of EGFR and HER2, in HER2-amplified breast cancer: from bench to bedside</span></div><div class="casAuthors">Tsang, Roger Y.; Sadeghi, Saeed; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Medicine Insights: Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">CMITB2</span>;
        ISSN:<span class="NLM_cas:issn">1179-559X</span>.
    
            (<span class="NLM_cas:orgname">Libertas Academica</span>)
        </div><div class="casAbstract">A review.  The HER-2/neu gene product is a 185 kDa Type I receptor tyrosine kinase which consists of an extracellular domain, transmembrane domain, kinase domain, and cytoplasmic tail.  The initial discovery that amplification and subsequent overexpression of the HER-2/neu oncogene plays a pivotal role in the pathogenesis of 20%-25% of breast cancers has since led to significant clin. advances in the management of this subtype of breast cancer.  The first approved HER2-targeted therapy, trastuzumab, is a humanized monoclonal antibody against the extracellular domain of HER2 and has demonstrated survival benefits in both the metastatic and adjuvant settings.  Lapatinib, a small mol. tyrosine kinase inhibitor of both the epidermal growth factor receptor (EGFR) and HER2 is now also approved for advanced HER2-amplified breast cancer and is currently being evaluated in the adjuvant setting.  Importantly, lapatinib has been shown to have activity in women with HER2-amplified breast cancer that is refractory to trastuzumab.  In addn., it has been shown to extend survival in the front-line setting in combination with letrozole for estrogen receptor (ER) pos., HER2-pos. breast cancer.  Here we will review the biol. rationale and pre-clin. data that drove its initial clin. development as well as current clin. data and ongoing studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV28DyXQ6Q-7Vg90H21EOLACvtfcHk0ljoPgt_qzb7BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyjtL8%253D&md5=f3b89fd99ad860e54295a844c9f29502</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.4137%2FCMT.S3783&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4137%252FCMT.S3783%26sid%3Dliteratum%253Aachs%26aulast%3DTsang%26aufirst%3DR.%2BY.%26aulast%3DSadeghi%26aufirst%3DS.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DLapatinib%252C%2520a%2520dual-targeted%2520small%2520molecule%2520inhibitor%2520of%2520EGFR%2520and%2520HER2%252C%2520in%2520HER2-amplified%2520breast%2520cancer%253A%2520from%2520bench%2520to%2520bedside%26jtitle%3DClin.%2520Med.%2520Insights%253A%2520Ther.%26date%3D2011%26volume%3D3%26spage%3D1%26epage%3D13%26doi%3D10.4137%2FCMT.S3783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Hurvitz, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Current approaches and future directions in the treatment of HER2-positive breast cancer</span> <span class="citation_source-journal">Cancer Treat. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">219</span><span class="NLM_x">–</span> <span class="NLM_lpage">229</span><span class="refDoi"> DOI: 10.1016/j.ctrv.2012.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.ctrv.2012.04.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=22658319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVSqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2013&pages=219-229&author=S.+A.+Hurvitzauthor=Y.+Huauthor=N.+O%E2%80%99Brienauthor=R.+S.+Finn&title=Current+approaches+and+future+directions+in+the+treatment+of+HER2-positive+breast+cancer&doi=10.1016%2Fj.ctrv.2012.04.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Current approaches and future directions in the treatment of HER2-positive breast cancer</span></div><div class="casAuthors">Hurvitz, Sara A.; Hu, Yufang; O'Brien, Neil; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">219-229</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Human epidermal growth factor receptor 2 (HER2), a member of the ErbB family of transmembrane receptor tyrosine kinases, is amplified in 20-30% of invasive breast cancers.  HER2 amplification is assocd. with metastasis and reduced survival.  Two HER2-directed therapies have been approved by the United States Food and Drug Administration for the treatment of HER2-overexpressing breast cancer: trastuzumab, a humanized monoclonal antibody against the extracellular portion of HER2; and lapatinib, a dual HER2- and epidermal growth factor receptor-specific tyrosine kinase inhibitor.  Despite the improvement in overall survival with the addn. of HER2-targeted agents to chemotherapy, many patients do not benefit from these agents because of inherent resistance.  In addn., many patients who achieve an initial response eventually acquire drug resistance.  Currently, several mechanisms of resistance have been described, including mutations in other signaling pathways, expression of a truncated form of HER2, receptor crosstalk, and autophagy.  There are several approaches under study to target these pathways of resistance, including blocking PI3 kinase and mammalian target of rapamycin signaling, blocking neoangiogenesis and the vascular endothelial growth factor axis, using monoclonal antibody targeting of the HER2 dimerization site, and using HER2 monoclonal antibody-drug conjugates.  Here we will review the current scientific rationale for these agents and how combinations of these agents may yield additive or synergistic effects and lead to improved outcomes for patients with HER2-amplified breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2Y-gBEc20hLVg90H21EOLACvtfcHk0lhVgY4MIHTzPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVSqsro%253D&md5=4a664c8a6e359cc85a7bb188416f49bd</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2012.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2012.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DHurvitz%26aufirst%3DS.%2BA.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DN.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DCurrent%2520approaches%2520and%2520future%2520directions%2520in%2520the%2520treatment%2520of%2520HER2-positive%2520breast%2520cancer%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2013%26volume%3D39%26spage%3D219%26epage%3D229%26doi%3D10.1016%2Fj.ctrv.2012.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hicks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trumpp-Kallmeyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">12022</span><span class="NLM_x">–</span> <span class="NLM_lpage">12027</span><span class="refDoi"> DOI: 10.1073/pnas.95.20.12022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor&doi=10.1073%2Fpnas.95.20.12022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0lhVgY4MIHTzPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027%26doi%3D10.1073%2Fpnas.95.20.12022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Mechanism of action of erbB tyrosine kinase inhibitors</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">139</span><span class="refDoi"> DOI: 10.1016/S0014-4827(02)00095-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS0014-4827%2802%2900095-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=12648472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitVyltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2003&pages=131-139&author=D.+W.+Fry&title=Mechanism+of+action+of+erbB+tyrosine+kinase+inhibitors&doi=10.1016%2FS0014-4827%2802%2900095-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of action of erbB tyrosine kinase inhibitors</span></div><div class="casAuthors">Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">131-139</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">A review.  Over the last decade, drug discovery efforts have generated a myriad of compds. that inhibit the activity of the erbB family of tyrosine kinases with potencies and selectivity that have surpassed original expectations.  These characteristics, along with improved pharmaceutical properties, have enabled inhibitors from this class of agents to finally realize their therapeutic potential, and indeed, some are currently producing significant clin. responses.  Interestingly, those properties that are essential for a clin. active inhibitor of the erbB family are most readily attained with compds. that bind at the ATP site, and the most successful compds. have shown a distinct convergence to certain common chem. features.  The reasons for this trend are beginning to be realized through the generation of an increasing array of cryst. structures for protein kinases as well as advances in mol. modeling.  This has allowed a more complete understanding of the precise phys. interactions that occur between erbB tyrosine kinase inhibitors and their target(s), which, in turn, has begun to shed light on the mechanism by which these mols. attain their remarkable affinity and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-o5XCjZZQdLVg90H21EOLACvtfcHk0lguyBLi2U5vsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitVyltL8%253D&md5=09c10abfc9a8e91617f468393b2d449a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0014-4827%2802%2900095-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-4827%252802%252900095-2%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DMechanism%2520of%2520action%2520of%2520erbB%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2003%26volume%3D284%26spage%3D131%26epage%3D139%26doi%3D10.1016%2FS0014-4827%2802%2900095-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrusin, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slintak, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliot, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patmore, S. J.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[<i>d</i>]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1803</span><span class="NLM_x">–</span> <span class="NLM_lpage">1815</span><span class="refDoi"> DOI: 10.1021/jm9806603</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9806603" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=1803-1815&author=J.+B.+Smaillauthor=B.+D.+Palmerauthor=G.+W.+Rewcastleauthor=W.+A.+Dennyauthor=D.+J.+McNamaraauthor=E.+M.+Dobrusinauthor=A.+J.+Bridgesauthor=H.+Zhouauthor=H.+D.+H.+Showalterauthor=R.+T.+Wintersauthor=W.+R.+Leopoldauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=V.+Slintakauthor=W.+L.+Elliotauthor=B.+J.+Robertsauthor=P.+W.+Vincentauthor=S.+J.+Patmore&title=Tyrosine+kinase+inhibitors.+15.+4-%28Phenylamino%29quinazoline+and+4-%28phenylamino%29pyrido%5Bd%5Dpyrimidine+acrylamides+as+irreversible+inhibitors+of+the+ATP+binding+site+of+the+epidermal+growth+factor+receptor&doi=10.1021%2Fjm9806603"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm9806603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9806603%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSlintak%26aufirst%3DV.%26aulast%3DElliot%26aufirst%3DW.%2BL.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DPatmore%26aufirst%3DS.%2BJ.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252015.%25204-%2528Phenylamino%2529quinazoline%2520and%25204-%2528phenylamino%2529pyrido%255Bd%255Dpyrimidine%2520acrylamides%2520as%2520irreversible%2520inhibitors%2520of%2520the%2520ATP%2520binding%2520site%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D1803%26epage%3D1815%26doi%3D10.1021%2Fjm9806603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges,  A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeJohn, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greis, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, O. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lipka, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides bearing additional solubilizing functions</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">43</span><span class="NLM_x">, </span> <span class="NLM_fpage">1380</span><span class="NLM_x">–</span> <span class="NLM_lpage">1397</span><span class="refDoi"> DOI: 10.1021/jm990482t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=+Bridgesauthor=H.+Zhouauthor=H.+D.+H.+Showalterauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=W.+L.+Elliottauthor=P.+W.+Vincentauthor=D.+DeJohnauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+17.+Irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions&doi=10.1021%2Fjm990482t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions</span></div><div class="casAuthors">Smaill, Jeff B.; Rewcastle, Gordon W.; Loo, Joseph A.; Greis, Kenneth D.; Chan, O. Helen; Reyner, Eric L.; Lipka, Elke; Showalter, H. D. Hollis; Vincent, Patrick W.; Elliott, William L.; Denny, William A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1380-1397</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-Anilinoquinazoline- and 4-anilinopyrido[3,2-d]pyrimidine-6-acrylamides substituted with solubilizing 7-alkylamine or 7-alkoxyamine side chains were prepd. by reaction of the corresponding 6-amines with acrylic acid or acrylic acid anhydrides.  In the pyrido[3,2-d]pyrimidine series, the intermediate 6-amino-7-alkylamines were prepd. from 7-bromo-6-fluoropyrido[3,2-d]pyrimidine via Stille coupling with the appropriate stannane under palladium(0) catalysis.  This proved a versatile method for the introduction of cationic solubilizing side chains.  The compds. were evaluated for their inhibition of phosphorylation of the isolated EGFR enzyme and for inhibition of EGF-stimulated autophosphorylation of EGFR in A431 cells and of heregulin-stimulated autophosphorylation of erbB2 in MDA-MB 453 cells.  Quinazoline analogs with 7-alkoxyamine solubilizing groups were potent irreversible inhibitors of the isolated EGFR enzyme, with IC50[app] values from 2 to 4 nM, and potently inhibited both EGFR and erbB2 autophosphorylation in cells. 7-Alkylamino- and 7-alkoxyaminopyrido[3,2-d]pyrimidines were also irreversible inhibitors with equal or superior potency against the isolated enzyme but were less effective in the cellular autophosphorylation assays.  Both quinazoline- and pyrido[3,2-d]pyrimidine-6-acrylamides bound at the ATP site alkylating cysteine 773, as shown by electrospray ionization mass spectrometry, and had similar rates of absorptive and secretory transport in Caco-2 cells.  A comparison of two 7-propoxymorpholide analogs showed that the pyrido[3,2-d]pyrimidine-6-acrylamide had greater amide instability and higher acrylamide reactivity, being converted to glutathione adducts in cells more rapidly than the corresponding quinazoline.  This difference may contribute to the obsd. lower cellular potency of the pyrido[3,2-d]pyrimidine-6-acrylamides.  Selected compds. showed high in vivo activity against A431 xenografts on oral dosing, with the quinazolines being superior to the pyrido[3,2-d]pyrimidines. Overall, the quinazolines proved superior to previous analogs in terms of aq. soly., potency, and in vivo antitumor activity, and one example (CI 1033) has been selected for clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpF5L1nBGlu6rVg90H21EOLACvtfcHk0lguyBLi2U5vsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhs1Crtr0%253D&md5=6c569a822c398df08559abde31a1d4ac</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DBridges%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DDeJohn%26aufirst%3DD.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252017.%2520Irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397%26doi%3D10.1021%2Fjm990482t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-<i>d</i>]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">440</span><span class="refDoi"> DOI: 10.1021/jm000372i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm000372i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=429-440&author=J.+B.+Smaillauthor=H.+D.+H.+Showalterauthor=H.+Zhouauthor=A.+J.+Bridgesauthor=D.+J.+McNamaraauthor=D.+W.+Fryauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=P.+W.+Vincentauthor=B.+J.+Robertsauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+18.+6-Substituted+4-anilinoquinazolines+and+4-anilinopyrido%5B3%2C4-d%5Dpyrimidines+as+soluble%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor&doi=10.1021%2Fjm000372i"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm000372i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm000372i%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252018.%25206-Substituted%25204-anilinoquinazolines%2520and%25204-anilinopyrido%255B3%252C4-d%255Dpyrimidines%2520as%2520soluble%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D429%26epage%3D440%26doi%3D10.1021%2Fjm000372i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Klutchko, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amato, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meade, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherwood, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pace, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smaill, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-<i>d</i>]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">1475</span><span class="NLM_x">–</span> <span class="NLM_lpage">1485</span><span class="refDoi"> DOI: 10.1021/jm050936o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050936o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=1475-1485&author=S.+R.+Klutchkoauthor=H.+Zhouauthor=R.+T.+Wintersauthor=T.+P.+Tranauthor=A.+J.+Bridgesauthor=I.+W.+Althausauthor=D.+M.+Amatoauthor=W.+L.+Elliottauthor=P.+A.+Ellisauthor=M.+A.+Meadeauthor=B.+J.+Robertsauthor=D.+W.+Fryauthor=A.+J.+Gonzalesauthor=P.+J.+Harveyauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=H.+K.+Hanauthor=G.+Paceauthor=J.+B.+Smaillauthor=W.+A.+Dennyauthor=H.+D.+H.+Showalter&title=Tyrosine+kinase+inhibitors.+19.+6-Alkynamides+of+4-anilinoquinazolines+and+4-anilinopyrido%5B3%2C4-d%5Dpyrimidines+as+irreversible+inhibitors+of+the+erbB+family+of+tyrosine+kinase+receptors&doi=10.1021%2Fjm050936o"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm050936o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050936o%26sid%3Dliteratum%253Aachs%26aulast%3DKlutchko%26aufirst%3DS.%2BR.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DTran%26aufirst%3DT.%2BP.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DAmato%26aufirst%3DD.%2BM.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DMeade%26aufirst%3DM.%2BA.%26aulast%3DRoberts%26aufirst%3DB.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DHan%26aufirst%3DH.%2BK.%26aulast%3DPace%26aufirst%3DG.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252019.%25206-Alkynamides%2520of%25204-anilinoquinazolines%2520and%25204-anilinopyrido%255B3%252C4-d%255Dpyrimidines%2520as%2520irreversible%2520inhibitors%2520of%2520the%2520erbB%2520family%2520of%2520tyrosine%2520kinase%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D1475%26epage%3D1485%26doi%3D10.1021%2Fjm050936o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hollander, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husain, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitchen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnick, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span> </span><span class="NLM_article-title">Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785)</span> <span class="citation_source-journal">Biochem. Pharmacol. (Amsterdam, Neth.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">917</span><span class="NLM_x">–</span> <span class="NLM_lpage">925</span><span class="refDoi"> DOI: 10.1016/S0006-2952(98)00356-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS0006-2952%2898%2900356-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1999&pages=917-925&author=C.+M.+Discafaniauthor=M.+L.+Carrollauthor=M.+B.+Floydauthor=I.+J.+Hollanderauthor=Z.+Husainauthor=B.+D.+Johnsonauthor=D.+Kitchenauthor=M.+K.+Mayauthor=M.+S.+Maloauthor=A.+A.+Minnickauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.-F.+Wangauthor=A.+Wissnerauthor=L.+M.+Greenberger&title=Irreversible+inhibition+of+epidermal+growth+factor+receptor+tyrosine+kinase+with+in+vivo+activity+by+N-%5B4-%283-bromophenyl%29amino%5D-6-quinazolinyl%5D-2-butynamide+%28CL-387%2C785%29&doi=10.1016%2FS0006-2952%2898%2900356-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2898%2900356-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252898%252900356-6%26sid%3Dliteratum%253Aachs%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DCarroll%26aufirst%3DM.%2BL.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DHollander%26aufirst%3DI.%2BJ.%26aulast%3DHusain%26aufirst%3DZ.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DKitchen%26aufirst%3DD.%26aulast%3DMay%26aufirst%3DM.%2BK.%26aulast%3DMalo%26aufirst%3DM.%2BS.%26aulast%3DMinnick%26aufirst%3DA.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26atitle%3DIrreversible%2520inhibition%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520with%2520in%2520vivo%2520activity%2520by%2520N-%255B4-%25283-bromophenyl%2529amino%255D-6-quinazolinyl%255D-2-butynamide%2520%2528CL-387%252C785%2529%26jtitle%3DBiochem.%2520Pharmacol.%2520%2528Amsterdam%252C%2520Neth.%2529%26date%3D1999%26volume%3D57%26spage%3D917%26epage%3D925%26doi%3D10.1016%2FS0006-2952%2898%2900356-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeBlanc, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehn, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2734</span><span class="refDoi"> DOI: 10.1021/jm0005555</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0005555" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFChsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2719-2734&author=H.-R.+Tsouauthor=N.+Mamuyaauthor=B.+D.+Johnsonauthor=M.+F.+Reichauthor=B.+C.+Gruberauthor=F.+Yeauthor=R.+Nilakantanauthor=R.+Shenauthor=C.+Discafaniauthor=R.+DeBlancauthor=R.+Davisauthor=F.+E.+Koehnauthor=L.+M.+Greenbergerauthor=Y.+F.+Wangauthor=A.+Wissner&title=6-Substituted-4-%283-bromophenylamino%29quinazolines+as+putative+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+human+epidermal+growth+factor+receptor+%28HER-2%29+tyrosine+kinases+with+enhanced+antitumor+activity&doi=10.1021%2Fjm0005555"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">6-Substituted-4-(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity</span></div><div class="casAuthors">Tsou, Hwei-Ru; Mamuya, Nellie; Johnson, Bernard D.; Reich, Marvin F.; Gruber, Brian C.; Ye, Fei; Nilakantan, Ramaswamy; Shen, Ru; Discafani, Carolyn; DeBlanc, Ronald; Davis, Rachel; Koehn, Frank E.; Greenberger, Lee M.; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2719-2734</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of new 6-substituted-4-(3-bromophenylamino)quinazoline derivs. that may function as irreversible inhibitors of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases have been prepd.  These inhibitors have, at the C-6 position, butynamide, crotonamide, and methacrylamide Michael acceptors bearing water-solubilizing substituents.  These compds. were prepd. by acylation of 6-amino-4-(3-bromophenylamino)quinazoline with unsatd. acid chlorides or mixed anhydrides.  We show that attaching a basic functional group onto the Michael acceptor results in greater reactivity, due to intramol. catalysis of the Michael addn. and/or an inductive effect of the protonated basic group. This, along with improved water soly., results in compds. with enhanced biol. properties.  We present mol. modeling and exptl. evidence that these inhibitors interact covalently with the target enzymes.  One compd., (I) was shown to have excellent oral activity in a human epidermoid carcinoma (A431) xenograft model in nude mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVl-zt4kiGDrVg90H21EOLACvtfcHk0ljrZMiQkb2CAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFChsb8%253D&md5=989e6e77195324d92e70ca13f532e1cf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm0005555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0005555%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDeBlanc%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DKoehn%26aufirst%3DF.%2BE.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3D6-Substituted-4-%25283-bromophenylamino%2529quinazolines%2520as%2520putative%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520%2528HER-2%2529%2520tyrosine%2520kinases%2520with%2520enhanced%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2719%26epage%3D2734%26doi%3D10.1021%2Fjm0005555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H.-R.</span><span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of 6, 7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1021/jm020241c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.-F.+Wangauthor=L.+M.+Greenbergerauthor=H.-R.+Tsou&title=Synthesis+and+structure-activity+relationships+of+6%2C+7-disubstituted+4-anilinoquinoline-3-carbonitriles.+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29&doi=10.1021%2Fjm020241c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.-R.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%25206%252C%25207-disubstituted%25204-anilinoquinoline-3-carbonitriles.%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63%26doi%3D10.1021%2Fjm020241c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Tsou, H.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek-Klumpers, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michalak, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upeslacis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Optimization of 6, 7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1107</span><span class="NLM_x">–</span> <span class="NLM_lpage">1131</span><span class="refDoi"> DOI: 10.1021/jm040159c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C+7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity&doi=10.1021%2Fjm040159c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C%25207-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131%26doi%3D10.1021%2Fjm040159c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shewchuk, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brignola, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brashear, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caferro, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donaldson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassell, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reno, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadepalli, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulrich, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagner, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderwall, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waterson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uehling, D. E.</span><span> </span><span class="NLM_article-title">6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of erbB kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2773</span><span class="NLM_x">–</span> <span class="NLM_lpage">2778</span><span class="refDoi"> DOI: 10.1073/pnas.0708281105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1073%2Fpnas.0708281105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=18287036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjtVSjtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2773-2778&author=E.+R.+Woodauthor=L.+M.+Shewchukauthor=B.+Ellisauthor=P.+Brignolaauthor=R.+L.+Brashearauthor=T.+R.+Caferroauthor=S.+H.+Dickersonauthor=H.+D.+Dicksonauthor=K.+H.+Donaldsonauthor=M.+Gaulauthor=R.+J.+Griffinauthor=A.+M.+Hassellauthor=B.+Keithauthor=R.+Mullinauthor=K.+G.+Petrovauthor=M.+J.+Renoauthor=D.+W.+Rusnakauthor=S.+M.+Tadepalliauthor=J.+C.+Ulrichauthor=C.+D.+Wagnerauthor=D.+E.+Vanderwallauthor=A.+G.+Watersonauthor=J.+D.+Williamsauthor=W.+L.+Whiteauthor=D.+E.+Uehling&title=6-Ethynylthieno%5B3%2C2-d%5D-+and+6-ethynylthieno%5B2%2C3-d%5Dpyrimidin-4-anilines+as+tunable+covalent+modifiers+of+erbB+kinases&doi=10.1073%2Fpnas.0708281105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases</span></div><div class="casAuthors">Wood, Edgar R.; Shewchuk, Lisa M.; Ellis, Byron; Brignola, Perry; Brashear, Ronald L.; Caferro, Thomas R.; Dickerson, Scott H.; Dickson, Hamilton D.; Donaldson, Kelly H.; Gaule, Michael; Griffin, Robert J.; Hassell, Anne M.; Keith, Barry; Mullin, Robert; Petrov, Kimberly G.; Reno, Michael J.; Rusnak, David W.; Tadepalli, Sarva M.; Ulrich, John C.; Wagner, Craig D.; Vanderwall, Dana E.; Waterson, Alex G.; Williams, Jon D.; White, Wendy L.; Uehling, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2773-2778</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Anal. of the x-ray crystal structure of mono-substituted acetylenic thienopyrimidine 6 complexed with the ErbB family enzyme ErbB-4 revealed a covalent bond between the terminal carbon of the acetylene moiety and the sulfhydryl group of Cys-803 at the solvent interface.  The identification of this covalent adduct suggested that acetylenic thienopyrimidine 6 and related analogs might also be capable of forming an analogous covalent adduct with EGFR, which has a conserved cysteine (797) near the ATP binding pocket.  To test this hypothesis, we treated a truncated, catalytically competent form of EGFR (678-1020) with a structurally related propargylic amine (8).  An investigation of the resulting complex by mass spectrometry revealed the formation of a covalent complex of thienopyrimidine 8 with Cys-797 of EGFR.  This finding enabled us to readily assess the irreversibility of various inhibitors and also facilitated a structure-activity relation understanding of the covalent modifying potential and biol. activity of a series of acetylenic thienopyrimidine compds. with potent antitumor activity.  Several ErbB family enzyme and cell potent 6-ethynyl thienopyrimidine kinase inhibitors were found to form covalent adducts with EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNoM38Ky48ELVg90H21EOLACvtfcHk0lhH9_VXCUvgoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjtVSjtbw%253D&md5=fbfeeff1f03e8f7fb2c9e228231ff92e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0708281105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0708281105%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DShewchuk%26aufirst%3DL.%2BM.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DBrignola%26aufirst%3DP.%26aulast%3DBrashear%26aufirst%3DR.%2BL.%26aulast%3DCaferro%26aufirst%3DT.%2BR.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DDickson%26aufirst%3DH.%2BD.%26aulast%3DDonaldson%26aufirst%3DK.%2BH.%26aulast%3DGaul%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DHassell%26aufirst%3DA.%2BM.%26aulast%3DKeith%26aufirst%3DB.%26aulast%3DMullin%26aufirst%3DR.%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DReno%26aufirst%3DM.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DTadepalli%26aufirst%3DS.%2BM.%26aulast%3DUlrich%26aufirst%3DJ.%2BC.%26aulast%3DWagner%26aufirst%3DC.%2BD.%26aulast%3DVanderwall%26aufirst%3DD.%2BE.%26aulast%3DWaterson%26aufirst%3DA.%2BG.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26aulast%3DWhite%26aufirst%3DW.%2BL.%26aulast%3DUehling%26aufirst%3DD.%2BE.%26atitle%3D6-Ethynylthieno%255B3%252C2-d%255D-%2520and%25206-ethynylthieno%255B2%252C3-d%255Dpyrimidin-4-anilines%2520as%2520tunable%2520covalent%2520modifiers%2520of%2520erbB%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2773%26epage%3D2778%26doi%3D10.1073%2Fpnas.0708281105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Carmi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vezzosi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bordi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vacondio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silva, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lodola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La Monica, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galetti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardizzoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronini, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span> </span><span class="NLM_article-title">Novel irreversible epidermal growth factor receptor inhibitors by chemical modulation of the cysteine-trap portion</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2038</span><span class="NLM_x">–</span> <span class="NLM_lpage">2050</span><span class="refDoi"> DOI: 10.1021/jm901558p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901558p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2038-2050&author=C.+Carmiauthor=A.+Cavazzoniauthor=S.+Vezzosiauthor=F.+Bordiauthor=F.+Vacondioauthor=C.+Silvaauthor=S.+Rivaraauthor=A.+Lodolaauthor=R.+R.+Alfieriauthor=S.+La+Monicaauthor=M.+Galettiauthor=A.+Ardizzoniauthor=P.+G.+Petroniniauthor=M.+Mor&title=Novel+irreversible+epidermal+growth+factor+receptor+inhibitors+by+chemical+modulation+of+the+cysteine-trap+portion&doi=10.1021%2Fjm901558p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm901558p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901558p%26sid%3Dliteratum%253Aachs%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DCavazzoni%26aufirst%3DA.%26aulast%3DVezzosi%26aufirst%3DS.%26aulast%3DBordi%26aufirst%3DF.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DRivara%26aufirst%3DS.%26aulast%3DLodola%26aufirst%3DA.%26aulast%3DAlfieri%26aufirst%3DR.%2BR.%26aulast%3DLa%2BMonica%26aufirst%3DS.%26aulast%3DGaletti%26aufirst%3DM.%26aulast%3DArdizzoni%26aufirst%3DA.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DMor%26aufirst%3DM.%26atitle%3DNovel%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520by%2520chemical%2520modulation%2520of%2520the%2520cysteine-trap%2520portion%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2038%26epage%3D2050%26doi%3D10.1021%2Fjm901558p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Cha, M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.-O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, M. S.</span><span> </span><span class="NLM_article-title">Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">6880</span><span class="NLM_x">–</span> <span class="NLM_lpage">6888</span><span class="refDoi"> DOI: 10.1021/jm901146p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901146p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=6880-6888&author=M.+Y.+Chaauthor=K.-O.+Leeauthor=J.+W.+Kimauthor=C.+G.+Leeauthor=J.+Y.+Songauthor=Y.+H.+Kimauthor=G.+S.+Leeauthor=S.+B.+Parkauthor=M.+S.+Kim&title=Discovery+of+a+novel+Her-1%2FHer-2+dual+tyrosine+kinase+inhibitor+for+the+treatment+of+Her-1+selective+inhibitor-resistant+non-small+cell+lung+cancer&doi=10.1021%2Fjm901146p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm901146p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901146p%26sid%3Dliteratum%253Aachs%26aulast%3DCha%26aufirst%3DM.%2BY.%26aulast%3DLee%26aufirst%3DK.-O.%26aulast%3DKim%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DC.%2BG.%26aulast%3DSong%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DG.%2BS.%26aulast%3DPark%26aufirst%3DS.%2BB.%26aulast%3DKim%26aufirst%3DM.%2BS.%26atitle%3DDiscovery%2520of%2520a%2520novel%2520Her-1%252FHer-2%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520Her-1%2520selective%2520inhibitor-resistant%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D6880%26epage%3D6888%26doi%3D10.1021%2Fjm901146p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, C.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, Y.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leou, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chittimalla, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, J.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Fastforwarding hit to lead: Aurora and epidermal growth factor receptor kinase inhibitor lead identification</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4980</span><span class="NLM_x">–</span> <span class="NLM_lpage">4988</span><span class="refDoi"> DOI: 10.1021/jm1000198</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1000198" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4980-4988&author=M.+S.+Coumarauthor=C.-Y.+Chuauthor=C.-W.+Linauthor=H.-Y.+Shiaoauthor=Y.-L.+Hoauthor=R.+Reddyauthor=W.-H.+Linauthor=C.-H.+Chenauthor=Y.-H.+Pengauthor=J.-S.+Leouauthor=T.-W.+Lienauthor=C.-T.+Huangauthor=M.-Y.+Fangauthor=S.-H.+Wuauthor=J.-S.+Wuauthor=S.+K.+Chittimallaauthor=J.-S.+Songauthor=J.+T.-A.+Hsuauthor=S.-Y.+Wuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Fastforwarding+hit+to+lead%3A+Aurora+and+epidermal+growth+factor+receptor+kinase+inhibitor+lead+identification&doi=10.1021%2Fjm1000198"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm1000198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1000198%26sid%3Dliteratum%253Aachs%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DC.-W.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DHo%26aufirst%3DY.-L.%26aulast%3DReddy%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DPeng%26aufirst%3DY.-H.%26aulast%3DLeou%26aufirst%3DJ.-S.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DHuang%26aufirst%3DC.-T.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DWu%26aufirst%3DS.-H.%26aulast%3DWu%26aufirst%3DJ.-S.%26aulast%3DChittimalla%26aufirst%3DS.%2BK.%26aulast%3DSong%26aufirst%3DJ.-S.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DWu%26aufirst%3DS.-Y.%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DFastforwarding%2520hit%2520to%2520lead%253A%2520Aurora%2520and%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520inhibitor%2520lead%2520identification%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4980%26epage%3D4988%26doi%3D10.1021%2Fjm1000198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Wu, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coumar, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, W.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiao, H.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rafi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lien, T.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, K.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeh, T.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsu, J. T.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, C.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, Y.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, H.-P.</span><span> </span><span class="NLM_article-title">Design and synthesis of tetrahydropyridothieno-[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7316</span><span class="NLM_x">–</span> <span class="NLM_lpage">7326</span><span class="refDoi"> DOI: 10.1021/jm100607r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100607r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7316-7326&author=C.-H.+Wuauthor=M.+S.+Coumarauthor=C.-Y.+Chuauthor=W.-H.+Linauthor=Y.-R.+Chenauthor=C.-T.+Chenauthor=H.-Y.+Shiaoauthor=S.+Rafiauthor=S.-Y.+Wangauthor=H.+Hsuauthor=C.-H.+Chenauthor=C.-Y.+Changauthor=T.-Y.+Changauthor=T.-W.+Lienauthor=M.-Y.+Fangauthor=K.-C.+Yehauthor=C.-P.+Chenauthor=T.-K.+Yehauthor=S.-H.+Hsiehauthor=J.+T.-A.+Hsuauthor=C.-C.+Liaoauthor=Y.-S.+Chaoauthor=H.-P.+Hsieh&title=Design+and+synthesis+of+tetrahydropyridothieno-%5B2%2C3-d%5Dpyrimidine+scaffold+based+epidermal+growth+factor+receptor+%28EGFR%29+kinase+inhibitors%3A+the+role+of+side+chain+chirality+and+Michael+acceptor+group+for+maximal+potency&doi=10.1021%2Fjm100607r"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm100607r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100607r%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.-H.%26aulast%3DCoumar%26aufirst%3DM.%2BS.%26aulast%3DChu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DW.-H.%26aulast%3DChen%26aufirst%3DY.-R.%26aulast%3DChen%26aufirst%3DC.-T.%26aulast%3DShiao%26aufirst%3DH.-Y.%26aulast%3DRafi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DHsu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.-H.%26aulast%3DChang%26aufirst%3DC.-Y.%26aulast%3DChang%26aufirst%3DT.-Y.%26aulast%3DLien%26aufirst%3DT.-W.%26aulast%3DFang%26aufirst%3DM.-Y.%26aulast%3DYeh%26aufirst%3DK.-C.%26aulast%3DChen%26aufirst%3DC.-P.%26aulast%3DYeh%26aufirst%3DT.-K.%26aulast%3DHsieh%26aufirst%3DS.-H.%26aulast%3DHsu%26aufirst%3DJ.%2BT.-A.%26aulast%3DLiao%26aufirst%3DC.-C.%26aulast%3DChao%26aufirst%3DY.-S.%26aulast%3DHsieh%26aufirst%3DH.-P.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520tetrahydropyridothieno-%255B2%252C3-d%255Dpyrimidine%2520scaffold%2520based%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520kinase%2520inhibitors%253A%2520the%2520role%2520of%2520side%2520chain%2520chirality%2520and%2520Michael%2520acceptor%2520group%2520for%2520maximal%2520potency%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7316%26epage%3D7326%26doi%3D10.1021%2Fjm100607r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Allen, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span> </span><span class="NLM_article-title">CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">Suppl 16</span><span class="NLM_x">) </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span><span class="refDoi"> DOI: 10.1053/j.seminoncol.2003.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1053%2Fj.seminoncol.2003.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=14613028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2003&pages=65-78&issue=Suppl+16&author=L.+F.+Allenauthor=I.+A.+Eisemanauthor=D.+W.+Fryauthor=P.+F.+Lenehan&title=CI-1033%2C+an+irreversible+pan-erbB+receptor+inhibitor+and+its+potential+application+for+the+treatment+of+breast+cancer&doi=10.1053%2Fj.seminoncol.2003.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer</span></div><div class="casAuthors">Allen, Lee F.; Eiseman, Irene A.; Fry, David W.; Lenehan, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  The erbB family of cell surface receptor proteins consists of four members, all of which play a role in the development and growth of the normal breast.  The activity of this signaling pathway is normally tightly controlled, and dysregulation has been shown to play a significant role in the pathogenesis and progression of breast and other cancers.  The potent transforming potential of these receptors is further enhanced by the coexpression of multiple members of this receptor family, which worsens prognosis.  Therapeutic blockade of erbB-2 receptor signaling has to date been shown to be effective in only a subset of chemotherapy-resistant breast cancer patients.  CI-1033 is a highly potent and selective pan-erbB inhibitor that efficiently blocks signal transduction through all four members of the erbB receptor family.  In addn., it covalently binds to these receptors, irreversibility inhibiting them, and thereby provides for prolonged suppression of erbB receptor-mediated signaling.  Clin., it has been shown to have an acceptable side effect profile at potentially therapeutic doses and schedules.  Biomarker studies have shown target inhibition in patients, and evidence of antitumor activity has also been obsd. in phase I studies.  Given the broad expression pattern of the erbB family of receptors in solid tumors, and the important proliferative effect of co-expression of multiple erbB receptors, CI-1033, as an irreversible, pan-erbB inhibitor, has the potential to have an important role in the future treatment of breast and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnHJoa4ri9ObVg90H21EOLACvtfcHk0liZ_vBa0UHw8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrF&md5=13e9d00d8a20f3c79b4f7fe1032f07b5</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2003.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2003.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DL.%2BF.%26aulast%3DEiseman%26aufirst%3DI.%2BA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26atitle%3DCI-1033%252C%2520an%2520irreversible%2520pan-erbB%2520receptor%2520inhibitor%2520and%2520its%2520potential%2520application%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2003%26volume%3D30%26issue%3DSuppl%252016%26spage%3D65%26epage%3D78%26doi%3D10.1053%2Fj.seminoncol.2003.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Calvo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammond, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCreery, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">7112</span><span class="NLM_x">–</span> <span class="NLM_lpage">7120</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-1187</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1078-0432.CCR-04-1187" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=15534081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVKltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=7112-7120&author=E.+Calvoauthor=A.+W.+Tolcherauthor=L.+A.+Hammondauthor=A.+Patnaikauthor=J.+S.+de+Bonoauthor=I.+A.+Eisemanauthor=S.+C.+Olsonauthor=P.+F.+Lenehanauthor=H.+McCreeryauthor=P.+LoRussoauthor=E.+K.+Rowinsky&title=Administration+of+CI-1033%2C+an+irreversible+pan-erbB+tyrosine+kinase+inhibitor%2C+is+feasible+on+a+7-day+on%2C+7-day+off+schedule%3A+a+phase+I+pharmacokinetic+and+food+effect+study&doi=10.1158%2F1078-0432.CCR-04-1187"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study</span></div><div class="casAuthors">Calvo, Emiliano; Tolcher, Anthony W.; Hammond, Lisa A.; Patnaik, Amita; de Bono, Johan S.; Eiseman, Irene A.; Olson, Stephen C.; Lenehan, Peter F.; McCreery, Heather; LoRusso, Patricia; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7112-7120</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">To det. the max. tolerated dose of administrating CI-1033, an oral 4-anilinoquinazoline that irreversibly inhibits the tyrosine kinase domain of all erbB subfamilies, on an intermittent schedule, and assess the interaction of CI-1033 with food on the pharmacokinetic behavior.  Escalating doses of CI-1033 from a dose level of 300 mg/day for 7 days every other week were administered to patients with advanced solid malignancies.  Plasma concn.-time data sets from all evaluable patients were used to develop a population pharmacokinetic model.  Noncompartmental methods were used to independently assess the effect of a high-fat meal on CI-1033 absorption and bioavailability.  Twenty-four patients were treated with 69 twenty-eight day courses.  The incidence of unacceptable toxicity, principally diarrhea and skin rash, was obsd. at the 300 mg/day dose level.  At the 250 mg/day level, toxicity was manageable, and protracted administration was feasible.  A one-compartment linear model with first-order absorption and elimination adequately described the pharmacokinetic disposition.  CL/F, apparent vol. of distribution (Vd/F), and ka (mean ± relative SD) were 280 L/h ± 33%, 684 L ± 20%, and 0.35 h-1± 69%, resp.  Cmax values were achieved in 2 to 4 h.  Systemic CI-1033 exposure was largely unaffected by administration of a high-fat meal.  At 250 mg, concn. values exceeded IC50 values required for prolonged pan-erbB tyrosine kinase inhibition in preclin. assays.  The recommended dose on this schedule is 250 mg/day.  Its tolerability and the biol. relevance of concns. achieved at the maximal tolerated dose warrant consideration of disease-directed evaluations.  This intermittent treatment schedule can be used without regard to meals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6W_Q3OL3jkrVg90H21EOLACvtfcHk0liZ_vBa0UHw8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVKltL4%253D&md5=6950bba7fc378f6c7ae7b0b1a643dedf</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1187%26sid%3Dliteratum%253Aachs%26aulast%3DCalvo%26aufirst%3DE.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26aulast%3DHammond%26aufirst%3DL.%2BA.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DEiseman%26aufirst%3DI.%2BA.%26aulast%3DOlson%26aufirst%3DS.%2BC.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26aulast%3DMcCreery%26aufirst%3DH.%26aulast%3DLoRusso%26aufirst%3DP.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DAdministration%2520of%2520CI-1033%252C%2520an%2520irreversible%2520pan-erbB%2520tyrosine%2520kinase%2520inhibitor%252C%2520is%2520feasible%2520on%2520a%25207-day%2520on%252C%25207-day%2520off%2520schedule%253A%2520a%2520phase%2520I%2520pharmacokinetic%2520and%2520food%2520effect%2520study%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D7112%26epage%3D7120%26doi%3D10.1158%2F1078-0432.CCR-04-1187" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Nunes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span> </span><span class="NLM_article-title">Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">27</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.4161%2Fcbt.3.1.538" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=14749472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntFajtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=21-27&author=M.+Nunesauthor=C.+Shiauthor=L.+M.+Greenberger&title=Phosphorylation+of+extracellular+signal-regulated+kinase+1+and+2%2C+protein+kinase+B%2C+and+signal+transducer+and+activator+of+transcription+3+are+differently+inhibited+by+an+epidermal+growth+factor+receptor+inhibitor%2C+EKB-569%2C+in+tumor+cells+and+normal+human+keratinocytes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes</span></div><div class="casAuthors">Nunes, Maria; Shi, Celine; Greenberger, Lee M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-27</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">EKB-569 is an irreversible inhibitor of epidermal growth factor receptor (EGF-R) tyrosine kinase.  It inhibits EGF-induced phosphorylation of EGF-R and the growth of tumors that overexpress EGF-R in animal models.  In clin. trials, EKB-569 and all other EGF-R inhibitors cause skin rashes.  To understand the latter phenomenon, the effect of EKB-569 on EGF-R as well as downstream signaling to phosphoinositide 3-kinase-protein kinase B (AKT), extracellular signal-regulated kinase 1 and 2 (ERK1/2), or signal transducer and activator of transcription 3 (STAT3) pathways were compared in tumor cell lines and normal human keratinocytes (NHEK) grown in tissue culture.  Tumor cell lines that have high (A431 epidermoid and MDA-468 breast carcinomas) and low (MCF-7 breast carcinoma) expression of EGF-R were used.  NHEK cells express at least 15-fold less EGF-R than A431 cells.  EKB-569 was a potent inhibitor of proliferation in NHEK, A431, and MDA-468 cells (IC50 = 61, 125, and 260 nM, resp.) but not MCF-7 cells (IC50 = 3600 nM).  EKB-569 was also a potent inhibitor of EGF-induced phosphorylated EGF-R (pEGF-R) in A431 and NHEK cells (IC50 = 20-80 nM).  The redn. in pEGF-R paralleled inhibition of phosphotyrosine-705 STAT3, while the inhibition of phosphorylated AKT and phosphorylated ERK1/2 occurred at higher concns. of EKB-569 (75-500 nM) in both A431 and NHEK cells.  The effects were specific because EKB-569 did not inhibit the nuclear factor-κB pathway.  It is proposed that skin toxicity assocd. with EKB-569 is due to inhibition of EGF-R signaling.  Downstream signal transduction markers, particularly the activation status of STAT3, may be useful surrogate markers to guide clin. development of EGF-R inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyN4PdUKYOdbVg90H21EOLACvtfcHk0liZ_vBa0UHw8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntFajtA%253D%253D&md5=a54cd8d19e1806fca4174afebd0da642</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.4161%2Fcbt.3.1.538&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.3.1.538%26sid%3Dliteratum%253Aachs%26aulast%3DNunes%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DC.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26atitle%3DPhosphorylation%2520of%2520extracellular%2520signal-regulated%2520kinase%25201%2520and%25202%252C%2520protein%2520kinase%2520B%252C%2520and%2520signal%2520transducer%2520and%2520activator%2520of%2520transcription%25203%2520are%2520differently%2520inhibited%2520by%2520an%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%252C%2520EKB-569%252C%2520in%2520tumor%2520cells%2520and%2520normal%2520human%2520keratinocytes%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D21%26epage%3D27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Chan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaloge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Silovski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gokmen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Minckwitz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ejlertsen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chia, S. K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mansi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gnant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryce, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, M.</span><span> </span><span class="NLM_article-title">Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span><span class="NLM_issue">suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">33</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=33&issue=suppl&author=A.+Chanauthor=S.+Delalogeauthor=F.+A.+Holmesauthor=B.+Moyauthor=H.+Iwataauthor=V.+J.+Harveyauthor=N.+J.+Robertauthor=T.+Silovskiauthor=E.+Gokmenauthor=G.+Von+Minckwitzauthor=B.+Ejlertsenauthor=S.+K.+L.+Chiaauthor=J.+Mansiauthor=C.+H.+Barriosauthor=M.+Gnantauthor=A.+Wongauthor=R.+Bryceauthor=B.+Yaoauthor=M.+Martin&title=Neratinib+after+adjuvant+chemotherapy+and+trastuzumab+in+HER2-positive+early+breast+cancer%3A+Primary+analysis+at+2+years+of+a+phase+3%2C+randomized%2C+placebo-controlled+trial+%28ExteNET%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DA.%26aulast%3DDelaloge%26aufirst%3DS.%26aulast%3DHolmes%26aufirst%3DF.%2BA.%26aulast%3DMoy%26aufirst%3DB.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DHarvey%26aufirst%3DV.%2BJ.%26aulast%3DRobert%26aufirst%3DN.%2BJ.%26aulast%3DSilovski%26aufirst%3DT.%26aulast%3DGokmen%26aufirst%3DE.%26aulast%3DVon%2BMinckwitz%26aufirst%3DG.%26aulast%3DEjlertsen%26aufirst%3DB.%26aulast%3DChia%26aufirst%3DS.%2BK.%2BL.%26aulast%3DMansi%26aufirst%3DJ.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DA.%26aulast%3DBryce%26aufirst%3DR.%26aulast%3DYao%26aufirst%3DB.%26aulast%3DMartin%26aufirst%3DM.%26atitle%3DNeratinib%2520after%2520adjuvant%2520chemotherapy%2520and%2520trastuzumab%2520in%2520HER2-positive%2520early%2520breast%2520cancer%253A%2520Primary%2520analysis%2520at%25202%2520years%2520of%2520a%2520phase%25203%252C%2520randomized%252C%2520placebo-controlled%2520trial%2520%2528ExteNET%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26issue%3Dsuppl%26spage%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Solca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoephel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanderson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraemer, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Himmelsbach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haaksma, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adolf, G. R.</span><span> </span><span class="NLM_article-title">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible erbB family blocker</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">343</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">350</span><span class="refDoi"> DOI: 10.1124/jpet.112.197756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1124%2Fjpet.112.197756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=22888144" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2012&pages=342-350&author=F.+Solcaauthor=G.+Dahlauthor=A.+Zoephelauthor=G.+Baderauthor=M.+Sandersonauthor=C.+Kleinauthor=O.+Kraemerauthor=F.+Himmelsbachauthor=E.+Haaksmaauthor=G.+R.+Adolf&title=Target+binding+properties+and+cellular+activity+of+afatinib+%28BIBW+2992%29%2C+an+irreversible+erbB+family+blocker&doi=10.1124%2Fjpet.112.197756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker</span></div><div class="casAuthors">Solca, Flavio; Dahl, Goeran; Zoephel, Andreas; Bader, Gerd; Sanderson, Michael; Klein, Christian; Kraemer, Oliver; Himmelsbach, Frank; Haaksma, Eric; Adolf, Guenther R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">342-350</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Deregulation of the ErbB (proto-oncogene B of the avian erythroblastosis virus AEV-H strain) receptor network is well recognized as an oncogenic driver in epithelial cancers.  Several targeted drugs have been developed, including antibodies and small-mol. kinase inhibitors, each of them characterized by distinct patterns of ErbB receptor interactions.  Understanding the precise pharmacol. properties of these compds. is important for optimal use in clin. practice.  Afatinib [BIBW 2992; N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide] is an ATP-competitive anilinoquinazoline deriv. harboring a reactive acrylamide group.  It was designed to covalently bind and irreversibly block enzymically active ErbB receptor family members.  Here, we show by X-ray crystallog. the covalent binding of afatinib to wild-type epidermal growth factor receptor (EGFR) and by mass spectrometry the covalent interaction with EGFR, EGFRL858R/T790M, human epidermal growth factor receptor 2 (HER2), and ErbB-4.  Afatinib potently inhibits the enzymatic activity of ErbB-4 (EC50 = 1 nM) and the proliferation of cancer cell lines driven by multiple ErbB receptor aberrations at concns. below 100 nM.  N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butanamide (BI 37781), a close analog of afatinib lacking the acrylamide group and thus incapable of covalent bond formation, had similar potency on cells driven by EGFR or EGFRL858R, but less or no detectable activity on cells expressing EGFRL858R/T790M HER2 or ErbB-4.  These results stress the importance of the acrylamide group and show that afatinib differs from approved ErbB targeting agents by irreversibly inhibiting the kinase activity of all ErbB family members.  They provide a mechanistic rationale for the distinct pharmacol. features of this compd. and explain the clin. activity seen in some patients who are resistant to antibody or kinase inhibitor therapy because of secondary mutations or ErbB receptor "reprogramming.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofXgQqaKXv-bVg90H21EOLACvtfcHk0ljQkUz16MTZ-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktbzE&md5=4a57df32abe8101f287fc6251f63f92d</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1124%2Fjpet.112.197756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.112.197756%26sid%3Dliteratum%253Aachs%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DZoephel%26aufirst%3DA.%26aulast%3DBader%26aufirst%3DG.%26aulast%3DSanderson%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DC.%26aulast%3DKraemer%26aufirst%3DO.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DHaaksma%26aufirst%3DE.%26aulast%3DAdolf%26aufirst%3DG.%2BR.%26atitle%3DTarget%2520binding%2520properties%2520and%2520cellular%2520activity%2520of%2520afatinib%2520%2528BIBW%25202992%2529%252C%2520an%2520irreversible%2520erbB%2520family%2520blocker%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D343%26spage%3D342%26epage%3D350%26doi%3D10.1124%2Fjpet.112.197756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Sanderson, K.</span><span> </span><span class="NLM_article-title">Irreversible kinase inhibitors gain traction</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">649</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span><span class="refDoi"> DOI: 10.1038/nrd4103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnrd4103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=649-651&author=K.+Sanderson&title=Irreversible+kinase+inhibitors+gain+traction&doi=10.1038%2Fnrd4103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnrd4103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4103%26sid%3Dliteratum%253Aachs%26aulast%3DSanderson%26aufirst%3DK.%26atitle%3DIrreversible%2520kinase%2520inhibitors%2520gain%2520traction%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D649%26epage%3D651%26doi%3D10.1038%2Fnrd4103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sordella, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godin-Heymann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okimoto, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brannigan, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Driscoll, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGinnis, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isselbacher, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">7665</span><span class="NLM_x">–</span> <span class="NLM_lpage">7670</span><span class="refDoi"> DOI: 10.1073/pnas.0502860102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1073%2Fpnas.0502860102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=15897464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=7665-7670&author=E.+L.+Kwakauthor=R.+Sordellaauthor=D.+W.+Bellauthor=N.+Godin-Heymannauthor=R.+A.+Okimotoauthor=B.+W.+Branniganauthor=P.+L.+Harrisauthor=D.+R.+Driscollauthor=P.+Fidiasauthor=T.+J.+Lynchauthor=S.+K.+Rabindranauthor=J.+P.+McGinnisauthor=A.+Wissnerauthor=S.+V.+Sharmaauthor=K.+J.+Isselbacherauthor=J.+Settlemanauthor=D.+A.+Haber&title=Irreversible+inhibitors+of+the+EGF+receptor+may+circumvent+acquired+resistance+to+gefitinib&doi=10.1073%2Fpnas.0502860102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib</span></div><div class="casAuthors">Kwak, Eunice L.; Sordella, Raffaella; Bell, Daphne W.; Godin-Heymann, Nadia; Okimoto, Ross A.; Brannigan, Brian W.; Harris, Patricia L.; Driscoll, David R.; Fidias, Panos; Lynch, Thomas J.; Rabindran, Sridhar K.; McGinnis, John P.; Wissner, Allan; Sharma, Sreenath V.; Isselbacher, Kurt J.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7665-7670</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Nonsmall cell lung cancers (NSCLCs) with activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) demonstrate dramatic, but transient, responses to the reversible tyrosine kinase inhibitors gefitinib (Iressa) and erlotinib (Tarceva).  Some recurrent tumors have a common secondary mutation in the EGFR kinase domain, T790M, conferring drug resistance, but in other cases the mechanism underlying acquired resistance is unknown.  In studying multiple sites of recurrent NSCLCs, the authors detected T790M in only a small percentage of tumor cells.  To identify addnl. mechanisms of acquired resistance to gefitinib, the authors used NSCLC cells harboring an activating EGFR mutation to generate multiple resistant clones in vitro.  These drug-resistant cells demonstrate continued dependence on EGFR and ERBB2 signaling for their viability and have not acquired secondary EGFR mutations.  However, they display increased internalization of ligand-activated EGFR, consistent with altered receptor trafficking.  Although gefitinib-resistant clones are cross-resistant to related anilinoquinazolines, they demonstrate sensitivity to a class of irreversible inhibitors of EGFR.  These inhibitors also show effective inhibition of signaling by T790M-mutant EGFR and killing of NSCLC cells with the T790M mutation.  Both mechanisms of gefitinib resistance are therefore circumvented by irreversible tyrosine kinase inhibitors.  Our findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW5BSM8yaZe7Vg90H21EOLACvtfcHk0lgXrUfD7OEN5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslOmsr0%253D&md5=f3fb866c3673fd4dff8a3f0a8c9be65b</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0502860102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0502860102%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DGodin-Heymann%26aufirst%3DN.%26aulast%3DOkimoto%26aufirst%3DR.%2BA.%26aulast%3DBrannigan%26aufirst%3DB.%2BW.%26aulast%3DHarris%26aufirst%3DP.%2BL.%26aulast%3DDriscoll%26aufirst%3DD.%2BR.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DMcGinnis%26aufirst%3DJ.%2BP.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DIsselbacher%26aufirst%3DK.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DIrreversible%2520inhibitors%2520of%2520the%2520EGF%2520receptor%2520may%2520circumvent%2520acquired%2520resistance%2520to%2520gefitinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D7665%26epage%3D7670%26doi%3D10.1073%2Fpnas.0502860102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varmus, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">Inhibition of drug- resistant mutants of ABL, KIT, and EGF receptor kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">11011</span><span class="NLM_x">–</span> <span class="NLM_lpage">11016</span><span class="refDoi"> DOI: 10.1073/pnas.0504952102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1073%2Fpnas.0504952102" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=11011-11016&author=T.+A.+Carterauthor=L.+M.+Wodickaauthor=N.+P.+Shahauthor=A.+M.+Velascoauthor=M.+A.+Fabianauthor=D.+K.+Treiberauthor=Z.+V.+Milanovauthor=C.+E.+Atteridgeauthor=W.+H.+Biggsauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=S.+A.+Mehtaauthor=H.+K.+Patelauthor=W.+Paoauthor=C.+L.+Sawyersauthor=H.+Varmusauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=Inhibition+of+drug-+resistant+mutants+of+ABL%2C+KIT%2C+and+EGF+receptor+kinases&doi=10.1073%2Fpnas.0504952102"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0504952102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0504952102%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DVarmus%26aufirst%3DH.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DInhibition%2520of%2520drug-%2520resistant%2520mutants%2520of%2520ABL%252C%2520KIT%252C%2520and%2520EGF%2520receptor%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D11011%26epage%3D11016%26doi%3D10.1073%2Fpnas.0504952102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0ljQmxlVfw7KzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rode, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heynck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peifer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klüter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weiss, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruddigkeit, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuza, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">868</span><span class="NLM_x">–</span> <span class="NLM_lpage">874</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.-H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+profiling+provides+insights+into+the+limited+activity+of+irreversible+EGFR+inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation&doi=10.1158%2F0008-5472.CAN-09-3106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0ljQmxlVfw7KzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.-H.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520profiling%2520provides%2520insights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874%26doi%3D10.1158%2F0008-5472.CAN-09-3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Kim, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, Z.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abolhoda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span> </span><span class="NLM_article-title">The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">784</span><span class="NLM_x">–</span> <span class="NLM_lpage">791</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1535-7163.MCT-11-0750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=22228822" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=784-791&author=Y.+Kimauthor=J.+Koauthor=Z.-Y.+Cuiauthor=A.+Abolhodaauthor=J.+S.+Ahnauthor=S.-H.+Ouauthor=M.-Y.+Ahnauthor=K.+Park&title=The+EGFR+T790M+mutation+in+acquired+resistance+to+an+irreversible+second-generation+EGFR+inhibitor&doi=10.1158%2F1535-7163.MCT-11-0750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor</span></div><div class="casAuthors">Kim, Youngwook; Ko, Jeonghun; Cui, ZhengYun; Abolhoda, Amir; Ahn, Jin Seok; Ou, Sai-Hong; Ahn, Myung-Ju; Park, Keunchil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">784-791</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Mol. target therapies using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as gefitinib or erlotinib, have been shown to be effective for patients with non-small cell lung cancer (NSCLC) who harbor activating mutations in EGFR.  However, these patients eventually develop resistance to the reversible TKIs, and this has led to the development of second-generation, irreversible EGFR inhibitors.  Currently, the mechanism of acquired resistance to irreversible EGFR inhibitors is not clear.  Using an in vitro cell culture system, we modeled the acquired resistance to first-line treatment with second-generation EGFR-TKIs using an EGFR-mutant NSCLC cell line.  Here, we report a mechanism of resistance involving T790M secondary mutation as well as a corresponding clin. case.  The results of these findings suggest that inhibition of EGFR by currently available second-generation EGFR-TKIs may not be sufficient to physiol. prevent the emergence of cells that are still dependent on EGFR signaling.  This finding bears important implications on the limitations of currently available second-generation EGFR-TKIs.  Mol Cancer Ther; 11(3); 784-91.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDhUxzW64OFLVg90H21EOLACvtfcHk0ljQmxlVfw7KzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKitr4%253D&md5=3cd09bb1dd73f8045b93b054c79480d3</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0750%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DKo%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DZ.-Y.%26aulast%3DAbolhoda%26aufirst%3DA.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DOu%26aufirst%3DS.-H.%26aulast%3DAhn%26aufirst%3DM.-Y.%26aulast%3DPark%26aufirst%3DK.%26atitle%3DThe%2520EGFR%2520T790M%2520mutation%2520in%2520acquired%2520resistance%2520to%2520an%2520irreversible%2520second-generation%2520EGFR%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D784%26epage%3D791%26doi%3D10.1158%2F1535-7163.MCT-11-0750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">638</span><span class="NLM_x">–</span> <span class="NLM_lpage">643</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M&doi=10.1016%2Fj.bmcl.2010.12.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0lizEbetleZo_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643%26doi%3D10.1016%2Fj.bmcl.2010.12.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.,  St</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M mediated resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=A.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M+mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DA.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M%2520mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Cross, D. A. E</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+E+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lgGgtb9ucUK1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Mitsudomi, T.; Tsai, C.; Shepherd, F.; Bazhenova, L.; Lee, J.; Chang, G.; Crino, L.; Satouchi, M.; Chu, Q.; Lawrance, R.; Cantarini, M.; Ghiorghiu, S.; Goss, G.</span><span> </span><span class="NLM_article-title">MINI16.08: AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 phase II study</span>.  <span class="citation_source-journal">J. Thorac. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span>, <span class="NLM_issue">Suppl. 2</span><span class="NLM_x">) </span> <span class="NLM_fpage">1406</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=1406&issue=Suppl.+2&author=T.+Mitsudomi&author=C.+Tsai&author=F.+Shepherd&author=L.+Bazhenova&author=J.+Lee&author=G.+Chang&author=L.+Crino&author=M.+Satouchi&author=Q.+Chu&author=R.+Lawrance&author=M.+Cantarini&author=S.+Ghiorghiu&author=G.+Goss&title=MINI16.08%3A+AZD9291+in+pre-treated+T790M+positive+advanced+NSCLC%3A+AURA2+phase+II+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMitsudomi%26aufirst%3DT.%26atitle%3DMINI16.08%253A%2520AZD9291%2520in%2520pre-treated%2520T790M%2520positive%2520advanced%2520NSCLC%253A%2520AURA2%2520phase%2520II%2520study%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26issue%3DSuppl.%25202%26spage%3D1406" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Zinner, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemunaitis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H. J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donato, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, D. M.</span><span> </span><span class="NLM_article-title">Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in Patients with refractory cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3006</span><span class="NLM_x">–</span> <span class="NLM_lpage">3014</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-1958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1078-0432.CCR-06-1958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=17505003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Krt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=3006-3014&author=R.+G.+Zinnerauthor=J.+Nemunaitisauthor=I.+Eisemanauthor=H.+J.+C.+Shinauthor=S.+C.+Olsonauthor=J.+Christensenauthor=X.+Huangauthor=P.+F.+Lenehanauthor=N.+J.+Donatoauthor=D.+M.+Shin&title=Phase+I+clinical+and+pharmacodynamic+evaluation+of+oral+CI-1033+in+Patients+with+refractory+cancer&doi=10.1158%2F1078-0432.CCR-06-1958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer</span></div><div class="casAuthors">Zinner, Ralph G.; Nemunaitis, John; Eiseman, Irene; Shin, Hyung Ju C.; Olson, Stephen C.; Christensen, James; Huang, Xin; Lenehan, Peter F.; Donato, Nicholas J.; Shin, Dong M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3006-3014</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To det. the tolerability and pharmacokinetics of CI-1033 given daily for 7 days of a 21-day cycle.  Tumor response and changes in erbB receptor tyrosine kinase activity in tumor and skin tissue were examd., and modulation of potential biomarkers in plasma was explored.  Design: This was a dose-finding phase I study in patients with advanced solid malignancies.  Patients were evaluated for safety, pharmacokinetics, and tumor response.  Pharmacodynamic markers, such as Ki67, p27, and erbB receptor status, were assessed in tumor and skin tissue using immunohistochem. and immunopptn. methodologies.  Plasma biomarkers HER2, vascular endothelial growth factor, interleukin-8, and matrix metalloproteinase-9 were evaluated using immunol. techniques.  Results: Fifty-three patients were enrolled in the study.  Dose-limiting toxicity (emesis, persistent rash, and mouth ulcer) was obsd. at 750 mg.  The max. tolerated dose was 650 mg.  There were no confirmed objective responses.  CI-1033 treatment showed down-regulation of epidermal growth factor receptor, HER2, and Ki67 in a variety of tumor tissues and up regulation of p27 in skin tissue.  Plasma HER2 was reduced following CI-1033 administration, but no consistent change in vascular endothelial growth factor, interleukin-8, or matrix metalloproteinase-9 was noted.  CI-1033 plasma concns. were proportional to dose.  Conclusion: The safety and pharmacokinetic profile of CI-1033 was favorable for multidose oral administration.  Evidence of modulation of erbB receptor activity in tumor and skin tissue was accompanied by changes in markers of proliferation and cell cycle inhibition.  Addnl. clin. trials are warranted in defining the role of CI-1033 in the treatment of cancer and further assessing the utility of antitumor markers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPny5s9HKAYLVg90H21EOLACvtfcHk0lgGgtb9ucUK1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Krt7w%253D&md5=d7cbd945bb7242152a2afe580dc4f0bf</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-1958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-1958%26sid%3Dliteratum%253Aachs%26aulast%3DZinner%26aufirst%3DR.%2BG.%26aulast%3DNemunaitis%26aufirst%3DJ.%26aulast%3DEiseman%26aufirst%3DI.%26aulast%3DShin%26aufirst%3DH.%2BJ.%2BC.%26aulast%3DOlson%26aufirst%3DS.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26aulast%3DDonato%26aufirst%3DN.%2BJ.%26aulast%3DShin%26aufirst%3DD.%2BM.%26atitle%3DPhase%2520I%2520clinical%2520and%2520pharmacodynamic%2520evaluation%2520of%2520oral%2520CI-1033%2520in%2520Patients%2520with%2520refractory%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D3006%26epage%3D3014%26doi%3D10.1158%2F1078-0432.CCR-06-1958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Nemunaitis, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cunningham, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senzer, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bycott, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlicht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zentgraff, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zinner, R. G.</span><span> </span><span class="NLM_article-title">Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">3846</span><span class="NLM_x">–</span> <span class="NLM_lpage">3853</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-04-1950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1078-0432.CCR-04-1950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=15897585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFyru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=3846-3853&author=J.+Nemunaitisauthor=I.+Eisemanauthor=C.+Cunninghamauthor=N.+Senzerauthor=A.+Williamsauthor=P.+F.+Lenehanauthor=S.+C.+Olsonauthor=P.+Bycottauthor=M.+Schlichtauthor=R.+Zentgraffauthor=D.+M.+Shinauthor=R.+G.+Zinner&title=Phase+1+clinical+and+pharmacokinetics+evaluation+of+oral+CI-1033+in+patients+with+refractory+cancer&doi=10.1158%2F1078-0432.CCR-04-1950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer</span></div><div class="casAuthors">Nemunaitis, John; Eiseman, Irene; Cunningham, Casey; Senzer, Neil; Williams, Adrienne; Lenehan, Peter F.; Olson, Stephen C.; Bycott, Paul; Schlicht, Michael; Zentgraff, Rebecca; Shin, Dong M.; Zinner, Ralph G.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3846-3853</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: To det. the tolerability and pharmacokinetics of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, administered over 14 consecutive days of a 21-day cycle.  Design: Phase 1, multicenter trial involving patients with solid tumors that are refractory to std. therapy.  CI-1033 was administered initially at 300 mg/day to a min. cohort of three patients.  Dose escalation proceeded at ≤40% increments.  Patients were evaluated for toxicity, pharmacokinetic profile, and evidence of response.  Results: Thirty-two patients entered the trial and were evaluable for safety assessment.  Dose-limiting toxicity (diarrhea, rash, and/or anorexia) occurred at the 560 mg dose level; the max. tolerated dose was 450 mg.  No patients achieved objective responses and six patients achieved stable disease.  Plasma CI-1033 concns. increased with increasing dose.  CI-1033 was not eliminated in urine to any appreciable extent.  Conclusions: CI-1033 is suitable for phase 2 testing at the 450 mg/day dose level when administered for 14 days in a 21-day cycle.  The pharmacokinetic profile is consistent with biol. relevant plasma concns. over the dosing interval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyQ3ltoWKM9rVg90H21EOLACvtfcHk0lgHUcJz-_SVTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFyru7Y%253D&md5=efeb265dd0a8eba66ce6dd9308bd3123</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-04-1950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-04-1950%26sid%3Dliteratum%253Aachs%26aulast%3DNemunaitis%26aufirst%3DJ.%26aulast%3DEiseman%26aufirst%3DI.%26aulast%3DCunningham%26aufirst%3DC.%26aulast%3DSenzer%26aufirst%3DN.%26aulast%3DWilliams%26aufirst%3DA.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26aulast%3DOlson%26aufirst%3DS.%2BC.%26aulast%3DBycott%26aufirst%3DP.%26aulast%3DSchlicht%26aufirst%3DM.%26aulast%3DZentgraff%26aufirst%3DR.%26aulast%3DShin%26aufirst%3DD.%2BM.%26aulast%3DZinner%26aufirst%3DR.%2BG.%26atitle%3DPhase%25201%2520clinical%2520and%2520pharmacokinetics%2520evaluation%2520of%2520oral%2520CI-1033%2520in%2520patients%2520with%2520refractory%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D3846%26epage%3D3853%26doi%3D10.1158%2F1078-0432.CCR-04-1950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Hur, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velentza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flatauer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valente, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagorska, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiDonato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balk, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peters, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5916</span><span class="NLM_x">–</span> <span class="NLM_lpage">5919</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.bmcl.2008.07.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=18667312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7vM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=5916-5919&author=W.+Hurauthor=A.+Velentzaauthor=S.+Kimauthor=L.+Flatauerauthor=X.+Jiangauthor=D.+Valenteauthor=D.+E.+Masonauthor=M.+Suzukiauthor=B.+Larsonauthor=J.+Zhangauthor=A.+Zagorskaauthor=M.+DiDonatoauthor=A.+Nagleauthor=M.+Warmuthauthor=S.+P.+Balkauthor=E.+C.+Petersauthor=N.+S.+Gray&title=Clinical+stage+EGFR+inhibitors+irreversibly+alkylate+Bmx+kinase&doi=10.1016%2Fj.bmcl.2008.07.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase</span></div><div class="casAuthors">Hur, Wooyoung; Velentza, Anastasia; Kim, Sungjoon; Flatauer, Laura; Jiang, Xinnong; Valente, David; Mason, Daniel E.; Suzuki, Melissa; Larson, Brad; Zhang, Jianming; Zagorska, Anna; DiDonato, Michael; Nagle, Advait; Warmuth, Markus; Balk, Steven P.; Peters, Eric C.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5916-5919</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Irreversible HER/erbB inhibitors selectively inhibit HER-family kinases by targeting a unique cysteine residue located within the ATP-binding pocket.  Sequence alignment reveals that this rare cysteine is also present in ten other protein kinases including all five Tec-family members.  We demonstrate that the Tec-family kinase Bmx is potently inhibited by irreversible modification at Cys496 by clin. stage EGFR inhibitors such as CI-1033.  This cross-reactivity may have significant clin. implications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_hlFgn2jwY7Vg90H21EOLACvtfcHk0lgHUcJz-_SVTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlOht7vM&md5=2f704e42920d0a18f9dfdcc688347f0a</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.062%26sid%3Dliteratum%253Aachs%26aulast%3DHur%26aufirst%3DW.%26aulast%3DVelentza%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DFlatauer%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DValente%26aufirst%3DD.%26aulast%3DMason%26aufirst%3DD.%2BE.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DLarson%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZagorska%26aufirst%3DA.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DBalk%26aufirst%3DS.%2BP.%26aulast%3DPeters%26aufirst%3DE.%2BC.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DClinical%2520stage%2520EGFR%2520inhibitors%2520irreversibly%2520alkylate%2520Bmx%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D5916%26epage%3D5919%26doi%3D10.1016%2Fj.bmcl.2008.07.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lhbva_7qe7l_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Campos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamid, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seiden, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oza, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plante, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potkul, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldjian, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varterasian, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charbonneau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirte, H.</span><span> </span><span class="NLM_article-title">Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5597</span><span class="NLM_x">–</span> <span class="NLM_lpage">5604</span><span class="refDoi"> DOI: 10.1200/JCO.2005.08.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1200%2FJCO.2005.08.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16110019" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVersr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5597-5604&author=S.+Camposauthor=O.+Hamidauthor=M.+V.+Seidenauthor=A.+Ozaauthor=M.+Planteauthor=R.+K.+Potkulauthor=P.+F.+Lenehanauthor=E.+P.+Kaldjianauthor=M.+L.+Varterasianauthor=C.+Jordanauthor=C.+Charbonneauauthor=H.+Hirte&title=Multicenter%2C+randomized+phase+II+trial+of+oral+CI-1033+for+previously+treated+advanced+ovarian+cancer&doi=10.1200%2FJCO.2005.08.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer</span></div><div class="casAuthors">Campos, Susana; Hamid, Oday; Seiden, Michael V.; Oza, Amit; Plante, Marie; Potkul, Ronald K.; Lenehan, Peter F.; Kaldjian, Eric P.; Varterasian, Mary L.; Jordan, Cheryl; Charbonneau, Claudie; Hirte, Hal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5597-5604</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: To evaluate the antitumor activity and toxicity of two doses of CI-1033 in patients with platinum-refractory or recurrent ovarian cancer, and to det. baseline expression of epidermal growth factor receptor in tumor cells.  Patients and Methods: This phase II, open-label clin. trial evaluated CI-1033 in patients with ovarian cancer who failed prior platinum-based therapy.  Two oral doses of CI-1033 were evaluated-a 50-mg and a 200-mg oral dose administered daily for 21 days in a 28-day cycle.  Patients were evaluated for tumor response and toxicity; in addn., archival baseline tumor samples were analyzed by immunohistochem. for erbB1 to erbB4 status.  Results: One hundred five eligible patients were treated.  Baseline demog. characteristics were balanced in this heavily pretreated patient population.  The median no. of prior chemotherapy regimens received was four.  The most commonly encountered drug-related adverse events for both dose arms were gastrointestinal (diarrhea, nausea, stomatitis) toxicity, asthenia, and rash.  No responses were obsd.  Stable disease was confirmed in 34% and 26% of patients in the 200-mg and 50-mg arms, resp., and 1-yr survival rates were 38.5% and 37.7%, resp.  Baseline erbB3 and erbB4 revealed the highest frequencies of expression, while erbB2 was the lowest.  Conclusion: CI-1033 did not show activity in unscreened patients with advanced ovarian cancer.  At 50 mg/d, CI-1033 had a more favorable adverse events profile than at 200 mg/d.  ErbB3 and erbB4 receptors showed the highest expression in tumor samples while erbB2 revealed the least.  There appears to be no assocn. between baseline erbB expression and disease stability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQbgq5slTwJLVg90H21EOLACvtfcHk0lhbva_7qe7l_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVersr%252FL&md5=35cb9a35e064461ad1bbf3097ee09de8</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.08.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.08.091%26sid%3Dliteratum%253Aachs%26aulast%3DCampos%26aufirst%3DS.%26aulast%3DHamid%26aufirst%3DO.%26aulast%3DSeiden%26aufirst%3DM.%2BV.%26aulast%3DOza%26aufirst%3DA.%26aulast%3DPlante%26aufirst%3DM.%26aulast%3DPotkul%26aufirst%3DR.%2BK.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26aulast%3DKaldjian%26aufirst%3DE.%2BP.%26aulast%3DVarterasian%26aufirst%3DM.%2BL.%26aulast%3DJordan%26aufirst%3DC.%26aulast%3DCharbonneau%26aufirst%3DC.%26aulast%3DHirte%26aufirst%3DH.%26atitle%3DMulticenter%252C%2520randomized%2520phase%2520II%2520trial%2520of%2520oral%2520CI-1033%2520for%2520previously%2520treated%2520advanced%2520ovarian%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5597%26epage%3D5604%26doi%3D10.1200%2FJCO.2005.08.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogs as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">918</span><span class="NLM_x">–</span> <span class="NLM_lpage">928</span><span class="refDoi"> DOI: 10.1021/jm950692f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm950692f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=918-928&author=G.+W.+Rewcastleauthor=B.+D.+Palmerauthor=A.+J.+Bridgesauthor=H.+D.+H.+Showalterauthor=L.+Sunauthor=J.+Nelsonauthor=A.+McMichaelauthor=A.+J.+Krakerauthor=D.+W.+Fryauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+9.+Synthesis+and+evaluation+of+fused+tricyclic+quinazoline+analogs+as+ATP+site+inhibitors+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor&doi=10.1021%2Fjm950692f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm950692f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm950692f%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DNelson%26aufirst%3DJ.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%25209.%2520Synthesis%2520and%2520evaluation%2520of%2520fused%2520tricyclic%2520quinazoline%2520analogs%2520as%2520ATP%2520site%2520inhibitors%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D918%26epage%3D928%26doi%3D10.1021%2Fjm950692f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cody, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-Bromophenyl)amino]pyrido[<i>d</i>]pyrimidines Are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">1823</span><span class="NLM_x">–</span> <span class="NLM_lpage">1835</span><span class="refDoi"> DOI: 10.1021/jm9508651</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9508651" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=1823-1835&author=G.+W.+Rewcastleauthor=B.+D.+Palmerauthor=A.+M.+Thompsonauthor=A.+J.+Bridgesauthor=D.+R.+Codyauthor=H.+Zhouauthor=D.+W.+Fryauthor=A.+McMichaelauthor=W.+A.+Denny&title=Tyrosine+Kinase+Inhibitors.+10.+Isomeric+4-%5B%283-Bromophenyl%29amino%5Dpyrido%5Bd%5Dpyrimidines+Are+Potent+ATP+Binding+Site+Inhibitors+of+the+Tyrosine+Kinase+Function+of+the+Epidermal+Growth+Factor+Receptor&doi=10.1021%2Fjm9508651"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm9508651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9508651%26sid%3Dliteratum%253Aachs%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DCody%26aufirst%3DD.%2BR.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520Kinase%2520Inhibitors.%252010.%2520Isomeric%25204-%255B%25283-Bromophenyl%2529amino%255Dpyrido%255Bd%255Dpyrimidines%2520Are%2520Potent%2520ATP%2520Binding%2520Site%2520Inhibitors%2520of%2520the%2520Tyrosine%2520Kinase%2520Function%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D1823%26epage%3D1835%26doi%3D10.1021%2Fjm9508651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Erlichman, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidalgo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boni, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zacharchuk, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amorusi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">2252</span><span class="NLM_x">–</span> <span class="NLM_lpage">2260</span><span class="refDoi"> DOI: 10.1200/JCO.2005.01.8960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1200%2FJCO.2005.01.8960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16710023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvV2ksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=2252-2260&author=C.+Erlichmanauthor=M.+Hidalgoauthor=J.+P.+Boniauthor=P.+Martinsauthor=S.+E.+Quinnauthor=C.+Zacharchukauthor=P.+Amorusiauthor=A.+A.+Adjeiauthor=E.+K.+Rowinsky&title=Phase+I+study+of+EKB-569%2C+an+irreversible+inhibitor+of+the+epidermal+growth+factor+receptor%2C+in+patients+with+advanced+solid+tumors&doi=10.1200%2FJCO.2005.01.8960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors</span></div><div class="casAuthors">Erlichman, Charles; Hidalgo, Manuel; Boni, Joseph P.; Martins, Patricia; Quinn, Susan E.; Zacharchuk, Charles; Amorusi, Peter; Adjei, Alex A.; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2252-2260</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">The max. tolerated dose (MTD) and the dose-limiting toxicities of EKB-569, a selective, irreversible inhibitor of the epidermal growth factor receptor (EGFR), when administered orally once daily on an intermittent-dose schedule (14 days of a 28-day cycle) or on a continuous-dose schedule (each day of a 28-day cycle), were detd. in patients with advanced solid tumors.  Planned dose escalation was 25, 50, 75, 125, 175, and 225 mg.  Pharmacokinetic sampling was performed on days 1 and 14 for the intermittent-dose cohort and on days 1 and 15 for the continuous-dose cohort.  Thirty patients received a median of two cycles (range, one to 10 cycles) in the intermittent-dose cohort; 29 patients received a median of three cycles (range, one to eight cycles) in the continuous-dose cohort.  Dose-limiting toxicity was grade 3 diarrhea, and the MTD was 75 mg EKB-569 per day for both cohorts.  Other common toxicities included rash, nausea, and asthenia.  Exposure to EKB-569 was dose proportional.  At the MTD, the mean ± std. deviation terminal half-life was 21.7 ± 4.2 h and peak concn. increased 1.2-fold from day 1 to day 14/15.  No major antitumor responses were obsd.  However, one patient with non-small-cell lung cancer and one with cutaneous squamous cell carcinoma had stable disease for 33 and 24 wk, resp.  The MTD of once-daily oral EKB-569 is 75 mg.  The tolerable toxicity profile and long half-life of this irreversible EGFR inhibitor warrant its further evaluation as a single agent and in combination with other drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoWU_wd20ORbVg90H21EOLACvtfcHk0ljfDQOScDpHvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvV2ksLk%253D&md5=3a7766538e63808314fe4ea73b5f766d</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.01.8960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.01.8960%26sid%3Dliteratum%253Aachs%26aulast%3DErlichman%26aufirst%3DC.%26aulast%3DHidalgo%26aufirst%3DM.%26aulast%3DBoni%26aufirst%3DJ.%2BP.%26aulast%3DMartins%26aufirst%3DP.%26aulast%3DQuinn%26aufirst%3DS.%2BE.%26aulast%3DZacharchuk%26aufirst%3DC.%26aulast%3DAmorusi%26aufirst%3DP.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DPhase%2520I%2520study%2520of%2520EKB-569%252C%2520an%2520irreversible%2520inhibitor%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D2252%26epage%3D2260%26doi%3D10.1200%2FJCO.2005.01.8960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Cockerill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubberfield, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stables, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guntrip, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKeown, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomsen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jowett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woollard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spalding, D.</span><span> </span><span class="NLM_article-title">Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1401</span><span class="NLM_x">–</span> <span class="NLM_lpage">1405</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00219-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS0960-894X%2801%2900219-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1401-1405&author=S.+Cockerillauthor=C.+Stubberfieldauthor=J.+Stablesauthor=M.+Carterauthor=S.+Guntripauthor=K.+Smithauthor=S.+McKeownauthor=R.+Shawauthor=P.+Topleyauthor=L.+Thomsenauthor=K.+Affleckauthor=A.+Jowettauthor=D.+Hayesauthor=M.+Willsonauthor=P.+Woollardauthor=D.+Spalding&title=Indazolylamino+quinazolines+and+pyridopyrimidines+as+inhibitors+of+the+EGFr+and+c-erbB-2&doi=10.1016%2FS0960-894X%2801%2900219-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900219-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900219-0%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DS.%26aulast%3DStubberfield%26aufirst%3DC.%26aulast%3DStables%26aufirst%3DJ.%26aulast%3DCarter%26aufirst%3DM.%26aulast%3DGuntrip%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DMcKeown%26aufirst%3DS.%26aulast%3DShaw%26aufirst%3DR.%26aulast%3DTopley%26aufirst%3DP.%26aulast%3DThomsen%26aufirst%3DL.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DJowett%26aufirst%3DA.%26aulast%3DHayes%26aufirst%3DD.%26aulast%3DWillson%26aufirst%3DM.%26aulast%3DWoollard%26aufirst%3DP.%26aulast%3DSpalding%26aufirst%3DD.%26atitle%3DIndazolylamino%2520quinazolines%2520and%2520pyridopyrimidines%2520as%2520inhibitors%2520of%2520the%2520EGFr%2520and%2520c-erbB-2%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1401%26epage%3D1405%26doi%3D10.1016%2FS0960-894X%2801%2900219-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Gaul, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Affleck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guntrip, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knight, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullin, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadepalli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span> </span><span class="NLM_article-title">Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">637</span><span class="NLM_x">–</span> <span class="NLM_lpage">640</span><span class="refDoi"> DOI: 10.1016/S0960-894X(02)01047-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS0960-894X%2802%2901047-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=637-640&author=M.+D.+Gaulauthor=Y.+Guoauthor=K.+Affleckauthor=G.+S.+Cockerillauthor=T.+M.+Gilmerauthor=R.+J.+Griffinauthor=S.+Guntripauthor=B.+R.+Keithauthor=W.+B.+Knightauthor=R.+J.+Mullinauthor=D.+M.+Murrayauthor=D.+W.+Rusnakauthor=K.+Smithauthor=S.+Tadepalliauthor=E.+R.+Woodauthor=K.+Lackey&title=Discovery+and+Biological+Evaluation+of+Potent+Dual+ErbB-2%2FEGFR+Tyrosine+Kinase+Inhibitors%3A+6-Thiazolylquinazolines&doi=10.1016%2FS0960-894X%2802%2901047-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2901047-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252901047-8%26sid%3Dliteratum%253Aachs%26aulast%3DGaul%26aufirst%3DM.%2BD.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DAffleck%26aufirst%3DK.%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DGriffin%26aufirst%3DR.%2BJ.%26aulast%3DGuntrip%26aufirst%3DS.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DKnight%26aufirst%3DW.%2BB.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DMurray%26aufirst%3DD.%2BM.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DTadepalli%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DLackey%26aufirst%3DK.%26atitle%3DDiscovery%2520and%2520Biological%2520Evaluation%2520of%2520Potent%2520Dual%2520ErbB-2%252FEGFR%2520Tyrosine%2520Kinase%2520Inhibitors%253A%25206-Thiazolylquinazolines%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D637%26epage%3D640%26doi%3D10.1016%2FS0960-894X%2802%2901047-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Zhang, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guntrip, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vanderwall, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K.</span><span> </span><span class="NLM_article-title">Synthesis and SAR of potent EGFR/erbB2 dual inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">114</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2003.10.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.bmcl.2003.10.010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=111-114&author=Y.-M.+Zhangauthor=S.+Cockerillauthor=S.+B.+Guntripauthor=D.+Rusnakauthor=K.+Smithauthor=D.+Vanderwallauthor=E.+Woodauthor=K.+Lackey&title=Synthesis+and+SAR+of+potent+EGFR%2FerbB2+dual+inhibitors&doi=10.1016%2Fj.bmcl.2003.10.010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.10.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.10.010%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.-M.%26aulast%3DCockerill%26aufirst%3DS.%26aulast%3DGuntrip%26aufirst%3DS.%2BB.%26aulast%3DRusnak%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DK.%26aulast%3DVanderwall%26aufirst%3DD.%26aulast%3DWood%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520potent%2520EGFR%252FerbB2%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D111%26epage%3D114%26doi%3D10.1016%2Fj.bmcl.2003.10.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Petrov, K. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cockerill, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickerson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gauthier, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lackey, K. E.</span><span> </span><span class="NLM_article-title">Optimization and SAR for dual erbB-1/erbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4686</span><span class="NLM_x">–</span> <span class="NLM_lpage">4691</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.05.090</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.bmcl.2006.05.090" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=16777410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4686-4691&author=K.+G.+Petrovauthor=Y.-M.+Zhangauthor=M.+Carterauthor=G.+S.+Cockerillauthor=S.+Dickersonauthor=C.+A.+Gauthierauthor=Y.+Guoauthor=R.+A.+Mookauthor=D.+W.+Rusnakauthor=A.+L.+Walkerauthor=E.+R.+Woodauthor=K.+E.+Lackey&title=Optimization+and+SAR+for+dual+erbB-1%2FerbB-2+tyrosine+kinase+inhibition+in+the+6-furanylquinazoline+series&doi=10.1016%2Fj.bmcl.2006.05.090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series</span></div><div class="casAuthors">Petrov, Kimberly G.; Zhang, Yue-Mei; Carter, Malcolm; Cockerill, G. Stuart; Dickerson, Scott; Gauthier, Cassandra A.; Guo, Yu; Mook, Robert A.; Rusnak, David W.; Walker, Ann L.; Wood, Edgar R.; Lackey, Karen E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4686-4691</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino structure provided the best enzyme potency and cellular selectivity.  Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy.  The discovery of lapatinib emerged from this work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtejUjyH9in7Vg90H21EOLACvtfcHk0lgU4MVj-B_wmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnsFOlu7o%253D&md5=946712927ab1a7940ea3ef2fea7574b5</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.05.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.05.090%26sid%3Dliteratum%253Aachs%26aulast%3DPetrov%26aufirst%3DK.%2BG.%26aulast%3DZhang%26aufirst%3DY.-M.%26aulast%3DCarter%26aufirst%3DM.%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26aulast%3DDickerson%26aufirst%3DS.%26aulast%3DGauthier%26aufirst%3DC.%2BA.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DWalker%26aufirst%3DA.%2BL.%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DLackey%26aufirst%3DK.%2BE.%26atitle%3DOptimization%2520and%2520SAR%2520for%2520dual%2520erbB-1%252FerbB-2%2520tyrosine%2520kinase%2520inhibition%2520in%2520the%25206-furanylquinazoline%2520series%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4686%26epage%3D4691%26doi%3D10.1016%2Fj.bmcl.2006.05.090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hook, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaney, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amato, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loi, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fakhoury, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlosser, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winters, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lettiere, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tecle, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span> </span><span class="NLM_article-title">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1880</span><span class="NLM_x">–</span> <span class="NLM_lpage">1889</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1535-7163.MCT-07-2232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=18606718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1880-1889&author=A.+J.+Gonzalesauthor=K.+E.+Hookauthor=I.+W.+Althausauthor=P.+A.+Ellisauthor=E.+Trachetauthor=A.+M.+Delaneyauthor=P.+J.+Harveyauthor=T.+A.+Ellisauthor=D.+M.+Amatoauthor=J.+M.+Nelsonauthor=D.+W.+Fryauthor=T.+Zhuauthor=C.-M.+Loiauthor=S.+A.+Fakhouryauthor=K.+M.+Schlosserauthor=K.+E.+Sextonauthor=R.+T.+Wintersauthor=J.+E.+Reedauthor=A.+J.+Bridgesauthor=D.+J.+Lettiereauthor=D.+A.+Bakerauthor=J.+Yangauthor=H.+T.+Leeauthor=H.+Tecleauthor=P.+W.+Vincent&title=Antitumor+activity+and+pharmacokinetic+properties+of+PF-00299804%2C+a+second-generation+irreversible+pan-erbB+receptor+tyrosine+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-07-2232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Gonzales, Andrea J.; Hook, Kenneth E.; Althaus, Irene W.; Ellis, Paul A.; Trachet, Erin; Delaney, Amy M.; Harvey, Patricia J.; Ellis, Teresa A.; Amato, Danielle M.; Nelson, James M.; Fry, David W.; Zhu, Tong; Loi, Cho-Ming; Fakhoury, Stephen A.; Schlosser, Kevin M.; Sexton, Karen E.; Winters, R. Thomas; Reed, Jessica E.; Bridges, Alex J.; Lettiere, Daniel J.; Baker, Deborah A.; Yang, Jianxin; Lee, Helen T.; Tecle, Haile; Vincent, Patrick W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1880-1889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types.  Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments.  PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor currently in phase I clin. trials.  PF-00299804 is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members.  Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) assocd. with resistance to gefitinib and erlotinib.  Furthermore, PF-00299804 shows exceptional distribution to human tumor xenografts and excellent pharmacokinetic properties across species. [Mol Cancer Ther 2008;7(7):1880-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbL0hP8K2G37Vg90H21EOLACvtfcHk0ljmROtbcV-nog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D&md5=3392275d1e4f4d5d70e3b22d4893e3c8</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2232%26sid%3Dliteratum%253Aachs%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DEllis%26aufirst%3DT.%2BA.%26aulast%3DAmato%26aufirst%3DD.%2BM.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DLoi%26aufirst%3DC.-M.%26aulast%3DFakhoury%26aufirst%3DS.%2BA.%26aulast%3DSchlosser%26aufirst%3DK.%2BM.%26aulast%3DSexton%26aufirst%3DK.%2BE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DLettiere%26aufirst%3DD.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacokinetic%2520properties%2520of%2520PF-00299804%252C%2520a%2520second-generation%2520irreversible%2520pan-erbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1880%26epage%3D1889%26doi%3D10.1158%2F1535-7163.MCT-07-2232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span> </span><span class="NLM_article-title">Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition</span> <span class="citation_source-journal">Structure</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1016/j.str.2012.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2Fj.str.2012.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=23273428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFeq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=209-219&author=K.+S.+Gajiwalaauthor=J.+Fengauthor=R.+Ferreauthor=K.+Ryanauthor=O.+Brodskyauthor=S.+Weinrichauthor=J.+C.+Kathauthor=A.+Stewart&title=Insights+into+the+aberrant+activity+of+mutant+EGFR+kinase+domain+and+drug+recognition&doi=10.1016%2Fj.str.2012.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition</span></div><div class="casAuthors">Gajiwala, Ketan S.; Feng, Junli; Ferre, RoseAnn; Ryan, Kevin; Brodsky, Oleg; Weinrich, Scott; Kath, John C.; Stewart, Al</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-219</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The oncogenicity of the L858R mutant form of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer is thought to be due to the constitutive activation of its kinase domain.  The selectivity of the marketed drugs gefitinib and erlotinib for L858R mutant is attributed to their specific recognition of the active kinase and to weaker ATP binding by L858R EGFR.  We present crystal structures showing that neither L858R nor the drug-resistant L858R+T790M EGFR kinase domain is in the constitutively active conformation.  Addnl. co-crystal structures show that gefitinib and dacomitinib, an irreversible anilinoquinazoline deriv. currently in clin. development, may not be conformation specific for the active state of the enzyme.  Structural data further reveal the potential mode of recognition of one of the autophosphorylation sites in the C-terminal tail, Tyr-1016, by the kinase domain.  Biochem. and biophys. evidence suggest that the oncogenic mutations impact the conformational dynamics of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi6kAQLM6h7LVg90H21EOLACvtfcHk0lhmojD2ArF9GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFeq&md5=439bfda2e4e33786a15742e53cc271bc</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DWeinrich%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DStewart%26aufirst%3DA.%26atitle%3DInsights%2520into%2520the%2520aberrant%2520activity%2520of%2520mutant%2520EGFR%2520kinase%2520domain%2520and%2520drug%2520recognition%26jtitle%3DStructure%26date%3D2013%26volume%3D21%26spage%3D209%26epage%3D219%26doi%3D10.1016%2Fj.str.2012.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an irreversible pan-erbB inhibitor, is effective in lung cancer models with EGFR and erbB2 mutations that are resistant to gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F0008-5472.CAN-07-1885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=18089823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjs7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+irreversible+pan-erbB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+erbB2+mutations+that+are+resistant+to+gefitinib&doi=10.1158%2F0008-5472.CAN-07-1885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Gale, Christopher-Michael; Lifshits, Eugene; Gonzales, Andrea J.; Shimamura, Takeshi; Zhao, Feng; Vincent, Patrick W.; Naumov, George N.; Bradner, James E.; Althaus, Irene W.; Gandhi, Leena; Shapiro, Geoffrey I.; Nelson, James M.; Heymach, John V.; Meyerson, Matthew; Wong, Kwok-Kin; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11924-11932</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective treatments for a subset of non-small cell lung cancers.  In particular, cancers with specific EGFR-activating mutations seem to be the most sensitive to these agents.  However, despite their initial response, such cancers almost invariably develop resistance.  In 50% of such cancers, a secondary EGFR mutation, T790M, has been identified that renders gefitinib and erlotinib ineffective inhibitors of EGFR kinase activity.  Thus, there is a clin. need to develop novel EGFR inhibitors that can effectively inactivate T790M-contg. EGFR proteins.  In this study, we evaluate the effectiveness of a novel compd., PF00299804, an irreversible pan-ERBB inhibitor.  The results from these studies show that PF00299804 is a potent inhibitor of EGFR-activating mutations as well as the EGFR T790M resistance mutation both in vitro and in vivo.  Addnl., PF00299804 is a highly effective inhibitor of both the wild-type ERBB2 and the gefitinib-resistant oncogenic ERBB2 mutation identified in lung cancers.  These preclin. evaluations support further clin. development of PF00299804 for cancers with mutations and/or amplifications of ERBB family members. [Cancer Res 2007;67(24):11924-32].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq02Cx_x26RirVg90H21EOLACvtfcHk0lhmojD2ArF9GA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjs7nL&md5=c210cf2fb3d1479df5915d317259696f</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1885%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520irreversible%2520pan-erbB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520erbB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932%26doi%3D10.1158%2F0008-5472.CAN-07-1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Ather, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamidi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fejzo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrent, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Head, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span> </span><span class="NLM_article-title">Dacomitinib, an irreversible pan-erbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e56112</span><span class="refDoi"> DOI: 10.1371/journal.pone.0056112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1371%2Fjournal.pone.0056112" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e56112&author=F.+Atherauthor=H.+Hamidiauthor=M.+S.+Fejzoauthor=S.+Letrentauthor=R.+S.+Finnauthor=F.+Kabbinavarauthor=C.+Headauthor=S.+G.+Wong&title=Dacomitinib%2C+an+irreversible+pan-erbB+inhibitor+significantly+abrogates+growth+in+head+and+neck+cancer+models+that+exhibit+low+response+to+cetuximab&doi=10.1371%2Fjournal.pone.0056112"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0056112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0056112%26sid%3Dliteratum%253Aachs%26aulast%3DAther%26aufirst%3DF.%26aulast%3DHamidi%26aufirst%3DH.%26aulast%3DFejzo%26aufirst%3DM.%2BS.%26aulast%3DLetrent%26aufirst%3DS.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26aulast%3DKabbinavar%26aufirst%3DF.%26aulast%3DHead%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DS.%2BG.%26atitle%3DDacomitinib%252C%2520an%2520irreversible%2520pan-erbB%2520inhibitor%2520significantly%2520abrogates%2520growth%2520in%2520head%2520and%2520neck%2520cancer%2520models%2520that%2520exhibit%2520low%2520response%2520to%2520cetuximab%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De56112%26doi%3D10.1371%2Fjournal.pone.0056112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Nam, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, Y.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Min, A.-R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span> </span><span class="NLM_article-title">The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2148</span><span class="NLM_x">–</span> <span class="NLM_lpage">2160</span><span class="refDoi"> DOI: 10.1007/s10637-011-9782-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1007%2Fs10637-011-9782-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2148-2160&author=H.-J.+Namauthor=H.-P.+Kimauthor=Y.-K.+Yoonauthor=S.-H.+Songauthor=A.-R.+Minauthor=S.-W.+Hanauthor=S.-A.+Imauthor=T.-Y.+Kimauthor=D.-Y.+Ohauthor=Y.-J.+Bang&title=The+irreversible+pan-HER+inhibitor+PF00299804+alone+or+combined+with+gemcitabine+has+an+antitumor+effect+in+biliary+tract+cancer+cell+lines&doi=10.1007%2Fs10637-011-9782-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1007%2Fs10637-011-9782-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-011-9782-6%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DH.-J.%26aulast%3DKim%26aufirst%3DH.-P.%26aulast%3DYoon%26aufirst%3DY.-K.%26aulast%3DSong%26aufirst%3DS.-H.%26aulast%3DMin%26aufirst%3DA.-R.%26aulast%3DHan%26aufirst%3DS.-W.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DBang%26aufirst%3DY.-J.%26atitle%3DThe%2520irreversible%2520pan-HER%2520inhibitor%2520PF00299804%2520alone%2520or%2520combined%2520with%2520gemcitabine%2520has%2520an%2520antitumor%2520effect%2520in%2520biliary%2520tract%2520cancer%2520cell%2520lines%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D2148%26epage%3D2160%26doi%3D10.1007%2Fs10637-011-9782-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Kalous, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Dacomitinib (PF-00299804), an irreversible pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1978</span><span class="NLM_x">–</span> <span class="NLM_lpage">1987</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1535-7163.MCT-11-0730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=22761403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1978-1987&author=O.+Kalousauthor=D.+Conklinauthor=A.+J.+Desaiauthor=N.+A.+O%E2%80%99Brienauthor=C.+Gintherauthor=L.+Andersonauthor=D.+J.+Cohenauthor=C.+D.+Brittenauthor=I.+Taylorauthor=J.+G.+Christensenauthor=D.+J.+Slamonauthor=R.+S.+Finn&title=Dacomitinib+%28PF-00299804%29%2C+an+irreversible+pan-HER+inhibitor%2C+inhibits+proliferation+of+HER2-amplified+breast+cancer+cell+lines+resistant+to+trastuzumab+and+lapatinib&doi=10.1158%2F1535-7163.MCT-11-0730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib</span></div><div class="casAuthors">Kalous, Ondrej; Conklin, Dylan; Desai, Amrita J.; O'Brien, Neil A.; Ginther, Charles; Anderson, Lee; Cohen, David J.; Britten, Carolyn D.; Taylor, Ian; Christensen, James G.; Slamon, Dennis J.; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1978-1987</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The human EGF (HER) family of receptors has been pursued as therapeutic targets in breast cancer and other malignancies.  Trastuzumab and lapatinib are std. treatments for HER2-amplified breast cancer, but a significant no. of patients do not respond or develop resistance to these drugs.  Here we evaluate the in vitro activity of dacomitinib (PF-00299804), an irreversible small mol. pan-HER inhibitor, in a large panel of human breast cancer cell lines with variable expression of the HER family receptors and ligands, and with variable sensitivity to trastuzumab and lapatinib.  Forty-seven human breast cancer and immortalized breast epithelial lines representing the known mol. subgroups of breast cancer were treated with dacomitinib to det. IC50 values.  HER2-amplified lines were far more likely to respond to dacomitinib than nonamplified lines (RR, 3.39; P < 0.0001).  Furthermore, HER2 mRNA and protein expression were quant. assocd. with response.  Dacomitinib reduced the phosphorylation of HER2, EGFR, HER4, AKT, and ERK in the majority of sensitive lines.  Dacomitinib exerted its antiproliferative effect through a combined G0-G1 arrest and an induction of apoptosis.  Dacomitinib inhibited growth in several HER2-amplified lines with de novo and acquired resistance to trastuzumab.  Dacomitinib maintained a high activity in lines with acquired resistance to lapatinib.  This study identifies HER2-amplified breast cancer lines as most sensitive to the antiproliferative effect of dacomitinib and provides a strong rationale for its clin. testing in HER2-amplified breast cancers resistant to trastuzumab and lapatinib.  Mol Cancer Ther; 11(9); 1978-87. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp55-QHIJqDk7Vg90H21EOLACvtfcHk0lisI7pTDy3gEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrvI&md5=b2b0677cbecb66e1e629742adffb0782</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0730%26sid%3Dliteratum%253Aachs%26aulast%3DKalous%26aufirst%3DO.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DN.%2BA.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DD.%2BJ.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DDacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520pan-HER%2520inhibitor%252C%2520inhibits%2520proliferation%2520of%2520HER2-amplified%2520breast%2520cancer%2520cell%2520lines%2520resistant%2520to%2520trastuzumab%2520and%2520lapatinib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1978%26epage%3D1987%26doi%3D10.1158%2F1535-7163.MCT-11-0730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Nam, H.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ching, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, H.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, S.-A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oh, D.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y.-J.</span><span> </span><span class="NLM_article-title">Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0494</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1158%2F1535-7163.MCT-11-0494" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=22135232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFWksr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=439-451&author=H.-J.+Namauthor=K.+A.+Chingauthor=J.+Kanauthor=H.-P.+Kimauthor=S.-W.+Hanauthor=S.-A.+Imauthor=T.-Y.+Kimauthor=J.+G.+Christensenauthor=D.-Y.+Ohauthor=Y.-J.+Bang&title=Evaluation+of+the+antitumor+effects+and+mechanisms+of+PF00299804%2C+a+pan-HER+inhibitor%2C+alone+or+in+combination+with+chemotherapy+or+targeted+agents+in+gastric+cancer&doi=10.1158%2F1535-7163.MCT-11-0494"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer</span></div><div class="casAuthors">Nam, Hyun-Jin; Ching, Keith A.; Kan, Julie; Kim, Hwang-Phill; Han, Sae-Won; Im, Seock-Ah; Kim, Tae-You; Christensen, James G.; Oh, Do-Youn; Bang, Yung-Jue</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">439-451</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recently, HER2-directed treatment, such as trastuzumab, has shown clin. benefit in HER2-amplified gastric cancer.  On the basis of recent studies about epidermal growth factor receptor (EGFR) or HER2-targeting agents (including gefitinib, lapatinib, and trastuzumab) in gastric cancer, the potent effects of pan-HER inhibitors targeting the HER family are anticipated.  In this study, we evaluated the activity and mechanisms of PF00299804, an irreversible pan-HER inhibitor, in gastric cancer in vitro and in vivo models.  PF00299804 showed significant growth-inhibitory effects in HER2-amplified gastric cancer cells (SNU216, N87), and it had lower 50% inhibitory concn. values compared with other EGFR tyrosine kinase inhibitors, including gefitinib, lapatinib, BIBW-2992, and CI-1033.  PF00299804 induced apoptosis and G1 arrest and inhibited phosphorylation of receptors in the HER family and downstream signaling pathways including STAT3, AKT, and extracellular signal-regulated kinases (ERK) in HER2-amplified gastric cancer cells.  PF00299804 also blocked EGFR/HER2, HER2/HER3, and HER3/HER4 heterodimer formation as well as the assocn. of HER3 with p85α in SNU216 cells.  The combination of PF00299804 with clin. relevant chemotherapeutic agents or mol.-targeted agents including trastuzumab (an anti-HER2 monoclonal antibody), CP751871 (an IGF1R inhibitor), PD0325901 (an ERK1/2 inhibitor), and PF04691502 (a PI3K/mTOR inhibitor) produced synergistic effects.  These findings indicate that PF00299804 can be used as a targeted therapy for the treatment of HER2-amplified gastric cancer through inhibition of HER family heterodimer formation and may augment antitumor efficacy of chemotherapeutic and/or mol.-targeted agents.  Mol Cancer Ther; 11(2); 439-51.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVUhH4_Ser5LVg90H21EOLACvtfcHk0liDJVIAe3MyCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFWksr8%253D&md5=36d48e8853974378c8d5477fe76b2260</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0494&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0494%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DH.-J.%26aulast%3DChing%26aufirst%3DK.%2BA.%26aulast%3DKan%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DH.-P.%26aulast%3DHan%26aufirst%3DS.-W.%26aulast%3DIm%26aufirst%3DS.-A.%26aulast%3DKim%26aufirst%3DT.-Y.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DOh%26aufirst%3DD.-Y.%26aulast%3DBang%26aufirst%3DY.-J.%26atitle%3DEvaluation%2520of%2520the%2520antitumor%2520effects%2520and%2520mechanisms%2520of%2520PF00299804%252C%2520a%2520pan-HER%2520inhibitor%252C%2520alone%2520or%2520in%2520combination%2520with%2520chemotherapy%2520or%2520targeted%2520agents%2520in%2520gastric%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D439%26epage%3D451%26doi%3D10.1158%2F1535-7163.MCT-11-0494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millham, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boss, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span> </span><span class="NLM_article-title">Preliminary activity and safety results from a phase I clinical trial of PF-00299804, an irreversible pan-HER inhibitor, in patients (pts) with NSCLC</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">15 Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">8027</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=8027&issue=15+Suppl&author=P.+A.+J%C3%A4nneauthor=J.+H.+Schellensauthor=J.+A.+Engelmanauthor=S.+G.+Eckhardtauthor=R.+Millhamauthor=L.+J.+Denisauthor=C.+D.+Brittenauthor=S.+G.+Wongauthor=D.+S.+Bossauthor=D.+R.+Camidge&title=Preliminary+activity+and+safety+results+from+a+phase+I+clinical+trial+of+PF-00299804%2C+an+irreversible+pan-HER+inhibitor%2C+in+patients+%28pts%29+with+NSCLC"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DMillham%26aufirst%3DR.%26aulast%3DDenis%26aufirst%3DL.%2BJ.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DWong%26aufirst%3DS.%2BG.%26aulast%3DBoss%26aufirst%3DD.%2BS.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26atitle%3DPreliminary%2520activity%2520and%2520safety%2520results%2520from%2520a%2520phase%2520I%2520clinical%2520trial%2520of%2520PF-00299804%252C%2520an%2520irreversible%2520pan-HER%2520inhibitor%252C%2520in%2520patients%2520%2528pts%2529%2520with%2520NSCLC%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26issue%3D15%2520Suppl%26spage%3D8027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millham, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span> </span><span class="NLM_article-title">PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x"> (</span><span class="NLM_issue">15 Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">7599</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=7599&issue=15+Suppl&author=K.+Parkauthor=D.+S.+Heoauthor=B.+Choauthor=D.+Kimauthor=M.+Ahnauthor=S.+Leeauthor=R.+D.+Millhamauthor=A.+Campbellauthor=H.+Zhangauthor=J.+Kim&title=PF-00299804+%28PF299%29+in+Asian+patients+%28pts%29+with+non-small+cell+lung+cancer+%28NSCLC%29+refractory+to+chemotherapy+%28CT%29+and+erlotinib+%28E%29+or+gefitinib+%28G%29%3A+A+phase+%28P%29+I%2FII+study"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DK.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCho%26aufirst%3DB.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DAhn%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DMillham%26aufirst%3DR.%2BD.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKim%26aufirst%3DJ.%26atitle%3DPF-00299804%2520%2528PF299%2529%2520in%2520Asian%2520patients%2520%2528pts%2529%2520with%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520refractory%2520to%2520chemotherapy%2520%2528CT%2529%2520and%2520erlotinib%2520%2528E%2529%2520or%2520gefitinib%2520%2528G%2529%253A%2520A%2520phase%2520%2528P%2529%2520I%252FII%2520study%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26issue%3D15%2520Suppl%26spage%3D7599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Takahashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boku, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murakami, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuya, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ono, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machida, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Imai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohki, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, N.</span><span> </span><span class="NLM_article-title">Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, −2, and −4 tyrosine kinases, in Japanese patients with advanced solid tumors</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2352</span><span class="NLM_x">–</span> <span class="NLM_lpage">2363</span><span class="refDoi"> DOI: 10.1007/s10637-011-9789-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1007%2Fs10637-011-9789-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2352-2363&author=T.+Takahashiauthor=N.+Bokuauthor=H.+Murakamiauthor=T.+Naitoauthor=A.+Tsuyaauthor=Y.+Nakamuraauthor=A.+Onoauthor=N.+Machidaauthor=K.+Yamazakiauthor=J.+Watanabeauthor=A.+Ruiz-Garciaauthor=K.+Imaiauthor=E.+Ohkiauthor=N.+Yamamoto&title=Phase+I+and+pharmacokinetic+study+of+dacomitinib+%28PF-00299804%29%2C+an+oral+irreversible%2C+small+molecule+inhibitor+of+human+epidermal+growth+factor+receptor-1%2C+%E2%88%922%2C+and+%E2%88%924+tyrosine+kinases%2C+in+Japanese+patients+with+advanced+solid+tumors&doi=10.1007%2Fs10637-011-9789-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs10637-011-9789-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-011-9789-z%26sid%3Dliteratum%253Aachs%26aulast%3DTakahashi%26aufirst%3DT.%26aulast%3DBoku%26aufirst%3DN.%26aulast%3DMurakami%26aufirst%3DH.%26aulast%3DNaito%26aufirst%3DT.%26aulast%3DTsuya%26aufirst%3DA.%26aulast%3DNakamura%26aufirst%3DY.%26aulast%3DOno%26aufirst%3DA.%26aulast%3DMachida%26aufirst%3DN.%26aulast%3DYamazaki%26aufirst%3DK.%26aulast%3DWatanabe%26aufirst%3DJ.%26aulast%3DRuiz-Garcia%26aufirst%3DA.%26aulast%3DImai%26aufirst%3DK.%26aulast%3DOhki%26aufirst%3DE.%26aulast%3DYamamoto%26aufirst%3DN.%26atitle%3DPhase%2520I%2520and%2520pharmacokinetic%2520study%2520of%2520dacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520oral%2520irreversible%252C%2520small%2520molecule%2520inhibitor%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-1%252C%2520%25E2%2588%25922%252C%2520and%2520%25E2%2588%25924%2520tyrosine%2520kinases%252C%2520in%2520Japanese%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2012%26volume%3D30%26spage%3D2352%26epage%3D2363%26doi%3D10.1007%2Fs10637-011-9789-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Brzezniak, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span> </span><span class="NLM_article-title">Dacomitinib, a new therapy for the treatment of non-small cell lung cancer</span> <span class="citation_source-journal">Expert Opin. Pharmacother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1517/14656566.2013.758714</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1517%2F14656566.2013.758714" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=23294134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVamt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=247-253&author=C.+Brzezniakauthor=C.+A.+Carterauthor=G.+Giaccone&title=Dacomitinib%2C+a+new+therapy+for+the+treatment+of+non-small+cell+lung+cancer&doi=10.1517%2F14656566.2013.758714"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">, a new therapy for the treatment of non-small cell lung cancer</span></div><div class="casAuthors">Brzezniak, Christina; Carter, Corey A.; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">247-253</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Advanced or metastatic non-small cell lung cancer (NSCLC) is characterized by a poor prognosis and few second- or third-line treatments.  First-generation reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibition (TKI) has paved the way for targeted treatment in lung cancer.  These drugs result in excellent responses in patients with activating EGFR mutations.  Unfortunately, resistance often develops.  Second-generation irreversible inhibitors hope to prevent mutational progression to a resistant clone or delay the use of alternative non-targeted therapies.Areas covered: This article focuses on the current published ongoing research using the second-generation irreversible TKI, .  The use of dacomitinib, a pan inhibitor of the HER family of tyrosine kinases, will be reviewed along with its efficacy in the advanced or metastatic NSCLC population.Expert opinion: Data available suggest dacomitinib is effective in NSCLC patients both in initial treatment and after failure of first-generation inhibitors.  Furthermore, preclin. data suggest dacomitinib can achieve responses in tumors harboring the T790M, gatekeeper mutation, present in up to 50% of tumors that have acquired resistant to first-generation inhibitors.  Its usefulness in potentially delaying development of resistant clones as well as in combination with other targeting strategies is under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWPg2gU0zXXbVg90H21EOLACvtfcHk0lhVUaSnT66PrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVamt7o%253D&md5=bd5088b56d16f6880d3b1254182a3864</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1517%2F14656566.2013.758714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2013.758714%26sid%3Dliteratum%253Aachs%26aulast%3DBrzezniak%26aufirst%3DC.%26aulast%3DCarter%26aufirst%3DC.%2BA.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DDacomitinib%252C%2520a%2520new%2520therapy%2520for%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2013%26volume%3D14%26spage%3D247%26epage%3D253%26doi%3D10.1517%2F14656566.2013.758714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, L.</span><span> </span><span class="NLM_article-title">Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">813</span><span class="NLM_x">–</span> <span class="NLM_lpage">822</span><span class="refDoi"> DOI: 10.2217/fon.14.22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.2217%2Ffon.14.22" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=24799062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsVSktbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=813-822&author=T.+Mokauthor=K.+Leeauthor=M.+Tangauthor=L.+Leung&title=Dacomitinib+for+the+treatment+of+advanced+or+metastatic+non-small-cell+lung+cancer&doi=10.2217%2Ffon.14.22"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer</span></div><div class="casAuthors">Mok, Tony; Lee, Kirsty; Tang, Michael; Leung, Linda</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">813-822</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Dacomitinib (PF-00299804) is a second-generation irreversible HER tyrosine kinase inhibitor (TKI).  In preclin. studies, dacomitinib has demonstrated anti-tumor activity in lung cancer cell lines with sensitive and resistant EGFR mutations (including the T790 mutation).  Safety and well tolerability of dacomitinib were demonstrated in Phase I studies with stomatitis, diarrhea and skin toxicities being the dose-limiting toxicities.  The max. tolerated dose was established to be 45 mg/day.  In Phase II and III studies, dacomitinib has shown clin. activity in both HER tyrosine kinase-naive and HER tyrosine kinase failure settings.  Further clin. trials are underway to evaluate the efficacy of dacomitinib in non-small-cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGjhkbZZr1U7Vg90H21EOLACvtfcHk0lhVUaSnT66PrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsVSktbw%253D&md5=9a5abeca52e35070d4d63b57e9512c76</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.2217%2Ffon.14.22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.14.22%26sid%3Dliteratum%253Aachs%26aulast%3DMok%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DLeung%26aufirst%3DL.%26atitle%3DDacomitinib%2520for%2520the%2520treatment%2520of%2520advanced%2520or%2520metastatic%2520non-small-cell%2520lung%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2014%26volume%3D10%26spage%3D813%26epage%3D822%26doi%3D10.2217%2Ffon.14.22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reckamp, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadgeel, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khuri, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denis, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">15 Suppl</span><span class="NLM_x">–</span> <span class="NLM_lpage">7596</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=15+Suppl-7596&author=A.+Campbellauthor=K.+L.+Reckampauthor=D.+R.+Camidgeauthor=G.+Giacconeauthor=S.+M.+Gadgeelauthor=F.+R.+Khuriauthor=J.+A.+Engelmanauthor=L.+J.+Denisauthor=J.+P.+O%E2%80%99Connellauthor=P.+A.+J%C3%A4nne&title=PF-00299804+%28PF299%29+patient+%28pt%29-reported+outcomes+%28PROs%29+and+efficacy+in+adenocarcinoma+%28adeno%29+and+nonadeno+non-small+cell+lung+cancer+%28NSCLC%29%3A+A+phase+%28P%29+II+trial+in+advanced+NSCLC+after+failure+of+chemotherapy+%28CT%29+and+erlotinib+%28E%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DReckamp%26aufirst%3DK.%2BL.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DGadgeel%26aufirst%3DS.%2BM.%26aulast%3DKhuri%26aufirst%3DF.%2BR.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DDenis%26aufirst%3DL.%2BJ.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%2BP.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF-00299804%2520%2528PF299%2529%2520patient%2520%2528pt%2529-reported%2520outcomes%2520%2528PROs%2529%2520and%2520efficacy%2520in%2520adenocarcinoma%2520%2528adeno%2529%2520and%2520nonadeno%2520non-small%2520cell%2520lung%2520cancer%2520%2528NSCLC%2529%253A%2520A%2520phase%2520%2528P%2529%2520II%2520trial%2520in%2520advanced%2520NSCLC%2520after%2520failure%2520of%2520chemotherapy%2520%2528CT%2529%2520and%2520erlotinib%2520%2528E%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D15%2520Suppl%26epage%3D7596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Ellis, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Millward, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perrone, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morabito, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leighl, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockler, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierzbicki, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blais, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sangha, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Favaretto, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsao, M.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goss, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, P. A.</span><span> </span><span class="NLM_article-title">Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomized, phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1379</span><span class="NLM_x">–</span> <span class="NLM_lpage">1388</span><span class="refDoi"> DOI: 10.1016/S1470-2045(14)70472-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS1470-2045%2814%2970472-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=25439692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKjtrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1379-1388&author=P.+M.+Ellisauthor=F.+A.+Shepherdauthor=M.+Millwardauthor=F.+Perroneauthor=L.+Seymourauthor=G.+Liuauthor=S.+Sunauthor=B.+C.+Choauthor=A.+Morabitoauthor=N.+B.+Leighlauthor=M.+R.+Stocklerauthor=C.+W.+Leeauthor=R.+Wierzbickiauthor=V.+Cohenauthor=N.+Blaisauthor=R.+S.+Sanghaauthor=A.+G.+Favarettoauthor=J.+H.+Kangauthor=M.-S.+Tsaoauthor=C.+F.+Wilsonauthor=Z.+Goldbergauthor=K.+Dingauthor=G.+D.+Gossauthor=P.+A.+Bradbury&title=Dacomitinib+compared+with+placebo+in+pretreated+patients+with+advanced+or+metastatic+non-small-cell+lung+cancer+%28NCIC+CTG+BR.26%29%3A+a+double-blind%2C+randomized%2C+phase+3+trial&doi=10.1016%2FS1470-2045%2814%2970472-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial</span></div><div class="casAuthors">Ellis, Peter M.; Shepherd, Frances A.; Millward, Michael; Perrone, Francesco; Seymour, Lesley; Liu, Geoffrey; Sun, Sophie; Cho, Byoung Chul; Morabito, Alessandro; Leighl, Natasha B.; Stockler, Martin R.; Lee, Christopher W.; Wierzbicki, Rafal; Cohen, Victor; Blais, Normand; Sangha, Randeep S.; Favaretto, Adolfo G.; Kang, Jin Hyoung; Tsao, Ming-Sound; Wilson, Carolyn F.; Goldberg, Zelanna; Ding, Keyue; Goss, Glenwood D.; Bradbury, Penelope Ann</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1379-1388</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclin. and clin. evidence of activity in non-small-cell lung cancer.  We designed BR.26 to assess whether dacomitinib improved overall survival in heavily pretreated patients with this disease.  In this double-blind, randomised, placebo-controlled, phase 3 trial, we enrolled adults (aged ≥18 years) with advanced or metastatic non-small-cell lung cancer from 75 centers in 12 countries.  Eligible patients had received up to three previous lines of chemotherapy and either gefitinib or erlotinib, and had assessable disease (RECIST 1.1) and tumor tissue samples for translational studies.  Patients were stratified according to center, performance status, tobacco use, best response to previous EGFR tyrosine-kinase inhibitor, wt. loss within the previous 3 mo, and ethnicity, and were then randomly allocated 2:1 to oral dacomitinib 45 mg once-daily or matched placebo centrally via a web-based system.  Treatment continued until disease progression or unacceptable toxicity.  The primary outcome was overall survival in the intention-to-treat population; secondary outcomes included overall survival in predefined mol. subgroups, progression-free survival, the proportion of patients who achieved an objective response, safety, and quality of life.  This study is completed, although follow-up is ongoing for patients on treatment.  This study is registered with ClinicalTrials.gov, no. NCT01000025.  Between Dec 23, 2009, and June 11, 2013, we randomly assigned 480 patients to dacomitinib and 240 patients to placebo.  At the final anal. (Jan., 2014), median follow-up was 23·4 mo (IQR 15·6-29·6) for patients in the dacomitinib group and 24·4 mo (11·5-38·9) for those in the placebo group.  Dacomitinib did not improve overall survival compared with placebo (median 6·83 mo [95% CI 6·08-7·49] for dacomitinib vs 6·31 mo [5·32-7·52] for placebo; hazard ratio [HR] 1·00 [95% CI 0·83-1·21]; p=0·506).  However, patients in the dacomitinib group had longer progression-free survival than those in the placebo group (median 2·66 mo [1·91-3·32] vs 1·38 mo [0·99-1·74], resp.; HR 0·66 [95% CI 0·55-0·79]; p<0·0001), and a significantly greater proportion of patients in the dacomitinb group achieved an objective response than in the placebo group (34 [7%] of 480 patients vs three [1%] of 240 patients, resp.; p=0·001).  Compared with placebo, the effect of dacomitinib on overall survival seemed similar in patients with EGFR-mutation-pos. tumors (HR 0·98, 95% CI 0·67-1·44) and EGFR wild-type tumors (0·93, 0·71-1·21; pinteraction=0·69).  However, we noted qual. differences in the effect of dacomitinib on overall survival for patients with KRAS-mutation-pos. tumors (2·10, 1·05-4·22) and patients with KRAS wild-type tumors (0·79, 0·61-1·03; pinteraction=0·08).  Compared with placebo, patients allocated dacomitinib had significantly longer time to deterioration of cough (p<0·0001), dyspnoea (p=0·049), and pain (p=0·041). 185 (39%) of 477 patients who received dacomitinib and 86 (36%) of 239 patients who received placebo had serious adverse events.  The most common grade 3-4 adverse events were diarrhoea (59 [12%] patients on dacomitinib vs no controls), acneiform rash (48 [10%] vs one [<1%]), oral mucositis (16 [3%] vs none), and fatigue (13 [3%] vs four [2%]).  Dacomitinib did not increase overall survival and cannot be recommended for treatment of patients with advanced non-small-cell lung cancer previously treated with chemotherapy and an EGFR tyrosine-kinase inhibitor.  Canadian Cancer Society Research Institute and Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSa-G6JOVCebVg90H21EOLACvtfcHk0lgt1JYIOhRhNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKjtrbI&md5=69185e91537e35ff7c45b737ed1d0ad7</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970472-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970472-3%26sid%3Dliteratum%253Aachs%26aulast%3DEllis%26aufirst%3DP.%2BM.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DMillward%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DF.%26aulast%3DSeymour%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DMorabito%26aufirst%3DA.%26aulast%3DLeighl%26aufirst%3DN.%2BB.%26aulast%3DStockler%26aufirst%3DM.%2BR.%26aulast%3DLee%26aufirst%3DC.%2BW.%26aulast%3DWierzbicki%26aufirst%3DR.%26aulast%3DCohen%26aufirst%3DV.%26aulast%3DBlais%26aufirst%3DN.%26aulast%3DSangha%26aufirst%3DR.%2BS.%26aulast%3DFavaretto%26aufirst%3DA.%2BG.%26aulast%3DKang%26aufirst%3DJ.%2BH.%26aulast%3DTsao%26aufirst%3DM.-S.%26aulast%3DWilson%26aufirst%3DC.%2BF.%26aulast%3DGoldberg%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DGoss%26aufirst%3DG.%2BD.%26aulast%3DBradbury%26aufirst%3DP.%2BA.%26atitle%3DDacomitinib%2520compared%2520with%2520placebo%2520in%2520pretreated%2520patients%2520with%2520advanced%2520or%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520%2528NCIC%2520CTG%2520BR.26%2529%253A%2520a%2520double-blind%252C%2520randomized%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1379%26epage%3D1388%26doi%3D10.1016%2FS1470-2045%2814%2970472-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krzakowski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrios, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bover, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seog Heo, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talbot, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrent, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz-Garcia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, M.</span><span> </span><span class="NLM_article-title">Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan–human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">3337</span><span class="NLM_x">–</span> <span class="NLM_lpage">3344</span><span class="refDoi"> DOI: 10.1200/JCO.2011.40.9433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1200%2FJCO.2011.40.9433" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=22753918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=3337-3344&author=S.+S.+Ramalingamauthor=F.+Blackhallauthor=M.+Krzakowskiauthor=C.+H.+Barriosauthor=K.+Parkauthor=I.+Boverauthor=D.+Seog+Heoauthor=R.+Rosellauthor=D.+C.+Talbotauthor=R.+Frankauthor=S.+P.+Letrentauthor=A.+Ruiz-Garciaauthor=I.+Taylorauthor=J.+L.+Liangauthor=A.+K.+Campbellauthor=J.+O%E2%80%99Connellauthor=M.+Boyer&title=Randomized+phase+II+study+of+dacomitinib+%28PF-00299804%29%2C+an+irreversible+pan%E2%80%93human+epidermal+growth+factor+receptor+inhibitor%2C+versus+erlotinib+in+patients+with+advanced+non-small-cell+lung+cancer&doi=10.1200%2FJCO.2011.40.9433"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study of dacomitinib (PF-00299804), and irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer</span></div><div class="casAuthors">Ramalingam, Suresh S.; Blackhall, Fiona; Krzakowski, Maciej; Barrios, Carlos H.; Park, Keunchil; Bover, Isabel; Heo, Dae Seog; Rosell, Rafael; Talbot, Denis C.; Frank, Richard; Letrent, Stephen P.; Ruiz-Garcia, Ana; Taylor, Ian; Liang, Jane Q.; Campbell, Alicyn K.; O'Connell, Joseph; Boyer, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3337-3344</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR1/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC).  Patients and Methods Patients with NSCLC, Eastern Cooperative Oncol. Group performance status 0 to 2, no prior HER-directed therapy, and one/two prior chemotherapy regimens received dacomitinib 45 mg or erlotinib 150 mg once daily.  Results One hundred eighty-eight patients were randomly assigned.  Treatment arms were balanced for most clin. and mol. characteristics.  Median progression-free survival (PFS; primary end point) was 2.86 mo for patients treated with dacomitinib and 1.91 mo for patients treated with erlotinib (hazard ratio [HR] = 0.66; 95% CI, 0.47 to 0.91; two-sided P = .012); in patients with KRAS wild-type tumors, median PFS was 3.71 mo for patients treated with dacomitinib and 1.91 mo for patients treated with erlotinib (HR = 0.55; 95% CI, 0.35 to 0.85; two-sided P = .006); and in patients with KRAS wild-type/EGFR wild-type tumors, median PFS was 2.21 mo for patients treated with dacomitinib and 1.84 mo for patients treated with erlotinib (HR = 0.61; 95% CI, 0.37 to 0.99; two-sided P = .043).  Median overall survival was 9.53 mo for patients treated with dacomitinib and 7.44 mo for patients treated with erlotinib (HR = 0.80; 95% CI, 0.56 to 1.13; two-sided P = .205).  Adverse event-related discontinuations were uncommon in both arms.  Common treatment-related adverse events were dermatol. and gastrointestinal, predominantly grade 1 to 2, and more frequent with dacomitinib.  Conclusion Dacomitinib demonstrated significantly improved PFS vs. erlotinib, with acceptable toxicity.  PFS benefit was obsd. in most clin. and mol. subsets, notably KRAS wild-type/EGFR any status, KRAS wild-type/EGFR wild-type, and EGFR mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHl-bReesXsbVg90H21EOLACvtfcHk0lgt1JYIOhRhNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Glt7%252FK&md5=bdc76102e0ae37fb3f5307c285f952d4</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.40.9433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.40.9433%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DKrzakowski%26aufirst%3DM.%26aulast%3DBarrios%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DSeog%2BHeo%26aufirst%3DD.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DTalbot%26aufirst%3DD.%2BC.%26aulast%3DFrank%26aufirst%3DR.%26aulast%3DLetrent%26aufirst%3DS.%2BP.%26aulast%3DRuiz-Garcia%26aufirst%3DA.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DLiang%26aufirst%3DJ.%2BL.%26aulast%3DCampbell%26aufirst%3DA.%2BK.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DBoyer%26aufirst%3DM.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520dacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520pan%25E2%2580%2593human%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitor%252C%2520versus%2520erlotinib%2520in%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D3337%26epage%3D3344%26doi%3D10.1200%2FJCO.2011.40.9433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Von Pawel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pluzanski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shtivelband, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Docampo, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennouna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doherty, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mather, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span> </span><span class="NLM_article-title">Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomized, double-blind, phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1369</span><span class="NLM_x">–</span> <span class="NLM_lpage">1378</span><span class="refDoi"> DOI: 10.1016/S1470-2045(14)70452-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS1470-2045%2814%2970452-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=25439691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslKjtrbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1369-1378&author=S.+S.+Ramalingamauthor=P.+A.+J%C3%A4nneauthor=T.+Mokauthor=K.+O%E2%80%99Byrneauthor=M.+J.+Boyerauthor=J.+Von+Pawelauthor=A.+Pluzanskiauthor=M.+Shtivelbandauthor=L.+I.+Docampoauthor=J.+Bennounaauthor=H.+Zhangauthor=J.+Q.+Liangauthor=J.+P.+Dohertyauthor=I.+Taylorauthor=C.+B.+Matherauthor=Z.+Goldbergauthor=J.+O%E2%80%99Connellauthor=L.+Paz-Ares&title=Dacomitinib+versus+erlotinib+in+patients+with+advanced-stage%2C+previously+treated+non-small-cell+lung+cancer+%28ARCHER+1009%29%3A+a+randomized%2C+double-blind%2C+phase+3+trial&doi=10.1016%2FS1470-2045%2814%2970452-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial</span></div><div class="casAuthors">Ramalingam, Suresh S.; Janne, Pasi A.; Mok, Tony; O'Byrne, Kenneth; Boyer, Michael J.; Von Pawel, Joachim; Pluzanski, Adam; Shtivelband, Mikhail; Docampo, Lara Iglesias; Bennouna, Jaafar; Zhang, Hui; Liang, Jane Q.; Doherty, Jim P.; Taylor, Ian; Mather, Cecile B.; Goldberg, Zelanna; O'Connell, Joseph; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1369-1378</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor.  Findings from a phase 2 study in non-small cell lung cancer showed favorable efficacy for dacomitinib compared with erlotinib.  We aimed to compare dacomitinib with erlotinib in a phase 3 study.  In a randomised, multicentre, double-blind phase 3 trial in 134 centers in 23 countries, we enrolled patients who had locally advanced or metastatic non-small-cell lung cancer, progression after one or two previous regimens of chemotherapy, Eastern Cooperative Oncol. Group (ECOG) performance status of 0-2, and presence of measurable disease.  We randomly assigned patients in a 1:1 ratio to dacomitinib (45 mg/day) or erlotinib (150 mg/day) with matching placebo.  Treatment allocation was masked to the investigator, patient, and study funder.  Randomisation was stratified by histol. (adenocarcinoma vs non-adenocarcinoma), ethnic origin (Asian vs non-Asian and Indian sub-continent), performance status (0-1 vs 2), and smoking status (never-smoker vs ever-smoker).  The coprimary endpoints were progression-free survival per independent review for all randomly assigned patients, and for all randomly assigned patients with KRAS wild-type tumors.  The study has completed accrual and is registered with ClinicalTrials.gov, no. NCT01360554.  Between June 22, 2011, and March 12, 2013, we enrolled 878 patients and randomly assigned 439 to dacomitinib (256 KRAS wild type) and 439 (263 KRAS wild type) to erlotinib.  Median progression-free survival was 2·6 mo (95% CI 1·9-2·8) in both the dacomitinib group and the erlotinib group (stratified hazard ratio [HR] 0·941, 95% CI 0·802-1·104, one-sided log-rank p=0·229).  For patients with wild-type KRAS, median progression-free survival was 2·6 mo for dacomitinib (95% CI 1·9-2·9) and erlotinib (95% CI 1·9-3·0; stratified HR 1·022, 95% CI 0·834-1·253, one-sided p=0·587).  In patients who received at least one dose of study drug, the most frequent grade 3-4 adverse events were diarrhoea (47 [11%] patients in the dacomitinib group vs ten [2%] patients in the erlotinib group), rash (29 [7%] vs 12 [3%]), and stomatitis (15 [3%] vs two [<1%]).  Serious adverse events were reported in 52 (12%) patients receiving dacomitinib and 40 (9%) patients receiving erlotinib.  Irreversible EGFR inhibition with dacomitinib was not superior to erlotinib in an unselected patient population with advanced non-small-cell lung cancer or in patients with KRAS wild-type tumors.  Further study of irreversible EGFR inhibitors should be restricted to patients with activating EGFR mutations.Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS7UYIyeysF7Vg90H21EOLACvtfcHk0lhhJ5pWBENQOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslKjtrbK&md5=4c28096b12811da70e4a158efd512462</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970452-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970452-8%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DBoyer%26aufirst%3DM.%2BJ.%26aulast%3DVon%2BPawel%26aufirst%3DJ.%26aulast%3DPluzanski%26aufirst%3DA.%26aulast%3DShtivelband%26aufirst%3DM.%26aulast%3DDocampo%26aufirst%3DL.%2BI.%26aulast%3DBennouna%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%2BQ.%26aulast%3DDoherty%26aufirst%3DJ.%2BP.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DMather%26aufirst%3DC.%2BB.%26aulast%3DGoldberg%26aufirst%3DZ.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DDacomitinib%2520versus%2520erlotinib%2520in%2520patients%2520with%2520advanced-stage%252C%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%2520%2528ARCHER%25201009%2529%253A%2520a%2520randomized%252C%2520double-blind%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26spage%3D1369%26epage%3D1378%26doi%3D10.1016%2FS1470-2045%2814%2970452-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">Ramalingam, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sbar, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span> </span><span class="NLM_article-title">Dacomitinib versus erlotinib in patients with EGFR mutated advanced non small-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">–</span> <span class="NLM_lpage">429</span><span class="refDoi"> DOI: 10.1093/annonc/mdv593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1093%2Fannonc%2Fmdv593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=26768165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A280%3ADC%252BC28ngtFGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2016&pages=423-429&author=S.+S.+Ramalingamauthor=K.+O%E2%80%99Byrneauthor=M.+Boyerauthor=T.+Mokauthor=P.+A.+J%C3%A4nneauthor=H.+Zhangauthor=J.+Liangauthor=I.+Taylorauthor=E.+I.+Sbarauthor=L.+Paz-Ares&title=Dacomitinib+versus+erlotinib+in+patients+with+EGFR+mutated+advanced+non+small-cell+lung+cancer+%28NSCLC%29%3A+pooled+subset+analyses+from+two+randomized+trials&doi=10.1093%2Fannonc%2Fmdv593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials</span></div><div class="casAuthors">Ramalingam S S; O'Byrne K; Boyer M; Mok T; Janne P A; Zhang H; Liang J; Taylor I; Sbar E I; Paz-Ares L</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">423-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The irreversible epidermal growth factor receptor (EGFR) inhibitors have demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown if they are superior to the reversible inhibitors.  Dacomitinib is an oral, small-molecule irreversible inhibitor of all enzymatically active HER family tyrosine kinases.  METHODS:  The ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067) studies randomized patients with locally advanced/metastatic NSCLC following progression with one or two prior chemotherapy regimens to dacomitinib or erlotinib.  EGFR mutation testing was performed centrally on archived tumor samples.  We pooled patients with exon 19 deletion and L858R EGFR mutations from both studies to compare the efficacy of dacomitinib to erlotinib.  RESULTS:  One hundred twenty-one patients with any EGFR mutation were enrolled; 101 had activating mutations in exon 19 or 21.  For patients with exon19/21 mutations, the median progression-free survival was 14.6 months [95% confidence interval (CI) 9.0-18.2] with dacomitinib and 9.6 months (95% CI 7.4-12.7) with erlotinib [unstratified hazard ratio (HR) 0.717 (95% CI 0.458-1.124), two-sided log-rank, P = 0.146].  The median survival was 26.6 months (95% CI 21.6-41.5) with dacomitinib versus 23.2 months (95% CI 16.0-31.8) with erlotinib [unstratified HR 0.737 (95% CI 0.431-1.259), two-sided log-rank, P = 0.265].  Dacomitinib was associated with a higher incidence of diarrhea and mucositis in both studies compared with erlotinib.  CONCLUSIONS:  Dacomitinib is an active agent with comparable efficacy to erlotinib in the EGFR mutated patients.  The subgroup with exon 19 deletion had favorable outcomes with dacomitinib.  An ongoing phase III study will compare dacomitinib to gefitinib in first-line therapy of patients with NSCLC harboring common activating EGFR mutations (ARCHER 1050; NCT01774721).  CLINICAL TRIALS NUMBER:  ARCHER 1009 (NCT01360554) and A7471028 (NCT00769067).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR3TTXce8SicyXXDYhVZBdlfW6udTcc2eacDe11foE-m7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28ngtFGqsQ%253D%253D&md5=f686fa296e6f5adf345bd81bde5ec664</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv593%26sid%3Dliteratum%253Aachs%26aulast%3DRamalingam%26aufirst%3DS.%2BS.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%26aulast%3DBoyer%26aufirst%3DM.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DSbar%26aufirst%3DE.%2BI.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DDacomitinib%2520versus%2520erlotinib%2520in%2520patients%2520with%2520EGFR%2520mutated%2520advanced%2520non%2520small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%253A%2520pooled%2520subset%2520analyses%2520from%2520two%2520randomized%2520trials%26jtitle%3DAnn.%2520Oncol.%26date%3D2016%26volume%3D27%26spage%3D423%26epage%3D429%26doi%3D10.1093%2Fannonc%2Fmdv593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, I. S.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Letrent, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">15 Suppl</span><span class="NLM_x">) </span> <span class="NLM_fpage">7530</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=7530&issue=15+Suppl&author=M.+G.+Krisauthor=T.+Mokauthor=I.+S.-H.+Ouauthor=R.+Martinsauthor=D.-W.+Kimauthor=Z.+Goldbergauthor=H.+Zhangauthor=I.+Taylorauthor=S.+P.+Letrentauthor=P.+A.+J%C3%A4nne&title=First-line+dacomitinib+%28PF-00299804%29%2C+an+irreversible+pan-HER+tyrosine+kinase+inhibitor%2C+for+patients+with+EGFR-mutant+lung+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DOu%26aufirst%3DI.%2BS.-H.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DGoldberg%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DLetrent%26aufirst%3DS.%2BP.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DFirst-line%2520dacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520pan-HER%2520tyrosine%2520kinase%2520inhibitor%252C%2520for%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26issue%3D15%2520Suppl%26spage%3D7530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Abdul Razak, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soulieres, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laurie, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hotte, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winquist, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Tourneau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen-Tan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, E. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mormont, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siu, L. L.</span><span> </span><span class="NLM_article-title">A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">769</span><span class="refDoi"> DOI: 10.1093/annonc/mds503</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1093%2Fannonc%2Fmds503" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=23108949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A280%3ADC%252BC3s%252FptFGiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2013&pages=761-769&author=A.+R.+Abdul+Razakauthor=D.+Soulieresauthor=S.+A.+Laurieauthor=S.+J.+Hotteauthor=S.+Singhauthor=E.+Winquistauthor=S.+Chiaauthor=C.+Le+Tourneauauthor=P.+F.+Nguyen-Tanauthor=E.+X.+Chenauthor=K.+K.+Chanauthor=T.+Wangauthor=N.+Giriauthor=C.+Mormontauthor=S.+Quinnauthor=L.+L.+Siu&title=A+phase+II+trial+of+dacomitinib%2C+an+oral+pan-human+EGF+receptor+%28HER%29+inhibitor%2C+as+first-line+treatment+in+recurrent+and%2For+metastatic+squamous-cell+carcinoma+of+the+head+and+neck&doi=10.1093%2Fannonc%2Fmds503"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck</span></div><div class="casAuthors">Abdul Razak A R; Soulieres D; Laurie S A; Hotte S J; Singh S; Winquist E; Chia S; Le Tourneau C; Nguyen-Tan P-F; Chen E X; Chan K K; Wang T; Giri N; Mormont C; Quinn S; Siu L L</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">761-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  An open-label, multicenter, single-arm phase II trial was conducted to investigate the clinical activity of dacomitinib in recurrent/metastatic squamous-cell carcinoma of the head and neck (RM-SCCHN).  PATIENTS AND METHODS:  Eligible patients were administered dacomitinib at 45 mg orally daily, in 21-day cycles.  Primary end point was objective response rate.  RESULTS:  Sixty-nine patients were enrolled with a median age of 62 years.  Among response-evaluable patients, 8 [12.7%, 95% confidence interval (CI) 5.6% to 23.5%] achieved a partial response and 36 (57.1%) had stable disease, lasting ≥24 weeks in 9 patients (14.3%).  The median progression-free survival (PFS) was 12.1 weeks and the median overall survival (OS) was 34.6 weeks.  Most adverse events (AEs) were tolerable.  The most common grade 3 or higher treatment-related AEs were diarrhea (15.9%), acneiform dermatitis (8.7%), and fatigue (8.7%).  Treatment-related AEs led to at least one dose interruption in 28 (40.6%) patients and dose reductions in 26 (37.7%).  Permanent treatment discontinuation occurred in 8 (11.6%) patients due to treatment-related AEs.  CONCLUSIONS:  Dacomitinib demonstrated clinical activity in RM-SCCHN, and the primary end point of this study was met.  The toxicity profile of this agent was generally manageable with dose interruptions and adjustments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRASc6h49NT8EloaUqgkFHkfW6udTcc2eZRdoHS5wcf7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s%252FptFGiuw%253D%253D&md5=30a57108c19363bd3d4c764ff0d723b0</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmds503&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmds503%26sid%3Dliteratum%253Aachs%26aulast%3DAbdul%2BRazak%26aufirst%3DA.%2BR.%26aulast%3DSoulieres%26aufirst%3DD.%26aulast%3DLaurie%26aufirst%3DS.%2BA.%26aulast%3DHotte%26aufirst%3DS.%2BJ.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DWinquist%26aufirst%3DE.%26aulast%3DChia%26aufirst%3DS.%26aulast%3DLe%2BTourneau%26aufirst%3DC.%26aulast%3DNguyen-Tan%26aufirst%3DP.%2BF.%26aulast%3DChen%26aufirst%3DE.%2BX.%26aulast%3DChan%26aufirst%3DK.%2BK.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DGiri%26aufirst%3DN.%26aulast%3DMormont%26aufirst%3DC.%26aulast%3DQuinn%26aufirst%3DS.%26aulast%3DSiu%26aufirst%3DL.%2BL.%26atitle%3DA%2520phase%2520II%2520trial%2520of%2520dacomitinib%252C%2520an%2520oral%2520pan-human%2520EGF%2520receptor%2520%2528HER%2529%2520inhibitor%252C%2520as%2520first-line%2520treatment%2520in%2520recurrent%2520and%252For%2520metastatic%2520squamous-cell%2520carcinoma%2520of%2520the%2520head%2520and%2520neck%26jtitle%3DAnn.%2520Oncol.%26date%3D2013%26volume%3D24%26spage%3D761%26epage%3D769%26doi%3D10.1093%2Fannonc%2Fmds503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxnard, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunphy, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paweletz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span> </span><span class="NLM_article-title">Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x"> (</span><span class="NLM_issue">13</span><span class="NLM_x">) </span> <span class="NLM_fpage">1433</span><span class="NLM_x">–</span> <span class="NLM_lpage">1441</span><span class="refDoi"> DOI: 10.1016/S1470-2045(14)70461-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1016%2FS1470-2045%2814%2970461-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=25456362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVOktLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=1433-1441&issue=13&author=P.+A.+J%C3%A4nneauthor=S.+H.+Ouauthor=D.+W.+Kimauthor=G.+R.+Oxnardauthor=R.+Martinsauthor=M.+G.+Krisauthor=F.+Dunphyauthor=M.+Nishioauthor=J.+O%E2%80%99Connellauthor=C.+Paweletzauthor=I.+Taylorauthor=H.+Zhangauthor=Z.+Goldbergauthor=T.+Mok&title=Dacomitinib+as+first-line+treatment+in+patients+with+clinically+or+molecularly+selected+advanced+non-small-cell+lung+cancer%3A+a+multicentre%2C+open-label%2C+phase+2+trial&doi=10.1016%2FS1470-2045%2814%2970461-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial</span></div><div class="casAuthors">Janne, Pasi A.; Ou, Sai-Hong I.; Kim, Dong-Wan; Oxnard, Geoffrey R.; Martins, Renato; Kris, Mark G.; Dunphy, Frank; Nishio, Makoto; O'Connell, Joseph; Paweletz, Cloud; Taylor, Ian; Zhang, Hui; Goldberg, Zelanna; Mok, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1433-1441</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with EGFR-mutant non-small-cell lung cancer generally have a progression-free survival of 9-13 mo while being treated with the EGFR tyrosine-kinase inhibitors gefitinib or erlotinib.  However, resistance inevitably develops, and more effective EGFR inhibitors are needed.  Dacomitinib is a covalent pan-HER inhibitor that has shown clin. activity in patients previously treated with gefitinib or erlotinib.  We did a trial of dacomitinib as initial systemic therapy in clin. and molecularly selected patients with advanced non-small-cell lung cancer.  In this open-label, multicentre, phase 2 trial, we enrolled treatment-naive patients with advanced lung cancer who had clin. (never-smokers [<100 cigarettes per lifetime] or former light smokers [<10 pack-years per lifetime] and ≥15 years since last cigarette) or mol. (EGFR mutation, regardless of smoking status) characteristics assocd. with response to EGFR inhibitors.  We gave dacomitinib orally once daily (45 mg or 30 mg) until progressive disease, unacceptable toxicity, or patient withdrawal.  We used Response Evaluation Criteria in Solid Tumors criteria (version 1.0) to investigate the activity of dacomitinib in all patients with a baseline scan and at least one post-treatment scan, with investigator assessment of response and progression.  The primary endpoint was progression-free survival at 4 mo in the as-enrolled population, with a null hypothesis of progression-free survival at 4 mo of 50% or less.  The study is registered with ClinicalTrials.gov, no. NCT00818441, and is no longer accruing patients.  Between March 11, 2009, and Apr. 1, 2011, we enrolled 89 patients from 25 centers, including 45 (51%) with EGFR-activating mutations in exon 19 (n=25) or exon 21 (n=20).  Progression-free survival at 4 mo was 76·8% (95% CI 66·4-84·4) in the as-enrolled population, and was 95·5% (95% CI 83·2-98·9) in the EGFR-mutant population.  The most common all-grade treatment-related adverse events were diarrhoea in 83 (93%) patients, dermatitis acneiform in 69 (78%) patients, dry skin in 39 (44%) patients, and stomatitis in 36 (40%) patients.  Two patients (2%) had grade 4 treatment-related events (one with hypokalemia and one with dyspnoea).  No grade 5 toxicities were recorded.  Dacomitinib had encouraging clin. activity as initial systemic treatment in clin. or molecularly selected patients with advanced non-small-cell lung cancer.Pfizer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9kNWlD10i2bVg90H21EOLACvtfcHk0ljDIKRG2h4RJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVOktLjL&md5=1f221dd93d690a832357db14d762efd7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2814%2970461-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252814%252970461-9%26sid%3Dliteratum%253Aachs%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DDunphy%26aufirst%3DF.%26aulast%3DNishio%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DJ.%26aulast%3DPaweletz%26aufirst%3DC.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGoldberg%26aufirst%3DZ.%26aulast%3DMok%26aufirst%3DT.%26atitle%3DDacomitinib%2520as%2520first-line%2520treatment%2520in%2520patients%2520with%2520clinically%2520or%2520molecularly%2520selected%2520advanced%2520non-small-cell%2520lung%2520cancer%253A%2520a%2520multicentre%252C%2520open-label%252C%2520phase%25202%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2014%26volume%3D15%26issue%3D13%26spage%3D1433%26epage%3D1441%26doi%3D10.1016%2FS1470-2045%2814%2970461-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Bridges, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cody, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewcastle, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMichael, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Showalter, H. D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kraker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Denny, W. A.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors: 8. An unusually steep structure-activity relationship for analogs of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">267</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span><span class="refDoi"> DOI: 10.1021/jm9503613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9503613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=267-276&author=A.+J.+Bridgesauthor=H.+Zhouauthor=D.+R.+Codyauthor=G.+W.+Rewcastleauthor=A.+McMichaelauthor=H.+D.+H.+Showalterauthor=D.+W.+Fryauthor=A.+J.+Krakerauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors%3A+8.+An+unusually+steep+structure-activity+relationship+for+analogs+of+4-%283-bromoanilino%29-6%2C7-dimethoxyquinazoline+%28PD+153035%29%2C+a+potent+inhibitor+of+the+epidermal+growth+factor+receptor&doi=10.1021%2Fjm9503613"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1021%2Fjm9503613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9503613%26sid%3Dliteratum%253Aachs%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DCody%26aufirst%3DD.%2BR.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DMcMichael%26aufirst%3DA.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DKraker%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors%253A%25208.%2520An%2520unusually%2520steep%2520structure-activity%2520relationship%2520for%2520analogs%2520of%25204-%25283-bromoanilino%2529-6%252C7-dimethoxyquinazoline%2520%2528PD%2520153035%2529%252C%2520a%2520potent%2520inhibitor%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D267%26epage%3D276%26doi%3D10.1021%2Fjm9503613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Nomoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teranishi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, K.</span><span> </span><span class="NLM_article-title">Studies on cardiotonic agents. I. Synthesis of some quinazoline derivatives</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">1591</span><span class="NLM_x">–</span> <span class="NLM_lpage">1595</span><span class="refDoi"> DOI: 10.1248/cpb.38.1591</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=10.1248%2Fcpb.38.1591" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1990&pages=1591-1595&author=Y.+Nomotoauthor=H.+Obaseauthor=H.+Takaiauthor=T.+Hirataauthor=M.+Teranishiauthor=J.+Nakamuraauthor=K.+Kubo&title=Studies+on+cardiotonic+agents.+I.+Synthesis+of+some+quinazoline+derivatives&doi=10.1248%2Fcpb.38.1591"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1248%2Fcpb.38.1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1248%252Fcpb.38.1591%26sid%3Dliteratum%253Aachs%26aulast%3DNomoto%26aufirst%3DY.%26aulast%3DObase%26aufirst%3DH.%26aulast%3DTakai%26aufirst%3DH.%26aulast%3DHirata%26aufirst%3DT.%26aulast%3DTeranishi%26aufirst%3DM.%26aulast%3DNakamura%26aufirst%3DJ.%26aulast%3DKubo%26aufirst%3DK.%26atitle%3DStudies%2520on%2520cardiotonic%2520agents.%2520I.%2520Synthesis%2520of%2520some%2520quinazoline%2520derivatives%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1990%26volume%3D38%26spage%3D1591%26epage%3D1595%26doi%3D10.1248%2Fcpb.38.1591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Ham, Y. J.; Gong, J. H.; Cha, M. Y.; Kim, J. W.; Kim, M. S.; Kim, E. Y.; Song, J. Y.; Kim, C. I.; Kim, S. Y.; Lee, G. S.</span><span> </span><span class="NLM_article-title">Preparation of quinazoline derivatives as inhibitors of epidermal growth factor receptor and growth of cancer cells</span>. PCT Int. Appl. WO 2006071017 A1,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=Y.+J.+Ham&author=J.+H.+Gong&author=M.+Y.+Cha&author=J.+W.+Kim&author=M.+S.+Kim&author=E.+Y.+Kim&author=J.+Y.+Song&author=C.+I.+Kim&author=S.+Y.+Kim&author=G.+S.+Lee&title=Preparation+of+quinazoline+derivatives+as+inhibitors+of+epidermal+growth+factor+receptor+and+growth+of+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHam%26aufirst%3DY.%2BJ.%26atitle%3DPreparation%2520of%2520quinazoline%2520derivatives%2520as%2520inhibitors%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520growth%2520of%2520cancer%2520cells%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Gaster, L. M.; Wyman, P. A.; Mulholland, K. R.; Davies, D. T.; Duckworth, D. M.; Forbes, I. T.; Jones, G. E.</span><span> </span><span class="NLM_article-title">Preparation of indolines as 5-HT2B/2C receptor antagonists</span>. PCT Int. Appl. WO 9623783 A1,<span class="NLM_x"> </span><span class="NLM_year">1996</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1996&author=L.+M.+Gaster&author=P.+A.+Wyman&author=K.+R.+Mulholland&author=D.+T.+Davies&author=D.+M.+Duckworth&author=I.+T.+Forbes&author=G.+E.+Jones&title=Preparation+of+indolines+as+5-HT2B%2F2C+receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGaster%26aufirst%3DL.%2BM.%26atitle%3DPreparation%2520of%2520indolines%2520as%25205-HT2B%252F2C%2520receptor%2520antagonists%26date%3D1996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Cockerill, G. S.; Carter, M. C.; Guntrip, S. B.; Smith, K. J.</span><span> </span><span class="NLM_article-title">Preparation of azolylquinazolines and related compounds as protein tyrosine kinase inhibitors</span>. PCT Int. Appl. WO 9802434 A1,<span class="NLM_x"> </span><span class="NLM_year">1998</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=G.+S.+Cockerill&author=M.+C.+Carter&author=S.+B.+Guntrip&author=K.+J.+Smith&title=Preparation+of+azolylquinazolines+and+related+compounds+as+protein+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCockerill%26aufirst%3DG.%2BS.%26atitle%3DPreparation%2520of%2520azolylquinazolines%2520and%2520related%2520compounds%2520as%2520protein%2520tyrosine%2520kinase%2520inhibitors%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Jacobsen, E. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stelzer, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TenBrink, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belonga, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Im, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sethy, V. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VonVoigtlander, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petke, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, W. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mickelson, J. W.</span><span> </span><span class="NLM_article-title">Piperazine imidazo[1,5-<i>a</i>]quinoxaline ureas as high-affinity GABAA ligands of dual functionality</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1123</span><span class="NLM_x">–</span> <span class="NLM_lpage">1144</span><span class="refDoi"> DOI: 10.1021/jm9801307</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9801307" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1999&pages=1123-1144&author=E.+J.+Jacobsenauthor=L.+S.+Stelzerauthor=R.+E.+TenBrinkauthor=K.+L.+Belongaauthor=D.+B.+Carterauthor=H.+K.+Imauthor=W.+B.+Imauthor=V.+H.+Sethyauthor=A.+H.+Tangauthor=P.+F.+VonVoigtlanderauthor=J.+D.+Petkeauthor=W.+Z.+Zhongauthor=J.+W.+Mickelson&title=Piperazine+imidazo%5B1%2C5-a%5Dquinoxaline+ureas+as+high-affinity+GABAA+ligands+of+dual+functionality&doi=10.1021%2Fjm9801307"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fjm9801307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9801307%26sid%3Dliteratum%253Aachs%26aulast%3DJacobsen%26aufirst%3DE.%2BJ.%26aulast%3DStelzer%26aufirst%3DL.%2BS.%26aulast%3DTenBrink%26aufirst%3DR.%2BE.%26aulast%3DBelonga%26aufirst%3DK.%2BL.%26aulast%3DCarter%26aufirst%3DD.%2BB.%26aulast%3DIm%26aufirst%3DH.%2BK.%26aulast%3DIm%26aufirst%3DW.%2BB.%26aulast%3DSethy%26aufirst%3DV.%2BH.%26aulast%3DTang%26aufirst%3DA.%2BH.%26aulast%3DVonVoigtlander%26aufirst%3DP.%2BF.%26aulast%3DPetke%26aufirst%3DJ.%2BD.%26aulast%3DZhong%26aufirst%3DW.%2BZ.%26aulast%3DMickelson%26aufirst%3DJ.%2BW.%26atitle%3DPiperazine%2520imidazo%255B1%252C5-a%255Dquinoxaline%2520ureas%2520as%2520high-affinity%2520GABAA%2520ligands%2520of%2520dual%2520functionality%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1999%26volume%3D42%26spage%3D1123%26epage%3D1144%26doi%3D10.1021%2Fjm9801307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenkopf, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brissette, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casavant, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shang-Poa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doty, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hines, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kent, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kudlacz, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lillie, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnuson, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCurdy, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munchhof, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strelevitz, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whipple, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Changelian, P. S.</span><span> </span><span class="NLM_article-title">Discovery of CP-690,550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">8468</span><span class="NLM_x">–</span> <span class="NLM_lpage">8484</span><span class="refDoi"> DOI: 10.1021/jm1004286</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm1004286" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8468-8484&author=M.+E.+Flanaganauthor=T.+A.+Blumenkopfauthor=W.+H.+Brissetteauthor=M.+F.+Brownauthor=J.+M.+Casavantauthor=C.+Shang-Poaauthor=J.+L.+Dotyauthor=E.+A.+Elliottauthor=M.+B.+Fisherauthor=M.+Hinesauthor=C.+Kentauthor=E.+M.+Kudlaczauthor=B.+M.+Lillieauthor=K.+S.+Magnusonauthor=S.+P.+McCurdyauthor=M.+J.+Munchhofauthor=B.+D.+Perryauthor=P.+S.+Sawyerauthor=T.+J.+Strelevitzauthor=C.+Subramanyamauthor=J.+Sunauthor=D.+A.+Whippleauthor=P.+S.+Changelian&title=Discovery+of+CP-690%2C550%3A+A+potent+and+selective+Janus+kinase+%28JAK%29+inhibitor+for+the+treatment+of+autoimmune+diseases+and+organ+transplant+rejection&doi=10.1021%2Fjm1004286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection</span></div><div class="casAuthors">Flanagan, Mark E.; Blumenkopf, Todd A.; Brissette, William H.; Brown, Matthew F.; Casavant, Jeffrey M.; Chang, Shang-Poa; Doty, Jonathan L.; Elliott, Eileen A.; Fisher, Michael B.; Hines, Michael; Kent, Craig; Kudlacz, Elizabeth M.; Lillie, Brett M.; Magnuson, Kelly S.; McCurdy, Sandra P.; Munchhof, Michael J.; Perry, Bret D.; Sawyer, Perry S.; Strelevitz, Timothy J.; Subramanyam, Chakrapani; Sun, Jianmin; Whipple, David A.; Changelian, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8468-8484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There is a crit. need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis.  Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions.  Blockade of the JAK1/JAK3-STAT pathway with a small mol. was anticipated to provide therapeutic immunosuppression/immunomodulation.  The Pfizer compd. library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by the hexahydrocarbazolyl pyrrolopyrimidine CP-352,664.  Synthetic analogs of CP-352,664 were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay.  Select compds. were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis.  Optimization within this chem. series led to identification of the cyanoacetylpiperidinylamino pyrrolopyrimidine CP-690,550, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbFS_8DSHkDbVg90H21EOLACvtfcHk0lgv8OMSakiMxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOgt7vP&md5=c1d31ce42ab3f1c1f3029c6f4f48df1a</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjm1004286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1004286%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DBlumenkopf%26aufirst%3DT.%2BA.%26aulast%3DBrissette%26aufirst%3DW.%2BH.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DCasavant%26aufirst%3DJ.%2BM.%26aulast%3DShang-Poa%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%2BL.%26aulast%3DElliott%26aufirst%3DE.%2BA.%26aulast%3DFisher%26aufirst%3DM.%2BB.%26aulast%3DHines%26aufirst%3DM.%26aulast%3DKent%26aufirst%3DC.%26aulast%3DKudlacz%26aufirst%3DE.%2BM.%26aulast%3DLillie%26aufirst%3DB.%2BM.%26aulast%3DMagnuson%26aufirst%3DK.%2BS.%26aulast%3DMcCurdy%26aufirst%3DS.%2BP.%26aulast%3DMunchhof%26aufirst%3DM.%2BJ.%26aulast%3DPerry%26aufirst%3DB.%2BD.%26aulast%3DSawyer%26aufirst%3DP.%2BS.%26aulast%3DStrelevitz%26aufirst%3DT.%2BJ.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DWhipple%26aufirst%3DD.%2BA.%26aulast%3DChangelian%26aufirst%3DP.%2BS.%26atitle%3DDiscovery%2520of%2520CP-690%252C550%253A%2520A%2520potent%2520and%2520selective%2520Janus%2520kinase%2520%2528JAK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520autoimmune%2520diseases%2520and%2520organ%2520transplant%2520rejection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D8468%26epage%3D8484%26doi%3D10.1021%2Fjm1004286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Cohen, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rutledge, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vass, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowy, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlegel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, J. T.</span><span> </span><span class="NLM_article-title">Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain</span> <span class="citation_source-journal">J. Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">5303</span><span class="NLM_x">–</span> <span class="NLM_lpage">5311</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=8394451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;key=1%3ACAS%3A528%3ADyaK3sXms1Oksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=1993&pages=5303-5311&author=B.+D.+Cohenauthor=D.+J.+Goldsteinauthor=L.+Rutledgeauthor=W.+C.+Vassauthor=D.+R.+Lowyauthor=R.+Schlegelauthor=J.+T.+Schiller&title=Transformation-specific+interaction+of+the+bovine+papillomavirus+E5+oncoprotein+with+the+platelet-derived+growth+factor+receptor+transmembrane+domain+and+the+epidermal+growth+factor+receptor+cytoplasmic+domain"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Transformation-specific interaction of the bovine papillomavirus E5 oncoprotein with the platelet-derived growth factor receptor transmembrane domain and the epidermal growth factor receptor cytoplasmic domain</span></div><div class="casAuthors">Cohen, Bruce D.; Goldstein, David J.; Rutledge, Laura; Vass, William C.; Lowy, Douglas R.; Schlegel, Richard; Schiller, John T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5303-11</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    </div><div class="casAbstract">The bovine papillomavirus E5 transforming protein appears to activate both the epidermal growth factor receptor (EGF-R) and the platelet-derived growth factor receptor (PDGF-R) by a ligand-independent mechanism.  To further investigate the ability of E5 to activate receptors of different classes and to det. whether this stimulation occurs through the extracellular domains required for ligand activation, the authors constructed chimeric genes encoding PDGF-R and EGF-R by interchanging the extracellular, membrane, and cytoplasmic coding domains.  Chimeras were transfected into NIH 3T3 and CHO(LR73) cells.  All chimeras expressed stable protein which, upon addn. of the appropriate ligand, could be activated as assayed by tyrosine autophosphorylation and biol. transformation.  Co-transfection of E5 with the wild-type and chimeric receptors resulted in the ligand-independent activation of receptors, provided that a receptor contained either the transmembrane domain of the PDGF-R or the cytoplasmic domain of the EGF-R.  Chimeric receptors that contained both of these domains exhibited the highest level of E5-induced biochem. and biol. stimulation.  These results imply that E3 activates the PDGF-R and EGR-R by two distinct mechanisms, neither of which specifically involves the extracellular domain of the receptor.  Consistent with the biochem. and biol. activation data, co-immunopptn. studies demonstrated that E5 formed a complex with any chimera that contained a PDGF-R transmembrane domain or an EGF-R cytoplasmic domain, with those chimeras contg. both domains demonstrating the greatest efficiency of complex formation.  These results suggest that although different domains of the PDGF-R and EGF-R are required for E5 activation, both receptors are activated directly by formation of an E5-contg. complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohxDkN9Ekd9rVg90H21EOLACvtfcHk0lgv8OMSakiMxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXms1Oksbo%253D&md5=30bc0a89087eb4396fe5f40dc71bcc13</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DB.%2BD.%26aulast%3DGoldstein%26aufirst%3DD.%2BJ.%26aulast%3DRutledge%26aufirst%3DL.%26aulast%3DVass%26aufirst%3DW.%2BC.%26aulast%3DLowy%26aufirst%3DD.%2BR.%26aulast%3DSchlegel%26aufirst%3DR.%26aulast%3DSchiller%26aufirst%3DJ.%2BT.%26atitle%3DTransformation-specific%2520interaction%2520of%2520the%2520bovine%2520papillomavirus%2520E5%2520oncoprotein%2520with%2520the%2520platelet-derived%2520growth%2520factor%2520receptor%2520transmembrane%2520domain%2520and%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520cytoplasmic%2520domain%26jtitle%3DJ.%2520Virol.%26date%3D1993%26volume%3D67%26spage%3D5303%26epage%3D5311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i111"><a href="/doi/suppl/10.1021/acs.jmedchem.6b00883">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_20477"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b00883">10.1021/acs.jmedchem.6b00883</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic procedures for the synthesis of anilines (A6, A11, A13, A14, A31, A32) of <a class="ref internalNav" href="#tbl2">Table 2</a> and combustion analytical data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_001.pdf">jm6b00883_si_001.pdf (237.56 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b00883/suppl_file/jm6b00883_si_002.csv">jm6b00883_si_002.csv (7.11 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b00883%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-17%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b00883" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b15db6bfd3cdc","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
